https://www.psychedelicfinance.com https://www.psychedelicfinance.com/news https://www.psychedelicfinance.com/companies https://www.psychedelicfinance.com/spotlights https://www.psychedelicfinance.com/subscribe https://www.psychedelicfinance.com/privacy-policy https://www.psychedelicfinance.com/archive https://www.psychedelicfinance.com/articles/17-canadian-healthcare-professionals-approved-to-use-psilocybin-for-professional-training https://www.psychedelicfinance.com/articles/4-palliative-canadians-approved-for-end-of-life-psilocybin-therapy-through-section-56-1-first-legal-medical-exemptions-for-psilocybin-in-canada-since-1970s https://www.psychedelicfinance.com/articles/aaron-bartlone-chief-operating-officer-cybin https://www.psychedelicfinance.com/articles/accomplished-clinical-researcher-matthew-macaluso-joins-as-scientific-and-clinical-advisor-for-pharmathers-ketamine-programs https://www.psychedelicfinance.com/articles/advancing-multiple-psychedelics-in-multiple-indications-initiating-with-a-buy-and-8-price-target https://www.psychedelicfinance.com/articles/albert-labs-announces-distinguished-clinical-and-scientific-advisory-boards https://www.psychedelicfinance.com/articles/albert-labs-announces-private-placement https://www.psychedelicfinance.com/articles/albert-labs-announces-the-addition-of-two-renowned-scientific-advisors-to-its-scientific-advisory-board-sab https://www.psychedelicfinance.com/articles/albert-labs-appoints-principal-investigator-for-real-world-evidence-study-for-krn-101 https://www.psychedelicfinance.com/articles/albert-labs-appoints-two-industry-leading-directors https://www.psychedelicfinance.com/articles/albert-labs-cse-abrt-closes-4-7m-private-placement-begins-trading-on-the-canadian-securities-exchange https://www.psychedelicfinance.com/articles/albert-labs-cse-abrt-receive-conditional-approval-for-cse-listing-appoint-chrystal-capital-partners-to-advise-on-european-listing https://www.psychedelicfinance.com/articles/albert-labs-files-new-international-pct-patent-application-for-scalable-api-manufacturing https://www.psychedelicfinance.com/articles/albert-labs-files-us-provisional-patent-application-and-proves-out-consistent-and-rapidly-scalable-production-for-psilocybin https://www.psychedelicfinance.com/articles/albert-labs-granted-health-canada-licence https://www.psychedelicfinance.com/articles/albert-labs-pre-clinical-analytical-and-toxicological-research-supports-companys-forthcoming-studies https://www.psychedelicfinance.com/articles/albert-labs-provides-corporate-update https://www.psychedelicfinance.com/articles/albert-labs-receives-preliminary-acceptance-of-35-novel-inventive-claims-for-patent-protected-manufacturing-technology https://www.psychedelicfinance.com/articles/albert-labs-signs-letter-of-intent-loi-with-ingenu-cro-for-first-in-human-clinical-studies https://www.psychedelicfinance.com/articles/alberta-puts-patients-first-by-regulating-psychedelic-therapy-optimi-health https://www.psychedelicfinance.com/articles/alex-speiser-coo-orthogonal-thinker https://www.psychedelicfinance.com/articles/algernon-announces-positive-feedback-on-its-planned-phase-1-2a-dmt-human-stroke-study https://www.psychedelicfinance.com/articles/algernon-files-meeting-request-with-mhra-for-use-of-dmt-in-phase-1-2a-human-stroke-study https://www.psychedelicfinance.com/articles/algernon-neuroscience-announces-40-patient-phase-2-psychedelic-drug-dmt-stroke-study https://www.psychedelicfinance.com/articles/algernon-neuroscience-announces-successful-dosing-of-2nd-cohort-in-phase-1-dmt-clinical-study https://www.psychedelicfinance.com/articles/algernon-neuroscience-announces-u-s-sec-qualification-of-regulation-a-tier-ii-offering-to-raise-up-to-usd-10m https://www.psychedelicfinance.com/articles/algernon-neuroscience-doses-first-subject-in-phase-1-dmt-clinical-stroke-study https://www.psychedelicfinance.com/articles/algernon-neuroscience-initiates-traumatic-brain-injury-research-program-with-dmt-appoints-global-tbi-expert-as-advisor https://www.psychedelicfinance.com/articles/algernon-neuroscience-provides-update-on-phase-1-dmt-clinical-study-drug-found-safe-to-proceed-to-next-phase https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-advancing-dmt-into-a-phase-1-clinical-trial-ceo-clips-video https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-50-enrollment-of-its-ifenprodil-ipf-and-chronic-cough-phase-2-human-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-70-enrollment-of-its-ifenprodil-ipf-and-chronic-cough-phase-2-human-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-appointment-of-global-expert-dr-steven-l-wolf-for-dmt-stroke-program https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-appointment-of-harry-bloomfield-qc-as-a-new-board-director-and-chairman https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-closing-of-private-placement https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-completion-of-enrollment-in-its-phase-2-study-of-ifenprodil-for-ipf-and-chronic-cough https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-database-lock-in-phase-2-study-of-ipf-and-chronic-cough https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-dr-rick-strassman-author-of-dmt-the-spirit-molecule-to-join-ceo-christopher-j-moreau-for-keynote-science-address-at-wonderland-conference https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-exclusive-licensing-agreement-with-dartmouth-college https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-its-addition-to-the-markets-first-psychedelic-stock-index-etf https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-launch-of-rights-offering https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-lead-chronic-kidney-disease-drug-repirinast-reduced-fibrosis-by-56-in-a-preclinical-nash-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-new-chief-financial-officer https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-notice-of-allowance-for-ifenprodil-patent-application-for-idiopathic-pulmonary-fibrosis https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-notice-of-allowance-for-method-of-use-u-s-patent-application https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-plans-for-a-180-patient-phase-2b-chronic-cough-study-of-ifenprodil https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-plans-for-a-phase-2-ifenprodil-chronic-cough-study-in-the-u-s https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-positive-feedback-from-u-s-fda-for-phase-1-ifenprodil-small-cell-lung-cancer-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-positive-feedback-from-u-s-fda-for-phase-2b-ifenprodil-chronic-cough-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-pricing-of-public-offering-of-units https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-private-placement https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-public-offering-of-units https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-receipt-of-cad-2m-cash-refund-from-australian-research-program-and-files-application-to-list-its-common-shares-on-nasdaq-capital-market https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-receipt-of-cdn-450k-cash-refund-from-australian-research-program https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-small-cell-lung-cancer-ifenprodil-research-program-and-appoints-dr-william-north-as-lead-consultant https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-the-appointment-of-dr-mark-williams-to-the-board-of-directors https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-announces-topline-data-from-its-phase-2b-3-covid-19-trial-of-ifenprodil https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-appoints-dr-peter-dicpinigaitis-to-chronic-cough-advisory-board https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-begins-manufacturing-of-repirinast-and-launches-new-chronic-kidney-disease-research-program https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-completes-manufacturing-of-psychedelic-drug-dmt-appoints-uk-stroke-experts-for-phase-2 https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-confirms-dmt-increased-growth-of-neurons-by-40-in-preclinical-study-at-sub-hallucinogenic-dose https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-discloses-novel-dmt-salt-patent-strategy-includes-bioactive-nicotinate-and-pamoate https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-discloses-novel-salt-patent-strategy-as-part-of-its-psychedelic-drug-dmt-intellectual-property https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-enters-into-a-clinical-trial-agreement-with-yale-university-for-a-dmt-phase-2-depression-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-establishes-6-hours-as-optimum-treatment-period-for-dmt-in-neuron-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-files-for-clinical-trial-and-ethics-approval-for-phase-1-dmt-human-stroke-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-files-for-orphan-designation-with-the-u-s-fda-for-ifenprodil-as-a-treatment-of-ipf https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-forms-private-subsidiary-to-advance-companys-psychedelic-dmt-stroke-program-files-form-1-a-offering-statement-with-u-s-sec-for-regulation-a-offering https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-highlights-new-animal-study-showing-effectiveness-of-psychedelic-drug-dmt-in-treatment-of-stroke https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-issues-compensation-options https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-largest-shareholder-alphanorth-asset-management-increases-ownership-position https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-launches-pancreatic-cancer-clinical-research-program-with-ifenprodil https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-provides-update-on-its-phase-1-dmt-stroke-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-provides-update-on-its-planned-phase-1-repirinast-chronic-kidney-disease-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-receives-approval-for-groundbreaking-phase-1-dmt-human-stroke-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-receives-positive-feedback-from-u-s-fda-for-psychedelic-drug-dmt-clinical-research-program-for-stroke https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-receives-u-s-fda-orphan-drug-designation-for-ifenprodil-for-the-treatment-of-idiopathic-pulmonary-fibrosis https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-reports-positive-results-from-full-data-set-of-its-phase-2-study-of-ifenprodil-for-ipf-and-chronic-cough https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-screens-first-subject-in-phase-1-dmt-human-stroke-study https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-secures-lead-sponsorship-of-2022-wonderland-psychedelic-conference-in-miami https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-submits-u-s-fda-pre-ind-meeting-request-for-psychedelic-drug-dmt-clinical-research-program-for-stroke https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-targets-first-human-study-of-its-psychedelic-drug-dmt-stroke-program-for-q4-2021 https://www.psychedelicfinance.com/articles/algernon-pharmaceuticals-to-file-end-of-phase-2-meeting-request-with-u-s-fda-for-possible-ifenprodil-phase-3-covid-19-trial https://www.psychedelicfinance.com/articles/amanda-galbraith-principal-at-navigator-joins-the-board-of-psyched-wellness https://www.psychedelicfinance.com/articles/american-journal-of-psychiatry-publishes-international-ketamine-and-esketamine-treatment-guidance-led-by-braxia-scientific-ceo-dr-roger-mcintyre https://www.psychedelicfinance.com/articles/another-public-company-first-silo-wellness-opens-jamaican-ecotourism-psilocybin-microdosing-resort-for-the-psychedelic-curious-shareholder-discounts-for-psychedelic-vacations-available https://www.psychedelicfinance.com/articles/apeiron-and-other-key-shareholders-of-atai-life-sciences-reinforce-support-by-entering-into-extended-voluntary-share-lock-up-agreements https://www.psychedelicfinance.com/articles/apex-labs-granted-approval-for-north-americas-first-take-home-psilocybin-clinical-trial https://www.psychedelicfinance.com/articles/atai https://www.psychedelicfinance.com/articles/atai-and-intelgenx-enter-into-feasibility-agreement-to-develop-pharmaceutical-grade-polymeric-film-technologies-for-delivery-of-psychedelic-medicines https://www.psychedelicfinance.com/articles/atai-impact-donates-to-the-multidisciplinary-association-for-psychedelic-studies-maps-to-support-pioneering-work-in-psychedelic-medicine https://www.psychedelicfinance.com/articles/atai-impact-establishes-the-atai-fellowship-fund-in-psychedelic-neuroscience-with-massachusetts-general-hospitals-center-for-the-neuroscience-of-psychedelics https://www.psychedelicfinance.com/articles/atai-launches-introspect-digital-therapeutics-appoints-veteran-software-engineer-david-keene-as-ceo https://www.psychedelicfinance.com/articles/atai-launches-revixia-life-sciences-to-develop-salvinorin-a-for-a-variety-of-mental-health-conditions https://www.psychedelicfinance.com/articles/atai-life-sciences-acquires-majority-stake-in-psyber-inc-to-develop-brain-computer-interface-enabled-digital-therapeutics-targeting-mental-health-disorders https://www.psychedelicfinance.com/articles/atai-life-sciences-and-introspect-digital-therapeutics-to-test-novel-digital-therapeutic-approach-in-patients-receiving-ketamine-for-treatment-resistant-depression https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-fda-investigational-new-drug-ind-clearance-for-pcn-101-r-ketamine-program https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-first-subject-dosed-in-phase-1-trial-of-buccal-and-iv-vls-01-a-synthetic-form-of-dmt https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-fourth-quarter-and-full-year-2021-financial-results-reports-on-r-d-progress-and-highlights-strategic-focus-areas-of-its-innovative-mental-health-platform https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-initiation-of-phase-1-proof-of-concept-clinical-trial-for-its-sol-gel-based-direct-to-brain-drug-delivery-technology https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-initiation-of-phase-1-trial-for-its-mdma-derivative-emp-01 https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-launch-of-initial-public-offering https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-neuronasal-completes-pilot-study-receives-ind-clearance-to-continue-into-phase-i-trials-of-mtbi-therapeutic https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-pricing-of-upsized-initial-public-offering https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-r-d-day-agenda https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-the-closing-of-its-157-million-series-d-financing-round https://www.psychedelicfinance.com/articles/atai-life-sciences-announces-the-launch-of-psyprotix-to-develop-a-precision-psychiatry-approach-for-treatment-resistant-depression-trd https://www.psychedelicfinance.com/articles/atai-life-sciences-appoints-new-chief-financial-officer-and-chief-medical-officer https://www.psychedelicfinance.com/articles/atai-life-sciences-company-kures-therapeutics-appoints-dr-chad-beyer-as-chief-executive-officer https://www.psychedelicfinance.com/articles/atai-life-sciences-increases-its-ownership-position-in-compass-pathways https://www.psychedelicfinance.com/articles/atai-life-sciences-launches-empathbio-to-treat-post-traumatic-stress-disorder-with-novel-mdma-product https://www.psychedelicfinance.com/articles/atai-life-sciences-launches-innarisbio-in-partnership-with-the-university-of-queensland-with-the-aim-to-develop-a-more-effective-nose-to-brain-delivery-method https://www.psychedelicfinance.com/articles/atai-life-sciences-launches-invyxis-to-accelerate-discovery-of-next-generation-mental-health-treatments https://www.psychedelicfinance.com/articles/atai-life-sciences-reports-first-quarter-2022-financial-results-and-business-update https://www.psychedelicfinance.com/articles/atai-life-sciences-reports-second-quarter-2021-financial-results-and-business-update https://www.psychedelicfinance.com/articles/atai-life-sciences-reports-second-quarter-2022-financial-results-business-update https://www.psychedelicfinance.com/articles/atai-life-sciences-reports-third-quarter-2021-financial-results-and-corporate-update https://www.psychedelicfinance.com/articles/atai-life-sciences-reports-third-quarter-2022-financial-results-and-business-update https://www.psychedelicfinance.com/articles/atai-life-sciences-secures-term-loan-facility-for-up-to-175-million-from-hercules-capital https://www.psychedelicfinance.com/articles/atai-life-sciences-takes-on-opioid-crisis-by-acquiring-kures-to-develop-novel-therapeutics-for-opioid-abuse https://www.psychedelicfinance.com/articles/atai-life-sciences-to-collaborate-with-massachusetts-general-hospital-to-accelerate-discovery-of-mechanisms-underlying-therapeutic-effects-of-psychedelic-agents https://www.psychedelicfinance.com/articles/atai-life-sciences-to-host-conference-call-and-webcast-to-discuss-results-for-the-fourth-quarter-and-full-year-2021-and-corporate-update https://www.psychedelicfinance.com/articles/atai-life-sciences-to-host-virtual-r-d-day-on-july-29-2020 https://www.psychedelicfinance.com/articles/atai-life-sciences-to-participate-in-upcoming-april-investor-conference https://www.psychedelicfinance.com/articles/atai-life-sciences-to-participate-in-upcoming-february-investor-conference https://www.psychedelicfinance.com/articles/atai-life-sciences-to-participate-in-upcoming-march-investor-conferences https://www.psychedelicfinance.com/articles/australia-allows-prescription-of-mdma-and-psilocybin-in-groundbreaking-regulatory-change https://www.psychedelicfinance.com/articles/awakn-chief-medical-officer-dr-ben-sessa-announces-results-of-the-worlds-first-mdma-in-alcohol-use-disorder-clinical-trial https://www.psychedelicfinance.com/articles/awakn-life-sciences-announces-closing-of-private-placement https://www.psychedelicfinance.com/articles/awakn-life-sciences-announces-closing-of-private-placement-2 https://www.psychedelicfinance.com/articles/awakn-life-sciences-announces-closing-of-the-second-tranche-and-upsizing-of-previously-announced-private-placement https://www.psychedelicfinance.com/articles/awakn-life-sciences-announces-location-for-larger-oslo-clinic https://www.psychedelicfinance.com/articles/awakn-life-sciences-announces-signing-of-lease-for-second-clinic-in-norway https://www.psychedelicfinance.com/articles/awakn-life-sciences-announces-the-opening-of-its-fourth-clinic https://www.psychedelicfinance.com/articles/awakn-life-sciences-appoints-biotech-and-investment-veteran-dennis-purcell-as-a-special-advisor-to-the-ceo https://www.psychedelicfinance.com/articles/awakn-life-sciences-appoints-cro-to-conduct-phase-ii-study-of-mdma-as-a-treatment-for-alcohol-use-disorder https://www.psychedelicfinance.com/articles/awakn-life-sciences-appoints-kevin-lorenz-as-u-s-head-of-commercial-development https://www.psychedelicfinance.com/articles/awakn-life-sciences-appoints-uk-leader-in-addictions-psychiatry-dr-arun-dhandayudham-as-chief-medical-officer https://www.psychedelicfinance.com/articles/awakn-life-sciences-ceo-anthony-tennyson-joins-dustin-robinson-of-iter-investments-for-the-investor-hotseat-via-live-stream-on-may-26th https://www.psychedelicfinance.com/articles/awakn-life-sciences-completes-worlds-first-ketamine-treatment-study-for-a-range-of-behavioral-addictions https://www.psychedelicfinance.com/articles/awakn-life-sciences-drug-discovery-program-files-patent-application-for-a-new-class-of-entactogen-like-molecules https://www.psychedelicfinance.com/articles/awakn-life-sciences-expands-commercial-operations-into-the-u-s-first-licensing-partnership-agreement-with-revitalist https://www.psychedelicfinance.com/articles/awakn-life-sciences-files-patent-application-for-a-new-class-of-entactogen-like-molecules-to-treat-a-broad-range-of-addictions https://www.psychedelicfinance.com/articles/awakn-life-sciences-files-patent-cooperation-treaty-pct-application-for-the-treatment-of-behavioral-addictions https://www.psychedelicfinance.com/articles/awakn-life-sciences-granted-fast-track-designation-from-uk-regulator-for-ketamine-assisted-therapy-for-alcohol-use-disorder https://www.psychedelicfinance.com/articles/awakn-life-sciences-initiates-feasibility-study-for-mdma-using-catalents-zydis-orally-disintegrating-tablet-odt-technology https://www.psychedelicfinance.com/articles/awakn-life-sciences-initiates-follow-on-behavioral-study-to-focus-on-gambling-disorder https://www.psychedelicfinance.com/articles/awakn-life-sciences-initiates-investigative-study-of-novel-formulation-of-s-ketamine-to-assess-dissociative-effect https://www.psychedelicfinance.com/articles/awakn-life-sciences-launches-clinical-research-division-with-prof-david-nutt-dr-ben-sessa-identifying-suitable-studies-across-europe-north-america https://www.psychedelicfinance.com/articles/awakn-life-sciences-phase-iii-trial-approved-for-approximately-ca-2-5-million-funding-from-uk-state-covering-66-of-costs https://www.psychedelicfinance.com/articles/awakn-life-sciences-professor-celia-morgan-named-one-of-the-most-influential-women-in-the-psychedelics-industry https://www.psychedelicfinance.com/articles/awakn-life-sciences-provides-a-business-and-corporate-update https://www.psychedelicfinance.com/articles/awakn-life-sciences-provides-shareholder-update-on-three-operational-ketamine-assisted-therapy-clinics-in-the-uk-and-norway https://www.psychedelicfinance.com/articles/awakn-life-sciences-receives-regulatory-approval-for-flagship-clinic-in-london-to-begin-delivering-treatments https://www.psychedelicfinance.com/articles/awakn-life-sciences-receives-uk-state-funding-to-identify-optimal-pathway-to-market-in-uk-us-for-its-lead-clinical-development-program-ketamine-assisted-therapy-for-alcohol-use-disorder https://www.psychedelicfinance.com/articles/awakn-life-sciences-reports-fiscal-fourth-quarter-and-fiscal-year-january-31-2022-results https://www.psychedelicfinance.com/articles/awakn-life-sciences-reports-results-for-quarter-ended-april-30-2022 https://www.psychedelicfinance.com/articles/awakn-life-sciences-reports-strong-q2-2022-results https://www.psychedelicfinance.com/articles/awakn-life-sciences-secures-funding-to-expand-nordic-commercial-operations https://www.psychedelicfinance.com/articles/awakn-life-sciences-signs-agreement-with-a-leading-drug-development-company-to-deepen-ip-moat-for-its-lead-program https://www.psychedelicfinance.com/articles/awakn-life-sciences-signs-collaboration-agreement-with-university-of-exeter-for-upcoming-phase-iii-trial https://www.psychedelicfinance.com/articles/awakn-life-sciences-signs-drug-development-agreement-with-catalent-for-zydis-r-technology-an-orally-disintegrating-tablet-to-conduct-feasibility-studies-to-improve-differentiation-of-its-mdma-program https://www.psychedelicfinance.com/articles/awakn-life-sciences-signs-its-first-licensing-partnership-agreement-in-europe https://www.psychedelicfinance.com/articles/awakn-life-sciences-signs-its-third-licensing-partnership-agreement-in-north-america-and-first-in-new-york https://www.psychedelicfinance.com/articles/awakn-life-sciences-signs-second-licensing-partnership-agreement-and-expands-commercial-operations-into-canada https://www.psychedelicfinance.com/articles/awakn-life-sciences-submits-clinical-trial-application-for-phase-iii-trial-of-awkn-p001 https://www.psychedelicfinance.com/articles/awakn-life-sciences-to-host-fireside-chat-with-dr-ben-sessa-chief-medical-officer-on-march-2nd-at-11-00am-est https://www.psychedelicfinance.com/articles/awakn-life-sciences-to-participate-at-upcoming-march-2022-conferences https://www.psychedelicfinance.com/articles/awakn-life-sciences-to-participate-in-upcoming-april-2022-conferences https://www.psychedelicfinance.com/articles/awakn-life-sciences-to-participate-in-upcoming-may-2022-conferences https://www.psychedelicfinance.com/articles/awakn-life-sciences-to-present-in-upcoming-june-2022-conferences https://www.psychedelicfinance.com/articles/awakn-strengthens-scientific-and-medical-leadership-with-appointment-of-chief-science-officer-and-head-of-ketamine-alcohol-use-disorder-practice https://www.psychedelicfinance.com/articles/awakn-successfully-completes-phase-one-of-its-drug-discovery-program https://www.psychedelicfinance.com/articles/b-more-psilocybin-for-aud-program-principal-investigator-dr-michael-bogenschutz-to-present-at-horizons-new-york-psychedelic-research-forum https://www.psychedelicfinance.com/articles/b-more-receives-fda-investigational-new-drug-approval-for-psilocybin-alcohol-use-disorder-program https://www.psychedelicfinance.com/articles/b-more-submits-fda-investigational-new-drug-application-for-psilocybin-alcohol-use-disorder-program https://www.psychedelicfinance.com/articles/beckley-psytech-announces-partnership-with-ksana-health-building-on-digital-strategy-to-deliver-optimised-patient-outcomes https://www.psychedelicfinance.com/articles/beckley-psytech-bolsters-pipeline-of-next-generation-psychedelic-medicines-with-research-collaboration-and-strengthening-of-relationship-with-lophora-aps https://www.psychedelicfinance.com/articles/beckley-psytech-launches-phase-iia-study-of-lead-candidate-bpl-003-a-novel-benzoate-formulation-of-5-meo-dmt-for-treatment-resistant-depression https://www.psychedelicfinance.com/articles/beckley-psytech-strengthens-pipeline-and-development-team-with-acquisition-of-eleusis-therapeutics-limited https://www.psychedelicfinance.com/articles/ben-greenfield-biohacker-and-new-york-times-best-selling-author https://www.psychedelicfinance.com/articles/ben-lightburn-ceo-filament-health https://www.psychedelicfinance.com/articles/better-plant-affiliate-neonmind-lists-on-the-frankfurt-stock-exchange https://www.psychedelicfinance.com/articles/better-plant-sciences-subsidiary-neonmind-signs-psilocybin-supply-agreement-for-clinical-trials https://www.psychedelicfinance.com/articles/better-plants-jusu-begins-expansion-into-u-s-market https://www.psychedelicfinance.com/articles/better-plants-subsidiary-neonmind-to-complete-fully-subscribed-ipo-and-commence-trading-on-monday-january-4-2021-under-the-symbol-neon https://www.psychedelicfinance.com/articles/betterlife-and-collaborators-to-submit-key-joint-research-publication https://www.psychedelicfinance.com/articles/betterlife-announces-closing-of-private-placement https://www.psychedelicfinance.com/articles/betterlife-announces-exercise-of-over-allotment-option-in-public-offering https://www.psychedelicfinance.com/articles/betterlife-carleton-university-research-team-secure-mitacs-accelerate-funding-to-study-the-therapeutic-effect-of-td-010-in-chronic-anxiety https://www.psychedelicfinance.com/articles/betterlife-closes-2-61-million-marketed-public-offering https://www.psychedelicfinance.com/articles/betterlife-fast-tracks-its-us-patent-for-betr-001-and-other-lsd-derivatives https://www.psychedelicfinance.com/articles/betterlife-files-comprehensive-patent-for-betr-001-and-other-lsd-derivatives https://www.psychedelicfinance.com/articles/betterlife-lead-drug-betr-001-promotes-structural-neural-plasticity-with-possible-nootropic-effects-similar-to-that-of-lsd-without-hallucinogenic-side-effects https://www.psychedelicfinance.com/articles/betterlife-pharma-appoints-henri-sant-cassia-of-the-conscious-fund-to-its-board-of-directors https://www.psychedelicfinance.com/articles/betterlife-pharma-engages-global-financial-and-corporate-communications-agency https://www.psychedelicfinance.com/articles/betterlife-pharma-retains-proactive-investors-and-psychedelic-finance-for-market-awareness https://www.psychedelicfinance.com/articles/betterlife-pharma-to-present-at-the-h-c-wainwright-psychedelics-in-psychiatry-and-beyond-virtual-conference-on-june-17th https://www.psychedelicfinance.com/articles/betterlife-provides-h1-2021-progress-update https://www.psychedelicfinance.com/articles/betterlife-secures-additional-mitacs-funding-in-collaboration-with-carleton-university-research-team-for-betr-001-preclinical-depression-studies https://www.psychedelicfinance.com/articles/betterlife-secures-mitacs-funding-in-collaboration-with-carleton-university-research-team-for-td-0148a-preclinical-depression-studies https://www.psychedelicfinance.com/articles/betterlife-to-participate-at-the-h-c-wainwright-1st-annual-mental-health-conference https://www.psychedelicfinance.com/articles/betterlife-to-present-betr-001-preclinical-data-at-the-61st-annual-meeting-of-the-american-college-of-neuropsychopharmacology-acnp-in-phoenix-arizona https://www.psychedelicfinance.com/articles/betterlife-to-present-betr-001-preclinical-data-at-the-upcoming-federation-of-european-neuroscience-societies-fens-forum https://www.psychedelicfinance.com/articles/betterplant-subsidiary-neonmind-closes-oversubscribed-initial-public-offering-and-exercise-in-full-of-the-agents-over-allotment-option https://www.psychedelicfinance.com/articles/bexson-biomedical-raises-4-8-million-in-oversubscribed-series-a https://www.psychedelicfinance.com/articles/biomind-labs-and-queens-university-of-belfast-receive-controlled-substances-license-to-commence-the-production-of-a-novel-transdermal-drug-delivery-system https://www.psychedelicfinance.com/articles/biomind-labs-announces-completion-of-dosing-in-phase-ii-trial-of-its-dmt-based-inhaled-formulation-bmnd01-for-treatment-resistant-depression https://www.psychedelicfinance.com/articles/biomind-labs-announces-fda-investigational-new-drug-clearance-for-its-new-chemical-entity-triptax-tm-targeting-treatment-resistant-depression-and-reports-third-quarter-financial-results https://www.psychedelicfinance.com/articles/biomind-labs-announces-positive-initial-results-from-its-phase-ii-trial-on-its-bmnd01-candidate-for-treatment-resistant-depression https://www.psychedelicfinance.com/articles/biomind-labs-announces-pre-ind-meeting-request-granted-by-fda-for-its-new-chemical-entity-triptax-tm-targeting-treatment-resistant-depression https://www.psychedelicfinance.com/articles/biomind-labs-announces-the-completion-of-the-first-sublingual-psychedelic-formulation-for-its-drug-candidate-bmnd08-for-depression-and-anxiety-in-alzheimers-disease https://www.psychedelicfinance.com/articles/biomind-labs-to-argument-which-psychedelic-medicines-will-lead-the-industry-into-its-next-phase-of-evolution-at-the-national-gallery-in-london https://www.psychedelicfinance.com/articles/biomind-receives-approval-for-a-third-phase-ii-clinical-trial-for-its-5-meo-dmt-based-bmnd08-candidate-for-depression-anxiety-in-alzheimers-disease https://www.psychedelicfinance.com/articles/bionomics-announces-plans-to-conduct-u-s-initial-public-offering https://www.psychedelicfinance.com/articles/biotech-veteran-david-kideckel-joins-the-board-of-pharmadrug https://www.psychedelicfinance.com/articles/blackhawk-appoints-justin-hanka-as-chairman-of-the-board https://www.psychedelicfinance.com/articles/blackhawk-ceo-frederick-pels-and-mindbio-therapeutics-co-founder-justin-hanka-will-lead-investor-presentation-and-q-a-session-wednesday-february-2nd-at-3pm-pacific-standard-time https://www.psychedelicfinance.com/articles/blackhawk-growth-announces-plan-to-spin-out-psychedelic-subsidiaries-and-proposes-1-1-distribution-ratio https://www.psychedelicfinance.com/articles/blackhawk-growth-announces-shareholder-meeting-for-december-22-2022-to-vote-on-the-spin-out-of-mindbio-therapeutics https://www.psychedelicfinance.com/articles/blackhawk-growth-appoints-new-advisor-to-support-expansion-into-psychedelics-and-mental-health-treatments https://www.psychedelicfinance.com/articles/blackhawk-growth-closes-investment-in-blum-distributors https://www.psychedelicfinance.com/articles/blackhawk-growth-closes-investment-in-stable-foods https://www.psychedelicfinance.com/articles/blackhawk-growth-corp-cse-blr-acquires-mindbio-therapeutics-pty-ltd https://www.psychedelicfinance.com/articles/blackhawk-growth-enters-into-credit-facility-for-up-to-10-million https://www.psychedelicfinance.com/articles/blackhawk-growth-files-quarter-ended-march-31-2022-financials-and-reports-increase-in-value-of-its-portfolio-by-8-8-quarter-over-quarter https://www.psychedelicfinance.com/articles/blackhawk-growth-fully-funds-phase-ii-clinical-trials-in-psychedelics-and-begins-development-of-digital-mental-health-treatments https://www.psychedelicfinance.com/articles/blackhawk-growth-receives-court-approval-to-hold-special-meeting-on-december-22nd-2022-to-approve-mindbio-therapeutics-spinout https://www.psychedelicfinance.com/articles/blackhawk-growth-reports-increase-in-value-of-its-portfolio-by-49-quarter-over-quarter https://www.psychedelicfinance.com/articles/blackhawk-growth-sets-agm-date-and-provides-corporate-update https://www.psychedelicfinance.com/articles/blackhawk-growth-to-acquire-mycology-supplier-and-cultivator-blum-distributors https://www.psychedelicfinance.com/articles/blackhawk-growth-to-acquire-remaining-49-of-nuwave-foods-nuwave-foods-changes-name-to-stable-foods https://www.psychedelicfinance.com/articles/blackhawk-growth-to-reprofile-existing-credit-facility-and-add-additional-2-million-dollar-facility https://www.psychedelicfinance.com/articles/blackhawk-growths-blum-distributors-expands-facility-and-starts-to-fulfill-applied-myco-order https://www.psychedelicfinance.com/articles/blackhawk-growths-digital-mind-technology-set-to-pioneer-novel-treatment-in-pain-management-in-cancer-patients-preparations-for-phase-1-clinical-trials-underway https://www.psychedelicfinance.com/articles/blackhawk-growths-mindbio-therapeutics-brings-digital-mental-health-technology-to-psychedelics-clinical-trials https://www.psychedelicfinance.com/articles/blackhawk-growths-spaced-food-adds-new-flavours-and-signs-partnership-agreement-with-gaia-grows-canadian-cannabis-laboratory-tru-extracts-for-manufacturing-of-blackhawks-spaced-food-products https://www.psychedelicfinance.com/articles/blackhawk-growths-spaced-food-manufacturing-partner-completes-development-of-spaced-food-edibles-prepares-for-commercial-production https://www.psychedelicfinance.com/articles/blackhawk-launches-new-website-corporate-presentation-and-engages-investor-relations-professional-to-expand-outreach https://www.psychedelicfinance.com/articles/blackhawk-publishes-mindbio-therapeutics-investor-presentation-q-a-event-on-website https://www.psychedelicfinance.com/articles/blackhawk-subsidiary-digital-mind-technology-starts-phase-1-development-of-digital-therapeutic-platform-and-is-on-track-for-completion-in-q2-2022 https://www.psychedelicfinance.com/articles/blackhawks-mindbio-announces-phase-2a-b-clinical-trials-microdosing-lsd-in-major-depressive-disorder-submitted-for-ethics-regulatory-approval https://www.psychedelicfinance.com/articles/blackhawks-mindbio-nominated-for-company-of-the-year-by-industry-peers-as-it-prepares-for-phase-2-clinical-trials https://www.psychedelicfinance.com/articles/blackhawks-mindbio-reveals-positive-data-from-phase-1-randomised-double-blind-placebo-controlled-clinical-trials-microdosing-lsd-in-80-healthy-participants https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-accelerates-global-communications-expansion-ahead-of-phase-2-clinical-trials https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-ahead-of-schedule-to-complete-phase-1-clinical-trial-microdosing-of-psychedelic-medicines-and-provides-updates-on-spinout-process https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-announces-completion-of-world-first-phase-1-microdosing-clinical-trial https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-announces-investment-in-health-research-platform-quantified-citizen-a-health-technology-company-disrupting-and-decentralizing-clinical-research https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-announces-platinum-sponsorship-of-plant-medicine-week-in-malta https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-announces-research-collaborators-at-university-of-auckland-receive-grant-funding-of-1-44-million-for-lsd-microdosing-trials-in-major-depressive-disorder https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-announces-reveal-date-for-presentation-of-phase-1-clinical-trial-data https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-enters-its-80th-and-final-patient-into-phase-1-clinical-trials-and-provides-update-for-mindbio-spinout https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-invests-nz-2-3-million-to-fast-track-psychedelic-microdosing-phase-2-clinical-trials https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-to-develop-proprietary-drug-delivery-technology-for-psychedelic-medicines https://www.psychedelicfinance.com/articles/blackhawks-mindbio-therapeutics-to-develop-psychedelic-medicine-in-microdoses-ready-for-commercial-use-to-treat-major-depressive-disorder https://www.psychedelicfinance.com/articles/blackhawks-shareholders-vote-in-favour-of-plan-of-arrangement-to-spin-out-its-subsidiary-1286409-b-c-ltd-mindbio-therapeutics-corp-to-form-an-independent-listed-company https://www.psychedelicfinance.com/articles/blackhawks-terp-wholesale-llc-expands-facility-launches-retail-delivery https://www.psychedelicfinance.com/articles/blackhawks-terp-wholesale-llc-receives-state-issued-micro-business-license-allowing-for-retail-delivery https://www.psychedelicfinance.com/articles/blackhawks-terp-wholesale-llc-reports-unaudited-2-503-133-in-gross-revenue-for-nine-months-ended-september-30th-2021 https://www.psychedelicfinance.com/articles/blackhawks-terp-wholesale-llc-reports-unaudited-cdn-1-644-043-in-gross-revenue-for-first-five-months-ended-may-31st-2022 https://www.psychedelicfinance.com/articles/blue-star-gold-outlines-several-high-potential-target-areas https://www.psychedelicfinance.com/articles/braxia-scientific-achieves-milestone-as-landmark-psilocybin-clinical-trial-commences-participants-receive-first-doses-of-psilocybin https://www.psychedelicfinance.com/articles/braxia-scientific-announces-board-appointment https://www.psychedelicfinance.com/articles/braxia-scientific-announces-cad-3-million-private-placement-with-institutional-investors https://www.psychedelicfinance.com/articles/braxia-scientific-announces-closing-of-cad-3-million-private-placement https://www.psychedelicfinance.com/articles/braxia-scientific-announces-offering-up-to-1-5-million-braxia-management-to-participate-in-concurrent-private-placement https://www.psychedelicfinance.com/articles/braxia-scientific-announces-participation-at-canaccord-genuity-2021-annual-growth-conference-august-10-12 https://www.psychedelicfinance.com/articles/braxia-scientific-announces-participation-at-h-c-wainwright-23rd-annual-global-investment-conference-september-13-15-2021 https://www.psychedelicfinance.com/articles/braxia-scientific-announces-participation-at-psych-investor-summit-on-july-7-2021 https://www.psychedelicfinance.com/articles/braxia-scientific-announces-symbol-change-on-otc-markets-to-braxf https://www.psychedelicfinance.com/articles/braxia-scientific-announces-voting-results-from-the-annual-general-and-special-meeting-of-shareholders https://www.psychedelicfinance.com/articles/braxia-scientific-appoints-dr-david-greenberg-to-board-of-directors https://www.psychedelicfinance.com/articles/braxia-scientific-awarded-government-of-canada-funding-to-complete-first-of-its-kind-ketamine-clinical-trial-for-bipolar-depression https://www.psychedelicfinance.com/articles/braxia-scientific-bolsters-leadership-with-strategic-hires-adds-chief-information-officer-and-global-pharmaceutical-industry-leader-as-vp-r-d-and-growth https://www.psychedelicfinance.com/articles/braxia-scientific-ceo-chief-medical-officer-awarded-918-000-by-canadian-government-to-study-benefits-of-integrating-ketamine-with-cognitive-behavioural-therapy-to-reduce-suicidality https://www.psychedelicfinance.com/articles/braxia-scientific-ceo-dr-roger-mcintyre-to-join-advisory-board-of-at-home-telemedicine-platform-ketamd https://www.psychedelicfinance.com/articles/braxia-scientific-ceo-dr-roger-mcintyre-to-share-stage-with-nba-champion-lamar-odom-and-psychedelic-concierge-zappy-zapolin-to-discuss-the-benefits-of-ketamine-treatment-for-mental-health https://www.psychedelicfinance.com/articles/braxia-scientific-ceo-to-deliver-keynote-address-at-h-c-wainwright-co-1st-annual-mental-health-conference-neuropsychiatry-psychedelics-and-beyond https://www.psychedelicfinance.com/articles/braxia-scientific-ceo-to-speak-at-american-psychiatric-association-annual-meeting-on-treatment-resistant-depression-and-ketamine-guidelines-published-in-american-journal-of-psychiatry https://www.psychedelicfinance.com/articles/braxia-scientific-enters-u-s-telemedicine-industry-acquires-ketamd-a-mental-health-platform-providing-beneficial-ketamine-treatments-in-florida-with-plans-to-expand-across-the-u-s https://www.psychedelicfinance.com/articles/braxia-scientific-expands-clinic-footprint-in-canada-providing-greater-access-to-network-of-specialists-delivering-ketamine-and-psilocybin-treatments-for-depression-and-related-mental-health-disorders https://www.psychedelicfinance.com/articles/braxia-scientific-graduates-first-cohort-of-medical-professionals-from-psilocybin-assisted-therapy-training-program-ready-to-start-health-canada-approved-psilocybin-clinical-trial https://www.psychedelicfinance.com/articles/braxia-scientific-introduces-the-braxia-institute-turning-research-to-clinical-action-over-200-physicians-and-health-care-providers-to-attend-braxias-symposium-on-rapid-acting-anti-depressants https://www.psychedelicfinance.com/articles/braxia-scientific-launches-ketamd-in-florida-first-patients-complete-initial-virtual-ketamine-treatments-at-home https://www.psychedelicfinance.com/articles/braxia-scientific-launches-psilocybin-assisted-clinical-therapy-training-program https://www.psychedelicfinance.com/articles/braxia-scientific-opens-first-ketamine-therapy-clinic-in-quebec-enters-joint-venture-with-neurotherapy-montreal-a-leading-brain-injury-solutions-clinic-for-adults-and-children https://www.psychedelicfinance.com/articles/braxia-scientific-presents-positive-preliminary-findings-from-phase-ii-randomized-multi-dose-clinical-trial-of-psilocybin-assisted-therapy-for-treatment-resistant-depression https://www.psychedelicfinance.com/articles/braxia-scientific-provides-corporate-update-and-reports-fiscal-fourth-quarter-and-full-year-2021-financial-results https://www.psychedelicfinance.com/articles/braxia-scientific-provides-update-on-large-proprietary-dataset-expected-to-support-pharmaceutical-and-industry-clinical-trials-for-ketamine-and-psilocybin-drug-development https://www.psychedelicfinance.com/articles/braxia-scientific-reaches-agreements-to-settle-class-actions-in-us-and-canada https://www.psychedelicfinance.com/articles/braxia-scientific-receives-health-canada-special-access-program-approval-to-provide-psilocybin-assisted-therapy-for-depression-in-ontario https://www.psychedelicfinance.com/articles/braxia-scientific-reports-encouraging-results-of-ketamine-study-showing-significant-reduction-in-depressive-symptoms-and-suicidality-with-ketamine-as-a-solo-treatment https://www.psychedelicfinance.com/articles/braxia-scientific-reports-first-quarter-2022-financial-results-company-achieves-80-revenue-growth-from-expanding-clinic-patient-base https://www.psychedelicfinance.com/articles/braxia-scientific-reports-q1-2023-financial-results-launches-ketamd-in-u-s-increasing-treatment-access-for-mental-health-patients https://www.psychedelicfinance.com/articles/braxia-scientific-reports-q2-2023-financial-results-focused-on-growing-clinic-and-telemedicine-delivery-of-novel-mental-health-treatments-in-north-america https://www.psychedelicfinance.com/articles/braxia-scientific-reports-q3-2022-financial-results-company-leads-in-psychedelic-research-access-and-therapist-training-with-first-multi-dose-psilocybin-trial-in-canada https://www.psychedelicfinance.com/articles/braxia-scientific-secures-approval-for-direct-billing-insurance-on-ketamine-treatments-for-veterans-affairs-canada-clients https://www.psychedelicfinance.com/articles/braxia-scientific-to-commence-landmark-clinical-trial-to-conduct-canadas-first-multiple-dose-psilocybin-clinical-trial-for-treatment-resistant-depression https://www.psychedelicfinance.com/articles/braxia-scientific-to-discuss-psychiatric-treatment-discovery-and-development-with-oxford-university-researchers-at-aimday-experimental-medicine-in-psychiatry-on-july-7-2021 https://www.psychedelicfinance.com/articles/braxia-scientific-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-september-12-14-2022 https://www.psychedelicfinance.com/articles/braxia-scientific-to-present-at-the-psychedelics-in-psychiatry-and-beyond-virtual-conference-hosted-by-h-c-wainwright-co-on-june-17-2021 https://www.psychedelicfinance.com/articles/brett-greene-chief-innovations-officer-cybin-inc https://www.psychedelicfinance.com/articles/bright-minds-announces-overnight-marketed-offering-of-units https://www.psychedelicfinance.com/articles/bright-minds-biosciences-announces-changes-to-its-executive-leadership-team-marking-the-transition-to-a-development-organization https://www.psychedelicfinance.com/articles/bright-minds-biosciences-announces-successful-completion-of-28-day-toxicology-studies-and-advancement-to-first-in-human-clinical-trial-2 https://www.psychedelicfinance.com/articles/bright-minds-biosciences-establishes-scientific-advisory-board-comprising-five-preeminent-physicians-and-scientists-across-mental-health-specialties https://www.psychedelicfinance.com/articles/bright-minds-biosciences-initiates-dosing-in-phase-i-clinical-trial-of-bmb-101-for-dravet-syndrome https://www.psychedelicfinance.com/articles/bright-minds-biosciences-provides-scientific-update-on-its-novel-5-ht2a-psychedelic-program-for-the-treatment-of-mental-diseases https://www.psychedelicfinance.com/articles/bright-minds-biosciences-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference https://www.psychedelicfinance.com/articles/canadian-military-veteran-master-corporal-scott-atkinson-submits-request-to-minister-of-health-hon-patty-hajdu-to-access-proven-psilocybin-assisted-psychotherapy-for-non-palliative-use https://www.psychedelicfinance.com/articles/canadian-patent-grant-strengthens-small-pharmas-international-position https://www.psychedelicfinance.com/articles/canadian-rapid-treatment-center-of-excellence-opens-second-location-providing-ketamine-treatment-for-adults-with-depression https://www.psychedelicfinance.com/articles/cannaglobal-appoints-world-class-board-and-announces-rebranding-to-goodcap-wellness https://www.psychedelicfinance.com/articles/cannaglobal-sansero-life-sciences-and-rise-wellness-merge-to-create-a-new-international-psychedelics-company https://www.psychedelicfinance.com/articles/celia-morgan-professor-of-psychopharmacology-at-university-of-exeter-and-leading-ketamine-investigator-joins-awakn-life-sciences https://www.psychedelicfinance.com/articles/ceruvia-collaborators-dr-christopher-pittenger-and-dr-emmanuelle-schindler-to-present-at-horizons-new-york-psychedelic-research-forum https://www.psychedelicfinance.com/articles/ceruvia-lifesciences-receives-fda-investigational-new-drug-approval-for-psilocybin-obsessive-compulsive-disorder-program-phase-2-trial https://www.psychedelicfinance.com/articles/ceruvia-lifesciences-submits-fda-investigational-new-drug-application-for-nyprg-101-migraine-prevention-program https://www.psychedelicfinance.com/articles/ceruvia-lifesciences-submits-fda-investigational-new-drug-application-for-psilocybin-obsessive-compulsive-disorder-program https://www.psychedelicfinance.com/articles/ceruvia-lifesciences-to-supply-lsd-to-qualified-researchers-at-no-cost https://www.psychedelicfinance.com/articles/champignon-announces-10-000-000-bought-deal-private-placement https://www.psychedelicfinance.com/articles/champignon-announces-closing-of-15-million-bought-deal-private-placement https://www.psychedelicfinance.com/articles/champignon-announces-filing-of-business-acquisition-reports-and-appointment-of-director https://www.psychedelicfinance.com/articles/champignon-announces-regulatory-review https://www.psychedelicfinance.com/articles/champignon-announces-voluntary-share-lock-up-retains-gold-standard-media-llc-for-financial-marketing-services https://www.psychedelicfinance.com/articles/champignon-appoints-dr-bill-wilkerson-executive-chairman-of-mental-health-international-to-board-of-directors https://www.psychedelicfinance.com/articles/champignon-appoints-dr-roger-mcintyre-as-chief-executive-officer https://www.psychedelicfinance.com/articles/champignon-appoints-pat-mccutcheon-to-board-of-directors https://www.psychedelicfinance.com/articles/champignon-brands https://www.psychedelicfinance.com/articles/champignon-brands-acquires-altmed https://www.psychedelicfinance.com/articles/champignon-brands-announces-new-cfo-and-new-general-counsel https://www.psychedelicfinance.com/articles/champignon-brands-announces-revocation-of-cease-trade-orders https://www.psychedelicfinance.com/articles/champignon-brands-canadian-rapid-treatment-center-of-excellence-opens-first-community-based-centre-in-ottawa-to-provide-ketamine-treatment-for-adults-with-depression https://www.psychedelicfinance.com/articles/champignon-brands-changes-name-to-braxia-scientific-to-reflect-the-integration-of-ketamine-and-psychedelic-clinics-and-its-research-and-development-priorities https://www.psychedelicfinance.com/articles/champignon-brands-forms-north-american-clinical-expansion-committee https://www.psychedelicfinance.com/articles/champignon-brands-restates-financial-statements-and-md-a-files-listing-statement https://www.psychedelicfinance.com/articles/champignon-brands-selected-as-headline-partner-for-psych-the-psychedelics-symposium-at-prohibition-partners-live https://www.psychedelicfinance.com/articles/champignon-brands-to-restate-financial-statements-and-md-a-has-prepared-cse-listing-statement https://www.psychedelicfinance.com/articles/champignon-commences-u-s-trading-on-the-otcqb-venture-market-under-ticker-symbol-shrmf https://www.psychedelicfinance.com/articles/champignon-expands-to-u-s-to-accquire-california-based-ketamine-centre-wellness-clinic-of-orange-county https://www.psychedelicfinance.com/articles/champignon-identifies-synthetic-ketamine-and-psilocybin-psilicin-metabolite-targets-selects-dalriada-to-advance-nce-ip-portfolio https://www.psychedelicfinance.com/articles/champignon-ketamine-treatment-to-be-dispensed-by-major-canadian-pharmacy-chain-closes-altmed https://www.psychedelicfinance.com/articles/champignon-provides-corporate-update https://www.psychedelicfinance.com/articles/champignon-provides-corporate-update-announces-name-change-rebranding-and-planned-spin-out https://www.psychedelicfinance.com/articles/champignon-releases-new-video-featuring-dr-roger-mcintyre https://www.psychedelicfinance.com/articles/champignon-secures-stable-psilocybn-supply-under-dea-schedule-i-license-for-tbi-ptsd-studies-at-the-university-of-miami https://www.psychedelicfinance.com/articles/champignon-sponsors-non-profit-coalition-therapsil-medical-psilocybin-access-project-for-palliative-cancer-patients-and-health-professionals https://www.psychedelicfinance.com/articles/champignon-to-begin-offering-esketamine-treatment-for-adults-with-major-depressive-disorder-at-the-canadian-rapid-treatment-centre-of-excellence https://www.psychedelicfinance.com/articles/champignons-dr-mcintyre-canadian-rapid-treatment-centre-of-excellence-crtce-published-in-two-peer-reviewed-study-journals https://www.psychedelicfinance.com/articles/chris-koddermann https://www.psychedelicfinance.com/articles/christian-angermayer-founder-atai-life-sciences https://www.psychedelicfinance.com/articles/christopher-j-moreau-chief-executive-officer-algernon https://www.psychedelicfinance.com/articles/christopher-j-moreau-chief-executive-officer-algernon-pharmaceuticals https://www.psychedelicfinance.com/articles/clairvoyant-therapeutics-rx-initiates-first-site-for-phase-2-psilocybin-therapy-clinical-trial-for-alcohol-use-disorder https://www.psychedelicfinance.com/articles/clarmin-explorations-inc-announces-proposed-management-team-and-board-of-directors-of-the-resulting-issuer https://www.psychedelicfinance.com/articles/clarmin-explorations-inc-enters-into-amalgamation-agreement-for-reverse-takeover-with-cybin-corp https://www.psychedelicfinance.com/articles/clearmind-announces-initiation-of-cmnd-100-manufacturing-program-to-address-its-upcoming-clinical-trial https://www.psychedelicfinance.com/articles/clearmind-announces-notice-of-proposed-stock-consolidation https://www.psychedelicfinance.com/articles/clearmind-announces-pre-ind-meeting-date-with-fda https://www.psychedelicfinance.com/articles/clearmind-announces-successful-pre-ind-meeting-with-u-s-fda-for-cmnd-100-for-alcohol-use-disorder https://www.psychedelicfinance.com/articles/clearmind-applies-for-patent-to-treat-obesity-and-metabolic-syndrome https://www.psychedelicfinance.com/articles/clearmind-medicine-and-scisparc-collaboration-yields-another-patent-application-for-cocaine-addiction-treatment https://www.psychedelicfinance.com/articles/clearmind-medicine-and-scisparc-collaboration-yields-positive-results-for-its-psychedelic-combination-treatment https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-additional-positive-pre-clinical-results-for-its-cocaine-addiction-treatment https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-clinical-research-collaboration-with-johns-hopkins-university-to-evaluate-cmnd-100-in-patients-with-alcohol-use-disorder https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-clinical-supply-agreement-for-its-upcoming-clinical-trial https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-closing-of-us-7-5-million-public-offering-and-uplisting-to-the-nasdaq-capital-market https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-irb-approval-to-conduct-clinical-trial-on-alcohol-use-disorder https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-positive-results-on-cmnd-100-trials https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-pricing-of-us-3-5-million-public-offering https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-pricing-of-us-7-5-million-public-offering-and-uplisting-to-the-nasdaq-capital-market https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-shareholders-meeting-results https://www.psychedelicfinance.com/articles/clearmind-medicine-announces-successful-pre-clinical-results-in-meai-treatment-for-alcohol-consumption https://www.psychedelicfinance.com/articles/clearmind-medicine-appoints-distinguished-addiction-experts-professor-wim-van-den-brink-and-professor-gabriele-fischer-to-its-scientific-advisory-board https://www.psychedelicfinance.com/articles/clearmind-medicine-appoints-new-chief-financial-officer https://www.psychedelicfinance.com/articles/clearmind-medicine-commences-trading-on-the-frankfurt-stock-exchange https://www.psychedelicfinance.com/articles/clearmind-medicine-engages-bar-ilan-university-to-evaluate-anti-addictive-properties-of-clearminds-proprietary-meai-compound https://www.psychedelicfinance.com/articles/clearmind-medicine-establishes-third-r-d-partnership-with-the-hebrew-university https://www.psychedelicfinance.com/articles/clearmind-medicine-featured-in-psychedelics-tonight-streaming-on-altrd-tv https://www.psychedelicfinance.com/articles/clearmind-medicine-files-provisional-patent-application-related-to-methods-of-drug-assisted-psychotherapy https://www.psychedelicfinance.com/articles/clearmind-medicine-granted-patent-approval-for-psychedelic-based-alcohol-substitute-in-india https://www.psychedelicfinance.com/articles/clearmind-medicine-launches-study-for-binge-eating-with-the-hebrew-university-using-its-proprietary-meai-compound https://www.psychedelicfinance.com/articles/clearmind-medicine-now-fully-eligible-for-settlement-through-the-depository-trust-company-dtc https://www.psychedelicfinance.com/articles/clearmind-medicine-partners-with-clinipace-to-commence-processes-towards-fda-approval https://www.psychedelicfinance.com/articles/clearmind-medicine-partners-with-dr-gabor-mate-to-discuss-alcohol-use-disorder-and-trauma-in-a-special-virtual-event-on-february-3 https://www.psychedelicfinance.com/articles/clearmind-medicine-partners-with-the-hebrew-university-to-develop-novel-psychedelic-drug https://www.psychedelicfinance.com/articles/clearmind-medicine-scisparc-launch-a-psychedelic-pharma-collaboration https://www.psychedelicfinance.com/articles/clearmind-medicine-secures-cad-1-6-million-in-private-placement https://www.psychedelicfinance.com/articles/clearmind-medicine-to-fund-second-r-d-partnership-with-hebrew-universitys-technology-transfer-company https://www.psychedelicfinance.com/articles/clearmind-medicine-to-host-psychedelic-for-alcoholism-from-molecule-to-medicine-virtual-event-on-january-26 https://www.psychedelicfinance.com/articles/clearmind-medicine-to-host-psychedelics-for-alcoholism-virtual-educational-event-on-october-20 https://www.psychedelicfinance.com/articles/clearmind-medicine-to-partner-with-microdose-for-psychedelic-capital-mar-2022-on-thursday-march-24th https://www.psychedelicfinance.com/articles/clearmind-medicine-to-pioneer-psychedelic-clinical-trials-for-alcohol-use-disorder-with-ivy-league-universities https://www.psychedelicfinance.com/articles/clearmind-medicine-to-pursue-dual-listing-on-nasdaq https://www.psychedelicfinance.com/articles/clearmind-medicines-vp-of-business-development-presented-at-the-canadian-psychedelics-association-event https://www.psychedelicfinance.com/articles/clearmind-signs-development-and-supply-agreement-to-produce-its-drug-candidate-meai-psychedelic-molecule-with-aragen-life-sciences https://www.psychedelicfinance.com/articles/clearmind-strengthens-its-scientific-advisory-board-with-substance-abuse-and-mental-health-professionals https://www.psychedelicfinance.com/articles/clinical-director-of-imperial-colleges-center-for-psychedelic-research-joins-entheon-advisory-board https://www.psychedelicfinance.com/articles/clinilabs-drug-development-corporation-begins-enrollment-for-phase-1-2a-trial-evaluating-cyb003-for-the-treatment-of-major-depressive-disorder https://www.psychedelicfinance.com/articles/cluny-capital-corp-completes-its-qualifying-transaction-and-changes-its-name-to-the-good-shroom-co-inc https://www.psychedelicfinance.com/articles/codebase-ventures-inc-closes-non-brokered-private-placement https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-announces-collaboration-with-alzheimers-society-to-further-expand-its-ai-algorithms https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-announces-commercial-pilot-with-large-us-healthcare-provider https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-announces-successful-completion-of-funding-round https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-ceo-to-deliver-keynote-speech-at-collision-2022-in-toronto https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-cfo-to-speak-at-intersystems-global-summit-in-seattle-on-june-23-2022 https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-cognica-platform-successfully-monitors-cognitive-performance-in-alzheimers-patients-receiving-disease-modifying-therapy https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-collaborating-with-baylor-college-of-medicine-in-ground-breaking-study-on-ocd https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-completes-successful-pilot-and-enters-commercial-agreement-prime-health-2 https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-enters-asia-via-pilot-agreement-with-leading-singaporean-senior-care-network https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-launches-paid-pilot-project-with-ms-ad-group-companies https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-provides-update-on-2022-corporate-achievements https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-releases-latest-version-of-ai-powered-brain-health-assessment-platform https://www.psychedelicfinance.com/articles/cognetivity-neurosciences-selected-to-present-to-roche-alzheimers-team https://www.psychedelicfinance.com/articles/comp360-psilocybin-therapy-shows-potential-in-exploratory-open-label-studies-for-anorexia-nervosa-and-severe-treatment-resistant-depression https://www.psychedelicfinance.com/articles/comp360-psilocybin-therapy-shows-potential-in-open-label-study-in-type-ii-bipolar-disorder-presented-at-acnp https://www.psychedelicfinance.com/articles/compass-pathways-and-partners-launch-the-centre-for-mental-health-research-and-innovation-in-the-uk https://www.psychedelicfinance.com/articles/compass-pathways-announces-closing-of-initial-public-offering-of-american-depositary-shares-and-full-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares https://www.psychedelicfinance.com/articles/compass-pathways-announces-phase-3-pivotal-program-design-for-comp360-in-treatment-resistant-depression-at-capital-markets-day https://www.psychedelicfinance.com/articles/compass-pathways-announces-positive-outcome-of-25mg-comp360-psilocybin-therapy-as-adjunct-to-ssri-antidepressants-in-open-label-treatment-resistant-depression-study https://www.psychedelicfinance.com/articles/compass-pathways-announces-positive-topline-results-from-groundbreaking-phase-iib-trial-of-investigational-comp360-psilocybin-therapy-for-treatment-resistant-depression https://www.psychedelicfinance.com/articles/compass-pathways-announces-pricing-of-upsized-initial-public-offering https://www.psychedelicfinance.com/articles/compass-pathways-announces-publication-in-frontiers-in-psychiatry-of-paper-on-therapist-training-programme-for-psilocybin-therapy https://www.psychedelicfinance.com/articles/compass-pathways-announces-publication-of-first-study-evaluating-potential-of-ai-model-to-predict-outcomes-of-comp360-psilocybin-treatment-in-treatment-resistant-depression https://www.psychedelicfinance.com/articles/compass-pathways-announces-publication-of-phase-2b-study-of-comp360-psilocybin-therapy-for-treatment-resistant-depression-in-the-new-england-journal-of-medicine https://www.psychedelicfinance.com/articles/compass-pathways-announces-up-to-285-million-private-placement-financing-joined-by-leading-healthcare-investors https://www.psychedelicfinance.com/articles/compass-pathways-appoints-kabir-nath-as-chief-executive-officer https://www.psychedelicfinance.com/articles/compass-pathways-appoints-wayne-j-riley-md-to-its-board-of-directors https://www.psychedelicfinance.com/articles/compass-pathways-becomes-founding-supporter-of-the-british-neuroscience-associations-inaugural-scholars-programme https://www.psychedelicfinance.com/articles/compass-pathways-completes-comp360-psilocybin-therapy-administration-for-216-patients-in-large-scale-phase-iib-psilocybin-therapy-trial-for-treatment-resistant-depression https://www.psychedelicfinance.com/articles/compass-pathways-concludes-successful-80m-series-b-investment-round https://www.psychedelicfinance.com/articles/compass-pathways-establishes-centre-of-excellence-with-sheppard-pratt-to-accelerate-research-and-improve-patient-experience-in-mental-health-care https://www.psychedelicfinance.com/articles/compass-pathways-expands-its-discovery-center-through-new-collaborations-with-world-leading-scientists https://www.psychedelicfinance.com/articles/compass-pathways-granted-two-us-patents https://www.psychedelicfinance.com/articles/compass-pathways-initiates-uk-component-of-global-phase-3-study-of-psilocybin-treatment-in-treatment-resistant-depression-and-launches-new-research-center https://www.psychedelicfinance.com/articles/compass-pathways-is-granted-new-us-patent-for-crystalline-psilocybin https://www.psychedelicfinance.com/articles/compass-pathways-joins-forces-with-kings-college-london-and-south-london-and-maudsley-nhs-foundation-trust https://www.psychedelicfinance.com/articles/compass-pathways-joins-the-psychiatry-consortium-in-a-collaboration-to-accelerate-drug-discovery-in-mental-health-care https://www.psychedelicfinance.com/articles/compass-pathways-launches-phase-ii-clinical-trial-of-psilocybin-therapy-in-anorexia-nervosa https://www.psychedelicfinance.com/articles/compass-pathways-partners-with-one-mind-to-fund-rising-star-awards-for-the-next-generation-of-mental-health-researchers https://www.psychedelicfinance.com/articles/compass-pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021 https://www.psychedelicfinance.com/articles/compass-pathways-plc-announces-financial-results-and-business-highlights-for-the-second-quarter-2021 https://www.psychedelicfinance.com/articles/compass-pathways-plc-announces-financial-results-for-third-quarter-2020 https://www.psychedelicfinance.com/articles/compass-pathways-plc-announces-first-quarter-2022-financial-results-and-business-highlights https://www.psychedelicfinance.com/articles/compass-pathways-plc-to-announce-first-quarter-2022-financial-results-on-10-may-2022 https://www.psychedelicfinance.com/articles/compass-pathways-plc-to-announce-third-quarter-2020-financial-results-on-november-12-2020 https://www.psychedelicfinance.com/articles/compass-pathways-plc-to-participate-in-canaccord-genuitys-new-paradigms-and-treatment-approaches-in-mental-health-conference https://www.psychedelicfinance.com/articles/compass-pathways-plc-to-participate-in-hc-wainwright-and-icr-investor-conferences https://www.psychedelicfinance.com/articles/compass-pathways-plc-to-ring-nasdaq-stock-exchange-opening-bell-in-celebration-of-its-successful-146-6-million-ipo https://www.psychedelicfinance.com/articles/compass-pathways-presents-largest-ever-study-of-psilocybin-therapy-at-american-psychiatric-association-annual-meeting https://www.psychedelicfinance.com/articles/compass-pathways-raises-80-million-to-prepare-its-psilocybin-therapy-for-phase-3-development https://www.psychedelicfinance.com/articles/compass-pathways-secures-term-loan-facility-for-up-to-50-million-from-hercules-capital https://www.psychedelicfinance.com/articles/compass-pathways-to-fund-study-of-comp360-psilocybin-in-autistic-adults https://www.psychedelicfinance.com/articles/compass-pathways-to-launch-phase-ii-trial-of-comp360-psilocybin-therapy-for-post-traumatic-stress-disorder https://www.psychedelicfinance.com/articles/compass-pathways-to-participate-in-upcoming-citis-biopharma-virtual-co-panel-day-and-h-c-wainwright-global-investment-conference https://www.psychedelicfinance.com/articles/conor-mcgregor-brings-tidl-sport-next-generation-recovery-products-to-the-netherlands-in-an-exclusive-partnership-with-red-light-holland https://www.psychedelicfinance.com/articles/core-one-labs-acquires-gmp-drug-inc-positioning-itself-as-a-full-cycle-psychedelics-supply-chain-solution-for-clinicians-researchers-and-other-drug-developers https://www.psychedelicfinance.com/articles/core-one-labs-acquires-new-path-laboratories https://www.psychedelicfinance.com/articles/core-one-labs-akome-achieves-another-milestone-in-development-of-its-psychedelic-drug-formulas-and-announces-positive-results-from-neuro-pharmacokinetics-studies https://www.psychedelicfinance.com/articles/core-one-labs-akome-achieves-significant-research-milestone-with-positive-neurogenesis-stimulation-studies-results https://www.psychedelicfinance.com/articles/core-one-labs-akome-biotech-initiates-neurogenesis-stimulation-and-modeling-studies-advancing-its-proprietary-psychedelic-based-pharmaceutical-formulations https://www.psychedelicfinance.com/articles/core-one-labs-akome-biotech-protects-new-ako003-ketamine-based-breakthrough-drug-formulation-for-depression-treatment https://www.psychedelicfinance.com/articles/core-one-labs-akome-biotech-signs-research-agreement-with-university-of-barcelona-faculty-of-pharmacy-and-food-sciences https://www.psychedelicfinance.com/articles/core-one-labs-akome-receives-positive-results-from-bioassay-studies https://www.psychedelicfinance.com/articles/core-one-labs-akome-seeks-to-revolutionize-treatment-of-parkinsons-disease-and-submits-application-to-protect-ip https://www.psychedelicfinance.com/articles/core-one-labs-akome-signs-contract-with-university-of-barcelona-initiating-animal-model-studies-on-psychedelics-drug-development-to-combat-a-variety-of-neurological-diseases https://www.psychedelicfinance.com/articles/core-one-labs-akome-signs-contract-with-university-of-barcelona-initiating-animal-model-studies-on-psychedelics-drug-development-to-combat-a-variety-of-neurological-diseases-2 https://www.psychedelicfinance.com/articles/core-one-labs-announces-adding-video-conference-capabilities-to-teleconference-call-scheduled-for-february-10-2021-1-30-p-m-pst-4-30-p-m-est https://www.psychedelicfinance.com/articles/core-one-labs-announces-breakthrough-in-solving-psilocybin-dosing-problems-by-introducing-biosynthetic-psilocybin-to-its-patented-thinstrip-delivery-method https://www.psychedelicfinance.com/articles/core-one-labs-announces-breakthrough-with-proprietary-isolation-and-purification-method-of-psilocybin-from-mushrooms-prepares-patent-application https://www.psychedelicfinance.com/articles/core-one-labs-announces-details-of-consolidation-to-meet-nasdaq-listing-requirements https://www.psychedelicfinance.com/articles/core-one-labs-announces-effective-date-of-share-consolidation https://www.psychedelicfinance.com/articles/core-one-labs-announces-its-entrance-into-the-ketamine-space-with-proposed-acquisition-of-ketamine-infusion-centers-of-texas https://www.psychedelicfinance.com/articles/core-one-labs-announces-resumption-of-trading https://www.psychedelicfinance.com/articles/core-one-labs-announces-successful-proof-of-concept-for-biosynthetic-n-methyltryptamine-nmt https://www.psychedelicfinance.com/articles/core-one-labs-announces-vocan-assembles-equipment-to-produce-biosynthesized-psilocybin https://www.psychedelicfinance.com/articles/core-one-labs-appoints-dr-stephen-peach-as-head-of-patient-research https://www.psychedelicfinance.com/articles/core-one-labs-appoints-new-chief-financial-officer https://www.psychedelicfinance.com/articles/core-one-labs-appoints-patent-expert-dr-dan-polonenko-to-advisory-board https://www.psychedelicfinance.com/articles/core-one-labs-biosynthesized-psilocybin-provisional-patent-imminent https://www.psychedelicfinance.com/articles/core-one-labs-clinics-submit-application-to-treat-patient-with-psilocybin-psychedelic-assisted-therapy https://www.psychedelicfinance.com/articles/core-one-labs-commences-development-on-patent-pending-psychedelic-drug-formulation-for-the-treatment-of-alzheimers-disease https://www.psychedelicfinance.com/articles/core-one-labs-completes-acquisition-of-interest-in-medical-clinic https://www.psychedelicfinance.com/articles/core-one-labs-completes-acquisition-of-ketamine-infusions-centers-of-texas-representing-the-companys-first-psychedelics-clinic-in-the-u-s-and-announces-fast-entry-inclusion-in-the-horizons-psychedelic-etf https://www.psychedelicfinance.com/articles/core-one-labs-completes-acquisition-of-vocan-biotechnologies-inc https://www.psychedelicfinance.com/articles/core-one-labs-completes-audit-starts-review-of-ops https://www.psychedelicfinance.com/articles/core-one-labs-completes-milestone-acquisition-of-akome-biotech https://www.psychedelicfinance.com/articles/core-one-labs-completes-sale-of-non-core-assets https://www.psychedelicfinance.com/articles/core-one-labs-completes-strategic-acquisition-of-awakened-biosciences-and-its-game-changing-provisional-patents https://www.psychedelicfinance.com/articles/core-one-labs-engages-donohoe-advisory-for-nasdaq-listing-and-schedules-special-investor-call-with-dr-robert-e-w-hancock-to-demonstrate-recent-research-outcome https://www.psychedelicfinance.com/articles/core-one-labs-expects-imminent-breakthrough-to-produce-nmt-precursor-to-dmt https://www.psychedelicfinance.com/articles/core-one-labs-files-application-to-list-its-common-shares-on-nasdaq https://www.psychedelicfinance.com/articles/core-one-labs-files-milestone-patent-for-protection-of-its-recombinant-production-system-for-optimized-biosynthetic-n-methyltryptamine-nmt https://www.psychedelicfinance.com/articles/core-one-labs-finalizes-deal-to-acquire-ketamine-infusions-centers-of-texas-entering-the-us-market-for-psychedelic-treatments https://www.psychedelicfinance.com/articles/core-one-labs-highlights-key-points-from-international-investor-call https://www.psychedelicfinance.com/articles/core-one-labs-in-collaboration-with-kict-to-explore-dmt-assisted-psychotherapy https://www.psychedelicfinance.com/articles/core-one-labs-initiates-first-strain-production-for-biosynthetic-psilocybin https://www.psychedelicfinance.com/articles/core-one-labs-initiates-first-strain-production-for-biosynthetic-psilocybin-2 https://www.psychedelicfinance.com/articles/core-one-labs-nearing-gmp-production-as-canadas-province-of-alberta-announces-game-changing-legislation https://www.psychedelicfinance.com/articles/core-one-labs-negotiates-milestone-acquisition-with-akome-biotech-ltd https://www.psychedelicfinance.com/articles/core-one-labs-plans-share-consolidation-in-preparation-of-listing-its-common-shares-on-nasdaq https://www.psychedelicfinance.com/articles/core-one-labs-prepares-first-in-series-of-patent-applications https://www.psychedelicfinance.com/articles/core-one-labs-prepares-for-commercial-production-of-api-grade-psilocybin-plans-initial-production-run-at-gmp-facility-in-january https://www.psychedelicfinance.com/articles/core-one-labs-proceeds-with-next-milestone-achievement-to-produce-psilocybin https://www.psychedelicfinance.com/articles/core-one-labs-reaches-definitive-agreement-to-acquire-akome-biotech https://www.psychedelicfinance.com/articles/core-one-labs-retains-canadas-highest-ranked-ip-law-firm-to-assist-with-patent-filings https://www.psychedelicfinance.com/articles/core-one-labs-scientists-successfully-complete-breakthrough-first-step-in-producing-api-grade-dmt https://www.psychedelicfinance.com/articles/core-one-labs-signs-definitive-agreement-for-acquisition-of-biosynthetic-psilocybin-research-firm-vocan-biotechnologies-inc https://www.psychedelicfinance.com/articles/core-one-labs-signs-letter-of-intent-to-acquire-vocan-viotechnologies https://www.psychedelicfinance.com/articles/core-one-labs-signs-letter-of-intent-to-sell-certain-assets https://www.psychedelicfinance.com/articles/core-one-labs-signs-letter-of-intent-with-gmp-manufacturing-partner-for-production-of-proprietary-psychedelic-compounds https://www.psychedelicfinance.com/articles/core-one-labs-subsidiary-vocan-to-work-with-former-canopy-ceo-mr-marcelo-galvao-to-license-bio-synthesized-psilocybin-in-brazil https://www.psychedelicfinance.com/articles/core-one-labs-successful-patent-application-filing-for-protection-of-its-biosynthetic-production-system-for-psilocybin-marks-a-significant-milestone-for-the-progression-of-psychedelic-health-care https://www.psychedelicfinance.com/articles/core-one-labs-takes-next-steps-to-prepare-for-potential-takeover-opportunities https://www.psychedelicfinance.com/articles/core-one-labs-to-commence-trading-in-the-us-on-otc-pink-market https://www.psychedelicfinance.com/articles/core-one-labs-to-explore-joint-venture-with-lobe-sciences-for-the-clinical-development-of-biosynthetic-psilocybin https://www.psychedelicfinance.com/articles/core-one-labs-to-investigate-soliciting-investment-and-potential-takeover-opportunities https://www.psychedelicfinance.com/articles/core-one-labs-to-move-its-psychedelic-formulations-for-the-treatment-of-stroke-and-depression-toward-clinical-development https://www.psychedelicfinance.com/articles/core-one-labs-to-rescind-share-exchange-with-plant-based-investment-corp https://www.psychedelicfinance.com/articles/core-one-labs-upgrades-to-otcqb-venture-market https://www.psychedelicfinance.com/articles/core-one-labs-virtual-town-hall-reveals-company-is-nearing-production-of-biosynthesized-psilocybin-breakthrough-in-the-psychedelic-space-expected-upon-successful-completion https://www.psychedelicfinance.com/articles/core-one-labs-vocan-biotechnologies-enters-into-collaborative-research-agreement-with-ubc https://www.psychedelicfinance.com/articles/core-one-labs-vocan-expands-product-commercialization-team https://www.psychedelicfinance.com/articles/core-one-labs-vocan-initiates-engineering-and-design-of-a-proprietary-production-system-for-manufacturing-of-api-grade-dmt https://www.psychedelicfinance.com/articles/core-one-labs-vocan-successfully-converts-psilocin-precursor-into-psilocybin https://www.psychedelicfinance.com/articles/core-one-labs-vocan-successfully-converts-psilocin-precursor-into-psilocybin-2 https://www.psychedelicfinance.com/articles/core-one-rolls-out-commercial-sales-strategy-for-its-revolutionary-api-grade-biosynthetic-psilocybin https://www.psychedelicfinance.com/articles/core-ones-dr-robert-e-w-hancock-to-host-virtual-townhall-webcast-and-present-on-proprietary-biosynthesized-psilocybin-wednesday-august-4-2021 https://www.psychedelicfinance.com/articles/core-ones-vocan-biotechnologies-and-awakened-biosciences-collaborate-to-advance-vocans-mass-production-capabilities https://www.psychedelicfinance.com/articles/corporate-update-tgsc-signs-retail-agency-agreement-for-the-us-market-and-engages-market-maker https://www.psychedelicfinance.com/articles/creso-pharma-and-red-light-holland-merge-to-introduce-the-highbrid-lab-tm https://www.psychedelicfinance.com/articles/creso-pharma-completes-us-otc-dual-listing https://www.psychedelicfinance.com/articles/creso-pharma-receives-commitments-totaling-a-18m https://www.psychedelicfinance.com/articles/creso-pharma-secures-first-purchase-order-from-red-light-holland-to-sell-hemp-cbd-products-in-the-netherlands https://www.psychedelicfinance.com/articles/creso-pharma-signs-agreement-to-acquire-established-canadian-psychedelics-company-halucenex-life-sciences-inc https://www.psychedelicfinance.com/articles/cse-bulletin-delist-field-trip-health-ltd-ftrp-ftrp-wt https://www.psychedelicfinance.com/articles/cube-psytech-enters-into-supply-agreement-with-psygen-labs https://www.psychedelicfinance.com/articles/cube-psytech-receives-site-plan-approval-to-build-45-000-sq-ft-facility-for-psychedelic-mushrooms https://www.psychedelicfinance.com/articles/cube-psytech-signs-exclusive-supply-agreement-with-havn-life https://www.psychedelicfinance.com/articles/cybin-achieves-research-and-development-milestones-ahead-of-projected-timelines https://www.psychedelicfinance.com/articles/cybin-acquires-dmt-clinical-study-from-entheon-biomedical https://www.psychedelicfinance.com/articles/cybin-advances-ind-enabling-studies-of-two-psychedelic-molecules-cyb003-and-cyb004-for-investigational-new-drug-applications https://www.psychedelicfinance.com/articles/cybin-and-clarmin-announce-closing-of-cdn-45-million-oversubscribed-private-placement-and-provide-update-on-rto https://www.psychedelicfinance.com/articles/cybin-and-clinilabs-granted-schedule-i-dea-license-for-cyb003-phase-1-2a-first-in-human-clinical-trial https://www.psychedelicfinance.com/articles/cybin-and-kernel-announce-results-from-kernel-flow-r-piloting-of-feasibility-study-measuring-ketamines-effects-on-the-brain https://www.psychedelicfinance.com/articles/cybin-announces-additional-adelia-milestone-achievement https://www.psychedelicfinance.com/articles/cybin-announces-additional-adelia-milestone-achievement-2 https://www.psychedelicfinance.com/articles/cybin-announces-additional-adelia-milestone-achievement-3 https://www.psychedelicfinance.com/articles/cybin-announces-additional-adelia-milestone-achievement-4 https://www.psychedelicfinance.com/articles/cybin-announces-additional-adelia-milestone-achievement-5 https://www.psychedelicfinance.com/articles/cybin-announces-additional-adelia-milestone-achievements https://www.psychedelicfinance.com/articles/cybin-announces-additional-adelia-milestone-achievements-2 https://www.psychedelicfinance.com/articles/cybin-announces-additional-adelia-milestone-achievements-3 https://www.psychedelicfinance.com/articles/cybin-announces-agreement-with-fluence-to-support-scaling-of-embark-training-for-cyb003-phase-3-trial https://www.psychedelicfinance.com/articles/cybin-announces-api-synthesis-and-optimization-of-multiple-tryptamine-derivatives-and-nomination-of-two-deuterated-candidates-for-full-ind-enabling-studies-based-on-second-milestone-achievement-pursuant-to-the-adelia-acquisition https://www.psychedelicfinance.com/articles/cybin-announces-api-synthesis-of-multiple-tryptamine-derivatives-based-on-the-first-milestone-achievement-pursuant-to-the-adelia-acquisition https://www.psychedelicfinance.com/articles/cybin-announces-appointment-of-dr-amir-inamdar-as-chief-medical-officer-for-european-operations-and-dr-geoff-varty-as-the-head-of-research-and-development https://www.psychedelicfinance.com/articles/cybin-announces-approval-of-first-in-human-dosing-of-its-proprietary-dmt-molecule-cyb004 https://www.psychedelicfinance.com/articles/cybin-announces-cdn-20-million-bought-deal-offering https://www.psychedelicfinance.com/articles/cybin-announces-closing-of-offering-of-units-led-by-one-of-the-companys-largest-institutional-shareholders https://www.psychedelicfinance.com/articles/cybin-announces-closing-of-overnight-marketed-public-offering-of-common-shares-and-exercise-of-over-allotment-option https://www.psychedelicfinance.com/articles/cybin-announces-closing-of-upsized-bought-deal-offering https://www.psychedelicfinance.com/articles/cybin-announces-completion-of-74-pre-clinical-studies https://www.psychedelicfinance.com/articles/cybin-announces-completion-of-its-51st-pre-clinical-psychedelic-molecule-study https://www.psychedelicfinance.com/articles/cybin-announces-conditional-listing-approval-from-nyse-american https://www.psychedelicfinance.com/articles/cybin-announces-cyb003-poster-to-be-presented-at-the-from-research-to-reality-global-summit-on-psychedelic-assisted-therapies-and-medicine https://www.psychedelicfinance.com/articles/cybin-announces-date-of-annual-meeting-of-shareholders https://www.psychedelicfinance.com/articles/cybin-announces-embark-open-access-the-first-free-online-course-providing-facilitator-training-for-psychedelic-therapy https://www.psychedelicfinance.com/articles/cybin-announces-fda-investigational-new-drug-and-institutional-review-board-approvals-for-a-co-funded-phase-2-clinical-trial-to-treat-frontline-clinicians https://www.psychedelicfinance.com/articles/cybin-announces-fda-investigational-new-drug-authorization-of-cybins-sponsored-feasibility-study-using-kernel-flow-technology https://www.psychedelicfinance.com/articles/cybin-announces-final-adelia-milestone-achievement https://www.psychedelicfinance.com/articles/cybin-announces-former-fda-psychiatry-division-director-dr-thomas-laughren-has-joined-clinical-advisory-board https://www.psychedelicfinance.com/articles/cybin-announces-grant-of-european-patent-protecting-its-proprietary-deuterated-programs https://www.psychedelicfinance.com/articles/cybin-announces-grant-of-two-new-united-states-patents-protecting-its-deuterated-dmt-program https://www.psychedelicfinance.com/articles/cybin-announces-grant-of-u-s-patent-covering-its-proprietary-compound-cyb004-deuterated-dmt-for-the-treatment-of-anxiety-disorders https://www.psychedelicfinance.com/articles/cybin-announces-grant-of-u-s-patent-covering-proprietary-deuterated-psilocybin-analog-in-its-cyb003-program https://www.psychedelicfinance.com/articles/cybin-announces-initiation-of-kernel-flow-r-feasibility-study-measuring-psychedelic-effects-on-the-brain https://www.psychedelicfinance.com/articles/cybin-announces-last-subject-dosed-in-part-b-of-its-phase-1-cyb004-e-trial https://www.psychedelicfinance.com/articles/cybin-announces-launch-of-embark-psychedelic-facilitator-training-program https://www.psychedelicfinance.com/articles/cybin-announces-overnight-marketed-public-offering-of-common-shares https://www.psychedelicfinance.com/articles/cybin-announces-phase-2-cohort-5-dosing-completion-of-cyb003-in-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybin-announces-positive-cyb003-data-demonstrating-significant-advantages-over-oral-psilocybin-for-treatment-of-mental-health https://www.psychedelicfinance.com/articles/cybin-announces-positive-cyb004-data-demonstrating-significant-advantages-over-intravenous-and-inhaled-dmt https://www.psychedelicfinance.com/articles/cybin-announces-positive-pre-clinical-results-with-multiple-proprietary-psychedelic-molecules-and-adelia-milestone-achievement https://www.psychedelicfinance.com/articles/cybin-announces-promising-results-from-sponsored-kernel-flow-r-feasibility-study-measuring-psychedelic-effects-on-the-brain https://www.psychedelicfinance.com/articles/cybin-announces-publication-in-frontiers-in-psychology-journal-introducing-embark-an-integrative-model-of-psychedelic-therapy https://www.psychedelicfinance.com/articles/cybin-announces-publication-of-international-pct-patent-application-for-inhalation-delivery-of-multiple-psychedelic-molecules https://www.psychedelicfinance.com/articles/cybin-announces-publication-of-sponsored-feasibility-study-validating-kernels-flow1-neuroimaging-technology-measuring-psychedelic-effects-on-the-brain https://www.psychedelicfinance.com/articles/cybin-announces-results-of-shareholders-meeting https://www.psychedelicfinance.com/articles/cybin-announces-roster-of-28-expert-faculty-and-advisors-for-its-embark-psychedelic-facilitator-training-program https://www.psychedelicfinance.com/articles/cybin-announces-scientific-presentation-at-the-5th-annual-neuropsychiatric-psychedelics-drug-development-summit https://www.psychedelicfinance.com/articles/cybin-announces-senior-management-changes-to-lead-buildout-of-development-and-clinical-capabilities-in-the-united-states-and-europe https://www.psychedelicfinance.com/articles/cybin-announces-size-and-pricing-of-previously-announced-overnight-marketed-public-offering-of-common-shares https://www.psychedelicfinance.com/articles/cybin-announces-sponsorship-of-a-kernel-flow-feasibility-study-to-measure-ketamines-psychedelic-effects-on-cerebral-cortex-hemodynamics https://www.psychedelicfinance.com/articles/cybin-announces-streamlined-clinical-alignment https://www.psychedelicfinance.com/articles/cybin-announces-successful-completion-of-in-vivo-preclinical-studies-for-its-deuterated-psilocybin-analog-cyb003-supporting-advancement-into-phase-1-2a-clinical-trial https://www.psychedelicfinance.com/articles/cybin-announces-the-development-of-a-scalable-psychedelic-facilitation-training-program-embarkct https://www.psychedelicfinance.com/articles/cybin-announces-up-to-usd-35-million-at-the-market-equity-program https://www.psychedelicfinance.com/articles/cybin-announces-upsize-to-previously-announced-bought-deal-offering https://www.psychedelicfinance.com/articles/cybin-applauds-therapsils-advocacy-to-bring-psilocybin-therapy-to-palliative-care-of-canadian-patients https://www.psychedelicfinance.com/articles/cybin-awarded-notice-of-allowance-from-u-s-patent-and-trademark-office-for-cyb004-deuterated-psychedelic-tryptamine-for-the-treatment-of-anxiety-disorders https://www.psychedelicfinance.com/articles/cybin-awards-grant-for-psychedelic-treatment-clinic-at-lenox-hill-hospital-to-benefit-underserved-communities https://www.psychedelicfinance.com/articles/cybin-closes-acquisition-of-adelia-therapeutics-bolsters-scientific-team-and-grows-ip-portfolio-to-7-patent-filings https://www.psychedelicfinance.com/articles/cybin-completes-acquisition-of-phase-1-dmt-study-from-entheon-biomedical https://www.psychedelicfinance.com/articles/cybin-completes-acquisition-of-small-pharma-inc-to-create-international-clinical-stage-leader-in-novel-psychedelic-therapeutics https://www.psychedelicfinance.com/articles/cybin-completes-reverse-take-over-transaction https://www.psychedelicfinance.com/articles/cybin-confirms-scientific-advice-meeting-with-uk-medical-and-healthcare-products-regulatory-agency-for-lead-candidate-cyb003-for-the-treatment-of-major-depressive-disorder-and-alcohol-use-disorder https://www.psychedelicfinance.com/articles/cybin-corp-and-intelgenx-corp-enter-into-feasibility-agreement-for-fast-acting-orally-dissolving-psilocybin-film https://www.psychedelicfinance.com/articles/cybin-corp-announces-doug-drysdale-as-chief-executive-officer https://www.psychedelicfinance.com/articles/cybin-corp-announces-partnership-with-the-toronto-centre-for-psychedelic-science https://www.psychedelicfinance.com/articles/cybin-corp-announces-reverse-take-over-transaction-and-the-engagement-of-stifel-gmp-and-eight-capital-to-co-lead-concurent-private-placement-of-up-to-21m https://www.psychedelicfinance.com/articles/cybin-corp-feature https://www.psychedelicfinance.com/articles/cybin-demonstrates-proof-of-concept-of-its-deuterated-tryptamines-for-the-treatment-of-depression-and-addiction https://www.psychedelicfinance.com/articles/cybin-enters-into-collaboration-agreement-with-greenbrook-tms-to-establish-mental-health-centers-of-excellence https://www.psychedelicfinance.com/articles/cybin-establishes-clinical-advisory-board-of-renowned-physicians-dr-maurizio-fava-dr-lynn-marie-morski-and-dr-anthony-back https://www.psychedelicfinance.com/articles/cybin-expands-to-europe-and-provides-update-on-intellectual-property-portfolio https://www.psychedelicfinance.com/articles/cybin-files-14th-patent-application-further-strengthening-its-ip-portfolio-and-receives-a-favorable-patent-claim-opinion https://www.psychedelicfinance.com/articles/cybin-files-an-international-patent-application-covering-psychedelic-delivery-methods https://www.psychedelicfinance.com/articles/cybin-files-an-international-patent-application-further-strengthening-its-psychedelic-derivative-drug-development-candidates-across-153-global-jurisdictions https://www.psychedelicfinance.com/articles/cybin-files-its-12th-patent-further-strengthening-ip-portfolio-of-novel-psychedelic-molecules-and-delivery-mechanisms https://www.psychedelicfinance.com/articles/cybin-files-its-13th-patent-application-and-announces-digital-therapeutics-strategy https://www.psychedelicfinance.com/articles/cybin-files-two-additional-international-patent-applications-in-support-of-the-companys-research-phase-programs https://www.psychedelicfinance.com/articles/cybin-goes-public-on-the-neo-exchange https://www.psychedelicfinance.com/articles/cybin-granted-dea-schedule-i-manufacturing-license https://www.psychedelicfinance.com/articles/cybin-granted-irb-approval-for-phase-ii-clinical-trials-of-its-sublingual-psilocybin-formulation-for-the-treatment-of-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybin-highlights-2022-accomplishments-and-milestones https://www.psychedelicfinance.com/articles/cybin-hosting-research-and-development-briefing-on-november-8-2021 https://www.psychedelicfinance.com/articles/cybin-inc-announces-2021-first-quarter-financial-results-and-business-highlights https://www.psychedelicfinance.com/articles/cybin-inc-announces-first-participants-dosed-in-its-phase-1-2a-trial-of-cyb003-for-the-treatment-of-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybin-inc-announces-uplisting-to-otcqb-venture-market https://www.psychedelicfinance.com/articles/cybin-inc-presents-cyb003-preclinical-data-at-neuroscience-2022 https://www.psychedelicfinance.com/articles/cybin-inc-releases-annual-financials-and-provides-business-highlights https://www.psychedelicfinance.com/articles/cybin-inc-releases-financial-highlights-and-provides-business-update https://www.psychedelicfinance.com/articles/cybin-inc-reports-fiscal-year-2022-financial-results-and-recent-business-highlights https://www.psychedelicfinance.com/articles/cybin-inc-reports-its-second-quarter-financial-results-and-recent-business-highlights https://www.psychedelicfinance.com/articles/cybin-inc-reports-third-quarter-financial-results-and-recent-business-highlights https://www.psychedelicfinance.com/articles/cybin-inc-shares-commence-trading-on-the-otcqb-venture-market-on-march-8-2021 https://www.psychedelicfinance.com/articles/cybin-included-in-first-psychedelic-exchange-traded-fund https://www.psychedelicfinance.com/articles/cybin-initiates-dosing-of-final-cohort-of-its-phase-2-trial-of-cyb003-in-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybin-initiates-first-in-human-dosing-of-cyb004-in-phase-1-clinical-trial https://www.psychedelicfinance.com/articles/cybin-launches-embark-and-co-sponsors-first-clinical-trial-to-treat-frontline-clinicians-experiencing-burnout-and-distress-with-psychedelic-assisted-psychotherapy https://www.psychedelicfinance.com/articles/cybin-obtains-exclusive-license-to-a-novel-catalog-of-psychedelic-based-compounds https://www.psychedelicfinance.com/articles/cybin-outlines-upcoming-priorities-and-milestones-for-its-clinical-development-programs https://www.psychedelicfinance.com/articles/cybin-partners-with-clinilabs-drug-development-corporation-for-phase-1-2a-trial-evaluating-cyb003-for-the-treatment-of-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybin-partners-with-kernel-to-leverage-its-breakthrough-neuroimaging-technology-for-psychedelic-therapeutics https://www.psychedelicfinance.com/articles/cybin-partners-with-worldwide-clinical-trials-to-support-future-clinical-development-of-cyb003-in-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybin-presents-cyb003-preclinical-data-at-2022-american-college-of-neuropsychopharmacology-annual-meeting https://www.psychedelicfinance.com/articles/cybin-progresses-two-psychedelic-investigational-new-drug-ind-candidates-and-announces-completion-of-its-20th-pre-clinical-study https://www.psychedelicfinance.com/articles/cybin-provides-2021-year-end-summary https://www.psychedelicfinance.com/articles/cybin-provides-update-on-its-intellectual-property-portfolio https://www.psychedelicfinance.com/articles/cybin-provides-update-on-patent-filings-development-of-therapeutics-program https://www.psychedelicfinance.com/articles/cybin-receives-fda-ind-clearance-for-its-phase-1-2a-clinical-trial-evaluating-cyb003-for-the-potential-treatment-of-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybin-receives-final-approval-to-commence-trading-on-the-nyse-american-on-or-about-august-5 https://www.psychedelicfinance.com/articles/cybin-receives-institutional-review-board-approval-for-its-phase-1-2a-clinical-trial-evaluating-cyb003-for-the-treatment-of-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybin-selects-alcohol-use-disorder-indication-for-psychedelic-molecule-cyb003 https://www.psychedelicfinance.com/articles/cybin-selects-anxiety-disorder-indications-for-proprietary-psychedelic-molecule-cyb004 https://www.psychedelicfinance.com/articles/cybin-selects-generalized-anxiety-disorder-as-target-indication-for-deuterated-dmt-molecule-cyb004 https://www.psychedelicfinance.com/articles/cybin-signs-definitive-agreement-to-acquire-adelia-therapeutics-as-part-of-its-commitment-to-strategic-growth https://www.psychedelicfinance.com/articles/cybin-signs-drug-development-agreement-with-catalent-for-its-fast-dissolve-formulation-of-novel-deuterated-tryptamine-cyb003 https://www.psychedelicfinance.com/articles/cybin-sponsored-feasibility-study-using-kernel-flow-technology-currently-recruiting-participants https://www.psychedelicfinance.com/articles/cybin-submits-ind-application-to-fda-for-its-phase-1-2a-first-in-human-trial-of-cyb003-for-the-treatment-of-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybin-the-chopra-foundation-recognize-world-mental-health-day https://www.psychedelicfinance.com/articles/cybin-to-acquire-small-pharma-inc https://www.psychedelicfinance.com/articles/cybin-to-announce-second-quarter-fy2021-financial-results-and-business-update-on-november-15-2021 https://www.psychedelicfinance.com/articles/cybin-to-announce-third-quarter-financial-results-and-business-update-on-february-10-2022 https://www.psychedelicfinance.com/articles/cybin-to-commence-trading-on-the-nyse-american-on-august-5 https://www.psychedelicfinance.com/articles/cybin-to-host-key-opinion-leader-webinar-on-june-9-2022 https://www.psychedelicfinance.com/articles/cybin-to-host-virtual-r-d-day-on-february-28-2023 https://www.psychedelicfinance.com/articles/cybin-to-participate-in-aegis-virtual-conference-on-february-24-2022 https://www.psychedelicfinance.com/articles/cybin-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-virtual-summit-on-july-13th https://www.psychedelicfinance.com/articles/cybin-to-participate-in-grizzle-psychedelics-con-on-june-28th https://www.psychedelicfinance.com/articles/cybin-to-participate-in-nyse-trading-bell-ceremony-on-may-18-2022 https://www.psychedelicfinance.com/articles/cybin-to-participate-in-the-11th-annual-lifesci-partners-corporate-access-event-and-h-c-wainwright-bioconnect-conference https://www.psychedelicfinance.com/articles/cybin-to-participate-in-the-2022-maxim-group-virtual-growth-conference-on-march-28-30-2022 https://www.psychedelicfinance.com/articles/cybin-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference https://www.psychedelicfinance.com/articles/cybin-to-participate-in-the-kcsa-psychedelics-virtual-investor-conference-on-april-28-2022 https://www.psychedelicfinance.com/articles/cybin-to-participate-in-the-oppenheimer-32nd-annual-healthcare-conference https://www.psychedelicfinance.com/articles/cybin-to-participate-in-upcoming-scientific-and-investor-conferences https://www.psychedelicfinance.com/articles/cybin-to-present-at-canaccord-genuitys-41st-annual-growth-conference-on-august-10th https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-2021-ld-micro-invitational-xi-on-june-10-2021 https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-benzinga-global-small-cap-conference https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-benzinga-psychedelics-capital-conference-in-miami-on-april-19-2022 https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-bloom-burton-co-healthcare-investor-conference https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-emerging-growth-conference-on-june-23rd https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-h-c-wainwright-1st-annual-mental-health-conference-on-june-27-2022 https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-on-september-13th https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-h-c-wainwright-global-investment-conference-on-may-25-2022 https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-h-c-wainwright-psychedelics-in-psychiatry-and-beyond-virtual-conference-on-june-17th https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-jefferies-london-healthcare-conference https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-jefferies-virtual-healthcare-conference-2021 https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-m-vest-and-maxim-group-2021-emerging-growth-virtual-conference https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-oppenheimer-31st-annual-healthcare-conference https://www.psychedelicfinance.com/articles/cybin-to-present-at-the-stifel-gmp-healthcare-conference-healthcare-psychedelics-addressing-the-global-mental-health-crisis https://www.psychedelicfinance.com/articles/cybin-to-present-at-upcoming-cantor-and-benzinga-investor-conferences https://www.psychedelicfinance.com/articles/cybin-to-provide-business-update-on-february-17-2021-conference-call https://www.psychedelicfinance.com/articles/cybin-video-profile https://www.psychedelicfinance.com/articles/cybins-cyb003-demonstrates-remarkable-interim-data-in-treating-major-depressive-disorder https://www.psychedelicfinance.com/articles/cybins-embark-program-announces-graduation-of-facilitators https://www.psychedelicfinance.com/articles/damon-michaels https://www.psychedelicfinance.com/articles/dan-clauw-tryp-therapeutics https://www.psychedelicfinance.com/articles/dane-stevens-cmo-director-optimi-health https://www.psychedelicfinance.com/articles/daniel-carcillo-founder-and-ceo-wesana-health https://www.psychedelicfinance.com/articles/daniel-cohen-ceo-pharmadrug https://www.psychedelicfinance.com/articles/david-harder-founder-co-ceo-atma-journey-centers https://www.psychedelicfinance.com/articles/delic-2021-revenue-shows-strong-growth-as-nations-largest-ketamine-clinic-chain-continues-expansion-of-mental-health-wellness-services https://www.psychedelicfinance.com/articles/delic-announces-postponement-of-meet-delic-conference https://www.psychedelicfinance.com/articles/delic-announces-two-key-executive-appointments https://www.psychedelicfinance.com/articles/delic-corp-to-present-on-strategy-and-expansion-of-nations-largest-ketamine-clinic-network-at-h-c-wainwright-annual-global-investment-conference https://www.psychedelicfinance.com/articles/delic-corp-to-present-vision-for-long-term-growth-and-industry-leading-clinic-developments-at-first-annual-h-c-wainwright-mental-health-conference https://www.psychedelicfinance.com/articles/delic-executive-chairman-matt-stang-named-to-world-biz-magazines-top-100-ceos-in-innovation https://www.psychedelicfinance.com/articles/delic-holdings-corp-announces-filing-of-annual-documents https://www.psychedelicfinance.com/articles/delic-holdings-corp-signs-loi-with-peter-petramd-to-acquire-ketamine-wellness-centers-and-facilitate-online-ketamine-treatments-nationwide https://www.psychedelicfinance.com/articles/delic-labs-president-and-cso-dr-markus-roggen-to-discuss-the-importance-of-r-d-for-business-growth-at-mjbizcon https://www.psychedelicfinance.com/articles/delic-labs-to-present-on-psychedelics-cannabis-extraction-at-grow-up-conference-and-expo https://www.psychedelicfinance.com/articles/delix-therapeutics-expands-world-class-team-with-first-head-of-r-d https://www.psychedelicfinance.com/articles/demerx-doses-first-subject-in-phase-1-2a-study-of-dmx-1002-ibogaine-in-opioid-use-disorder https://www.psychedelicfinance.com/articles/diamond-therapeutics-announces-first-patient-dosed-in-health-canada-approved-trial-evaluating-low-dose-psilocybin https://www.psychedelicfinance.com/articles/diamond-therapeutics-announces-health-canada-approval-of-clinical-trial-with-low-dose-psilocybin https://www.psychedelicfinance.com/articles/diamond-therapeutics-appoints-renowned-psychiatrist-and-author-dr-torsten-passie-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/diamond-therapeutics-contracts-biopharma-services-for-phase-1-clinical-trial https://www.psychedelicfinance.com/articles/diamond-therapeutics-hires-industry-veteran-david-brown-phd-to-further-advance-formulation-of-psilocybin https://www.psychedelicfinance.com/articles/diamond-therapeutics-quantified-citizen-and-ontario-brain-institute-launch-attitudes-towards-psychedelics-study https://www.psychedelicfinance.com/articles/diamond-therapeutics-signs-agreement-with-mcgill-university-for-research-on-low-dose-lsd https://www.psychedelicfinance.com/articles/diamond-therapeutics-to-present-groundbreaking-study-at-nih-event https://www.psychedelicfinance.com/articles/distinguished-psychedelic-researcher-professor-of-psychiatry-and-neuroscience-rachel-yehuda-phd-joins-wesana-health-scientific-advisory-board https://www.psychedelicfinance.com/articles/doug-drysdale-ceo-cybin-corp https://www.psychedelicfinance.com/articles/doug-drysdale-ceo-cybin-corp-2 https://www.psychedelicfinance.com/articles/douglas-k-gordan-ceo-silo-wellness https://www.psychedelicfinance.com/articles/dr-alan-k-davis-clinical-psychologist-and-the-director-at-ohio-state-university https://www.psychedelicfinance.com/articles/dr-albert-garcia-romeu-assistant-professor-johns-hopkins-university-school-of-medicine https://www.psychedelicfinance.com/articles/dr-carl-laird-birmingham-advisory-board-consultant-neonmind https://www.psychedelicfinance.com/articles/dr-corey-hilmas-kgk-chief-regulatory-officer https://www.psychedelicfinance.com/articles/dr-dan-engle-joins-mind-cures-advisory-board https://www.psychedelicfinance.com/articles/dr-david-e-nichols https://www.psychedelicfinance.com/articles/dr-david-mokler-havn-life-sciences https://www.psychedelicfinance.com/articles/dr-david-nutt-dmt-stroke-consultant-algernon-pharmaceuticals https://www.psychedelicfinance.com/articles/dr-devon-christie-md-ccfp-rtc-ifmcp-joins-numinus-as-medical-director https://www.psychedelicfinance.com/articles/dr-elizabeth-nielson-fluence-co-founder-and-lead-trainer https://www.psychedelicfinance.com/articles/dr-eric-vermetten-advisor-mydecine-innovations https://www.psychedelicfinance.com/articles/dr-evan-wood-chief-medical-officer-numinus-inc https://www.psychedelicfinance.com/articles/dr-evan-wood-recognized-leader-in-the-field-of-substance-use-research-and-treatment-joins-numinus-as-chief-medical-officer https://www.psychedelicfinance.com/articles/dr-gabor-mate-recognised-physician-and-bestselling-author-joins-numinus-as-member-of-the-clinical-advisory-council https://www.psychedelicfinance.com/articles/dr-glen-z-brooks-medical-director-founder-new-york-ketamine-infusions https://www.psychedelicfinance.com/articles/dr-ivan-casselman-chief-psychedelic-officer-havn-life-sciences https://www.psychedelicfinance.com/articles/dr-jennifer-miller https://www.psychedelicfinance.com/articles/dr-jill-hagel https://www.psychedelicfinance.com/articles/dr-joel-raskin-a-leader-in-psychiatry-and-neuroscience-drug-development-joins-mindcure-as-chief-medical-officer https://www.psychedelicfinance.com/articles/dr-john-fahy-joins-revive-therapeutics-as-scientific-and-clinical-advisor-for-covid-19-fda-phase-3-study https://www.psychedelicfinance.com/articles/dr-joseph-tucker-founder-ceo-magicmed-industries https://www.psychedelicfinance.com/articles/dr-joseph-tucker-grunder-und-ceo-von-magicmed-industries https://www.psychedelicfinance.com/articles/dr-matthew-johnson-joins-awakn-life-sciences https://www.psychedelicfinance.com/articles/dr-michael-mithoefer-ann-mithoefer-from-maps-join-awakns-scientific-board https://www.psychedelicfinance.com/articles/dr-michael-verbora https://www.psychedelicfinance.com/articles/dr-mike-dow-field-trip-health https://www.psychedelicfinance.com/articles/dr-neil-maresky-ceo-psyence-group https://www.psychedelicfinance.com/articles/dr-paul-van-slyke-chief-scientific-officer-pharmadrug https://www.psychedelicfinance.com/articles/dr-peter-facchini-magicmed-industries https://www.psychedelicfinance.com/articles/dr-peter-facchini-magicmed-industries-2 https://www.psychedelicfinance.com/articles/dr-reid-robison-chief-medical-officer-novamind-ventures https://www.psychedelicfinance.com/articles/dr-roger-mcintyre-announces-changes-to-the-board-of-champignon-brands-inc https://www.psychedelicfinance.com/articles/dr-roger-mcintyre-elected-board-chair-of-champignon-brands-inc https://www.psychedelicfinance.com/articles/dr-sagar-parikh-md-appointed-to-neonmind-specialty-clinics-advisory-board https://www.psychedelicfinance.com/articles/dr-ty-tashiro-phd-senior-translational-psychometric-architect-mindcure https://www.psychedelicfinance.com/articles/egf-theramed-completes-private-placement-and-raises-528-502 https://www.psychedelicfinance.com/articles/egf-theramed-raises-352-502-in-first-tranche-of-private-placement https://www.psychedelicfinance.com/articles/egf-theramed-signs-agreement-to-acquire-seedadelic-med-corp https://www.psychedelicfinance.com/articles/ehave-inc-announces-psychedelics-precision-medicine-platform-for-clinical-research https://www.psychedelicfinance.com/articles/ehave-shareholder-from-ceo-ben-kaplan-and-corporate-update https://www.psychedelicfinance.com/articles/eleusis-accelerates-psychedelic-drug-discovery-and-development-team-with-appointment-of-david-nichols-ph-d-as-director-of-molecular-pharmacology https://www.psychedelicfinance.com/articles/empower-clinics-announces-first-ever-agoracom-video-q-a-with-shareholders-submitting-questions-for-direct-response-by-ceo-steven-mcauley https://www.psychedelicfinance.com/articles/empower-clinics-announces-receipt-of-over-5-500-000-from-exercise-of-warrants-launches-new-corporate-website-for-future-integrated-healthcare https://www.psychedelicfinance.com/articles/empower-clinics-closes-agreement-to-acquire-canadian-clinics-announces-significant-discussions-with-nationwide-rollout-partners-and-proceeds-from-exercise-of-warrants-now-exceeding-6-900-000-to-conclude-its-most-successful-year-ever https://www.psychedelicfinance.com/articles/empower-clinics-continues-to-advance-development-of-psilocybin-and-psychedelics-division-to-address-significant-mental-health-issues https://www.psychedelicfinance.com/articles/empower-clinics-doubling-kai-medical-laboratory-size-in-anticipation-of-test-volumes-by-end-of-q1-files-mdel-application-with-health-canada-to-import-and-sell-kai-saliva-pcr-test-in-canada https://www.psychedelicfinance.com/articles/empower-clinics-kai-medical-laboratory-sells-out-first-5-000-units-of-fda-eua-approved-saliva-covid-19-test-kits-issues-order-for-next-25-000-kai-saliva-pcr-test-kits-with-sales-value-of-5-5m-discussions-with-major-airlines-underway https://www.psychedelicfinance.com/articles/empower-clinics-signs-definitive-agreement-to-acquire-momentum-health-with-7-canadian-clinics-begins-planning-for-nationwide-rollout https://www.psychedelicfinance.com/articles/entheon-announces-closing-of-previously-announced-sale-of-certain-dmt-clinical-assets https://www.psychedelicfinance.com/articles/entheon-announces-sale-of-certain-dmt-clinical-assets-and-filing-of-provisional-novel-compound-patents https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-cro-agreement-with-chdr-for-phase-1-clinical-trial-centre-for-human-drug-research-led-dmt-study-to-start-in-2021 https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-ebiq-101-first-patient-dose https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-eeg-patent-application-provides-research-update https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-enrollment-in-phase-1-study-of-dmt https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-ethics-approval-for-in-vivo-dmt-study https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-expanded-psychedelics-genetic-test-panel https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-expanded-psychedelics-genetic-test-panel-new-clinical-research-platform https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-investment-and-business-arrangement-with-heading-health-llc https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-medical-advisor-dr-dinesh-bhayana https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-nancy-maher-special-advisor-of-data-science-and-regulatory-affairs https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-non-brokered-private-placement-financing https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-private-placement https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-private-placement-to-begin-pre-clinical-trials-with-psychedelic-compounds-dmt-5-meo-dmt https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-recruitment-underway-in-ebiq-101-clinical-study https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-sponsorship-of-a-clinical-study-to-assess-the-electroneurophysiologic-effects-of-ketamine https://www.psychedelicfinance.com/articles/entheon-biomedical-announces-the-approval-of-dmt-clinical-trial https://www.psychedelicfinance.com/articles/entheon-biomedical-closes-private-placement https://www.psychedelicfinance.com/articles/entheon-biomedical-corp-announces-acquisition-of-halugen-life-sciences-inc https://www.psychedelicfinance.com/articles/entheon-biomedical-corp-announces-dtc-eligibility https://www.psychedelicfinance.com/articles/entheon-biomedical-corp-launches-halugens-psychedelics-genetic-test https://www.psychedelicfinance.com/articles/entheon-biomedical-corp-provides-update-on-subsidiary-halugen-life-sciences https://www.psychedelicfinance.com/articles/entheon-biomedical-engages-star-finance-gmbh-for-investor-relations https://www.psychedelicfinance.com/articles/entheon-biomedical-engages-world-renowned-media-personality-dj-skee-aka-scott-keeney-as-media-advisor https://www.psychedelicfinance.com/articles/entheon-biomedical-further-strengthens-advisory-board-with-appointment-of-dr-andy-greenshaw https://www.psychedelicfinance.com/articles/entheon-biomedical-hires-chief-business-officer-senior-pharma-executive-dr-brian-jahns-to-oversee-business-development https://www.psychedelicfinance.com/articles/entheon-biomedical-hires-cleartv-executive-as-vp-of-digital-experience-entertainment-veteran-jonna-birgans-to-oversee-digital-and-vr-content-development https://www.psychedelicfinance.com/articles/entheon-biomedical-partners-with-divergence-neuro-technologies-inc-for-predictive-biomarker-platform-development https://www.psychedelicfinance.com/articles/entheon-biomedical-partners-with-wavepaths-on-upcoming-observational-study https://www.psychedelicfinance.com/articles/entheon-biomedical-provides-corporate-update-on-studies-and-clinical-trials https://www.psychedelicfinance.com/articles/entheon-biomedical-provides-update-on-centre-for-human-drug-research-license-amendments https://www.psychedelicfinance.com/articles/entheon-biomedical-provides-update-on-clinical-and-preclinical-dmt-programs https://www.psychedelicfinance.com/articles/entheon-biomedical-provides-update-on-dmt-human-trial-and-announces-regulatory-submission-to-ethics-committee https://www.psychedelicfinance.com/articles/entheon-biomedical-subsidiary-halugen-life-sciences-announces-agreement-with-third-wave https://www.psychedelicfinance.com/articles/entheon-biomedical-to-be-included-in-first-north-american-psychedelic-etf https://www.psychedelicfinance.com/articles/entheon-biomedicals-wholly-owned-subsidiary-halugen-life-sciences-and-silo-wellness-announces-psychedelics-genetic-test-kit-partnership https://www.psychedelicfinance.com/articles/entheon-subsidiary-halugen-life-sciences-partners-with-maya-health-to-drive-psychedelics-genetic-test-kit-awareness https://www.psychedelicfinance.com/articles/enveric-biosciences-advances-drug-development-for-mental-health-indications-and-intellectual-property-portfolio https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-artificial-intelligence-platform-psyai-tm-has-identified-viable-drug-candidates-from-its-psybrary-of-psychedelic-molecular-compounds https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-closing-of-10-million-public-offering https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-closing-of-magicmed-industries-acquisition https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-definitive-agreement-to-acquire-magicmed-industries https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-distribution-of-series-c-preferred-stock-to-holders-of-its-common-stock https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-formation-of-scientific-advisory-board-to-drive-further-growth-of-next-generation-mental-health-medicines https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-inclusion-in-advisorshares-psychedelics-etf https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-plans-to-spin-off-and-dividend-its-cannabinoid-pipeline-to-shareholders https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-positive-preclinical-data-for-ev102-radiodermatitis-drug-candidate https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-pricing-of-10-million-public-offering https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-publication-of-four-patent-applications-for-psychedelic-inspired-drug-candidates https://www.psychedelicfinance.com/articles/enveric-biosciences-announces-successful-synthesis-and-filing-of-provisional-patent-for-ev104-cannabinoid-celecoxib-conjugate https://www.psychedelicfinance.com/articles/enveric-biosciences-appoints-dr-bob-dagher-as-chief-medical-officer https://www.psychedelicfinance.com/articles/enveric-biosciences-ceo-dr-joseph-tucker-provides-2021-year-in-review-and-2022-outlook-in-letter-to-shareholders https://www.psychedelicfinance.com/articles/enveric-biosciences-expands-portfolio-of-drug-development-candidates-and-files-new-provisional-patent-application https://www.psychedelicfinance.com/articles/enveric-biosciences-files-portfolio-of-patent-applications-for-tryptamine-based-molecules https://www.psychedelicfinance.com/articles/enveric-biosciences-reports-full-year-2021-financial-results-and-provides-business-update https://www.psychedelicfinance.com/articles/enveric-biosciences-to-host-fireside-chat-with-dr-bob-dagher-chief-medical-officer-on-may-17th-at-10-00-a-m-et https://www.psychedelicfinance.com/articles/enveric-biosciences-to-participate-in-the-h-c-wainwright-2nd-annual-psychedelics-virtual-conference-on-december-6th https://www.psychedelicfinance.com/articles/enveric-biosciences-to-participate-in-the-h-c-wainwright-global-investment-conference-on-may-23-26-2022 https://www.psychedelicfinance.com/articles/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-april-2022 https://www.psychedelicfinance.com/articles/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-february-2022 https://www.psychedelicfinance.com/articles/epidemiologist-dr-joel-moody-joins-revive-therapeutics-as-medical-and-clinical-advisor https://www.psychedelicfinance.com/articles/european-patent-grant-strengthens-small-pharmas-ketamine-based-patent-portfolio-for-the-treatment-of-depressive-disorders https://www.psychedelicfinance.com/articles/european-synthetic-biology-company-octarine-raises-1-8m-usd-in-funding-and-enters-pre-clinical-studies-with-novel-improved-cannabinoid-and-psychedelic-derivatives https://www.psychedelicfinance.com/articles/european-university-to-fund-core-one-labs-akome-advanced-neurogenesis-stimulation-studies https://www.psychedelicfinance.com/articles/evan-levine-chairman-ceo-psybio-therapeutics https://www.psychedelicfinance.com/articles/exclusively-natural-psychedelic-pharma-company-filament-health-lists-on-the-neo-exchange https://www.psychedelicfinance.com/articles/family-of-bob-marley-and-silo-wellness-collaborate-to-debut-exclusive-worldwide-functional-psychedelic-mushroom-brand https://www.psychedelicfinance.com/articles/fda-and-health-canada-clear-ind-for-fsd-pharma-to-proceed-with-phase-2-trial-of-fsd201-for-nociplastic-pain-associated-with-idiopathic-mast-cell-activation-syndrome https://www.psychedelicfinance.com/articles/fda-approves-of-spravato-r-esketamine-ciii-nasal-spray-to-treat-depressive-symptoms-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior https://www.psychedelicfinance.com/articles/fda-clears-mindmed-ind-for-mm-120-in-treatment-of-generalized-anxiety-disorder https://www.psychedelicfinance.com/articles/fda-issues-first-draft-guidance-on-clinical-trials-with-psychedelic-drugs https://www.psychedelicfinance.com/articles/field-trip-adds-acclaimed-physician-dr-andrew-weil-to-medical-advisory-board https://www.psychedelicfinance.com/articles/field-trip-and-nue-life-are-collaborating-to-bring-psychedelic-therapy-into-the-home https://www.psychedelicfinance.com/articles/field-trip-announces-closing-of-plan-of-arrangement-and-19-9-million-private-placement-financing https://www.psychedelicfinance.com/articles/field-trip-announces-first-dosings-in-phase-i-clinical-study-of-ft-104 https://www.psychedelicfinance.com/articles/field-trip-announces-intention-to-make-applications-on-behalf-of-patients-to-health-canadas-special-access-program-sap-for-access-to-psilocybin-and-mdma-assisted-therapies https://www.psychedelicfinance.com/articles/field-trip-announces-relaunch-and-refresh-of-its-award-winning-psychedelic-app https://www.psychedelicfinance.com/articles/field-trip-health-and-cerebral-partner-to-provide-end-to-end-mental-health-care https://www.psychedelicfinance.com/articles/field-trip-health-announces-50-million-bought-deal-offering-of-common-shares https://www.psychedelicfinance.com/articles/field-trip-health-announces-upsize-to-previously-announced-bought-deal-public-offering https://www.psychedelicfinance.com/articles/field-trip-health-ltd-and-whoop-announce-partnership-to-measure-effect-of-psychedelic-therapies-on-physiology-and-mental-health https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-15-million-bought-deal-offering-of-units https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-closing-of-95-million-bought-deal-financing https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-closing-of-bought-deal-financing https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-completion-of-dmpk-studies-engineering-batch-for-ft-104-its-novel-psychedelic-compound https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-dtc-eligibility https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-expansion-to-the-netherlands-and-launch-of-proprietary-truffle-program https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-increase-to-bought-deal-financing-to-17-4-million https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-increased-participation-in-arrangement-financing-and-postponement-of-shareholder-meeting-date https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-intention-to-separate-the-field-trip-discovery-and-field-trip-health-divisions-into-two-independent-public-companies https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-launch-of-kap-co-operative-program https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-official-opening-of-psychedelic-research-and-cultivation-facility-in-jamaica https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-opening-of-field-trip-health-center-in-atlanta-ga-as-it-continues-expansion-in-the-us https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston-locations-of-next-5-field-trip-health-centers https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-participation-in-a-maps-sponsored-multi-site-study-of-mdma-assisted-therapy-to-treat-eating-disorders https://www.psychedelicfinance.com/articles/field-trip-health-ltd-announces-voting-results-from-special-shareholder-meeting https://www.psychedelicfinance.com/articles/field-trip-health-ltd-applies-to-list-its-common-shares-on-the-nasdaq-stock-market https://www.psychedelicfinance.com/articles/field-trip-health-ltd-common-shares-to-trade-on-the-otcqx-best-market https://www.psychedelicfinance.com/articles/field-trip-health-ltd-completes-reverse-take-over-transaction-and-prepares-for-listing-on-the-canadian-securities-exchange https://www.psychedelicfinance.com/articles/field-trip-health-ltd-continues-expansion-with-psychedelic-assisted-therapy-centers-in-seattle-vancouver-and-fredericton https://www.psychedelicfinance.com/articles/field-trip-health-ltd-continues-expansion-with-psychedelic-enhanced-therapy-center-in-chicago https://www.psychedelicfinance.com/articles/field-trip-health-ltd-granted-us-patent-covering-novel-psychedelic-molecule-ft-104 https://www.psychedelicfinance.com/articles/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp https://www.psychedelicfinance.com/articles/field-trip-health-ltd-prepares-to-enter-oregon-market-following-the-passage-of-measure-109-in-oregon-creating-the-first-legal-market-for-psilocybin-services https://www.psychedelicfinance.com/articles/field-trip-health-ltd-provides-operational-and-investor-update-announces-expanded-hours-at-its-field-trip-health-center-in-toronto-plus-rollout-of-portal-field-trips-proprietary-digital-mental-health-platform https://www.psychedelicfinance.com/articles/field-trip-health-ltd-provides-update-on-ft-104-its-next-generation-psychedelic-molecule-in-development https://www.psychedelicfinance.com/articles/field-trip-health-ltd-receives-conditional-approval-for-listing-of-common-shares-of-field-trip-health-wellness-ltd-on-the-tsx-venture-exchange https://www.psychedelicfinance.com/articles/field-trip-health-ltd-receives-conditional-approval-to-up-list-to-the-toronto-stock-exchange https://www.psychedelicfinance.com/articles/field-trip-health-ltd-receives-final-court-approval-for-reorganization-of-the-discovery-and-wellness-businesses-into-two-publicly-traded-companies https://www.psychedelicfinance.com/articles/field-trip-health-ltd-reports-fiscal-first-quarter-2022-financial-results https://www.psychedelicfinance.com/articles/field-trip-health-ltd-reports-fiscal-fourth-quarter-and-full-year-2021-financial-results https://www.psychedelicfinance.com/articles/field-trip-health-ltd-reports-fiscal-fourth-quarter-and-full-year-2022-financial-results-and-provides-business-update-including-corporate-reorganization https://www.psychedelicfinance.com/articles/field-trip-health-ltd-reports-third-fiscal-quarter-2021-financial-results https://www.psychedelicfinance.com/articles/field-trip-health-ltd-reports-third-fiscal-quarter-2021-financial-results-2 https://www.psychedelicfinance.com/articles/field-trip-health-ltd-reports-third-fiscal-quarter-2022-financial-results-and-provides-business-update https://www.psychedelicfinance.com/articles/field-trip-health-ltd-schedules-first-fiscal-quarter-2022-financial-results-conference-call-for-tuesday-august-17-2021-at-8-30-am-et https://www.psychedelicfinance.com/articles/field-trip-health-ltd-schedules-fiscal-first-quarter-2023-conference-call-for-tuesday-august-16-2022-at-8-30-am-et https://www.psychedelicfinance.com/articles/field-trip-health-ltd-schedules-fiscal-fourth-quarter-and-full-year-2021-financial-results-conference-call-for-friday-june-25-2021-at-8-00-am-et https://www.psychedelicfinance.com/articles/field-trip-health-ltd-schedules-fiscal-fourth-quarter-and-full-year-2022-results-conference-call-for-thursday-june-30-2022-at-8-30-am-et https://www.psychedelicfinance.com/articles/field-trip-health-ltd-schedules-second-fiscal-quarter-2022-financial-results-conference-call-for-tuesday-november-16-2021-at-8-30-am-et https://www.psychedelicfinance.com/articles/field-trip-health-ltd-schedules-third-fiscal-quarter-2021-financial-results-conference-call-for-wednesday-february-17-2021-at-8-00-am-et https://www.psychedelicfinance.com/articles/field-trip-health-ltd-schedules-third-fiscal-quarter-2022-financial-results-conference-call-for-february-16-2022-at-8-30-am-et https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-commence-trading-on-the-cse-on-october-6-under-ticker-symbol-ftrp https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-commence-trading-on-the-nasdaq-on-july-29-2021-under-the-symbol-ftrp https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-commence-trading-on-the-toronto-stock-exchange-on-june-7-2021 https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-participate-in-34th-annual-roth-conference-in-march-2022 https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-participate-in-four-investor-conferences-in-september https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-participate-in-h-c-wainwright-bioconnect-virtual-conference-in-january-2022 https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-participate-in-maxim-group-2nd-annual-virtual-growth-conference https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-participate-in-upcoming-conferences-in-november-2021 https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-participate-in-upcoming-investor-conferences https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-participate-in-upcoming-investor-conferences-in-may-2022 https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-present-at-the-cowen-psychedelics-novel-mechanisms-in-neuropsychiatry-summit https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-present-at-the-h-c-wainwright-1st-annual-mental-healthcare-conference-on-june-27-2022 https://www.psychedelicfinance.com/articles/field-trip-health-ltd-to-pursue-treatment-resistant-depression-and-postpartum-depression-as-indications-for-ft-104 https://www.psychedelicfinance.com/articles/field-trip-health-opens-europes-first-psychedelic-therapy-healthcare-facility https://www.psychedelicfinance.com/articles/field-trip-health-releases-renderings-of-jamaica-facility https://www.psychedelicfinance.com/articles/field-trip-health-video-profile https://www.psychedelicfinance.com/articles/field-trip-health-wellness-ltd-reports-fiscal-first-quarter-2023-financial-and-operating-results https://www.psychedelicfinance.com/articles/field-trip-health-wellness-to-participate-in-the-cantor-fitzgerald-symposium-on-mental-health-clinics-on-october-11th https://www.psychedelicfinance.com/articles/field-trip-launches-site-management-organization-smo-services-hires-stephan-cote-as-head-of-quality https://www.psychedelicfinance.com/articles/field-trip-psychedelics-inc-announces-closing-of-11-0-million-financing-entry-into-amalgamation-agreement-with-newton-energy-corporation https://www.psychedelicfinance.com/articles/field-trip-psychedelics-inc-announces-creation-of-field-trip-discovery-the-companys-drug-development-division https://www.psychedelicfinance.com/articles/field-trip-psychedelics-inc-announces-launch-of-virtual-psychedelic-therapy-and-covid-coping-therapy https://www.psychedelicfinance.com/articles/field-trip-psychedelics-inc-announces-successful-glp-synthesis-results-from-initial-preclinical-testing-for-ft-104-its-first-molecule-in-development https://www.psychedelicfinance.com/articles/field-trip-psychedelics-inc-launches-field-trip-basecamp-a-therapeutic-program-designed-for-combat-veterans-first-responders-and-healthcare-workers https://www.psychedelicfinance.com/articles/field-trip-receives-notice-of-allowance-for-us-patent-application-covering-ft-104-isoprocin-glutarate-its-novel-psychedelic-molecule-in-development https://www.psychedelicfinance.com/articles/field-trip-sponsors-therapsil-a-non-profit-advocating-for-legal-medically-supervised-psilocybin-assisted-psychotherapy https://www.psychedelicfinance.com/articles/filament-announces-c-10m-offering-and-filing-of-initial-listing-application https://www.psychedelicfinance.com/articles/filament-announces-first-gmp-batch-of-pharmaceutical-grade-natural-psilocybin https://www.psychedelicfinance.com/articles/filament-announces-shareholder-approval-of-amalgamation-and-closing-of-private-placement-financing https://www.psychedelicfinance.com/articles/filament-cultivates-20th-psychedelic-mushroom-variety-and-provides-propagation-update https://www.psychedelicfinance.com/articles/filament-health-and-atma-journey-centers-announce-14-subjects-dosed-in-health-canada-approved-psilocybin-clinical-trial https://www.psychedelicfinance.com/articles/filament-health-and-atma-journey-centers-announce-licensing-agreement https://www.psychedelicfinance.com/articles/filament-health-and-cybin-therapeutics-announce-approval-for-phase-ii-clinical-trial-for-depression https://www.psychedelicfinance.com/articles/filament-health-and-cybin-therapeutics-announce-licensing-agreement https://www.psychedelicfinance.com/articles/filament-health-and-jaguar-health-sign-letter-of-intent-to-develop-botanical-prescription-drugs-for-specific-mental-health-indications https://www.psychedelicfinance.com/articles/filament-health-announces-clinical-trial-approval-in-partnership-with-psychiatric-centre-copenhagen https://www.psychedelicfinance.com/articles/filament-health-announces-closing-of-2-500-080-private-placement https://www.psychedelicfinance.com/articles/filament-health-announces-co-development-and-exclusive-licensing-agreement-with-entheotech-bioscience https://www.psychedelicfinance.com/articles/filament-health-announces-dtc-eligibility-and-up-list-to-the-otcqb-exchange https://www.psychedelicfinance.com/articles/filament-health-announces-eighth-patent-issuance https://www.psychedelicfinance.com/articles/filament-health-announces-fda-approval-of-two-clinical-trials-studying-its-botanical-psilocybin-drug-candidate-pex010 https://www.psychedelicfinance.com/articles/filament-health-announces-fda-authorization-of-clinical-trial-with-first-ever-direct-psilocin-administration-and-first-ever-psychedelic-botanical-drug-candidates https://www.psychedelicfinance.com/articles/filament-health-announces-first-dosing-in-groundbreaking-fda-approved-psilocin-clinical-trial https://www.psychedelicfinance.com/articles/filament-health-announces-fourth-patent-issuance https://www.psychedelicfinance.com/articles/filament-health-announces-health-canada-approval-for-phase-ii-trial-administering-new-psilocybin-microdose-formulation https://www.psychedelicfinance.com/articles/filament-health-announces-interim-results-from-phase-i-clinical-trial-at-the-university-of-california-san-francisco https://www.psychedelicfinance.com/articles/filament-health-announces-new-united-states-patent-issuances https://www.psychedelicfinance.com/articles/filament-health-announces-participation-in-project-solace https://www.psychedelicfinance.com/articles/filament-health-announces-patient-dosing-through-health-canada-special-access-program https://www.psychedelicfinance.com/articles/filament-health-announces-pre-ind-meeting-with-united-states-food-and-drug-administration https://www.psychedelicfinance.com/articles/filament-health-announces-private-placement-of-units-and-convertible-debenture-units-of-up-to-2-500-000 https://www.psychedelicfinance.com/articles/filament-health-announces-psilocybin-supply-agreement-with-the-centre-for-addiction-and-mental-health https://www.psychedelicfinance.com/articles/filament-health-announces-q2-2021-financial-results https://www.psychedelicfinance.com/articles/filament-health-announces-second-patent-issuance https://www.psychedelicfinance.com/articles/filament-health-announces-second-psilocybin-supply-agreement-with-the-centre-for-addiction-and-mental-health https://www.psychedelicfinance.com/articles/filament-health-announces-second-quarter-2022-financial-results-and-operational-highlights https://www.psychedelicfinance.com/articles/filament-health-announces-sixth-patent-issuance https://www.psychedelicfinance.com/articles/filament-health-announces-third-quarter-2022-financial-results-and-operational-highlights https://www.psychedelicfinance.com/articles/filament-health-appoints-new-members-to-board-of-directors-and-advisory-council https://www.psychedelicfinance.com/articles/filament-health-corp-announces-approval-for-listing-on-the-neo-exchange https://www.psychedelicfinance.com/articles/filament-health-cultivates-70th-psychedelic-mushroom-variety-and-announces-annual-general-meeting https://www.psychedelicfinance.com/articles/filament-health-files-20th-patent-application-including-three-international-pct-applications https://www.psychedelicfinance.com/articles/filament-health-is-issued-patent-by-united-states-patent-and-trademark-office https://www.psychedelicfinance.com/articles/filament-health-is-issued-second-patent-by-united-states-patent-and-trademark-office-and-reports-q1-results https://www.psychedelicfinance.com/articles/filament-health-is-the-first-public-company-to-be-issued-a-patent-for-extraction-of-natural-psilocybin https://www.psychedelicfinance.com/articles/filament-health-issued-third-patent-by-united-states-patent-and-trademark-office https://www.psychedelicfinance.com/articles/filament-health-partners-with-trpr-psychedelic-research-program-at-ucsf-to-advance-first-drug-candidates-through-fda-phase-1-and-phase-2-clinical-trials https://www.psychedelicfinance.com/articles/filament-health-recognizes-the-restoration-of-access-to-restricted-drugs-via-the-health-canada-special-access-program https://www.psychedelicfinance.com/articles/filament-health-refiles-q2-and-q3-interim-financial-statements-and-md-a https://www.psychedelicfinance.com/articles/filament-health-reports-q4-and-year-end-2021-financial-results-and-operational-highlights https://www.psychedelicfinance.com/articles/filament-health-reports-third-quarter-2021-financial-results-and-operational-highlights https://www.psychedelicfinance.com/articles/filament-health-shares-to-commence-trading-on-the-otc-market https://www.psychedelicfinance.com/articles/filament-health-subsidiary-psilo-scientific-announces-inclusion-in-health-canada-list-of-licensed-psilocybin-producers https://www.psychedelicfinance.com/articles/filament-health-successfully-completes-industry-first-export-of-natural-gmp-psychedelics-to-the-united-states https://www.psychedelicfinance.com/articles/filament-health-to-host-virtual-investor-event https://www.psychedelicfinance.com/articles/filament-health-to-host-virtual-investor-update https://www.psychedelicfinance.com/articles/filament-health-to-host-virtual-investor-update-2 https://www.psychedelicfinance.com/articles/filament-health-to-participate-in-key-psychedelics-conferences-in-december-2021 https://www.psychedelicfinance.com/articles/filament-health-to-participate-in-prominent-psychedelic-investor-conferences-in-april-2022 https://www.psychedelicfinance.com/articles/filament-health-to-participate-in-the-34th-annual-roth-conference https://www.psychedelicfinance.com/articles/first-clinical-study-results-of-psilocybin-treatment-in-anorexia-nervosa-published-in-nature-medicine https://www.psychedelicfinance.com/articles/first-patient-dosed-in-intelgenxs-resumed-buena-montelukast-versafilm-r-phase-2a-clinical-trial-in-patients-with-mild-to-moderate-alzheimers-disease https://www.psychedelicfinance.com/articles/first-patient-dosed-in-phase-iia-dmt-assisted-therapy-clinical-trial https://www.psychedelicfinance.com/articles/first-patient-dosed-in-small-pharmas-phase-i-study-exploring-intramuscular-administration-of-spl026 https://www.psychedelicfinance.com/articles/first-subject-dosed-in-small-pharmas-first-in-human-phase-i-clinical-trial-with-spl028 https://www.psychedelicfinance.com/articles/fluence-partners-with-phaneros-institute-to-advance-psychedelic-therapy-training-in-brazil https://www.psychedelicfinance.com/articles/former-lifelabs-coo-joins-novamind-leadership-team https://www.psychedelicfinance.com/articles/former-senate-majority-leader-tom-daschle-appointed-special-adviser-to-field-trip-health-ltd https://www.psychedelicfinance.com/articles/former-senior-leader-of-apotex-joins-nova-mentis-life-science-board-and-is-named-coo https://www.psychedelicfinance.com/articles/founder-profile-payton-nyquvest-ceo-of-numinus-wellness https://www.psychedelicfinance.com/articles/fsd-pharma-announces-cancellation-of-certain-shares-issued-to-former-chief-executive-officer-dr-raza-bokhari https://www.psychedelicfinance.com/articles/fsd-pharma-announces-changes-to-the-board-of-directors https://www.psychedelicfinance.com/articles/fsd-pharma-announces-engagement-with-tekkfund-capital-and-share-issuance-to-crystal-research-associates https://www.psychedelicfinance.com/articles/fsd-pharma-announces-executive-informational-overview-report-produced-by-crystal-research-associates-llc https://www.psychedelicfinance.com/articles/fsd-pharma-announces-filing-of-year-end-2021-results https://www.psychedelicfinance.com/articles/fsd-pharma-appoints-julia-levy-award-recipient-david-allan-and-dr-john-mcgraw-to-advisory-board https://www.psychedelicfinance.com/articles/fsd-pharma-closes-cad-16-4-million-sale-of-non-core-assets https://www.psychedelicfinance.com/articles/fsd-pharma-files-investigational-new-drug-application-ind-with-fda-and-health-canada-for-phase-2-trial-of-fsd-201-for-an-inflammatory-disorder-and-provides-corporate-updates https://www.psychedelicfinance.com/articles/fsd-pharma-inc-announces-results-of-annual-general-meeting-of-shareholders-and-other-corporate-updates https://www.psychedelicfinance.com/articles/fsd-pharma-inc-incorporates-new-subsidiary-to-capitalize-on-drug-development-incentives-in-australia https://www.psychedelicfinance.com/articles/fsd-pharma-inc-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency https://www.psychedelicfinance.com/articles/fsd-pharma-issues-circular-adopts-incentive-plan-and-grants-psus https://www.psychedelicfinance.com/articles/fsd-pharma-issues-corporate-updates https://www.psychedelicfinance.com/articles/fsd-pharma-launches-a-new-research-and-development-program-targeting-unmet-medical-needs-for-alcohol-misuse https://www.psychedelicfinance.com/articles/fsd-pharma-participating-in-h-c-wainwright-24th-annual-global-investment-conference-on-demand-presentation-available https://www.psychedelicfinance.com/articles/fsd-pharma-receives-regulatory-clearance-for-its-proposed-phase-1-clinical-trial-of-lucid-21-302-lucid-ms-first-in-class-multiple-sclerosis-drug-candidate https://www.psychedelicfinance.com/articles/fsd-pharma-regains-compliance-with-nasdaq-continued-listing-requirements https://www.psychedelicfinance.com/articles/fsd-pharma-submits-its-phase-1-clinical-trial-application-for-lucid-ms-lucid-21-302-for-first-in-human-safety-and-tolerability-investigation https://www.psychedelicfinance.com/articles/fsd-pharma-subsidiary-lucid-psycheceuticals-files-for-patent-on-novel-formulations-of-palmitoylethanolamide-presents-preclinical-toxicology-results-at-an-international-symposium https://www.psychedelicfinance.com/articles/fsd-pharma-to-attend-41st-annual-j-p-morgan-healthcare-conference-2023 https://www.psychedelicfinance.com/articles/gary-leong-chief-scientific-officer-havn-life-sciences https://www.psychedelicfinance.com/articles/garyn-angel-founder-ceo-magical-brands https://www.psychedelicfinance.com/articles/geoff-belair-chief-technology-officer-mindcure https://www.psychedelicfinance.com/articles/george-mashour-m-d-tryp-therapeutics https://www.psychedelicfinance.com/articles/george-tziras-to-succeed-peter-rands-as-small-pharma-chief-executive-officer https://www.psychedelicfinance.com/articles/ghp-noetic-science-psychedelic-pharma-and-diamond-therapeutics-announce-proposed-qualifying-transaction https://www.psychedelicfinance.com/articles/gilgamesh-pharmaceuticals-closes-on-27-million-series-a-round https://www.psychedelicfinance.com/articles/global-investors-back-psychedelic-medicine-start-up-with-3-8m-series-a-round https://www.psychedelicfinance.com/articles/good2go-corp-and-magical-brands-inc-announce-update-to-proposed-qualifying-transaction https://www.psychedelicfinance.com/articles/goodmind-tm-available-for-sale-in-the-united-kingdom-and-europe-exclusive-distribution-agreement-concluded-with-this-works https://www.psychedelicfinance.com/articles/greenstar-biosciences-announces-closing-of-private-placement-and-debt-settlement https://www.psychedelicfinance.com/articles/greenstar-biosciences-announces-name-change https://www.psychedelicfinance.com/articles/greenstar-biosciences-signs-agreement-to-acquire-100-percent-of-eleusian-biosciences-corp https://www.psychedelicfinance.com/articles/greg-mckee-chief-executive-officer-tryp-therapeutics https://www.psychedelicfinance.com/articles/halucenex-life-sciences-inc-enters-into-advisory-agreement-with-biotechnology-company-growing-together-research-inc-2 https://www.psychedelicfinance.com/articles/havn-labs-jamaica-facility-now-fully-operational https://www.psychedelicfinance.com/articles/havn-life-acquires-bennetts-choice-patented-brain-health-and-recovery-formulations https://www.psychedelicfinance.com/articles/havn-life-announces-a-30-1-consolidation-of-its-common-shares https://www.psychedelicfinance.com/articles/havn-life-announces-changes-to-board-composition-and-departure-of-ms-rasode https://www.psychedelicfinance.com/articles/havn-life-announces-distribution-deal-with-jonluca-enterprises-inc https://www.psychedelicfinance.com/articles/havn-life-announces-dtc-eligibility-of-its-common-shares-in-the-united-states https://www.psychedelicfinance.com/articles/havn-life-announces-financing-commitment-of-cad-9-000-000-through-the-issuance-of-convertible-debentures-and-warrants https://www.psychedelicfinance.com/articles/havn-life-announces-gary-leongs-appointment-to-board-of-directors https://www.psychedelicfinance.com/articles/havn-life-announces-launch-of-a-range-of-natural-health-products https://www.psychedelicfinance.com/articles/havn-life-announces-retail-partnership-with-alberta-grocer-calgary-co-op https://www.psychedelicfinance.com/articles/havn-life-announces-retail-partnership-with-grocer-choices-markets https://www.psychedelicfinance.com/articles/havn-life-announces-strategic-clinical-trial-partnership-with-healthtech-connex-inc https://www.psychedelicfinance.com/articles/havn-life-announces-strategic-partnership-with-non-profit-coalition-therapsil https://www.psychedelicfinance.com/articles/havn-life-announces-termination-of-amalgamation-agreement-to-acquire-spore-life-sciences https://www.psychedelicfinance.com/articles/havn-life-announces-the-close-of-the-first-tranche-of-its-previously-announced-financing-commitment-by-alpha-blue-ocean-and-warrant-amendments-and-the-issuance-of-shares-for-debt https://www.psychedelicfinance.com/articles/havn-life-announces-voluntary-escrow-of-6-300-000-shares https://www.psychedelicfinance.com/articles/havn-life-applies-for-licence-to-produce-and-sell-psilocybin https://www.psychedelicfinance.com/articles/havn-life-attracts-international-drug-science-and-policy-expert-joins-uk-policy-reform-group https://www.psychedelicfinance.com/articles/havn-life-ceo-tim-moore-to-appear-at-upcoming-q2-investor-summithavn-life-ceo-tim-moore-to-appear-at-upcoming-q2-investor-summit https://www.psychedelicfinance.com/articles/havn-life-ceo-to-present-at-zooming-with-ld-a-leading-platform-for-microcap-companies https://www.psychedelicfinance.com/articles/havn-life-closes-c-2-000-000-private-placement-with-u-s-institutional-investors https://www.psychedelicfinance.com/articles/havn-life-completes-acquisition-of-clinical-stage-ip-for-development-of-cluster-headache-drug https://www.psychedelicfinance.com/articles/havn-life-completes-acquisition-of-strategic-manufacturing-packaging-facility-for-its-retail-division https://www.psychedelicfinance.com/articles/havn-life-develops-new-method-for-rapid-psilocybin-testing https://www.psychedelicfinance.com/articles/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches https://www.psychedelicfinance.com/articles/havn-life-enters-into-definitive-agreement-to-acquire-spore-life-sciences-inc https://www.psychedelicfinance.com/articles/havn-life-enters-into-distribution-agreement-with-mycrodose-therapeutics-for-u-s-market https://www.psychedelicfinance.com/articles/havn-life-enters-supply-agreement-with-mpb-group-inc https://www.psychedelicfinance.com/articles/havn-life-expands-supply-agreement-with-mycotopia-therapies-inc https://www.psychedelicfinance.com/articles/havn-life-files-final-base-shelf-prospectus https://www.psychedelicfinance.com/articles/havn-life-introduces-industry-leader-jenna-pozar-as-chief-operating-officer https://www.psychedelicfinance.com/articles/havn-life-joins-uk-psychedelics-working-group-with-leading-international-scientists https://www.psychedelicfinance.com/articles/havn-life-launches-new-line-of-natural-health-products https://www.psychedelicfinance.com/articles/havn-life-launches-the-brain-evolve-series https://www.psychedelicfinance.com/articles/havn-life-natural-health-products-now-available-on-amazon-com https://www.psychedelicfinance.com/articles/havn-life-provides-corporate-update https://www.psychedelicfinance.com/articles/havn-life-sciences-and-nesters-market-a-leading-canadian-retailer-of-natural-health-and-wellness-products-announce-an-authorized-products-listing https://www.psychedelicfinance.com/articles/havn-life-sciences-announces-5-46-million-warrant-exercise https://www.psychedelicfinance.com/articles/havn-life-sciences-announces-5-million-bought-deal-financing https://www.psychedelicfinance.com/articles/havn-life-sciences-announces-appointment-of-dennis-staudt-to-the-board-of-directors-senior-management-reorganization https://www.psychedelicfinance.com/articles/havn-life-sciences-announces-appointments-of-vic-neufeld-as-chairman-and-rick-brar-as-vice-chairman-of-the-board-of-directors-respectively-and-the-acceleration-of-warrants https://www.psychedelicfinance.com/articles/havn-life-sciences-announces-closing-of-c-11-5-million-bought-deal-financing https://www.psychedelicfinance.com/articles/havn-life-sciences-announces-completion-of-acquisition-transaction https://www.psychedelicfinance.com/articles/havn-life-sciences-announces-filing-of-final-prospectus-and-conditional-approval-for-listing-on-cse https://www.psychedelicfinance.com/articles/havn-life-sciences-announces-inclusion-in-first-psychedelic-exchange-traded-fund https://www.psychedelicfinance.com/articles/havn-life-sciences-announces-listing-approval-on-the-frankfurt-stock-exchange https://www.psychedelicfinance.com/articles/havn-life-sciences-earns-health-canada-approval-for-natural-health-product-formulations https://www.psychedelicfinance.com/articles/havn-life-sciences-enters-definitive-agreement-to-acquire-strategic-manufacturing-packaging-facility-for-its-retail-division https://www.psychedelicfinance.com/articles/havn-life-sciences-files-preliminary-prospectus-in-connection-with-bought-deal-equity-financing https://www.psychedelicfinance.com/articles/havn-life-sciences-granted-section-56-exemption-to-begin-scientific-work-with-psilocybin https://www.psychedelicfinance.com/articles/havn-life-sciences-hits-major-milestone-with-research-partner-complex-biotech-discovery-ventures https://www.psychedelicfinance.com/articles/havn-life-sciences-inc-announces-appointment-of-gary-leong-as-chief-science-officer https://www.psychedelicfinance.com/articles/havn-life-sciences-inc-announces-launch-filing-of-preliminary-prospectus https://www.psychedelicfinance.com/articles/havn-life-sciences-partners-with-veterans-mental-health-non-profit-westwood-institute https://www.psychedelicfinance.com/articles/havn-life-sciences-provides-update-on-retail-strategy-and-product-development https://www.psychedelicfinance.com/articles/havn-life-sciences-signs-finished-goods-supply-agreement-with-allied-health https://www.psychedelicfinance.com/articles/havn-life-sciences-signs-loi-to-research-and-develop-medical-psilocybin-with-jamaican-company-hypha-wellness https://www.psychedelicfinance.com/articles/havn-life-sciences-submits-range-of-natural-health-products-to-health-canada https://www.psychedelicfinance.com/articles/havn-life-sciences-to-host-investor-webcast-on-march-3-2021 https://www.psychedelicfinance.com/articles/havn-life-sciences-to-supply-psychedelic-compounds-to-clinical-studies-focused-on-veterans-and-ptsd https://www.psychedelicfinance.com/articles/havn-life-sciences-to-support-the-first-modern-psilocybin-depression-study-in-germany-with-mind-foundation https://www.psychedelicfinance.com/articles/havn-life-sciences-undertakes-one-of-the-first-preclinical-studies-on-psilocybin-and-the-immune-system https://www.psychedelicfinance.com/articles/havn-life-secures-production-supply-agreement-to-expand-retail-product-offerings https://www.psychedelicfinance.com/articles/havn-life-secures-purchase-order-for-controlled-substance-sale-to-revive-therapeutics-ltd-for-use-in-clinical-research https://www.psychedelicfinance.com/articles/havn-life-secures-supply-agreement-with-atman-retreats https://www.psychedelicfinance.com/articles/havn-life-ships-first-white-label-order-to-distribution-partner-woke-pharmaceuticals-in-australia https://www.psychedelicfinance.com/articles/havn-life-signs-agreement-to-enable-export-of-psilocybin-into-canada-the-us-and-europe https://www.psychedelicfinance.com/articles/havn-life-signs-agreement-to-supply-psilocybin-for-mycotopia-therapies https://www.psychedelicfinance.com/articles/havn-life-signs-exclusive-supply-agreement-with-atma-journey-centers https://www.psychedelicfinance.com/articles/havn-life-signs-exclusive-supply-agreement-with-cube-psytech https://www.psychedelicfinance.com/articles/havn-life-signs-supply-agreement-with-licenced-jamaican-cannabis-producer-green-stripe-naturals-ltd https://www.psychedelicfinance.com/articles/havn-life-successfully-exports-psilocybin-from-its-jamaica-facility-into-canada https://www.psychedelicfinance.com/articles/havn-life-successfully-exports-psilocybin-from-jamaica-facility-into-the-u-s-for-research-purposes https://www.psychedelicfinance.com/articles/havn-life-to-be-featured-on-viewpoint-with-dennis-quaid https://www.psychedelicfinance.com/articles/havn-life-to-begin-supplying-its-naturally-derived-psilocybin-products-for-use-in-worlds-largest-medical-psilocybin-and-real-world-data-project https://www.psychedelicfinance.com/articles/havn-life-to-present-at-upcoming-emerging-growth-conference-26 https://www.psychedelicfinance.com/articles/havn-life-to-present-at-upcoming-ld-micro-invitational-xii https://www.psychedelicfinance.com/articles/headlines-july-3-2020 https://www.psychedelicfinance.com/articles/headlines-june-12 https://www.psychedelicfinance.com/articles/headlines-june-19 https://www.psychedelicfinance.com/articles/headlines-june-5 https://www.psychedelicfinance.com/articles/headlines-may-29th-2020 https://www.psychedelicfinance.com/articles/health-canada-approves-expansion-of-mydecines-cultivation-capabilities-for-psilocybin-producing-mushrooms https://www.psychedelicfinance.com/articles/health-canada-grants-mdma-production-and-distribution-amendment-to-optimi-health https://www.psychedelicfinance.com/articles/hebrew-university-yissum-and-israeli-biotech-clearmind-medicines-psychedelic-derived-obesity-treatment-presented-by-professor-joseph-tam-d-m-d-ph-d-at-isranalytica-2023 https://www.psychedelicfinance.com/articles/heroic-hearts-project-and-field-trip-health-ltd-enter-into-a-strategic-relationship-to-increase-legal-psychedelic-therapy-access-for-military-veterans-in-north-america https://www.psychedelicfinance.com/articles/hinterland-to-acquire-novamind-ventures-inc https://www.psychedelicfinance.com/articles/hmnc-brain-health-expands-international-patent-portfolio-with-two-stress-axis-related-substances-for-major-depressive-disorder https://www.psychedelicfinance.com/articles/hmnc-brain-health-to-participate-in-h-c-wainwright-bioconnect-conference-in-january-2022 https://www.psychedelicfinance.com/articles/hollister-biosciences-closes-acquisition-of-alphamind-brands-inc https://www.psychedelicfinance.com/articles/hollister-biosciences-enters-into-definitive-agreement-to-acquire-alphamind-brands-inc https://www.psychedelicfinance.com/articles/hollister-biosciences-inc-ceo-provides-corporate-update https://www.psychedelicfinance.com/articles/hollister-biosciences-inc-provides-update-on-q2-2020-performance-and-announces-distribution-license-renewal https://www.psychedelicfinance.com/articles/hollister-biosciences-inc-subsidiary-alphamind-brands-inc-plans-to-launch-initial-medicinal-mushroom-based-product-line https://www.psychedelicfinance.com/articles/horizons-etfs-announces-methodology-update-for-the-north-american-psychedelics-index https://www.psychedelicfinance.com/articles/horizons-etfs-completes-rebalance-of-worlds-first-psychedelics-etf https://www.psychedelicfinance.com/articles/horizons-files-preliminary-long-form-prospectus-for-first-psychedelic-etf https://www.psychedelicfinance.com/articles/horizons-psychedelic-etf-psyk-holdings-january-27-2021 https://www.psychedelicfinance.com/articles/ian-burnstein-joins-wesana-health-advisory-board https://www.psychedelicfinance.com/articles/ian-burnstein-joins-wesana-health-board-of-directors https://www.psychedelicfinance.com/articles/incannex-completes-listing-of-american-depositary-shares-on-nasdaq-rings-nasdaq-closing-bell https://www.psychedelicfinance.com/articles/incannex-completes-loyalty-option-program-to-raise-a-23-6m-current-cash-at-bank-is-approximately-a-40-0m https://www.psychedelicfinance.com/articles/incannex-executes-license-agreement-with-monash-university-to-develop-a-combination-treatment-using-virtual-reality-and-psychedelics https://www.psychedelicfinance.com/articles/incannex-observes-substantial-reduction-in-ahi-in-preliminary-results-of-clinical-trial-assessing-ihl-42x-in-patients-with-osa-proceeds-to-pivotal-studies https://www.psychedelicfinance.com/articles/incannex-to-acquire-apirx-pharmaceuticals-usa-llc https://www.psychedelicfinance.com/articles/institutional-review-board-grants-approval-for-cybin-sponsored-feasibility-study-using-kernel-flow-technology-to-measure-psychedelic-effects-on-the-brain https://www.psychedelicfinance.com/articles/intelgenx-announces-enrollment-reaches-halfway-mark-in-buena-montelukast-versafilm-r-phase-2a-clinical-trial-in-patients-with-mild-to-moderate-alzheimers-disease https://www.psychedelicfinance.com/articles/intelgenx-announces-initial-closing-of-atai-investment https://www.psychedelicfinance.com/articles/intelgenx-announces-intention-to-issue-shares-in-payment-of-principal-and-interest-on-outstanding-debentures https://www.psychedelicfinance.com/articles/intelgenx-announces-issuance-of-new-u-s-patent-covering-versafilm-r-technology https://www.psychedelicfinance.com/articles/intelgenx-announces-noteholder-approval-of-proposed-amendments-to-convertible-notes https://www.psychedelicfinance.com/articles/intelgenx-announces-research-collaboration-with-renowned-neurologist-to-evaluate-montelukast-versafilm-r-for-the-treatment-of-parkinsons-disease https://www.psychedelicfinance.com/articles/intelgenx-announces-shareholder-approval-of-atai-investment https://www.psychedelicfinance.com/articles/intelgenx-expands-psychedelics-collaboration-with-atai-life-sciences-with-signing-of-second-feasibility-agreement https://www.psychedelicfinance.com/articles/intelgenx-files-provisional-u-s-patent-application-for-advanced-oral-film-formulation-improving-cannabinoid-onset-of-action https://www.psychedelicfinance.com/articles/intelgenx-receives-fda-gdufa-date-for-xiromed-partnered-development-candidate-buprenorphine-buccal-film https://www.psychedelicfinance.com/articles/intelgenx-receives-final-approval-to-graduate-to-toronto-stock-exchange https://www.psychedelicfinance.com/articles/intelgenx-receives-fourth-and-final-loan-tranche-from-atai https://www.psychedelicfinance.com/articles/intelgenx-receives-u-s-6-million-in-additional-loans-from-atai-life-sciences-and-conditional-approval-to-graduate-to-toronto-stock-exchange https://www.psychedelicfinance.com/articles/intelgenx-reports-first-quarter-2021-financial-results https://www.psychedelicfinance.com/articles/intelgenx-reports-fourth-quarter-and-full-year-2021-financial-results https://www.psychedelicfinance.com/articles/intelgenx-reports-second-quarter-2022-financial-results https://www.psychedelicfinance.com/articles/intelgenx-reports-third-quarter-2022-financial-results https://www.psychedelicfinance.com/articles/intelgenx-strengthens-board-with-the-appointments-of-dr-srinivas-g-rao-and-frank-stegert https://www.psychedelicfinance.com/articles/intelgenx-submits-response-to-crl-from-fda-for-rizaport-r-versafilm-r https://www.psychedelicfinance.com/articles/intelgenx-to-participate-in-the-2022-bloom-burton-co-healthcare-investor-conference https://www.psychedelicfinance.com/articles/intelgenx-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-24-2022-conference-call-to-follow https://www.psychedelicfinance.com/articles/intelgenx-to-report-second-quarter-2021-financial-results-on-august-4-2021-conference-call-to-follow https://www.psychedelicfinance.com/articles/intelgenx-to-report-second-quarter-2022-financial-results-on-august-11-2022-conference-call-to-follow https://www.psychedelicfinance.com/articles/intelgenx-to-report-third-quarter-2021-financial-results-on-november-11-2021-conference-call-to-follow https://www.psychedelicfinance.com/articles/intelgenxs-collaboration-with-atai-life-sciences-culminates-in-the-initiation-of-first-in-human-clinical-study-of-an-oral-thin-film-psychedelic-drug-candidate https://www.psychedelicfinance.com/articles/intelgenxs-vetafilm-tm-platform-to-be-evaluated-by-one-of-the-worlds-fastest-growing-animal-healthcare-companies https://www.psychedelicfinance.com/articles/interim-analysis-shows-at-least-90-chance-of-statistically-significant-difference-in-ptsd-symptoms-after-mdma-assisted-psychotherapy https://www.psychedelicfinance.com/articles/interview-adam-halberstadt-uc-san-diego https://www.psychedelicfinance.com/articles/interview-amanda-feilding-founder-and-executive-director-beckley-foundation https://www.psychedelicfinance.com/articles/interview-amir-inamdar-chief-medical-officer-cybin-inc https://www.psychedelicfinance.com/articles/interview-ben-nikolaevsky-ceo-pure-extracts https://www.psychedelicfinance.com/articles/interview-derrick-welsh https://www.psychedelicfinance.com/articles/interview-psychedelics-emerging-therapies-husch-blackwell-law-firm https://www.psychedelicfinance.com/articles/irie-selkirk-co-founder-rise-wellness-retreat https://www.psychedelicfinance.com/articles/irwin-naturals-agrees-to-add-idaho-clinic-to-its-national-chain-of-psychedelic-mental-health-clinics https://www.psychedelicfinance.com/articles/irwin-naturals-and-braxia-scientific-announce-partnership-for-in-human-clinical-studies-supporting-pharmaceutical-companies-in-the-us https://www.psychedelicfinance.com/articles/irwin-naturals-announces-intention-to-file-draft-registration-statement https://www.psychedelicfinance.com/articles/irwin-naturals-completes-acquisition-of-midwest-ketafusion https://www.psychedelicfinance.com/articles/irwin-naturals-completes-georgia-acquisition-adds-two-ketamine-clinics-to-national-chain https://www.psychedelicfinance.com/articles/irwin-naturals-continues-to-expand-clinic-footprint https://www.psychedelicfinance.com/articles/irwin-naturals-emergence-adds-new-england-clinic-to-its-national-footprint https://www.psychedelicfinance.com/articles/irwin-naturals-emergence-making-immediate-impact-in-new-england https://www.psychedelicfinance.com/articles/irwin-naturals-emergence-to-add-ohio-ketamine-clinic https://www.psychedelicfinance.com/articles/irwin-naturals-expands-operations-into-northeast-with-acquisition-of-vermont-based-clinic https://www.psychedelicfinance.com/articles/irwin-naturals-files-q1-2022-financials https://www.psychedelicfinance.com/articles/irwin-naturals-files-q2-2022-financials https://www.psychedelicfinance.com/articles/irwin-naturals-leverages-household-brand-status-in-effort-to-be-worlds-largest-chain-of-psychedelic-mental-health-clinics https://www.psychedelicfinance.com/articles/irwin-naturals-looks-to-add-pacific-northwest-ketamine-clinic-to-its-national-footprint https://www.psychedelicfinance.com/articles/irwin-naturals-looks-to-add-to-florida-foothold-in-expanding-chain-of-healthcare-clinics https://www.psychedelicfinance.com/articles/irwin-naturals-secures-40-million-of-financing-for-its-current-operations-including-psychedelic-mental-health-clinic-rollup-potential-for-up-to-60-million https://www.psychedelicfinance.com/articles/irwin-naturals-signs-letter-of-intent-to-acquire-braxia-scientific https://www.psychedelicfinance.com/articles/israel-based-clearmind-announces-additional-positive-results-from-the-third-part-of-its-pre-clinical-study-for-cocaine-addiction-treatment https://www.psychedelicfinance.com/articles/israel-based-clearmind-medicine-announces-first-clinical-center-to-join-its-clinical-trial-for-alcohol-use-disorder https://www.psychedelicfinance.com/articles/israel-based-clearmind-medicine-granted-u-s-patent-for-psychedelic-based-alcohol-substitute https://www.psychedelicfinance.com/articles/israel-based-clearmind-medicine-inc-ceo-discusses-the-potential-of-psychedelics-for-addiction-treatment-in-audio-interview-with-smallcapvoice-com https://www.psychedelicfinance.com/articles/israel-based-clearmind-medicine-shows-efficacy-of-psychedelic-derived-obesity-treatment-in-pre-clinical-trial https://www.psychedelicfinance.com/articles/israel-based-clearmind-medicine-successfully-completes-production-of-cmnd-100-drug-candidate-for-clinical-trial https://www.psychedelicfinance.com/articles/israel-based-clearmind-medicine-to-present-at-the-ourcrowd-global-investor-summit-sponsored-by-greenberg-traurig-tel-aviv https://www.psychedelicfinance.com/articles/israel-based-clearmind-successfully-completed-two-r-d-projects-with-the-hebrew-university-of-jerusalems-tech-transfer-company-yissum https://www.psychedelicfinance.com/articles/israeli-based-clearmind-medicine-to-host-virtual-investor-conference-on-psychedelics-for-obesity https://www.psychedelicfinance.com/articles/israeli-biotech-clearmind-medicine-announces-positive-pre-clinical-results-treating-major-depression-with-a-novel-ketamine-based-compound https://www.psychedelicfinance.com/articles/ixtlan-bioscience-announces-the-filing-of-new-patent-for-the-psilocybin-treatment-of-alzheimers-disease-and-brain-pathologies https://www.psychedelicfinance.com/articles/jaguar-health-and-filament-health-with-funding-from-one-small-planet-form-joint-venture-magdalena-biosciences-to-develop-botanical-pharmaceutical-drug-candidates-for-mental-health-illnesses https://www.psychedelicfinance.com/articles/jaguar-health-announces-establishment-of-board-of-directors-for-newly-formed-joint-venture-magdalena-biosciences https://www.psychedelicfinance.com/articles/james-kuo-md-mba-ceo-tryp-therapeutics https://www.psychedelicfinance.com/articles/jeff-siegel-managing-partner-jls-fund https://www.psychedelicfinance.com/articles/jeff-stevens-ceo-psyched-wellness https://www.psychedelicfinance.com/articles/jerry-march-coo-new-york-ketamine-infusions https://www.psychedelicfinance.com/articles/jj-wilson-chairman-of-the-board-optimi-health https://www.psychedelicfinance.com/articles/jody-aufrichtig-co-founder-president-and-ceo-the-psyence-group https://www.psychedelicfinance.com/articles/joel-raskin https://www.psychedelicfinance.com/articles/joint-feasibility-assessment-of-bionomics-bnc210-and-empathbios-mdma-derivative-emp-01-treatment-regimen-for-ptsd https://www.psychedelicfinance.com/articles/joseph-del-moral-founder-ceo-field-trip-health https://www.psychedelicfinance.com/articles/joseph-tucker-ceo-magicmed-industries https://www.psychedelicfinance.com/articles/journal-of-psychedelic-studies https://www.psychedelicfinance.com/articles/judy-blumstock-ceo-founder-diamond-therapeutics https://www.psychedelicfinance.com/articles/justin-hanka-co-founder-mindbio-therapeutics https://www.psychedelicfinance.com/articles/justin-kirkland-cso-optimi-spotlight-interview https://www.psychedelicfinance.com/articles/kelsey-ramsden-ceo-mind-cure-health https://www.psychedelicfinance.com/articles/ketamd-expands-access-to-breakthrough-ketamine-therapy-in-florida-to-battle-the-growing-mental-health-crisis-and-shortage-of-mental-health-care-providers https://www.psychedelicfinance.com/articles/ketamine-one-adds-seattle-location-to-us-clinical-network https://www.psychedelicfinance.com/articles/ketamine-one-advances-research-capabilities-via-controlled-substance-dealers-licence-application https://www.psychedelicfinance.com/articles/ketamine-one-announced-intention-to-submit-draft-registration-statement-for-proposed-u-s-initial-public-offering https://www.psychedelicfinance.com/articles/ketamine-one-announces-adam-deffett-as-interim-ceo https://www.psychedelicfinance.com/articles/ketamine-one-announces-lifting-of-management-cease-trade-order https://www.psychedelicfinance.com/articles/ketamine-one-announces-virtual-mental-healthcare-platform-in-partnership-with-ihealthox https://www.psychedelicfinance.com/articles/ketamine-one-appoints-joe-ramelli-as-its-new-chief-financial-officer https://www.psychedelicfinance.com/articles/ketamine-one-appoints-loreto-grimaldi-to-board-of-directors https://www.psychedelicfinance.com/articles/ketamine-one-appoints-two-new-members-to-its-medical-advisory-board https://www.psychedelicfinance.com/articles/ketamine-one-becomes-exclusive-ketamine-treatment-provider-to-victoria-wellness https://www.psychedelicfinance.com/articles/ketamine-one-begins-trading-on-the-otcqb-marketplace-on-january-12-2022 https://www.psychedelicfinance.com/articles/ketamine-one-changes-name-to-wellbeing-digital-sciences https://www.psychedelicfinance.com/articles/ketamine-one-closes-previously-announced-acquisition-of-integrated-rehab-and-performance https://www.psychedelicfinance.com/articles/ketamine-one-engages-psychology-counselling-services-group-for-irp-health-pcsg-to-provide-psychology-therapy-dietary-and-other-mental-health-services-for-the-wholly-owned-ketamine-one-subsidiary https://www.psychedelicfinance.com/articles/ketamine-one-establishes-medical-advisory-board https://www.psychedelicfinance.com/articles/ketamine-one-features-biostrap-as-part-of-inaugural-research-studies https://www.psychedelicfinance.com/articles/ketamine-one-highlights-psychedelic-research-and-announces-new-clinical-trial https://www.psychedelicfinance.com/articles/ketamine-one-launches-immersive-virtual-reality-r-d-program-at-mindscape-clinic https://www.psychedelicfinance.com/articles/ketamine-one-launching-two-inaugural-research-studies https://www.psychedelicfinance.com/articles/ketamine-one-partners-with-cognetivity-neurosciences-in-collaborative-clinical-study-on-depression-and-ptsd https://www.psychedelicfinance.com/articles/ketamine-one-reports-audited-financial-results-for-the-2021-fiscal-year https://www.psychedelicfinance.com/articles/ketamine-one-reports-strong-1q22-financial-results https://www.psychedelicfinance.com/articles/ketamine-one-signs-definitive-agreement-to-acquire-integrated-rehab-and-performance-ltd https://www.psychedelicfinance.com/articles/ketamine-one-signs-loi-for-two-ketamine-infusion-clinics-in-texas https://www.psychedelicfinance.com/articles/ketamine-one-signs-loi-with-veteran-services-usa-to-open-therapy-center https://www.psychedelicfinance.com/articles/ketamine-one-subsidiary-irp-health-expands-with-new-veteran-focused-clinics https://www.psychedelicfinance.com/articles/ketamine-one-subsidiary-irp-health-opens-two-new-veteran-focused-clinics https://www.psychedelicfinance.com/articles/ketamine-one-subsidiary-kgk-science-becomes-the-first-founding-sponsor-of-the-psychedelic-science-2023-event https://www.psychedelicfinance.com/articles/ketamine-one-subsidiary-kgk-science-contracted-to-support-a-ketamine-clinical-trial-in-the-united-states https://www.psychedelicfinance.com/articles/ketamine-one-subsidiary-kgk-science-secures-multiple-new-contracts https://www.psychedelicfinance.com/articles/ketamine-one-to-deploy-cognetivitys-integrated-cognitive-assessment-tool https://www.psychedelicfinance.com/articles/ketamine-one-to-provide-scent-enabled-virtual-reality-via-exclusive-agreement-for-psychedelic-molecules-with-ovr-technology https://www.psychedelicfinance.com/articles/ketamine-ones-irp-clinic-using-innovative-neurocatch-platform-to-measure-brain-function-in-injured-veterans https://www.psychedelicfinance.com/articles/ketamine-wellness-centers-kwc-expands-insurance-coverage-with-medicare-for-ketamine-therapy-patients https://www.psychedelicfinance.com/articles/ketamine-wellness-centers-kwc-launches-ketamine-wellness-integrative-therapist-directory https://www.psychedelicfinance.com/articles/ketamine-wellness-centers-kwc-launches-spravato-r-nasal-spray-therapy-in-minneapolis-salt-lake-city-and-dallas https://www.psychedelicfinance.com/articles/ketamine-wellness-centers-kwc-partners-with-veterans-administration-community-care-network-va-ccn-to-expand-spravato-r-coverage https://www.psychedelicfinance.com/articles/ketamineone-subsidiary-kgk-science-helps-client-receive-new-dietary-ingredient-status-from-u-s-fda https://www.psychedelicfinance.com/articles/leading-microbiologist-dr-robert-e-w-hancock-appointed-as-executive-chairman-of-core-one-labs https://www.psychedelicfinance.com/articles/leading-parkinsons-researcher-dr-robert-a-hauser-joins-pharmather-as-scientific-advisor https://www.psychedelicfinance.com/articles/legal-psychedelic-therapy-comes-to-alberta-with-ground-breaking-health-canada-decision https://www.psychedelicfinance.com/articles/levitee-clinics-and-levitee-pharmacies-provide-insight-on-integrated-acquisition-strategy-for-its-addiction-and-pain-services https://www.psychedelicfinance.com/articles/levitee-labs-acquires-five-addiction-clinics-in-alberta https://www.psychedelicfinance.com/articles/levitee-labs-acquires-three-specialized-alberta-pharmacies https://www.psychedelicfinance.com/articles/levitee-labs-announces-agreement-with-adracare-a-well-health-company-to-support-individuals-with-addiction-and-mental-health-conditions https://www.psychedelicfinance.com/articles/levitee-labs-announces-azim-qazi-as-head-of-ecommerce-and-consumer-packaged-goods https://www.psychedelicfinance.com/articles/levitee-labs-announces-closing-of-oversubscribed-private-placement https://www.psychedelicfinance.com/articles/levitee-labs-announces-completion-of-acquisition-of-blockmd-telemedicine-platform https://www.psychedelicfinance.com/articles/levitee-labs-announces-dtc-eligibility-approval https://www.psychedelicfinance.com/articles/levitee-labs-announces-gold-sponsorship-of-wonderland-psychedelic-conference-in-miami https://www.psychedelicfinance.com/articles/levitee-labs-announces-listing-on-frankfurt-stock-exchange https://www.psychedelicfinance.com/articles/levitee-labs-announces-medical-advisory-board https://www.psychedelicfinance.com/articles/levitee-labs-announces-philip-van-den-berg-to-join-as-interim-ceo-and-the-board-of-directors-and-close-first-tranche-of-private-placement-for-1-5-million https://www.psychedelicfinance.com/articles/levitee-labs-announces-strategic-partnership-with-liverx-research-group-to-provide-equitable-access-to-hepatitis-c-care-throughout-alberta-canada https://www.psychedelicfinance.com/articles/levitee-labs-appoints-dr-mohammed-mosli-as-chief-people-officer-of-levitee-clinics-and-pharmacies-in-alberta-canada https://www.psychedelicfinance.com/articles/levitee-labs-appoints-nih-physician-scientist-dr-fady-hannah-shmouni-as-chief-medical-and-scientific-officer https://www.psychedelicfinance.com/articles/levitee-labs-appoints-noha-elsayed-as-executive-director-for-levitee-clinics-and-levitee-pharmacies-in-the-alberta-region https://www.psychedelicfinance.com/articles/levitee-labs-commences-trading-in-u-s-under-ticker-lvttf https://www.psychedelicfinance.com/articles/levitee-labs-completes-acquisition-of-earth-circle-organics-adds-superfoods-company-to-portfolio https://www.psychedelicfinance.com/articles/levitee-labs-enters-into-credit-facility-for-up-to-12-million https://www.psychedelicfinance.com/articles/levitee-labs-partners-with-canntab-therapeutics-to-provide-alternatives-to-opioids https://www.psychedelicfinance.com/articles/levitee-labs-provides-company-update-following-cse-listing https://www.psychedelicfinance.com/articles/levitee-labs-publishes-first-revenue-figures-for-august-2021 https://www.psychedelicfinance.com/articles/levitee-labs-signs-definitive-agreements-to-acquire-clinics-pharmacies-and-a-telemedicine-company-in-alberta https://www.psychedelicfinance.com/articles/levitee-labs-signs-letter-of-intent-to-acquire-a-chain-of-specialty-addiction-pharmacies-located-in-british-columbia https://www.psychedelicfinance.com/articles/levitee-labs-signs-letter-of-intent-to-acquire-calgary-addiction-and-compounding-pharmacy https://www.psychedelicfinance.com/articles/levitee-labs-signs-loi-to-acquire-controlling-interest-in-a-r-d-compounding-pharmacy-focus-to-be-on-levitee-branded-products https://www.psychedelicfinance.com/articles/levitee-labs-signs-retail-distribution-agreement-with-body-energy-club-for-monke-nutraceuticals https://www.psychedelicfinance.com/articles/levitee-labs-to-commence-trading-on-the-canadian-securities-exchange-under-the-ticker-symbol-lvt-on-wednesday-july-21st-2021 https://www.psychedelicfinance.com/articles/life-sciences-virtual-investor-conference-company-executives-present-live-march-10th https://www.psychedelicfinance.com/articles/lobe-announces-krysalis-vx-innovations-inc-a-company-equally-owned-by-lobe-sciences-ltd-and-virtual-psychedelics-incorporated-appointment-of-interdisciplinary-team-of-advisors https://www.psychedelicfinance.com/articles/lobe-sciences-acquires-vitamind-line-of-wellness-products https://www.psychedelicfinance.com/articles/lobe-sciences-added-to-horizons-psychedelic-stock-index-etf https://www.psychedelicfinance.com/articles/lobe-sciences-and-cantheon-capital-enter-into-exclusive-investment-agreement-to-fund-1-5m-usd-toward-clinical-trials-in-australia https://www.psychedelicfinance.com/articles/lobe-sciences-and-the-world-boxing-association-announce-initiative-targeting-mtbi-and-ptsd https://www.psychedelicfinance.com/articles/lobe-sciences-announces-cad-23-000-000-sale-of-cowlitz-cannabis-option-to-ionic-brands-corp https://www.psychedelicfinance.com/articles/lobe-sciences-announces-changes-to-board-of-directors https://www.psychedelicfinance.com/articles/lobe-sciences-announces-closing-of-private-placement https://www.psychedelicfinance.com/articles/lobe-sciences-announces-common-stock-to-trade-under-the-symbol-lobef-in-us-markets https://www.psychedelicfinance.com/articles/lobe-sciences-announces-data-demonstrating-that-its-combination-therapeutic-candidates-are-significantly-more-effective-than-monotherapy-in-mtbi-and-ptsd https://www.psychedelicfinance.com/articles/lobe-sciences-announces-filing-of-pct-application https://www.psychedelicfinance.com/articles/lobe-sciences-announces-further-upsizing-and-second-closing-of-non-brokered-private-placement https://www.psychedelicfinance.com/articles/lobe-sciences-announces-incorporation-of-australian-subsidiary https://www.psychedelicfinance.com/articles/lobe-sciences-announces-jonathan-gilbert-appointed-executive-chairman-of-the-board-of-directors https://www.psychedelicfinance.com/articles/lobe-sciences-announces-launch-of-preclinical-study-in-collaboration-with-the-university-of-miami-miller-school-of-medicine https://www.psychedelicfinance.com/articles/lobe-sciences-announces-management-changes-and-new-director https://www.psychedelicfinance.com/articles/lobe-sciences-announces-non-brokered-private-placement https://www.psychedelicfinance.com/articles/lobe-sciences-announces-publication-of-pct-patent-application-for-its-combination-therapy-for-mtbi-and-ptsd https://www.psychedelicfinance.com/articles/lobe-sciences-announces-roadmap-for-remainder-of-2022-and-early-2023 https://www.psychedelicfinance.com/articles/lobe-sciences-announces-share-consolidation https://www.psychedelicfinance.com/articles/lobe-sciences-announces-that-its-shares-will-trade-on-the-otcqb-r-market-in-the-united-states https://www.psychedelicfinance.com/articles/lobe-sciences-announces-the-appointment-of-baxter-f-phillips-iii-to-its-board-of-directors https://www.psychedelicfinance.com/articles/lobe-sciences-announces-the-completion-of-cgmp-production-of-clinical-supplies-for-upcoming-clinical-trials https://www.psychedelicfinance.com/articles/lobe-sciences-announces-the-expansion-of-its-patent-portfolio-with-international-filings https://www.psychedelicfinance.com/articles/lobe-sciences-announces-update-on-corporate-slide-deck-highlighting-its-psilocin-compounds-and-development-plans https://www.psychedelicfinance.com/articles/lobe-sciences-announces-upsizing-and-first-closing-of-non-brokered-private-placement https://www.psychedelicfinance.com/articles/lobe-sciences-appoints-benjamin-kelmendi-md-from-yale-university-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/lobe-sciences-appoints-ilan-hayman-to-advisory-board https://www.psychedelicfinance.com/articles/lobe-sciences-appoints-nfl-alumni-association-president-bart-oates-esq-to-advisory-board https://www.psychedelicfinance.com/articles/lobe-sciences-becomes-enterprise-member-of-nfl-alumni-association https://www.psychedelicfinance.com/articles/lobe-sciences-board-of-directors-elects-to-receive-shares-in-lieu-of-cash-for-all-board-fees https://www.psychedelicfinance.com/articles/lobe-sciences-commences-engineering-of-nasal-mist-device https://www.psychedelicfinance.com/articles/lobe-sciences-completes-previously-announced-sale-of-cannabis-assets-to-ionic-brands https://www.psychedelicfinance.com/articles/lobe-sciences-congratulates-australia-for-becoming-the-first-nation-to-approve-the-medicinal-use-of-psilocybin-and-mdma https://www.psychedelicfinance.com/articles/lobe-sciences-enters-into-an-exclusive-agreement-with-ingenu-to-conduct-clinical-trials-in-australia https://www.psychedelicfinance.com/articles/lobe-sciences-enters-into-joint-venture-with-virtual-psychedelics-incorporated-to-develop-multi-sensory-pods-for-clinical-psychedelic-use https://www.psychedelicfinance.com/articles/lobe-sciences-enters-into-loi-with-core-one-labs-to-form-a-joint-venture-for-the-clinical-development-of-biosynthetic-psilocybin https://www.psychedelicfinance.com/articles/lobe-sciences-files-patent-application-covering-the-preparation-of-stable-psilocin-prodrugs-and-analogues-and-their-uses-further-strengthening-its-intellectual-property-portfolio https://www.psychedelicfinance.com/articles/lobe-sciences-initiates-phase-1-clinical-trial-of-l-130 https://www.psychedelicfinance.com/articles/lobe-sciences-invites-you-to-join-us-at-the-q2-virtual-investor-summit https://www.psychedelicfinance.com/articles/lobe-sciences-invites-you-to-join-us-at-the-q4-virtual-investor-summit https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-acquires-securities-of-ionic-brands-corp https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-and-clearway-global-llc-enter-into-a-development-agreement-to-manage-lobe-sciences-ltd-s-global-regulatory-and-development-strategy-and-its-implementation https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-announces-exclusive-collaboration-with-quality-chemical-laboratories-llc https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-announces-regulatory-and-clinical-development-plans-for-2022-and-early-2023 https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-announces-the-acquisition-of-altemia-tm-company https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-enters-collaborative-clinical-research-agreement-with-integrative-headache-medicine-of-new-york-to-study-the-effects-of-l-130-in-the-treatment-of-chronic-cluster-headache https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-invites-you-to-join-us-at-the-q1-virtual-investor-summit https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-strengthens-its-balance-sheet https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-group-llc-and-hosted-by-m-vest-on-march-28th-30th-from-9-00-a-m-5-00-p-m-edt https://www.psychedelicfinance.com/articles/lobe-sciences-ltd-to-participate-in-the-lytham-partners-spring-2022-investor-conference https://www.psychedelicfinance.com/articles/lobe-sciences-provides-an-update-to-clinical-development-plans-for-its-proprietary-psilocin-product-l-130 https://www.psychedelicfinance.com/articles/lobe-sciences-provides-corporate-update-to-investors-and-stakeholders https://www.psychedelicfinance.com/articles/lobe-sciences-provides-update-for-2023-milestones https://www.psychedelicfinance.com/articles/lobe-sciences-retains-jolt-communications-to-increase-investor-awareness https://www.psychedelicfinance.com/articles/lobe-sciences-secures-production-and-supply-agreement-for-vitamind-consumer-packaged-goods-products https://www.psychedelicfinance.com/articles/lobe-sciences-signs-definitive-agreement-for-sale-of-cowlitz-cannabis-assets-to-ionic-brands-corp https://www.psychedelicfinance.com/articles/lobe-sciences-sponsors-the-international-summit-on-psychedelic-therapies-for-mental-illness https://www.psychedelicfinance.com/articles/lobe-sciences-successfully-completes-proof-of-concept-of-proprietary-nasal-mist-device https://www.psychedelicfinance.com/articles/lobe-sciences-to-participate-at-the-advances-in-mental-health-psychedelics-and-non-psychedelics-conference https://www.psychedelicfinance.com/articles/lobe-sciences-to-present-at-h-c-wainwright-bioconnect-investment-conference https://www.psychedelicfinance.com/articles/lobe-sciences-to-present-at-moneyshow-virtual-expo-november-10-2022 https://www.psychedelicfinance.com/articles/lobe-sciences-to-present-at-psychedelic-capital-virtual-investor-conference https://www.psychedelicfinance.com/articles/lobe-sciences-to-present-at-the-benzinga-global-small-cap-conference https://www.psychedelicfinance.com/articles/lobe-sciences-to-present-at-the-benzinga-healthcare-small-cap-conference https://www.psychedelicfinance.com/articles/lobe-sciences-to-present-at-the-biofuture-2021-moneyshow-virtual-expo-investor-conferences https://www.psychedelicfinance.com/articles/lobe-sciences-to-present-at-the-emerging-growth-conference-on-april-14-2021 https://www.psychedelicfinance.com/articles/lobe-sciences-to-present-at-virtual-one2one-investor-forum https://www.psychedelicfinance.com/articles/lorne-gertner-chairman-cannaglobal-wellness https://www.psychedelicfinance.com/articles/maghsoud-dariani-chief-sciences-officer-lobe-sciences https://www.psychedelicfinance.com/articles/magicmed-industries-announces-2-5-million-unit-offering-led-by-gravitas-securities https://www.psychedelicfinance.com/articles/magicmed-industries-announces-agreements-with-the-university-of-calgary-to-accelerate-development-of-the-magicmed-psybrary-tm https://www.psychedelicfinance.com/articles/magicmed-industries-announces-closing-of-upsized-and-oversubscribed-8-1-million-private-placement-of-units-led-by-gravitas-securities-due-to-significant-investor-demand https://www.psychedelicfinance.com/articles/magicmed-industries-announces-collaboration-with-artificial-intelligence-thought-leaders-and-the-launch-of-psyai https://www.psychedelicfinance.com/articles/magicmed-industries-announces-the-establishment-of-psilocybin-derivatives-portfolio-and-launch-of-candidate-selection-program https://www.psychedelicfinance.com/articles/magicmed-industries-closes-oversubscribed-private-placement-for-1-642-880-with-mackie-research-capital-corporation https://www.psychedelicfinance.com/articles/magicmed-industries-files-first-psychedelic-derivative-patent https://www.psychedelicfinance.com/articles/magicmed-industries-inc-announces-brokered-private-placement-with-mackie-research-capital-corporation https://www.psychedelicfinance.com/articles/maps-and-vine-ventures-pioneer-novel-regenerative-funding-structure-to-infuse-psychedelic-assisted-therapy-research-and-access-with-timely-70-million https://www.psychedelicfinance.com/articles/maps-and-wesana-health-resume-negotiations https://www.psychedelicfinance.com/articles/maps-completes-enrollment-as-planned-for-the-confirmatory-phase-3-trial-of-mdma-assisted-therapy-for-ptsd https://www.psychedelicfinance.com/articles/maps-receives-5-million-grant-from-the-steven-alexandra-cohen-foundation https://www.psychedelicfinance.com/articles/maria-sabina https://www.psychedelicfinance.com/articles/mark-haden-psychedelic-medicine-expert-joins-clearmind-medicines-advisory-board https://www.psychedelicfinance.com/articles/mark-haden-scientific-advisory-board-clearmind https://www.psychedelicfinance.com/articles/mary-elizabeth-gifford-executive-vice-president-psyence-group https://www.psychedelicfinance.com/articles/matthew-singh-coo-psyched-wellness https://www.psychedelicfinance.com/articles/maxim-group-initiates-coverage-of-mind-cure-health https://www.psychedelicfinance.com/articles/mcoa-subsidiary-cdistro-signs-distribution-agreement-with-silo-wellness-and-marley-one-functional-mushrooms https://www.psychedelicfinance.com/articles/mdma-assisted-psychotherapy-may-have-lasting-benefits-for-ptsd-results-published-in-psychopharmacology https://www.psychedelicfinance.com/articles/mental-health-care-company-compass-pathways-strengthens-leadership-team-with-appointment-of-trevor-mill-as-chief-development-officer https://www.psychedelicfinance.com/articles/mind-cure-adds-alain-roy-as-a-product-development-specialist https://www.psychedelicfinance.com/articles/mind-cure-announces-addition-of-global-technology-leader-robert-c-hill-to-board-of-directors https://www.psychedelicfinance.com/articles/mind-cure-announces-addition-of-neuroscientist-dr-wolfram-tetzlaff-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/mind-cure-announces-build-out-of-digital-therapeutics-istrym-a-technology-platform-for-mental-wellness-optimization-psychedelic-research https://www.psychedelicfinance.com/articles/mind-cure-announces-closing-of-23-million-bought-deal-offering-including-full-exercise-of-over-allotment-option https://www.psychedelicfinance.com/articles/mind-cure-announces-closing-of-oversubscribed-3-6-million-offering https://www.psychedelicfinance.com/articles/mind-cure-announces-closing-of-oversubscribed-upsized-initial-public-offering https://www.psychedelicfinance.com/articles/mind-cure-announces-commencement-of-trading-on-the-cse https://www.psychedelicfinance.com/articles/mind-cure-announces-geoff-belair-as-chief-technology-officer https://www.psychedelicfinance.com/articles/mind-cure-announces-hiring-of-award-winning-experimental-scientist-dr-ryan-hartwell-as-chief-science-officer https://www.psychedelicfinance.com/articles/mind-cure-announces-its-research-program-with-psychedelic-compounds https://www.psychedelicfinance.com/articles/mind-cure-announces-kelsey-ramsden-as-new-chief-operating-officer https://www.psychedelicfinance.com/articles/mind-cure-announces-loi-for-acquisition-of-epiphany360-digital-therapeutics-platform-for-treating-mental-health https://www.psychedelicfinance.com/articles/mind-cure-announces-non-brokered-private-placement-of-3-million https://www.psychedelicfinance.com/articles/mind-cure-announces-novel-supplement-product-to-address-teen-wellness https://www.psychedelicfinance.com/articles/mind-cure-announces-retail-roll-out-of-nootropics-lineup-across-north-america-with-body-energy-club https://www.psychedelicfinance.com/articles/mind-cure-announces-update-on-upsized-initial-public-offering https://www.psychedelicfinance.com/articles/mind-cure-comments-on-recent-promotional-activity https://www.psychedelicfinance.com/articles/mind-cure-engages-dr-dan-engle-as-primary-investigator-for-research-in-traumatic-brain-injury-with-psychedelics https://www.psychedelicfinance.com/articles/mind-cure-health-inc-announces-10-million-bought-deal-public-offering https://www.psychedelicfinance.com/articles/mind-cure-health-inc-announces-an-increase-to-previously-announced-bought-deal-public-offering https://www.psychedelicfinance.com/articles/mind-cure-moves-into-psychedelic-assisted-therapy-with-british-columbia-location-offering-ketamine-and-psilocybin-therapy https://www.psychedelicfinance.com/articles/mind-cure-promotes-kelsey-ramsden-to-president-and-chief-executive-officer https://www.psychedelicfinance.com/articles/mind-cure-receives-health-canada-authorization-to-sell-its-moonbeam-mushroom-products-in-canada https://www.psychedelicfinance.com/articles/mind-cure-signs-loi-to-acquire-an-ownership-interest-in-psychedelic-treatment-center-atma-selected-by-section-56-exempt-patient-for-psilocybin-therapy https://www.psychedelicfinance.com/articles/mind-cure-welcomes-award-winning-journalist-and-science-researcher-hamilton-morris-to-advisory-board https://www.psychedelicfinance.com/articles/mind-cure-welcomes-dr-jason-wallach-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/mind-medicine-mindmed-inc-announces-q2-2020-financial-results https://www.psychedelicfinance.com/articles/mindcure-achieves-key-development-milestone-for-novel-ibogaine-program https://www.psychedelicfinance.com/articles/mindcure-adopts-advance-notice-policy https://www.psychedelicfinance.com/articles/mindcure-announces-additional-equity-investment-in-atma-the-first-government-approved-psychedelic-journey-centers-in-canada-mcur-president-and-ceo-kelsey-ramsden-named-to-atma-board-of-directors https://www.psychedelicfinance.com/articles/mindcure-announces-certification-of-hipaa-compliance-bringing-istrym-closer-to-commercial-deployment-in-the-second-quarter-of-2022 https://www.psychedelicfinance.com/articles/mindcure-announces-commencement-of-trading-on-the-otcqx-best-market https://www.psychedelicfinance.com/articles/mindcure-announces-experienced-finance-executive-michael-wolfe-as-cfo-and-appoints-larissa-chaikowsky-to-its-board-of-directors https://www.psychedelicfinance.com/articles/mindcure-announces-filing-of-u-s-provisional-patent-applications-for-companys-first-fully-synthetic-routes-to-create-an-ibogaine-psychedelic-compound https://www.psychedelicfinance.com/articles/mindcure-announces-financial-results-for-fiscal-2021 https://www.psychedelicfinance.com/articles/mindcure-announces-financial-results-for-the-second-quarter-of-fiscal-2022 https://www.psychedelicfinance.com/articles/mindcure-announces-financial-results-for-the-third-quarter-of-fiscal-2022 https://www.psychedelicfinance.com/articles/mindcure-announces-inclusion-in-advisorshares-psychedelics-etf https://www.psychedelicfinance.com/articles/mindcure-announces-listing-of-warrants https://www.psychedelicfinance.com/articles/mindcure-announces-manufacturing-of-synthetic-ibogaine-to-be-used-in-companys-clinical-research https://www.psychedelicfinance.com/articles/mindcure-announces-participation-at-upcoming-events-in-november-2021 https://www.psychedelicfinance.com/articles/mindcure-announces-partnership-with-soma-breath-inc-to-license-its-breathwork-program-and-develop-custom-breathwork-for-psychedelic-assisted-psychotherapies-within-istrym https://www.psychedelicfinance.com/articles/mindcure-announces-partnership-with-speak-ai-to-enhance-istrym-the-companys-psychedelic-digital-therapeutics-technology-platform https://www.psychedelicfinance.com/articles/mindcure-announces-platinum-sponsorship-of-the-2021-sana-symposium https://www.psychedelicfinance.com/articles/mindcure-announces-pre-and-post-psychedelic-therapy-adaptogen-supplements-defining-new-product-category https://www.psychedelicfinance.com/articles/mindcure-announces-strategic-review https://www.psychedelicfinance.com/articles/mindcure-announces-the-addition-of-daniel-herrera-a-pharmaceutical-industry-executive-with-specific-experience-in-medical-psychoactive-segment https://www.psychedelicfinance.com/articles/mindcure-appoints-dr-doron-sagman-as-chief-medical-officer https://www.psychedelicfinance.com/articles/mindcure-appoints-dr-john-brownstein-the-chief-innovation-officer-at-boston-childrens-hospital-as-company-advisor https://www.psychedelicfinance.com/articles/mindcure-appoints-jerry-white-award-winning-humanitarian-activist-who-shares-in-the-1997-nobel-peace-prize-as-company-advisor https://www.psychedelicfinance.com/articles/mindcure-completes-its-initial-strategic-equity-investment-in-atma-canadas-first-commercial-provider-of-legal-psychedelic-assisted-therapy-utilizing-psilocybin https://www.psychedelicfinance.com/articles/mindcure-develops-proprietary-ketamine-enhanced-psychotherapy-protocols-for-treatment-of-pain-and-depression https://www.psychedelicfinance.com/articles/mindcure-discovers-potential-opportunity-for-ibogaine-assisted-psychotherapy-to-treat-neuropathic-pain-and-traumatic-brain-injury https://www.psychedelicfinance.com/articles/mindcure-files-provisional-patent-application-for-istrym-its-proprietary-ai-digital-therapeutics-dtx-saas-platform-designed-to-enhance-effectiveness-of-psychedelic-assisted-therapies-for-practitioners-and-patients https://www.psychedelicfinance.com/articles/mindcure-hires-dr-clare-purvis-from-headspace-to-the-position-of-chief-product-officer-to-advance-mental-health-digital-therapeutics-platform https://www.psychedelicfinance.com/articles/mindcure-included-in-first-psychedelic-etf-north-american-psychedelics-index https://www.psychedelicfinance.com/articles/mindcure-joins-digital-therapeutics-alliance-to-drive-innovation-in-the-mental-health-industry https://www.psychedelicfinance.com/articles/mindcure-launches-desire-project-to-treat-female-hypoactive-sexual-desire-disorder-with-mdma-assisted-psychotherapy https://www.psychedelicfinance.com/articles/mindcure-launches-second-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research https://www.psychedelicfinance.com/articles/mindcure-names-tarik-lebbadi-as-chief-operating-officer https://www.psychedelicfinance.com/articles/mindcure-partners-its-istrym-technology-with-lucid-to-discover-and-create-proprietary-music-experiences-for-use-during-psychedelic-assisted-therapy-sessions https://www.psychedelicfinance.com/articles/mindcure-provides-update-on-strategic-review https://www.psychedelicfinance.com/articles/mindcure-provides-update-on-studies-and-clinical-trials https://www.psychedelicfinance.com/articles/mindcure-reaches-milestone-releasing-first-of-its-kind-mental-health-digital-therapeutics-platform-to-partner-clinics-in-north-america https://www.psychedelicfinance.com/articles/mindcure-receives-unconditional-ethics-approval-for-its-psychedelic-integration-protocol-research-study https://www.psychedelicfinance.com/articles/mindcure-shares-update-on-strong-financial-position-near-term-revenue-drivers-and-timeline-for-istryms-market-launch-delivering-mental-wealth https://www.psychedelicfinance.com/articles/mindcure-signs-exclusive-digital-clinical-data-licensing-agreement-with-atma-journey-centers https://www.psychedelicfinance.com/articles/mindcure-signs-loi-with-awakn-life-sciences-to-distribute-ketamine-protocol-for-alcohol-use-disorder-into-clinics-across-united-states-and-canada-through-istrym-mindcures-digital-therapeutics-platform https://www.psychedelicfinance.com/articles/mindcure-successfully-completes-first-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research https://www.psychedelicfinance.com/articles/mindcure-to-participate-in-maxim-group-llcs-advances-in-mental-health-virtual-conference https://www.psychedelicfinance.com/articles/mindcure-to-participate-in-the-h-c-wainwright-bioconnect-conference-in-january-2022 https://www.psychedelicfinance.com/articles/mindcure-to-participate-in-upcoming-conferences-in-december-2021 https://www.psychedelicfinance.com/articles/mindcure-to-present-at-the-benzinga-healthcare-small-cap-conference https://www.psychedelicfinance.com/articles/mindcure-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference https://www.psychedelicfinance.com/articles/mindcure-to-webcast-live-at-the-kcsa-psychedelics-virtual-investor-conference-on-october-13-2021 https://www.psychedelicfinance.com/articles/mindcure-welcomes-dr-ken-weingardt-digital-therapy-visionary-as-a-senior-clinical-technology-advisor-to-its-psychedelic-digital-therapeutics-team https://www.psychedelicfinance.com/articles/mindcures-proprietary-bioinformatics-platform-psycollage-beta-tested-and-deployed-for-product-discovery-and-lead-optimization https://www.psychedelicfinance.com/articles/mindleap-health-announces-the-launch-of-the-worlds-first-telehealth-platform-for-psychedelic-integration https://www.psychedelicfinance.com/articles/mindleap-health-implements-hipaa-compliance-standards-and-appoints-former-canadian-ministry-of-health-telemedicine-expert-as-head-of-program-management https://www.psychedelicfinance.com/articles/mindleap-health-signs-agreement-with-brightmind-to-launch-comprehensive-meditation-program https://www.psychedelicfinance.com/articles/mindleap-health-tm-expands-its-digital-mental-health-programs-for-addiction-psychedelic-integration-and-holistic-wellness https://www.psychedelicfinance.com/articles/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience https://www.psychedelicfinance.com/articles/mindmed-adds-mdma-to-develop-next-gen-psychedelic-therapies https://www.psychedelicfinance.com/articles/mindmed-adds-psychedelic-assisted-therapy-expert-dr-peter-gasser-as-clinical-advisor-for-project-lucy https://www.psychedelicfinance.com/articles/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator https://www.psychedelicfinance.com/articles/mindmed-and-bioxcel-therapeutics-publish-an-international-patent-application-describing-a-system-for-identifying-agitation-episodes https://www.psychedelicfinance.com/articles/mindmed-and-liechti-lab-announce-r-d-collaboration-on-psilocybin https://www.psychedelicfinance.com/articles/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing https://www.psychedelicfinance.com/articles/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-r-d-collaboration https://www.psychedelicfinance.com/articles/mindmed-and-liechti-lab-publish-first-human-data-on-the-interacting-effects-of-an-ssri-and-psilocybin https://www.psychedelicfinance.com/articles/mindmed-announces-10-million-bought-deal-equity-financing-to-fund-university-hospital-basel-collaboration https://www.psychedelicfinance.com/articles/mindmed-announces-2020-year-end-financial-results-current-cash-balance-of-161-million-usd-203-million-cad-to-support-drug-development-pipeline-and-creation-of-psychedelic-medicine-tech-platform https://www.psychedelicfinance.com/articles/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline https://www.psychedelicfinance.com/articles/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline https://www.psychedelicfinance.com/articles/mindmed-announces-25-million-bought-deal-public-offering https://www.psychedelicfinance.com/articles/mindmed-announces-25-million-bought-deal-public-offering-2 https://www.psychedelicfinance.com/articles/mindmed-announces-50-million-bought-deal-public-offering https://www.psychedelicfinance.com/articles/mindmed-announces-appointment-of-andreas-krebs-and-carol-vallone-as-directors-and-transition-of-bruce-linton https://www.psychedelicfinance.com/articles/mindmed-announces-appointment-of-dr-sarah-y-vinson-as-additional-director https://www.psychedelicfinance.com/articles/mindmed-announces-at-the-market-offering https://www.psychedelicfinance.com/articles/mindmed-announces-c-19-5-million-bought-deal-private-placement-offering https://www.psychedelicfinance.com/articles/mindmed-announces-chief-executive-officer-transition https://www.psychedelicfinance.com/articles/mindmed-announces-collaboration-with-forian-to-advance-development-of-personalized-psychiatry-for-anxiety-disorders https://www.psychedelicfinance.com/articles/mindmed-announces-completion-of-share-redesignation https://www.psychedelicfinance.com/articles/mindmed-announces-compliance-with-nasdaq-listing-requirements https://www.psychedelicfinance.com/articles/mindmed-announces-filing-of-preliminary-base-shelf-prospectus-and-f-10-with-the-sec-under-mjds https://www.psychedelicfinance.com/articles/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights-cash-balance-of-145-9-usd-185-4-cad-to-execute-on-diverse-clinical-pipeline https://www.psychedelicfinance.com/articles/mindmed-announces-first-ever-clinical-trial-combining-mdma-and-lsd https://www.psychedelicfinance.com/articles/mindmed-announces-first-patient-dosed-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder https://www.psychedelicfinance.com/articles/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt https://www.psychedelicfinance.com/articles/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system https://www.psychedelicfinance.com/articles/mindmed-announces-participation-at-upcoming-investor-conferences https://www.psychedelicfinance.com/articles/mindmed-announces-partnership-with-datavant-a-leading-health-data-connectivity-company https://www.psychedelicfinance.com/articles/mindmed-announces-positive-results-from-collaborators-placebo-controlled-investigator-initiated-trial-published-in-peer-reviewed-journal https://www.psychedelicfinance.com/articles/mindmed-announces-pricing-of-public-offering-of-common-shares-and-warrants https://www.psychedelicfinance.com/articles/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics https://www.psychedelicfinance.com/articles/mindmed-announces-proposed-public-offering-of-common-shares https://www.psychedelicfinance.com/articles/mindmed-announces-shareholder-meeting-results https://www.psychedelicfinance.com/articles/mindmed-announces-strategic-research-collaboration-with-sphere-health https://www.psychedelicfinance.com/articles/mindmed-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-project-lucy https://www.psychedelicfinance.com/articles/mindmed-announces-the-addition-of-stanford-university-neuroscientist-as-chair-of-the-scientific-advisory-board https://www.psychedelicfinance.com/articles/mindmed-announces-the-approval-of-mescaline-study https://www.psychedelicfinance.com/articles/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd https://www.psychedelicfinance.com/articles/mindmed-announces-the-publication-of-new-data-on-personalized-mdma-dosing https://www.psychedelicfinance.com/articles/mindmed-announces-the-start-of-the-first-ever-clinical-trial-combining-mdma-and-lsd https://www.psychedelicfinance.com/articles/mindmed-announces-transitions-to-management-team https://www.psychedelicfinance.com/articles/mindmed-appoints-dr-maria-oquendo-to-its-scientific-advisory-board https://www.psychedelicfinance.com/articles/mindmed-appoints-dr-robert-dworkin-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/mindmed-appoints-mgh-psychiatrist-in-chief-dr-maurizio-fava-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-m-d-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director https://www.psychedelicfinance.com/articles/mindmed-appoints-schond-l-greenway-as-chief-financial-officer https://www.psychedelicfinance.com/articles/mindmed-appoints-university-of-north-carolina-psychiatrist-and-pharmacologist-dr-bryan-roth-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/mindmed-begins-trading-on-nasdaq https://www.psychedelicfinance.com/articles/mindmed-board-of-directors-approves-reverse-share-split https://www.psychedelicfinance.com/articles/mindmed-bolsters-management-team-appoints-peter-mack-phd-as-vice-president-of-pharmaceutical-development https://www.psychedelicfinance.com/articles/mindmed-building-diverse-pipeline-and-leadership-position-in-psychedelic-inspired-medicines-industry https://www.psychedelicfinance.com/articles/mindmed-chosen-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-virtual-summit https://www.psychedelicfinance.com/articles/mindmed-closes-acquisition-of-healthmode-a-leading-machine-learning-digital-medicine-company https://www.psychedelicfinance.com/articles/mindmed-closes-upsized-financing-of-13-2m https://www.psychedelicfinance.com/articles/mindmed-closes-upsized-financing-of-cad-28-75m-with-strong-institutional-demand-for-psychedelic-medicines https://www.psychedelicfinance.com/articles/mindmed-closes-upsized-financing-of-cad-92-1m-usd-72-7m-to-meet-high-investor-demand https://www.psychedelicfinance.com/articles/mindmed-cmo-to-chair-digital-biomarkers-summit https://www.psychedelicfinance.com/articles/mindmed-collaborator-dr-matthias-liechti-to-present-topline-clinical-trial-results-for-lsd-in-anxiety-disorders-at-psych-symposium https://www.psychedelicfinance.com/articles/mindmed-collaborators-announce-positive-topline-data-from-phase-2-trial-of-lysergide-lsd-in-major-depressive-disorder-mdd https://www.psychedelicfinance.com/articles/mindmed-collaborators-dose-first-patient-in-phase-1-investigator-initiated-trial-of-mdma-like-substances https://www.psychedelicfinance.com/articles/mindmed-collaborators-initiate-phase-1-comparative-pk-pd-trial-of-r-s-and-racemic-mdma https://www.psychedelicfinance.com/articles/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders https://www.psychedelicfinance.com/articles/mindmed-completes-1-for-15-reverse-share-split https://www.psychedelicfinance.com/articles/mindmed-completes-dosing-18-mc-phase-1-study https://www.psychedelicfinance.com/articles/mindmed-converts-multiple-voting-shares-to-subordinate-voting-shares https://www.psychedelicfinance.com/articles/mindmed-corporate-update-and-investor-q-a-video-with-co-ceos-jr-rahn-and-stephen-hurst https://www.psychedelicfinance.com/articles/mindmed-developing-ip-for-personalized-psychedelic-assisted-therapies https://www.psychedelicfinance.com/articles/mindmed-develops-lsd-neutralizer-technology-to-shorten-and-stop-lsd-trips https://www.psychedelicfinance.com/articles/mindmed-engages-in-productive-pre-submission-meeting-with-fda-for-development-of-the-mindmed-session-monitoring-system https://www.psychedelicfinance.com/articles/mindmed-enrolls-first-participant-in-a-study-of-its-session-monitoring-system https://www.psychedelicfinance.com/articles/mindmed-expanding-r-d-in-europe-appoints-dr-miri-halperin-wernli-as-president https://www.psychedelicfinance.com/articles/mindmed-expands-its-drug-development-pipeline-with-launch-of-r-mdma-program https://www.psychedelicfinance.com/articles/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers https://www.psychedelicfinance.com/articles/mindmed-files-final-prospectus-in-connection-with-bought-deal-equity-financing https://www.psychedelicfinance.com/articles/mindmed-files-final-prospectus-in-connection-with-bought-deal-equity-financing-2 https://www.psychedelicfinance.com/articles/mindmed-files-preliminary-prospectus-in-connection-with-bought-deal-equity-financing https://www.psychedelicfinance.com/articles/mindmed-included-in-ftse-russell-3000-r-index https://www.psychedelicfinance.com/articles/mindmed-increases-cash-on-hand-to-cad-205-2m-usd-162m-closes-financing-of-cad-19-5m-usd-15-4m https://www.psychedelicfinance.com/articles/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd https://www.psychedelicfinance.com/articles/mindmed-joins-clinical-trials-transformation-initiative https://www.psychedelicfinance.com/articles/mindmed-joins-critical-path-institutes-patient-reported-outcome-consortium https://www.psychedelicfinance.com/articles/mindmed-joins-digital-medicine-society-to-improve-health-outcomes-and-equity-using-technology https://www.psychedelicfinance.com/articles/mindmed-launches-project-lucy-focused-on-lsd-experiential-therapy-for-anxiety-disorders https://www.psychedelicfinance.com/articles/mindmed-launches-study-of-low-dose-lsd-effects-on-sleep-and-cognitive-measures https://www.psychedelicfinance.com/articles/mindmed-partners-with-nyu-langone-medical-center-to-launch-groundbreaking-training-program-for-psychedelic-therapies-and-medicines https://www.psychedelicfinance.com/articles/mindmed-provides-corporate-update-and-2023-outlook https://www.psychedelicfinance.com/articles/mindmed-provides-status-update-on-ind-for-phase-2b-trial-of-lsd-for-the-treatment-of-generalized-anxiety-disorder https://www.psychedelicfinance.com/articles/mindmed-publishes-report-by-leading-fda-experts-validating-mindmeds-mm-120-drug-development-strategy https://www.psychedelicfinance.com/articles/mindmed-reaches-agreement-to-acquire-healthmode-a-leading-machine-learning-digital-medicine-company https://www.psychedelicfinance.com/articles/mindmed-receives-approval-of-protocol-design-to-evaluate-microdoses-of-lsd-for-adult-adhd-in-phase-2a-clinical-trial-from-swiss-and-dutch-health-authorities https://www.psychedelicfinance.com/articles/mindmed-receives-fda-type-c-meeting-response-for-project-lucy-phase-2b-clinical-trial https://www.psychedelicfinance.com/articles/mindmed-reports-first-quarter-2020-results-and-corporate-update https://www.psychedelicfinance.com/articles/mindmed-reports-first-quarter-2022-financial-results-and-business-highlights https://www.psychedelicfinance.com/articles/mindmed-reports-full-year-2021-financial-results-and-business-highlights https://www.psychedelicfinance.com/articles/mindmed-reports-proposed-change-in-auditor-for-2022-fiscal-year https://www.psychedelicfinance.com/articles/mindmed-reports-second-quarter-2022-financial-results-and-business-highlights https://www.psychedelicfinance.com/articles/mindmed-reports-third-quarter-2022-financial-results-and-business-highlights https://www.psychedelicfinance.com/articles/mindmed-reports-topline-data-from-phase-1-trial-of-mm-110-in-development-for-the-treatment-of-opioid-withdrawal https://www.psychedelicfinance.com/articles/mindmed-signs-partnership-with-swiss-psychedelic-drug-discovery-startup-mindshift-compounds-ag-expands-development-pipeline-and-ip-portfolio-with-next-gen-psychedelic-and-empathogenic-compounds https://www.psychedelicfinance.com/articles/mindmed-streamlines-leadership-with-further-emphasis-on-integrating-psychedelic-drug-development-with-digital-medicines-and-therapeutics https://www.psychedelicfinance.com/articles/mindmed-strengthens-board-with-appointment-of-two-new-independent-directors https://www.psychedelicfinance.com/articles/mindmed-submits-application-for-nasdaq-up-listing-appoints-canaccord-genuity-as-financial-advisor https://www.psychedelicfinance.com/articles/mindmed-successfully-completes-phase-1-clinical-trial-of-18-mc https://www.psychedelicfinance.com/articles/mindmed-to-attend-8th-annual-mobile-in-clinical-trials-conference https://www.psychedelicfinance.com/articles/mindmed-to-commence-trading-on-nasdaq https://www.psychedelicfinance.com/articles/mindmed-to-evaluate-ayahuascas-active-ingredient-dmt-in-phase-1-clinical-trial-collaboration https://www.psychedelicfinance.com/articles/mindmed-to-host-earnings-call-to-discuss-first-quarter-2022-financial-results-and-provide-business-update https://www.psychedelicfinance.com/articles/mindmed-to-host-earnings-call-to-discuss-full-year-2021-financial-results-and-provide-business-update https://www.psychedelicfinance.com/articles/mindmed-to-host-earnings-call-to-discuss-second-quarter-2022-financial-results-and-provide-business-update https://www.psychedelicfinance.com/articles/mindmed-to-host-earnings-call-to-discuss-third-quarter-2022-financial-results-and-provide-business-update https://www.psychedelicfinance.com/articles/mindmed-to-host-key-opinion-leader-webinar-on-substance-use-disorders-and-withdrawal-management https://www.psychedelicfinance.com/articles/mindmed-to-launch-albert-a-digital-medicine-division-for-psychedelic-medicines-1 https://www.psychedelicfinance.com/articles/mindmed-to-participate-in-h-c-wainwright-global-investment-conference https://www.psychedelicfinance.com/articles/mindmed-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference https://www.psychedelicfinance.com/articles/mindmed-to-participate-in-the-canaccord-genuity-new-paradigms-and-treatment-approaches-in-mental-health-conference https://www.psychedelicfinance.com/articles/mindmed-to-participate-in-the-cantor-fitzgerald-neurology-psychiatry-conference https://www.psychedelicfinance.com/articles/mindmed-to-participate-in-the-jefferies-global-healthcare-conference https://www.psychedelicfinance.com/articles/mindmed-to-participate-in-the-jefferies-london-healthcare-conference https://www.psychedelicfinance.com/articles/mindmed-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference https://www.psychedelicfinance.com/articles/mindmed-to-present-at-h-c-wainwright-2nd-annual-psychedelics-conference https://www.psychedelicfinance.com/articles/mindmed-to-present-at-the-benzinga-healthcare-small-cap-conference https://www.psychedelicfinance.com/articles/mindmed-to-present-at-the-jefferies-london-healthcare-conference https://www.psychedelicfinance.com/articles/mindmed-upsizes-previously-announced-bought-deal-public-offering https://www.psychedelicfinance.com/articles/mindmed-upsizes-previously-announced-bought-deal-public-offeringm https://www.psychedelicfinance.com/articles/mindmeds-lsd-neutralizer-study-begins https://www.psychedelicfinance.com/articles/mindmeds-microdosing-division-further-expands-phase-2-clinical-trial-of-microdosing-lsd-for-adult-adhd https://www.psychedelicfinance.com/articles/mindset-announces-milestone-in-new-drug-program-with-successful-proof-of-concept-animal-studies-of-its-patent-pending-psilocybin-inspired-drug-candidates https://www.psychedelicfinance.com/articles/mindset-files-multiple-final-patent-applications-on-its-novel-psilocybin-inspired-compounds https://www.psychedelicfinance.com/articles/mindset-further-expands-portfolio-of-psychedelic-drug-candidates-with-third-u-s-provisional-patent-application-50-total-new-psychedelic-patent-pending-compounds-synthesized https://www.psychedelicfinance.com/articles/mindset-generates-promising-in-vitro-results-from-third-patent-family-of-novel-psychedelic-compounds-suggesting-range-of-potential-clinical-use-cases-including-micro-dosing https://www.psychedelicfinance.com/articles/mindset-pharma-added-to-north-american-psychedelics-index https://www.psychedelicfinance.com/articles/mindset-pharma-and-intervivo-solutions-to-jointly-develop-advanced-cooperative-psychedelics-evaluation-platform-cope-cope-expected-to-be-worlds-first-in-vivo-psychedelic-benchmark-data-set https://www.psychedelicfinance.com/articles/mindset-pharma-and-pharmala-biotech-enter-into-exclusive-sales-agreement https://www.psychedelicfinance.com/articles/mindset-pharma-and-top-psychiatric-research-hospital-camh-enter-innovative-collaboration-to-build-molecular-profile-of-msp-1014-compared-to-psilocybin https://www.psychedelicfinance.com/articles/mindset-pharma-announces-5-million-bought-deal-financing https://www.psychedelicfinance.com/articles/mindset-pharma-announces-closing-of-7-5-million-bought-deal-public-offering https://www.psychedelicfinance.com/articles/mindset-pharma-announces-development-of-novel-optimized-intranasal-formulation https://www.psychedelicfinance.com/articles/mindset-pharma-announces-dtc-eligibility-for-otcqb-r-venture-listing https://www.psychedelicfinance.com/articles/mindset-pharma-announces-exercise-of-over-allotment-option-for-additional-gross-proceeds-of-1-052-million https://www.psychedelicfinance.com/articles/mindset-pharma-announces-filing-of-amended-and-restated-fs-and-md-a-for-the-three-and-six-month-period-ended-december-31-2020 https://www.psychedelicfinance.com/articles/mindset-pharma-announces-poster-presentations-at-two-upcoming-scientific-conferences https://www.psychedelicfinance.com/articles/mindset-pharma-announces-strong-confirmation-of-in-vivo-proof-of-concept-across-its-entire-new-drug-program-portfolio https://www.psychedelicfinance.com/articles/mindset-pharma-announces-u-s-listing-application-for-otcqb-venture-market https://www.psychedelicfinance.com/articles/mindset-pharma-appoints-leading-molecular-pharmacologist-formulation-expert-dr-joseph-gabriele-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/mindset-pharma-ceo-james-lanthier-issues-letter-to-shareholders https://www.psychedelicfinance.com/articles/mindset-pharma-ceo-james-lanthier-issues-letter-to-shareholders-2 https://www.psychedelicfinance.com/articles/mindset-pharma-expands-scientific-team-dr-malik-slassi-appointed-senior-vp-innovation-and-ian-dean-appointed-director-preclinical-development https://www.psychedelicfinance.com/articles/mindset-pharma-files-a-sixth-u-s-provisional-patent-further-expanding-its-psychedelic-drug-candidates-pipeline-with-novel-dmt-5-meo-dmt-analogs https://www.psychedelicfinance.com/articles/mindset-pharma-files-national-patents-protecting-family-1-application-in-16-different-countries https://www.psychedelicfinance.com/articles/mindset-pharma-further-expands-its-ip-portfolio-with-three-additional-non-tryptamine-families-of-next-generation-psychedelic-compounds https://www.psychedelicfinance.com/articles/mindset-pharma-invited-to-present-at-upcoming-canaccord-genuity-mental-health-conference https://www.psychedelicfinance.com/articles/mindset-pharma-presents-poster-at-neuroscience-2022-highlighting-preclinical-data-on-msp-1014-its-psilocybin-like-lead-drug-candidate https://www.psychedelicfinance.com/articles/mindset-pharma-progresses-plans-for-clinical-trials-of-its-advanced-pre-clinical-psychedelic-msp-1014 https://www.psychedelicfinance.com/articles/mindset-pharma-provides-strategic-intellectual-property-license-to-cybin https://www.psychedelicfinance.com/articles/mindset-pharma-reaches-agreement-to-manufacture-large-quantity-of-pharmaceutical-grade-psilocybin-using-patent-pending-synthesis-process https://www.psychedelicfinance.com/articles/mindset-pharma-receives-allowance-for-patent-application-covering-its-short-duration-novel-psychedelic-medications-for-the-treatment-of-central-nervous-system-disorders https://www.psychedelicfinance.com/articles/mindset-pharma-receives-allowance-for-u-s-patent-application-covering-composition-of-matter-for-its-lead-psychedelic-therapeutic-candidate-msp-1014-and-additional-family-1-tryptamine-prodrug-candidates https://www.psychedelicfinance.com/articles/mindset-pharma-receives-another-allowance-from-uspto-for-patent-application-expanding-composition-of-matter-for-family-1-psilocybin-analogs https://www.psychedelicfinance.com/articles/mindset-pharma-receives-approval-for-phase-ii-clinical-trial-evaluating-msp-1014-for-the-treatment-of-major-depressive-disorder https://www.psychedelicfinance.com/articles/mindset-pharma-receives-notice-of-allowance-for-patent-application-covering-psilocin-derivatives-for-the-treatment-of-central-nervous-system-disorders https://www.psychedelicfinance.com/articles/mindset-pharma-receives-scientific-advice-from-uk-regulator-facilitating-advancement-of-phase-1-first-in-human-clinical-trial-plan-for-its-lead-clinical-candidate-msp-1014 https://www.psychedelicfinance.com/articles/mindset-pharma-selects-lead-clinical-candidates-from-family-2-of-its-next-generation-psychedelic-drug-portfolio https://www.psychedelicfinance.com/articles/mindset-pharma-to-commence-trading-on-the-cse-on-december-23-2020-under-the-symbol-mset https://www.psychedelicfinance.com/articles/mindset-pharma-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference-on-september-12-14-2022 https://www.psychedelicfinance.com/articles/mindset-pharma-to-participate-in-upcoming-conferences-in-december-2022 https://www.psychedelicfinance.com/articles/mindset-pharma-to-participate-in-upcoming-conferences-in-june-2022 https://www.psychedelicfinance.com/articles/mindset-pharma-to-present-at-inaugural-kcsa-psychedelic-investor-conference https://www.psychedelicfinance.com/articles/mindset-pharma-to-present-at-the-stifel-gmp-conference-psychedelics-addressing-the-global-mental-health-crisis https://www.psychedelicfinance.com/articles/mindset-selects-compounds-from-its-third-psilocybin-inspired-drug-family-to-move-into-in-vivo-poc-studies https://www.psychedelicfinance.com/articles/mira-x-acquisition-corp-announces-proposed-qualifying-transaction-with-field-trip-psychedelics https://www.psychedelicfinance.com/articles/mira-x-terminates-qt-with-field-trip-psychedelics https://www.psychedelicfinance.com/articles/miri-halperin-wernli-president-mindmed https://www.psychedelicfinance.com/articles/miriam-volat-director-of-the-indigenous-medicine-conservation-fund https://www.psychedelicfinance.com/articles/mobile-app-quantified-citizen-disrupts-health-research-with-automation-and-the-citizen-science-movement https://www.psychedelicfinance.com/articles/molecular-science-corp-receives-gmp-licence-from-health-canada https://www.psychedelicfinance.com/articles/mount-sinai-health-system-launches-center-for-psychedelic-research https://www.psychedelicfinance.com/articles/mpv-announces-cses-conditional-approval-of-its-transaction-with-entheon-biomedical-corp https://www.psychedelicfinance.com/articles/mpv-exploration-inc-announces-definitive-agreement-for-amalgamation-with-entheon-biomedical-corp-and-financing https://www.psychedelicfinance.com/articles/myconic-capital-acquires-clinic-assets-from-aleafia-health https://www.psychedelicfinance.com/articles/myconic-capital-announces-closing-of-mindscape-ketamine-infusions-therapy-acquisition https://www.psychedelicfinance.com/articles/myconic-capital-becomes-ketamine-one https://www.psychedelicfinance.com/articles/myconic-capital-corp-enters-into-letter-of-intent-to-acquire-a-49-interest-in-miami-based-tristar-wellness-llc-and-develop-satellite-ketamine-micro-clinics https://www.psychedelicfinance.com/articles/myconic-capital-corp-signs-letter-of-intent-for-acquisition-of-ny-ketamine-medical-practice-pllc https://www.psychedelicfinance.com/articles/myconic-capital-lists-on-the-neo-exchange https://www.psychedelicfinance.com/articles/myconic-capital-to-acquire-kgk-science-from-auxly-cannabis-group https://www.psychedelicfinance.com/articles/mycotopia-therapies-announces-plan-to-develop-psychedelic-sublingual-tablet-to-help-treat-depression https://www.psychedelicfinance.com/articles/mycotopia-therapies-inc-expands-presence-in-the-registered-mushroom-sector-with-havn-life-sciences-inc https://www.psychedelicfinance.com/articles/mycrodose-therapeutics-and-nova-mentis-announce-loi-to-co-develop-advanced-drug-delivery-system https://www.psychedelicfinance.com/articles/mycrodose-therapeutics-granted-dea-and-fda-approval-to-cultivate-psilocybin-mushrooms-in-the-united-states https://www.psychedelicfinance.com/articles/mydecine-announces-api-naming-structure-of-four-lead-candidates-and-prepares-for-pre-ind https://www.psychedelicfinance.com/articles/mydecine-announces-change-of-auditor https://www.psychedelicfinance.com/articles/mydecine-announces-closing-of-overnight-marketed-public-offering-of-units https://www.psychedelicfinance.com/articles/mydecine-announces-exclusive-partnership-and-increased-capabilities-with-applied-pharmaceutical-innovation-api-at-the-university-of-alberta https://www.psychedelicfinance.com/articles/mydecine-announces-first-quarter-2022-financial-results-and-highlights https://www.psychedelicfinance.com/articles/mydecine-announces-launch-of-cutting-edge-therapeutic-compound-screening https://www.psychedelicfinance.com/articles/mydecine-announces-myco-005-family-of-improved-safety-microdose-novel-molecules https://www.psychedelicfinance.com/articles/mydecine-announces-partnership-with-leadgen-labs https://www.psychedelicfinance.com/articles/mydecine-announces-reverse-stock-split https://www.psychedelicfinance.com/articles/mydecine-announces-size-of-previously-announced-overnight-marketed-public-offering-of-units https://www.psychedelicfinance.com/articles/mydecine-discovers-over-40-groundbreaking-potential-pharmacologically-active-novel-compounds-in-mushrooms https://www.psychedelicfinance.com/articles/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds https://www.psychedelicfinance.com/articles/mydecine-files-full-patent-application-covering-multiple-families-of-psilocin-analogs https://www.psychedelicfinance.com/articles/mydecine-files-full-patent-application-covering-myco-006-family-of-novel-short-acting-mdma-analogs https://www.psychedelicfinance.com/articles/mydecine-files-full-patent-application-covering-new-formulations-that-bring-nanoemulsion-technology-to-traditional-medicine-ingredients https://www.psychedelicfinance.com/articles/mydecine-files-myco-003-final-patent-application-and-reports-positive-preclinical-data https://www.psychedelicfinance.com/articles/mydecine-fully-completes-the-first-ever-international-export-of-psilocybin-mushrooms-and-solidifies-its-clinical-and-commercial-supply-chain https://www.psychedelicfinance.com/articles/mydecine-innovations-group-adds-dr-robin-carhart-harris-and-dr-david-erritzoe-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/mydecine-innovations-group-adds-former-pfizer-novartis-yale-drug-discovery-expert-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/mydecine-innovations-group-adds-world-renowned-7-time-nobel-peace-prize-nominee-dr-m-s-reddy-to-its-scientific-advisory-board https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-c-10-million-bought-deal-offering-of-units https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-closing-of-17-250-000-bought-deal-public-offering-including-full-exercise-of-the-over-allotment-option https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-closing-of-first-tranche-under-share-subscription-agreement https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-closing-under-share-subscription-agreement https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-and-welcomes-new-cfo https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-common-share-subscription-agreement https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-extended-lock-up-arrangement https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-filing-of-a-provisional-patent-for-mindleaps-mental-health-technology https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-filing-of-a-provisional-patent-for-mindleaps-mental-health-technology-2 https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-filing-of-provisional-patent-for-the-treatment-of-ptsd-with-psilocybin https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-migration-to-neo-exchange https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-myco-001-seamless-phase-2-3-smoking-cessation-clinical-trial https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-plans-to-spin-out-of-its-u-s-cannabis-assets https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-private-placement-interim-changes-to-management-and-board-of-directors https://www.psychedelicfinance.com/articles/mydecine-innovations-group-announces-the-official-mindleap-health-mobile-app-launch-in-ios-and-android-stores-today https://www.psychedelicfinance.com/articles/mydecine-innovations-group-appoints-boustead-capital-markets-llp-as-financial-advisor-for-its-planned-dual-listing-on-the-london-stock-exchange https://www.psychedelicfinance.com/articles/mydecine-innovations-group-appoints-gordon-neal-to-board-of-directors-and-dean-ditto-as-chief-financial-officer https://www.psychedelicfinance.com/articles/mydecine-innovations-group-appoints-josephine-wu-to-board-of-directors https://www.psychedelicfinance.com/articles/mydecine-innovations-group-bolsters-scientific-advisory-board-adding-a-leading-neuroscientist-and-a-psychopharmacology-specialist https://www.psychedelicfinance.com/articles/mydecine-innovations-group-closes-sale-of-its-wholly-owned-subsidiary-mindleap-health-inc https://www.psychedelicfinance.com/articles/mydecine-innovations-group-completes-acquisition-of-neuropharm-inc https://www.psychedelicfinance.com/articles/mydecine-innovations-group-engages-ethica-cro-as-contract-research-organization-partner-for-phase-2a-ptsd-clinical-trials https://www.psychedelicfinance.com/articles/mydecine-innovations-group-engages-the-propharma-group-to-proceed-with-fda-filings-and-approval-for-novel-research-and-multiple-phase-clinical-trials https://www.psychedelicfinance.com/articles/mydecine-innovations-group-featured-in-forbes-for-the-first-of-its-kind-clinicals-using-psilocybin-therapy-for-ptsd https://www.psychedelicfinance.com/articles/mydecine-innovations-group-files-amended-and-restated-financial-statements https://www.psychedelicfinance.com/articles/mydecine-innovations-group-files-application-to-list-to-the-nasdaq https://www.psychedelicfinance.com/articles/mydecine-innovations-group-files-final-prospectus-in-connection-with-bought-deal-offering-of-units https://www.psychedelicfinance.com/articles/mydecine-innovations-group-files-preliminary-prospectus-in-connection-with-bought-deal-offering-of-units https://www.psychedelicfinance.com/articles/mydecine-innovations-group-files-prospectus-supplement https://www.psychedelicfinance.com/articles/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement https://www.psychedelicfinance.com/articles/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement-2 https://www.psychedelicfinance.com/articles/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement-3 https://www.psychedelicfinance.com/articles/mydecine-innovations-group-graduates-listing-to-neo-exchange https://www.psychedelicfinance.com/articles/mydecine-innovations-group-inc-announces-neuropharm-inc-commences-ptsd-clinical-trial-initiative-with-leading-european-research-institute https://www.psychedelicfinance.com/articles/mydecine-innovations-group-inc-appoints-previous-red-bull-sports-marketing-director-jim-gunning-as-cmo https://www.psychedelicfinance.com/articles/mydecine-innovations-group-inc-signs-definitive-agreement-for-acquisition-of-neuropharm-inc https://www.psychedelicfinance.com/articles/mydecine-innovations-group-inc-signs-partnership-agreement-with-applied-pharmaceutical-innovation https://www.psychedelicfinance.com/articles/mydecine-innovations-group-inc-to-create-special-committee-for-the-spin-out-of-us-related-assets https://www.psychedelicfinance.com/articles/mydecine-innovations-group-included-in-first-ever-psychedelics-etf https://www.psychedelicfinance.com/articles/mydecine-innovations-group-offers-management-and-clinical-trials-update https://www.psychedelicfinance.com/articles/mydecine-innovations-group-provides-inaugural-corporate-update-in-the-expanding-psychedelic-medicines-sector https://www.psychedelicfinance.com/articles/mydecine-innovations-group-provides-update-on-european-operations https://www.psychedelicfinance.com/articles/mydecine-innovations-group-receives-conditional-approval-to-list-on-neo-exchange https://www.psychedelicfinance.com/articles/mydecine-innovations-group-shares-intellectual-property-update https://www.psychedelicfinance.com/articles/mydecine-innovations-group-signs-a-letter-of-intent-to-sell-its-wholly-owned-subsidiary-mindleap-health-inc https://www.psychedelicfinance.com/articles/mydecine-innovations-group-signs-definitive-agreement-to-acquire-mindleap-healths-advanced-digital-telehealth-platform https://www.psychedelicfinance.com/articles/mydecine-innovations-group-signs-five-year-master-collaboration-research-agreement-with-johns-hopkins-university-school-of-medicine https://www.psychedelicfinance.com/articles/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia https://www.psychedelicfinance.com/articles/mydecine-innovations-group-sponsors-study-on-neuron-level-response-to-psilocybin-at-university-of-maryland https://www.psychedelicfinance.com/articles/mydecine-innovations-group-subsidiary-neuropharm-engages-freemind-group-to-access-non-dilutive-global-funding-opportunities https://www.psychedelicfinance.com/articles/mydecine-innovations-group-to-acquire-neuropharm-inc https://www.psychedelicfinance.com/articles/mydecine-innovations-group-to-make-first-commercial-export-of-legal-psilocybin-mushrooms https://www.psychedelicfinance.com/articles/mydecine-innovations-group-upsizes-previously-announced-bought-deal https://www.psychedelicfinance.com/articles/mydecine-innovations-group-would-like-to-give-thanks-to-its-shareholders-for-extending-the-lockup-on-the-five-cent-placement-for-another-120-days https://www.psychedelicfinance.com/articles/mydecine-overnight-marketed-public-offering-of-units https://www.psychedelicfinance.com/articles/mydecine-provides-company-update-welcomes-new-board-member https://www.psychedelicfinance.com/articles/mydecine-receives-conditional-irb-approval-for-phase-2b-smoking-cessation-study https://www.psychedelicfinance.com/articles/mydecine-reports-financial-results-for-the-fiscal-year-2021-and-provides-a-business-update https://www.psychedelicfinance.com/articles/mydecine-reports-financial-results-for-the-second-quarter-of-fiscal-year-2022 https://www.psychedelicfinance.com/articles/mydecine-reports-financial-results-for-the-third-quarter-of-fiscal-year-2022 https://www.psychedelicfinance.com/articles/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update https://www.psychedelicfinance.com/articles/mydecine-reports-full-year-2020-financial-results-and-provides-business-update https://www.psychedelicfinance.com/articles/mydecine-reports-positive-pre-ind-meeting-with-fda-for-myco-001-smoking-cessation-study https://www.psychedelicfinance.com/articles/mydecine-reports-second-quarter-2021-financial-results-and-provides-business-update https://www.psychedelicfinance.com/articles/mydecine-reports-successful-synthesis-of-novel-tryptamine-improving-the-pharmaceutical-properties-of-psilocin https://www.psychedelicfinance.com/articles/mydecine-reports-third-quarter-2021-financial-results-and-provides-business-update https://www.psychedelicfinance.com/articles/mydecine-secures-financing-and-provides-company-update-on-clinical-trials-drug-development-and-technology-initiatives https://www.psychedelicfinance.com/articles/mydecine-selects-substance-use-disorder-and-smoking-cessation-for-novel-psychedelic-molecule-myco-004 https://www.psychedelicfinance.com/articles/mydecine-signs-loi-with-maya-to-co-develop-a-novel-prescription-digital-therapeutic-platform-aiming-to-further-increase-safety-efficacy-and-accessibility-of-psychedelic-assisted-treatments https://www.psychedelicfinance.com/articles/mydecine-signs-loi-with-the-newly-institute-to-provide-psychedelic-assisted-psychotherapy-to-patients-under-health-canadas-special-access-program https://www.psychedelicfinance.com/articles/mydecine-submits-pre-investigational-new-drug-briefing-package-to-the-fda-for-myco-001-seamless-phase-2-3-smoking-cessation-clinical-trial https://www.psychedelicfinance.com/articles/mydecine-tm-launches-worlds-first-natural-sourced-cgmp-psilocybin-for-global-research-sales-and-distribution-enterprise https://www.psychedelicfinance.com/articles/mydecine-to-participate-in-the-benzinga-global-small-cap-conference-on-may-13th https://www.psychedelicfinance.com/articles/mydecine-to-participate-in-the-roth-virtual-healthcare-private-company-forum-on-june-28th https://www.psychedelicfinance.com/articles/mydecine-to-present-at-the-kcsa-psychedelics-virtual-investor-conference-on-october-14th https://www.psychedelicfinance.com/articles/mydecine-to-supply-lead-drug-candidate-myco-001-for-multi-site-nida-grant-funded-smoking-cessation-study-lead-by-dr-matthew-johnson https://www.psychedelicfinance.com/articles/mydecine-unveils-artificial-intelligence-drug-discovery-program https://www.psychedelicfinance.com/articles/mydecines-exclusive-dealer-identified-as-licensed-psilocybin-and-mdma-supplier-in-canada https://www.psychedelicfinance.com/articles/mynd-diagnostics-inc-announces-participation-in-approved-monash-university-australia-government-funded-3-million-clinical-trial https://www.psychedelicfinance.com/articles/mynd-life-sciences-announces-3-5-million-share-offering https://www.psychedelicfinance.com/articles/mynd-life-sciences-announces-chief-scientific-officer-dr-wilf-jefferies-induction-as-a-national-academy-of-inventors-fellow https://www.psychedelicfinance.com/articles/mynd-life-sciences-announces-new-testing-methodologies-for-measuring-cellular-responses-to-microdosing-with-psilocybins https://www.psychedelicfinance.com/articles/mynd-life-sciences-announces-stock-option-grant https://www.psychedelicfinance.com/articles/mynd-life-sciences-executes-a-non-binding-mou-with-tidal-psychedelics-2 https://www.psychedelicfinance.com/articles/mynd-life-sciences-inc-announces-the-recruitment-of-a-senior-operations-and-research-manager https://www.psychedelicfinance.com/articles/najla-guthrie-ceo-president-kgk-science https://www.psychedelicfinance.com/articles/natalie-dolphin-direktorin-marketing-magicmed-industries-de https://www.psychedelicfinance.com/articles/natalie-dolphin-marketing-director-magicmed-industries https://www.psychedelicfinance.com/articles/negev-capital-invests-in-production-and-distribution-of-artisanal-functional-mushrooms https://www.psychedelicfinance.com/articles/neo-exchange-announces-inclusion-in-ftse-russell-indexes https://www.psychedelicfinance.com/articles/neonmind-advances-strategy-for-specialty-clinic-launch https://www.psychedelicfinance.com/articles/neonmind-and-bioscript-solutions-announce-strategic-partnership-expanding-neonminds-specialty-clinic-network-for-interventional-psychiatry-treatments https://www.psychedelicfinance.com/articles/neonmind-and-srx-health-solutions-announce-strategic-alliance-to-establish-specialty-mental-health-clinics-for-interventional-psychiatry-treatments https://www.psychedelicfinance.com/articles/neonmind-and-translational-life-sciences-to-design-psilocybin-mushroom-clinical-trials https://www.psychedelicfinance.com/articles/neonmind-announces-corporate-update-and-strategic-reorganization-of-its-pharmaceutical-division https://www.psychedelicfinance.com/articles/neonmind-announces-creation-of-medical-clinics-advisory-board-to-guide-planning-and-operation-of-company-branded-clinics-across-canada https://www.psychedelicfinance.com/articles/neonmind-announces-divestiture-of-consumer-related-and-other-non-core-assets https://www.psychedelicfinance.com/articles/neonmind-announces-dtc-eligibility https://www.psychedelicfinance.com/articles/neonmind-announces-grants-pursuant-to-stock-option-plan https://www.psychedelicfinance.com/articles/neonmind-announces-launch-of-functional-mushroom-coffees-as-dietary-supplements-in-the-us https://www.psychedelicfinance.com/articles/neonmind-announces-new-division-to-deliver-innovative-mental-health-services-appoints-new-vp-corporate-development https://www.psychedelicfinance.com/articles/neonmind-announces-plan-to-launch-10-clinics-for-innovative-treatments-as-mental-health-crisis-grows https://www.psychedelicfinance.com/articles/neonmind-announces-positive-preclinical-results-demonstrating-the-efficacy-of-psilocybin-in-reducing-weight-gain-in-obese-animal-subjects https://www.psychedelicfinance.com/articles/neonmind-announces-successful-completion-of-pre-ind-consultation-with-fda-on-clinical-path-for-obesity-drug-candidate-neo-001 https://www.psychedelicfinance.com/articles/neonmind-announces-vitasave-will-carry-neonmind-functional-mushroom-products https://www.psychedelicfinance.com/articles/neonmind-appoints-canadian-medical-leader-in-anesthesiology-dr-daniel-bainbridge-md-frcpc-to-its-specialty-clinics-advisory-board https://www.psychedelicfinance.com/articles/neonmind-appoints-dr-frank-russo-to-lead-development-of-music-based-program-for-psilocybin-clinical-trials https://www.psychedelicfinance.com/articles/neonmind-appoints-emergency-and-addiction-expert-dr-dinesh-bhayana-as-site-medical-director-of-its-inaugural-specialty-mental-health-clinic https://www.psychedelicfinance.com/articles/neonmind-appoints-ketamine-and-neurostimulation-expert-dr-roumen-milev-md-phd-to-specialty-clinic-advisory-board https://www.psychedelicfinance.com/articles/neonmind-appoints-robert-tessarolo-as-president-and-chief-executive-officer https://www.psychedelicfinance.com/articles/neonmind-appoints-trevor-millar-as-chief-psychedelic-officer https://www.psychedelicfinance.com/articles/neonmind-ceo-provides-update-on-the-progress-of-its-psilocybin-drug-development-research-plan-and-team https://www.psychedelicfinance.com/articles/neonmind-ceo-robert-tessarolo-to-speak-at-the-psychedelic-therapeutics-drug-development-conference https://www.psychedelicfinance.com/articles/neonmind-commences-preclinical-trial-to-examine-psilocybin-for-weight-loss https://www.psychedelicfinance.com/articles/neonmind-completes-design-of-preclinical-psilocybin-psychedelic-mushroom-study https://www.psychedelicfinance.com/articles/neonmind-developing-music-playlist-for-psychedelic-therapy-sessions https://www.psychedelicfinance.com/articles/neonmind-engages-certara-to-advance-its-synthetic-psilocybin-drug-candidates-for-obesity https://www.psychedelicfinance.com/articles/neonmind-engages-dr-c-laird-birmingham-to-develop-protocols-for-phase-2-clinical-trial-using-psilocybin-to-treat-obesity https://www.psychedelicfinance.com/articles/neonmind-engages-kcsa-strategic-communications-to-provide-public-relations-and-investor-relations-services https://www.psychedelicfinance.com/articles/neonmind-engages-leading-digital-platform-for-medical-education-and-adoption-of-ketamine-treatments-in-preparation-of-opening-its-inaugural-specialty-mental-health-clinic https://www.psychedelicfinance.com/articles/neonmind-engages-pharma-executive-philippe-martin-to-advance-its-psilocybin-drug-candidates-for-obesity https://www.psychedelicfinance.com/articles/neonmind-expands-development-of-psychedelic-patent-portfolio https://www.psychedelicfinance.com/articles/neonmind-files-for-u-s-provisional-patent-to-use-psychedelic-assisted-psychotherapy-for-weight-loss https://www.psychedelicfinance.com/articles/neonmind-files-four-additional-provisional-patents-on-psilocybin-preclinical-data https://www.psychedelicfinance.com/articles/neonmind-files-new-provisional-patent-application-covering-novel-mechanism-of-weight-loss https://www.psychedelicfinance.com/articles/neonmind-files-patent-application-for-therapeutic-use-of-dmt https://www.psychedelicfinance.com/articles/neonmind-obtains-health-canada-approval-to-advance-psilocybin-research https://www.psychedelicfinance.com/articles/neonmind-provides-integrated-drug-development-plan-update-for-neo-001-to-treat-obesity https://www.psychedelicfinance.com/articles/neonmind-purchases-gmp-grade-synthetic-psilocybin-from-psygen-labs-for-phase-2-human-clinical-trial https://www.psychedelicfinance.com/articles/neonmind-ready-to-launch-four-mushroom-coffee-blends https://www.psychedelicfinance.com/articles/neonmind-receives-health-canada-approval-for-its-functional-mushroom-formulation-mindful-blend https://www.psychedelicfinance.com/articles/neonmind-reports-business-highlights-on-partnership-activities-clinical-pipeline-and-corporate-developments https://www.psychedelicfinance.com/articles/neonmind-strengthens-its-specialty-clinics-advisory-board-with-appointment-of-mood-disorders-and-ketamine-expert-dr-gustavo-vazquez-md-phd https://www.psychedelicfinance.com/articles/neonmind-submits-application-for-psilocybin-research-to-health-canada https://www.psychedelicfinance.com/articles/neonmind-submits-applications-to-health-canada-for-product-formulas-to-support-cognitive-and-immune-function-and-to-fight-stress https://www.psychedelicfinance.com/articles/neonmind-taking-steps-to-prove-psilocybin-effective-for-weight-loss https://www.psychedelicfinance.com/articles/neonmind-to-commence-trading-on-the-otcqb-venture-market https://www.psychedelicfinance.com/articles/neonmind-to-improve-patient-care-and-data-management-by-adopting-digital-platform-for-ketamine-treatments-in-preparation-of-opening-its-inaugural-specialty-mental-health-clinic https://www.psychedelicfinance.com/articles/neonmind-to-open-its-inaugural-specialty-mental-health-clinic-in-mississauga-ontario https://www.psychedelicfinance.com/articles/neonmind-to-participate-in-panel-discussion-at-lift-co-expos-psychedelics-business-summit-on-november-19-2021 https://www.psychedelicfinance.com/articles/neonmind-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference https://www.psychedelicfinance.com/articles/neonmind-to-present-at-h-c-wainwright-bioconnect-conference https://www.psychedelicfinance.com/articles/neonmind-to-present-at-h-c-wainwright-psychedelics-in-psychiatry-and-beyond-virtual-conference https://www.psychedelicfinance.com/articles/neonmind-to-present-at-the-benzinga-global-small-cap-conference https://www.psychedelicfinance.com/articles/neonmind-to-start-trading-on-cse-today https://www.psychedelicfinance.com/articles/neonmind-unveils-initial-treatment-offering-at-specialty-mental-health-clinic-in-mississauga https://www.psychedelicfinance.com/articles/new-edmonton-biotech-startup-psilotec-health-solutions-targets-projected-100-billion-us-market-for-psychedelic-drugs https://www.psychedelicfinance.com/articles/new-poll-shows-large-majority-of-canadians-approve-of-legal-access-to-psilocybin-for-terminally-ill-patients https://www.psychedelicfinance.com/articles/new-psychedelic-drug-formula-believed-to-work-to-mitigate-neurological-damage-due-to-stroke-provisional-patent-application-filed https://www.psychedelicfinance.com/articles/new-psychedelic-research-nonprofit-teams-with-johns-hopkins-university-for-real-world-study-on-use-of-psilocybin-mushrooms https://www.psychedelicfinance.com/articles/new-rapid-mood-screener-rms-screens-for-manic-symptoms-and-bipolar-i-disorder-features-to-address-unmet-clinical-need https://www.psychedelicfinance.com/articles/new-wave-announces-definitive-agreement-with-anahit-therapeutics-ltd https://www.psychedelicfinance.com/articles/new-wave-enters-into-definitive-agreement-to-acquire-way-of-will-inc-a-leading-retailer-of-aromatherpy-products-extracted-from-natural-aromatic-plant-extracts-and-essential-oils https://www.psychedelicfinance.com/articles/new-wave-enters-into-letter-of-intent-to-acquire-way-of-will-inc-a-leading-retailer-of-aromatherpy-products-extracted-from-natural-aromatic-plant-extracts-and-essential-oils https://www.psychedelicfinance.com/articles/new-wave-enters-into-partnership-with-the-university-of-west-indies-mona-jamaica-for-medicinal-drug-discovery https://www.psychedelicfinance.com/articles/new-wave-esports-announces-share-consolidation-and-name-change https://www.psychedelicfinance.com/articles/new-wave-holdings-announces-4-million-equity-offering https://www.psychedelicfinance.com/articles/new-wave-holdings-announces-closing-of-first-tranche-of-equity-offering https://www.psychedelicfinance.com/articles/new-wave-holdings-corp-appoints-daniel-fox-as-chief-executive-officer-and-diego-gianelli-as-a-director https://www.psychedelicfinance.com/articles/new-wave-holdings-corp-appoints-dr-carolyn-myers-as-vp-of-commercial-development https://www.psychedelicfinance.com/articles/new-wave-holdings-corp-appoints-dr-dennis-mckenna-to-psychedelic-research-advisory-board https://www.psychedelicfinance.com/articles/new-wave-holdings-corp-appoints-dr-wade-davis-to-psychedelic-research-advisory-board https://www.psychedelicfinance.com/articles/new-wave-holdings-corp-completes-private-placement-and-acquires-a-50-interest-in-anahit-therapeutics-ltd https://www.psychedelicfinance.com/articles/new-wave-holdings-corp-forms-psychedelic-research-advisory-board-and-appoints-dr-richard-knowles https://www.psychedelicfinance.com/articles/new-wave-holdings-corp-provides-funding-for-lsd-research-study https://www.psychedelicfinance.com/articles/new-wave-holdings-corp-provides-update-on-jamacian-mushroom-cultivation-and-extraction-facilities https://www.psychedelicfinance.com/articles/new-wave-holdings-corp-to-launch-functional-mushroom-products-for-the-north-american-market https://www.psychedelicfinance.com/articles/new-wave-holdings-sponsors-non-profit-coalition-therapsil-to-launch-a-medical-psilocybin-access-project-for-canadians-in-palliative-care https://www.psychedelicfinance.com/articles/new-wave-holdings-subsidiary-way-of-will-inc-is-pleased-to-announce-its-launch-of-high-quality-mushroom-products-for-q1-2021 https://www.psychedelicfinance.com/articles/new-wave-n2-logics-acquires-bloom-botanics-e-commerce-platform-one-of-europes-leading-nutraceuticals-online-superstore-for-cbd-and-mushroom-blend-products https://www.psychedelicfinance.com/articles/new-wave-welcomes-iman-nevab-homeopathic-research-expert-to-the-scientific-advisory-board https://www.psychedelicfinance.com/articles/newleaf-brands-agrees-to-acquire-mindleap-health-inc https://www.psychedelicfinance.com/articles/newleaf-brands-announces-appointment-of-former-manager-of-ebbu-co-founder-of-mydecine-damon-michaels-to-the-role-of-chief-operations-officer-coo https://www.psychedelicfinance.com/articles/newleaf-brands-announces-name-and-stock-ticker-symbol-change-to-mydecine-innovations-group-inc-cse-myco https://www.psychedelicfinance.com/articles/newleaf-brands-appoints-new-advisor-dr-aubrey-oliver-set-to-spearhead-jamaican-based-psilocybin-healing-retreat-efforts https://www.psychedelicfinance.com/articles/newleaf-brands-inc-signs-definitive-agreement-to-acquire-37-5-of-trellis-holdings-and-comments-on-initiative-petition-34-to-legalize-psilocybin-therapy-in-oregon https://www.psychedelicfinance.com/articles/newscope-announces-name-change https://www.psychedelicfinance.com/articles/newscope-announces-name-change-to-pharmather-holdings-ltd https://www.psychedelicfinance.com/articles/newscope-capital-corporation-announces-definitive-agreement-with-pharmather-inc https://www.psychedelicfinance.com/articles/newscope-capital-corporation-d-b-a-pharmather-provides-update https://www.psychedelicfinance.com/articles/newscope-capital-d-b-a-pharmather-announces-listing-on-the-canadian-securities-exchange https://www.psychedelicfinance.com/articles/newscope-capital-provides-dial-in-information-for-special-meeting https://www.psychedelicfinance.com/articles/newton-energy-corporation-announces-letter-of-intent-with-field-trip-psychedelics-inc https://www.psychedelicfinance.com/articles/nick-milne-co-founder-and-cso-at-octarine-bio https://www.psychedelicfinance.com/articles/nick-von-christierson-of-woven-science https://www.psychedelicfinance.com/articles/ninnion-therapeutics-to-webcast-live-at-virtualinvestorconferences-com-april-27th https://www.psychedelicfinance.com/articles/nirvana-life-sciences-announces-approval-to-build-vancouver-facility-from-health-canada https://www.psychedelicfinance.com/articles/nirvana-life-sciences-announces-filing-of-patent-for-novel-isolation-of-4-po-psilocin-prodrug-compound https://www.psychedelicfinance.com/articles/nirvana-life-sciences-announces-partner-symeres-can-produce-high-volume-controlled-substances https://www.psychedelicfinance.com/articles/nirvana-life-sciences-announces-patent-filing https://www.psychedelicfinance.com/articles/nirvana-life-sciences-announces-positive-results-for-addiction-relapse-prevention-from-their-latest-pre-clinical-psychedelic-drug-study https://www.psychedelicfinance.com/articles/nirvana-life-sciences-inc-announces-a-method-for-producing-mdma-that-reduces-manufacturing-time-by-two-thirds https://www.psychedelicfinance.com/articles/nirvana-life-sciences-inc-announces-agreement-to-acquire-the-licensed-distributor-of-a-patented-who-approved-herbal-treatment-for-opiate-addiction https://www.psychedelicfinance.com/articles/nirvana-life-sciences-inc-announces-license-for-a-delivery-system-for-psychedelic-apis https://www.psychedelicfinance.com/articles/nirvana-life-sciences-inc-announces-license-for-a-delivery-system-for-psychedelic-apis-2 https://www.psychedelicfinance.com/articles/nirvana-life-sciences-inc-announces-the-appointment-of-sheldon-inwentash-to-the-board-of-directors https://www.psychedelicfinance.com/articles/nirvana-life-sciences-inc-deuterates-7-hydroxymitragynine-to-create-d7-h-an-analogue-that-may-improve-research-and-formulations-using-kratom-derivatives https://www.psychedelicfinance.com/articles/nirvana-signs-letter-of-intent-with-innovate-phytotechnologies-inc https://www.psychedelicfinance.com/articles/nova-launches-preclinical-autism-spectrum-disorder-therapeutic-study https://www.psychedelicfinance.com/articles/nova-mentis-and-kgk-science-form-tactical-partnership https://www.psychedelicfinance.com/articles/nova-mentis-and-mycrodose-therapeutics-announce-major-milestone-with-transdermal-technology-for-fragile-x-syndrome-clinical-program https://www.psychedelicfinance.com/articles/nova-mentis-and-university-of-central-florida-to-develop-saliva-serotonin-assay https://www.psychedelicfinance.com/articles/nova-mentis-announces-closing-of-non-brokered-financing https://www.psychedelicfinance.com/articles/nova-mentis-announces-participant-screening-underway-in-canadas-first-psilocybin-clinical-trial-for-fragile-x-syndrome https://www.psychedelicfinance.com/articles/nova-mentis-announces-promising-research-results https://www.psychedelicfinance.com/articles/nova-mentis-applies-to-us-fda-for-psilocybin-orphan-drug-designation-fragile-x-syndrome-treatment https://www.psychedelicfinance.com/articles/nova-mentis-appoints-derek-ivany-as-executive-chairman https://www.psychedelicfinance.com/articles/nova-mentis-appoints-dr-julia-v-perederiy-phd-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/nova-mentis-appoints-dr-kyle-ambert-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/nova-mentis-appoints-dr-marvin-s-hausman-as-chairman-of-scientific-advisory-board https://www.psychedelicfinance.com/articles/nova-mentis-appoints-dr-stephen-glazer-as-director-and-chief-science-officer https://www.psychedelicfinance.com/articles/nova-mentis-appoints-gary-r-harlem-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/nova-mentis-autism-clinical-study-approved-by-canadian-institutional-review-board https://www.psychedelicfinance.com/articles/nova-mentis-autism-clinical-study-approved-by-institutional-review-board https://www.psychedelicfinance.com/articles/nova-mentis-begins-enrollment-in-north-american-autism-study https://www.psychedelicfinance.com/articles/nova-mentis-begins-recruitment-in-first-of-its-kind-health-canada-psilocybin-trial https://www.psychedelicfinance.com/articles/nova-mentis-biotech-corp-signs-psilocybin-research-agreement-with-france-based-physiogenex https://www.psychedelicfinance.com/articles/nova-mentis-completes-production-of-psilocybin-microdose-capsules https://www.psychedelicfinance.com/articles/nova-mentis-earns-psilocybin-orphan-drug-designation-in-europe-for-fragile-x-syndrome https://www.psychedelicfinance.com/articles/nova-mentis-establishes-serotonin-research-centre https://www.psychedelicfinance.com/articles/nova-mentis-expands-pre-clinical-development-pipeline-company-begins-fragile-x-syndrome-treatment-with-its-proprietary-psilocybin-drug https://www.psychedelicfinance.com/articles/nova-mentis-expands-psilocybin-research-program-targets-obesity-and-diabetes https://www.psychedelicfinance.com/articles/nova-mentis-expands-psychedelic-drug-pipeline https://www.psychedelicfinance.com/articles/nova-mentis-files-fragile-x-orphan-drug-designation-with-european-medicines-agency https://www.psychedelicfinance.com/articles/nova-mentis-files-genetic-neuroinflammatory-disease-patent https://www.psychedelicfinance.com/articles/nova-mentis-files-patent-on-diagnosing-monitoring-and-treating-neurological-diseases-with-psychoactive-tryptamine-derivatives https://www.psychedelicfinance.com/articles/nova-mentis-files-u-s-patent-application-for-psilocybin-based-therapeutics https://www.psychedelicfinance.com/articles/nova-mentis-granted-health-canada-section-56-exemption-to-begin-psilocybin-clinical-trial https://www.psychedelicfinance.com/articles/nova-mentis-launches-autism-clinical-study https://www.psychedelicfinance.com/articles/nova-mentis-launches-autism-microbiome-study-in-the-united-states https://www.psychedelicfinance.com/articles/nova-mentis-life-science-acquisition-target-pilz-bioscience-corp-provides-corporate-update https://www.psychedelicfinance.com/articles/nova-mentis-life-science-acquisition-target-pilz-bioscience-corp-signs-psilocybin-manufacturing-agreement https://www.psychedelicfinance.com/articles/nova-mentis-life-science-announces-receipt-of-pilz-shareholder-approval https://www.psychedelicfinance.com/articles/nova-mentis-life-science-completes-acquisition-of-pilz-bioscience https://www.psychedelicfinance.com/articles/nova-mentis-life-science-signs-agreement-to-acquire-100-of-psychedelic-focused-autism-research-company-pilz-bioscience-corp https://www.psychedelicfinance.com/articles/nova-mentis-life-science-signs-amalgamation-agreement-to-acquire-100-of-pilz-bioscience-corp https://www.psychedelicfinance.com/articles/nova-mentis-organizes-autism-data-bank-in-north-america https://www.psychedelicfinance.com/articles/nova-mentis-provides-corporate-update-2022-planned-catalysts https://www.psychedelicfinance.com/articles/nova-mentis-psilocybin-approved-for-shipment-to-italy https://www.psychedelicfinance.com/articles/nova-mentis-psilocybin-manufacturer-receives-approved-health-canada-importation-permit https://www.psychedelicfinance.com/articles/nova-mentis-psilocybin-microdose-capsule-formulation-to-be-submitted-in-health-canada-phase-2a-clinical-trial-application https://www.psychedelicfinance.com/articles/nova-mentis-psilocybin-preclinical-study-published-in-international-science-journal https://www.psychedelicfinance.com/articles/nova-mentis-receives-controlled-substances-export-approval-from-the-u-s-dea-for-the-companys-proprietary-psilocybin-drug-nm-1001 https://www.psychedelicfinance.com/articles/nova-mentis-receives-institutional-review-board-approval-to-commence-psilocybin-clinical-trial https://www.psychedelicfinance.com/articles/nova-mentis-sees-rapid-enrollment-in-autism-study https://www.psychedelicfinance.com/articles/nova-mentis-study-confirms-oral-microdose-psilocybin-treatment-of-autism https://www.psychedelicfinance.com/articles/nova-mentis-to-be-listed-in-the-first-ever-psychedelic-index https://www.psychedelicfinance.com/articles/nova-mentis-to-present-at-the-h-c-wainwright-global-investment-conference https://www.psychedelicfinance.com/articles/nova-mentis-to-present-at-the-h-c-wainwright-mental-health-conference https://www.psychedelicfinance.com/articles/nova-mentis-to-present-at-the-h-c-wainwright-psychedelics-conference https://www.psychedelicfinance.com/articles/nova-mentis-to-present-promising-psilocybin-microdose-data-at-18th-nfxf-international-fragile-x-conference https://www.psychedelicfinance.com/articles/nova-mentis-to-produce-psilocybin-capsules-for-phase-2a-clinical-study https://www.psychedelicfinance.com/articles/nova-mentis-uncovers-diagnostic-biomarkers-in-preclinical-autism-study https://www.psychedelicfinance.com/articles/nova-mentis-upgrades-u-s-listing-to-the-otcqb-venture-market https://www.psychedelicfinance.com/articles/nova-mentis-welcomes-autism-behaviour-analyst-to-its-science-team https://www.psychedelicfinance.com/articles/nova-submits-phase-ii-a-psilocybin-clinical-trial-application-to-health-canada https://www.psychedelicfinance.com/articles/novamind-advances-clinical-pilot-for-frontline-kap https://www.psychedelicfinance.com/articles/novamind-and-hinterland-metals-enter-into-amalgamation-agreement https://www.psychedelicfinance.com/articles/novamind-announces-cad-5-million-private-placement-with-institutional-investor https://www.psychedelicfinance.com/articles/novamind-announces-closing-of-cad-5-million-private-placement-with-institutional-investor https://www.psychedelicfinance.com/articles/novamind-announces-closing-of-oversubscribed-private-placement https://www.psychedelicfinance.com/articles/novamind-announces-dtc-eligibility-for-its-common-shares https://www.psychedelicfinance.com/articles/novamind-announces-inclusion-in-nyse-listed-advisorshares-psychedelics-etf https://www.psychedelicfinance.com/articles/novamind-announces-marketing-services-agreements https://www.psychedelicfinance.com/articles/novamind-announces-new-patient-financing-options https://www.psychedelicfinance.com/articles/novamind-announces-participation-at-the-planet-microcap-showcase-on-april-20-22-2021 https://www.psychedelicfinance.com/articles/novamind-announces-strategic-investment-in-bionomics-to-support-ptsd-clinical-trial https://www.psychedelicfinance.com/articles/novamind-announces-symbol-change-on-otc-market-to-nvmdf https://www.psychedelicfinance.com/articles/novamind-announces-us-1-000-000-strategic-investment-in-stealth-mode-drug-development-company https://www.psychedelicfinance.com/articles/novamind-announces-virtual-group-health-coaching https://www.psychedelicfinance.com/articles/novamind-appoints-chuck-rifici-to-its-board-of-directors https://www.psychedelicfinance.com/articles/novamind-appoints-dr-reid-robison-as-chief-medical-officer https://www.psychedelicfinance.com/articles/novamind-appoints-prakash-gowd-as-chief-operating-officer https://www.psychedelicfinance.com/articles/novamind-closes-arizona-acquisition https://www.psychedelicfinance.com/articles/novamind-closes-oversubscribed-cad-10-million-private-placement https://www.psychedelicfinance.com/articles/novamind-closes-the-acquisition-of-cedar-psychiatry-a-leading-psychedelic-therapy-organization-in-the-u-s https://www.psychedelicfinance.com/articles/novamind-collaborates-with-center-for-change https://www.psychedelicfinance.com/articles/novamind-completes-reverse-takeover-transaction https://www.psychedelicfinance.com/articles/novamind-doubles-in-size-adds-four-new-psychedelic-mental-health-clinics https://www.psychedelicfinance.com/articles/novamind-expands-group-therapy-model https://www.psychedelicfinance.com/articles/novamind-expands-leadership-team-accelerating-m-a https://www.psychedelicfinance.com/articles/novamind-expands-psychedelic-medicine-access-in-utah https://www.psychedelicfinance.com/articles/novamind-fast-tracked-for-inclusion-in-horizons-psychedelic-etf https://www.psychedelicfinance.com/articles/novamind-files-management-information-circular-for-special-meeting-of-shareholders-and-announces-receipt-of-interim-court-order-for-plan-of-arrangement https://www.psychedelicfinance.com/articles/novamind-granted-dea-licenses-for-psilocybin-research https://www.psychedelicfinance.com/articles/novamind-grants-restricted-share-units https://www.psychedelicfinance.com/articles/novamind-has-applied-to-have-its-common-shares-posted-for-trading-on-the-otcqb-in-the-united-states https://www.psychedelicfinance.com/articles/novamind-hosts-clinical-trial-to-advance-ketamine-therapy-for-end-of-life-patients https://www.psychedelicfinance.com/articles/novamind-hosts-pioneering-psychedelic-clinical-trial-for-opioid-use-disorder https://www.psychedelicfinance.com/articles/novamind-increases-strategic-investment-in-bionomics https://www.psychedelicfinance.com/articles/novamind-launches-group-psychedelic-treatment-for-frontline-workers https://www.psychedelicfinance.com/articles/novamind-launches-new-psychedelic-palliative-care-program https://www.psychedelicfinance.com/articles/novamind-launches-psychedelic-therapy-frontiers-podcast https://www.psychedelicfinance.com/articles/novamind-launches-psychedelic-therapy-protocol-for-frontline-healthcare-workers https://www.psychedelicfinance.com/articles/novamind-opens-5th-clinic-location-specialized-in-integrative-psychiatry-for-patients-with-treatment-resistant-conditions https://www.psychedelicfinance.com/articles/novamind-opens-6th-integrative-psychiatry-clinic-adds-3rd-clinical-research-site https://www.psychedelicfinance.com/articles/novamind-opens-8th-integrative-psychiatry-clinic https://www.psychedelicfinance.com/articles/novamind-opens-client-care-center-to-support-high-demand-for-treatments https://www.psychedelicfinance.com/articles/novamind-opens-new-clinic-with-specialized-focus-on-substance-use-disorders https://www.psychedelicfinance.com/articles/novamind-participates-in-alto-neuroscience-phase-ii-clinical-trial-for-mdd-and-ptsd https://www.psychedelicfinance.com/articles/novamind-partner-to-acquire-specialized-ibogaine-group-in-brazil https://www.psychedelicfinance.com/articles/novamind-partners-with-merck-for-new-treatment-resistant-depression-trial https://www.psychedelicfinance.com/articles/novamind-partners-with-uruguay-based-bienstar-wellness-to-develop-latin-americas-first-integrative-mental-health-clinic-network https://www.psychedelicfinance.com/articles/novamind-publishes-psychedelic-therapy-patient-case-studies https://www.psychedelicfinance.com/articles/novamind-reaches-major-milestones-for-ketamine-and-spravato-tm-treatments https://www.psychedelicfinance.com/articles/novamind-receives-cse-conditional-listing-approval-under-the-ticker-nm https://www.psychedelicfinance.com/articles/novamind-reports-company-highlights-and-strong-revenue-growth-in-fiscal-second-quarter https://www.psychedelicfinance.com/articles/novamind-reports-fiscal-q1-financial-results-and-operating-highlights https://www.psychedelicfinance.com/articles/novamind-reports-fiscal-q2-2022-financial-results-and-operating-highlights https://www.psychedelicfinance.com/articles/novamind-reports-fiscal-q3-2022-financial-results-and-operating-highlights https://www.psychedelicfinance.com/articles/novamind-reports-fiscal-q3-financial-results-and-operating-highlights https://www.psychedelicfinance.com/articles/novamind-reports-fy2021-financial-results-and-operating-highlights https://www.psychedelicfinance.com/articles/novamind-secures-insurance-coverage-for-ketamine-from-four-major-payors https://www.psychedelicfinance.com/articles/novamind-selected-as-research-site-for-bionomics-ptsd-clinical-trial https://www.psychedelicfinance.com/articles/novamind-shareholders-approve-proposed-acquisition-by-numinus https://www.psychedelicfinance.com/articles/novamind-signs-definitive-agreement-to-acquire-arizona-based-clinics https://www.psychedelicfinance.com/articles/novamind-signs-loi-to-acquire-two-mental-health-clinics-in-arizona https://www.psychedelicfinance.com/articles/novamind-sponsors-therapsil-an-advocate-for-the-compassionate-use-of-psilocybin-in-canada https://www.psychedelicfinance.com/articles/novamind-strengthens-mental-health-expertise-adds-communications-leader https://www.psychedelicfinance.com/articles/novamind-to-commence-trading-cse-nm-on-january-5th-2021 https://www.psychedelicfinance.com/articles/novamind-to-conduct-phase-ii-psilocybin-trial-for-major-depressive-disorder https://www.psychedelicfinance.com/articles/novamind-to-discuss-the-role-of-ketamine-in-eating-disorder-treatment-at-leading-psychiatry-conference https://www.psychedelicfinance.com/articles/novamind-to-host-bionomics-prevail-trial-for-acute-treatment-of-social-anxiety-disorder https://www.psychedelicfinance.com/articles/novamind-to-host-mindmed-phase-iib-trial-for-lsd-and-anxiety https://www.psychedelicfinance.com/articles/novamind-to-present-at-benzinga-biotech-conference https://www.psychedelicfinance.com/articles/novamind-to-present-at-benzinga-conference https://www.psychedelicfinance.com/articles/novamind-to-present-at-canaccord-genuity-conference-new-paradigms-treatment-approaches-in-mental-health https://www.psychedelicfinance.com/articles/novamind-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference https://www.psychedelicfinance.com/articles/novamind-to-present-at-inaugural-kcsa-psychedelics-investor-conference https://www.psychedelicfinance.com/articles/novamind-to-present-at-ld-micro-and-kcsa-conferences https://www.psychedelicfinance.com/articles/novamind-to-present-at-life-sciences-investor-forum https://www.psychedelicfinance.com/articles/novamind-to-present-at-life-sciences-investor-forum-2 https://www.psychedelicfinance.com/articles/novamind-to-present-at-the-h-c-wainwright-psychedelics-conference-on-june-17-2021 https://www.psychedelicfinance.com/articles/novamind-to-present-at-the-planet-microcap-virtual-event-on-april-22-2021 https://www.psychedelicfinance.com/articles/novamind-to-present-at-the-snn-network-canada-virtual-event-on-january-7-2021 https://www.psychedelicfinance.com/articles/novamind-to-serve-as-research-site-for-karuna-therapeutics-late-stage-clinical-trial https://www.psychedelicfinance.com/articles/novamind-unveils-new-design-concept-for-clinics https://www.psychedelicfinance.com/articles/novamind-unveils-stealth-mode-investment-in-alto-neuroscience https://www.psychedelicfinance.com/articles/novamind-uplists-to-otcqb-venture-market https://www.psychedelicfinance.com/articles/novamind-video-profile https://www.psychedelicfinance.com/articles/novamind-welcomes-dr-paul-thielking-as-chief-scientific-officer https://www.psychedelicfinance.com/articles/numinus https://www.psychedelicfinance.com/articles/numinus-adds-ayahuasca-san-pedro-to-federal-license-for-psychedelic-research https://www.psychedelicfinance.com/articles/numinus-advances-phase-1-trial-on-proprietary-psilocybin-product https://www.psychedelicfinance.com/articles/numinus-aligns-business-initiatives-to-prepare-for-future-approval-of-mdma-assisted-therapy https://www.psychedelicfinance.com/articles/numinus-and-maps-public-benefit-corporation-announce-collaboration-agreement-to-seek-approval-of-mdma-assisted-psychotherapy-for-ptsd-single-arm-open-label-trial https://www.psychedelicfinance.com/articles/numinus-and-maps-public-benefit-corporation-announce-collaboration-agreement-to-seek-approval-of-mdma-assisted-psychotherapy-for-ptsd-single-arm-open-label-trial-2 https://www.psychedelicfinance.com/articles/numinus-and-syreon-provide-psilocybin-compassionate-access-trial-update https://www.psychedelicfinance.com/articles/numinus-and-together-we-can-partner-to-support-addiction-recovery-and-mental-wellness https://www.psychedelicfinance.com/articles/numinus-announces-2020-operational-plans-to-scale https://www.psychedelicfinance.com/articles/numinus-announces-agreement-with-healingmaps-to-drive-strategic-clinic-growth https://www.psychedelicfinance.com/articles/numinus-announces-clinical-advisory-council-to-advance-integrated-wellness-model https://www.psychedelicfinance.com/articles/numinus-announces-closing-of-17-million-bought-deal-offering-including-full-exercise-of-over-allotment-option https://www.psychedelicfinance.com/articles/numinus-announces-closing-of-40-million-bought-deal-financing https://www.psychedelicfinance.com/articles/numinus-announces-closing-of-oversubscribed-4-6-million-offering https://www.psychedelicfinance.com/articles/numinus-announces-compassionate-access-trial-of-psilocybin-assisted-psychotherapy-for-substance-use-disorders https://www.psychedelicfinance.com/articles/numinus-announces-filing-of-final-short-form-prospectus-for-offering-of-up-to-4-000-000 https://www.psychedelicfinance.com/articles/numinus-announces-four-peer-reviewed-publications-from-its-chief-clinical-officer-in-2023 https://www.psychedelicfinance.com/articles/numinus-announces-grant-of-stock-options https://www.psychedelicfinance.com/articles/numinus-announces-grant-of-stock-options-2 https://www.psychedelicfinance.com/articles/numinus-announces-health-canada-approval-of-maps-sponsored-open-label-study-for-mdma-assisted-therapy-for-ptsd https://www.psychedelicfinance.com/articles/numinus-announces-iss-recommends-shareholders-vote-in-favor-of-the-share-issuance-to-acquire-novamind https://www.psychedelicfinance.com/articles/numinus-announces-key-milestones-in-maps-sponsored-mdma-assisted-therapy-for-ptsd-clinical-trial https://www.psychedelicfinance.com/articles/numinus-announces-listing-of-warrants https://www.psychedelicfinance.com/articles/numinus-announces-listing-of-warrants-2 https://www.psychedelicfinance.com/articles/numinus-announces-listing-of-warrants-and-change-of-trading-symbol-for-previously-listed-warrants https://www.psychedelicfinance.com/articles/numinus-announces-milestones-in-compassionate-access-trial-for-mdma-assisted-therapy-in-collaboration-with-maps-public-benefit-corporation https://www.psychedelicfinance.com/articles/numinus-announces-partnership-with-maps-to-support-therapist-psychedelic-experiential-training https://www.psychedelicfinance.com/articles/numinus-announces-phase-1-clinical-trial-of-natural-psilocybin-mushroom-extraction-prepared-at-company-lab https://www.psychedelicfinance.com/articles/numinus-announces-short-form-prospectus-offering-of-units-for-gross-proceeds-of-up-to-4-05-million https://www.psychedelicfinance.com/articles/numinus-announces-the-music-as-medicine-event-series https://www.psychedelicfinance.com/articles/numinus-applies-for-international-patent-filing-of-psychedelics-production-process https://www.psychedelicfinance.com/articles/numinus-appoints-multidisciplinary-global-leaders-to-its-general-advisory-council https://www.psychedelicfinance.com/articles/numinus-appoints-new-bioscience-advisors-to-advance-ip-development https://www.psychedelicfinance.com/articles/numinus-closes-rto-commences-trading-numi https://www.psychedelicfinance.com/articles/numinus-commences-psilocybe-mushroom-cultivation-at-its-health-canada-licensed-laboratory https://www.psychedelicfinance.com/articles/numinus-commences-trading-on-the-tsx-venture-exchange-as-numi https://www.psychedelicfinance.com/articles/numinus-completes-acquisition-of-neurology-centre-of-toronto https://www.psychedelicfinance.com/articles/numinus-completes-first-extraction-of-its-psilocybe-mushrooms https://www.psychedelicfinance.com/articles/numinus-completes-first-mdma-administration-in-ptsd-trial-sponsored-by-maps https://www.psychedelicfinance.com/articles/numinus-congratulates-maps-on-phase-3-clinical-trial-demonstrating-significant-benefits-of-mdma-assisted-therapy-for-severe-ptsd https://www.psychedelicfinance.com/articles/numinus-develops-mushroom-tea-for-use-in-psychedelic-research https://www.psychedelicfinance.com/articles/numinus-develops-proprietary-psychedelic-tests-with-new-toxicity-and-potency-scans https://www.psychedelicfinance.com/articles/numinus-engages-native-ads-inc-for-digital-media-services https://www.psychedelicfinance.com/articles/numinus-expands-ketamine-therapy-for-mental-health-in-montreal-and-announces-new-brand-awareness-initiatives https://www.psychedelicfinance.com/articles/numinus-expands-natural-psychedelic-research-with-new-biosecurity-license https://www.psychedelicfinance.com/articles/numinus-expands-research-capabilities-with-new-phoenix-clinical-research-site https://www.psychedelicfinance.com/articles/numinus-files-restated-financial-reports https://www.psychedelicfinance.com/articles/numinus-files-u-s-provisional-patent-application-for-a-proprietary-rapid-production-process-for-psilocybe-and-other-psychoactive-fungi-species https://www.psychedelicfinance.com/articles/numinus-first-canadian-public-company-to-complete-legal-harvest-of-psilocybe-mushrooms https://www.psychedelicfinance.com/articles/numinus-identified-as-a-licensed-psilocybin-supplier-by-health-canada https://www.psychedelicfinance.com/articles/numinus-launches-psychedelic-assisted-therapy-for-chronic-and-serious-medical-illness https://www.psychedelicfinance.com/articles/numinus-mails-materials-for-special-meeting-of-shareholders-and-announces-interim-court-order-for-plan-of-arrangement https://www.psychedelicfinance.com/articles/numinus-now-offers-ketamine-assisted-therapy-in-toronto https://www.psychedelicfinance.com/articles/numinus-pilots-mental-health-program-for-corporate-clients-in-utah https://www.psychedelicfinance.com/articles/numinus-provides-update-on-acquisition-integration-and-announces-new-client-financing-options https://www.psychedelicfinance.com/articles/numinus-re-launches-psychedelic-therapy-frontiers-podcast-with-additional-hosts-and-topics https://www.psychedelicfinance.com/articles/numinus-receives-clinical-trial-application-approval-from-health-canada-for-experiential-psychedelic-assisted-therapy-training-using-psilocybe-cubensis-tea https://www.psychedelicfinance.com/articles/numinus-receives-conditional-approval-to-graduate-to-the-toronto-stock-exchange https://www.psychedelicfinance.com/articles/numinus-receives-health-canada-licence-amendment-to-produce-and-extract-psilocybin-from-mushrooms https://www.psychedelicfinance.com/articles/numinus-revolutionary-therapy-corporate-profile https://www.psychedelicfinance.com/articles/numinus-signs-lab-services-agreement-with-optimi-health-to-advance-research-and-development-of-psychedelic-products https://www.psychedelicfinance.com/articles/numinus-submits-clinical-trial-application-for-phase-1-trial-on-proprietary-psilocybin-product https://www.psychedelicfinance.com/articles/numinus-submits-clinical-trial-application-to-health-canada-for-experiential-psilocybin-assisted-therapy-training-research https://www.psychedelicfinance.com/articles/numinus-to-acquire-novamind-creating-the-north-american-industry-leader-in-psychedelic-therapy-and-research https://www.psychedelicfinance.com/articles/numinus-to-begin-trading-on-the-otc-under-symbol-numif https://www.psychedelicfinance.com/articles/numinus-to-expand-state-of-the-art-psychedelics-research-laboratory https://www.psychedelicfinance.com/articles/numinus-to-host-extension-of-maps-sponsored-mdma-assisted-therapy-for-ptsd-trials https://www.psychedelicfinance.com/articles/numinus-to-host-q1-2022-results-conference-call-on-january-13-2022 https://www.psychedelicfinance.com/articles/numinus-to-host-q1-2023-results-conference-call-on-january-16-2023 https://www.psychedelicfinance.com/articles/numinus-to-host-q2-2022-results-conference-call-on-april-14-2022 https://www.psychedelicfinance.com/articles/numinus-to-host-q3-2022-results-conference-call-on-july-14-2022 https://www.psychedelicfinance.com/articles/numinus-to-host-q4-and-2021-annual-results-conference-call-on-december-9-2021 https://www.psychedelicfinance.com/articles/numinus-to-host-q4-and-year-end-2022-results-conference-call-on-november-29-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-thursday-december-8-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-thursday-october-13-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-aaas-2022-annual-meeting-on-february-17-20-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-citis-psychedelic-drug-call-series-on-february-2-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-maxims-2022-virtual-growth-conference-on-march-28-30-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-microdose-hosted-events-psychedelic-capital-and-wonderland-miami https://www.psychedelicfinance.com/articles/numinus-to-participate-in-the-cantor-neurology-psychiatry-conference-on-october-6-7-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference-on-september-12-14-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-the-h-c-wainwright-2nd-annual-psychedelics-virtual-conference-on-december-6th https://www.psychedelicfinance.com/articles/numinus-to-participate-in-the-h-c-wainwright-global-investment-conference-on-may-23-26-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-upcoming-investor-conferences-in-april-2022 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-upcoming-investor-conferences-in-september-2021 https://www.psychedelicfinance.com/articles/numinus-to-participate-in-upcoming-research-industry-conferences https://www.psychedelicfinance.com/articles/numinus-to-participate-in-wonderland-miami-on-november-3-5-2022 https://www.psychedelicfinance.com/articles/numinus-to-research-comp360-psilocybin-therapy-in-treatment-resistant-depression-as-part-of-large-phase-3-study https://www.psychedelicfinance.com/articles/numinus-unveils-new-logo-and-brand-identity https://www.psychedelicfinance.com/articles/numinus-upgrades-psychedelics-lab-to-increase-research-service-capabilities https://www.psychedelicfinance.com/articles/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application https://www.psychedelicfinance.com/articles/numinus-wellness-announces-key-leadership-hires-to-support-rapid-growth-and-innovation https://www.psychedelicfinance.com/articles/numinus-wellness-announces-national-expansion-with-acquisition-of-montreal-based-mindspace-wellbeing-a-full-service-well-being-organization-and-pioneer-in-psychedelic-programming https://www.psychedelicfinance.com/articles/numinus-wellness-closes-q1-2021-with-strong-cash-position-and-industry-firsts https://www.psychedelicfinance.com/articles/numinus-wellness-closes-q3-2021-with-63-2-million-cash-position-lab-and-trial-advances-and-strategic-expansion-into-psychedelic-neurology https://www.psychedelicfinance.com/articles/numinus-wellness-commends-health-canada-on-special-access-programme-amendments-to-restore-potential-access-to-psychedelic-medicines https://www.psychedelicfinance.com/articles/numinus-wellness-completes-acquisition-of-montreal-based-mindspace-wellbeing https://www.psychedelicfinance.com/articles/numinus-wellness-forges-forward-into-psychedelic-discovery-research-with-the-orbitrap-exploris-120-mass-spectometer https://www.psychedelicfinance.com/articles/numinus-wellness-graduates-to-tier-1-on-the-tsx-venture-exchange https://www.psychedelicfinance.com/articles/numinus-wellness-inc-announces-10-million-bought-deal-public-offering https://www.psychedelicfinance.com/articles/numinus-wellness-inc-announces-30-million-bought-deal-public-offering https://www.psychedelicfinance.com/articles/numinus-wellness-inc-announces-upsized-bought-deal-public-offering-to-35-million https://www.psychedelicfinance.com/articles/numinus-wellness-inc-graduates-to-the-otcqx-best-market https://www.psychedelicfinance.com/articles/numinus-wellness-inc-reports-q1-2023-results https://www.psychedelicfinance.com/articles/numinus-wellness-inc-reports-q3-2022-results https://www.psychedelicfinance.com/articles/numinus-wellness-inc-reports-q4-2022-and-annual-results https://www.psychedelicfinance.com/articles/numinus-wellness-inc-reports-q4-and-year-end-2021-results https://www.psychedelicfinance.com/articles/numinus-wellness-inc-to-commence-trading-on-the-tsx-on-december-16-2021 https://www.psychedelicfinance.com/articles/numinus-wellness-opens-the-market https://www.psychedelicfinance.com/articles/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing-mindspace-wellbeing-acquisition-and-clinical-trial-collaboration-with-maps-pbc https://www.psychedelicfinance.com/articles/numinus-wellness-receives-health-canada-special-access-program-applicant-approval-to-provide-psychedelic-assisted-therapy-treatment https://www.psychedelicfinance.com/articles/numinus-wellness-to-acquire-neurology-centre-of-toronto-plans-to-create-centre-for-psychedelic-neurology https://www.psychedelicfinance.com/articles/ontario-brain-institute-increases-investment-in-diamond-therapeutics-to-accelerate-innovation-in-mental-health https://www.psychedelicfinance.com/articles/optimi-completes-first-grow-of-psilocybin-mushrooms-and-introduces-head-of-cultivation https://www.psychedelicfinance.com/articles/optimi-completes-proprietary-natural-psilocybin-extraction-process-and-files-u-s-provisional-patent https://www.psychedelicfinance.com/articles/optimi-health-accelerates-psilocybin-clinical-trial-program-with-impact https://www.psychedelicfinance.com/articles/optimi-health-acquires-extensive-catalog-of-psychedelic-and-functional-mushroom-genetics https://www.psychedelicfinance.com/articles/optimi-health-adds-to-corporate-and-advisory-team https://www.psychedelicfinance.com/articles/optimi-health-aims-to-expand-its-shareholder-base https://www.psychedelicfinance.com/articles/optimi-health-and-numinus-wellness-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application https://www.psychedelicfinance.com/articles/optimi-health-and-numinus-wellness-to-conduct-psychedelic-lab-research-and-development https://www.psychedelicfinance.com/articles/optimi-health-announces-canadian-retail-and-e-commerce-distribution-agreements-for-functional-mushroom-supplements-and-appoints-chief-financial-officer-to-its-board-of-directors https://www.psychedelicfinance.com/articles/optimi-health-announces-closing-of-strategic-non-brokered-private-placement https://www.psychedelicfinance.com/articles/optimi-health-announces-dtc-eligibility-up-list-to-otcqb https://www.psychedelicfinance.com/articles/optimi-health-announces-investor-relations-agreement https://www.psychedelicfinance.com/articles/optimi-health-announces-product-distribution-agreement-with-vitasave https://www.psychedelicfinance.com/articles/optimi-health-applauds-health-canadas-position-on-drug-quality-and-goods-and-manufacturing-practices-gmp-for-psilocybin https://www.psychedelicfinance.com/articles/optimi-health-appointed-new-chief-executive-officer https://www.psychedelicfinance.com/articles/optimi-health-appoints-chief-science-officer https://www.psychedelicfinance.com/articles/optimi-health-appoints-principal-investigator-for-clinical-dosing-study https://www.psychedelicfinance.com/articles/optimi-health-approved-to-supply-psilocybin-under-health-canadas-special-access-program https://www.psychedelicfinance.com/articles/optimi-health-atma-journey-centers-to-proceed-with-phase-i-natural-psilocybin-and-mdma-clinical-trial-application-to-health-canada https://www.psychedelicfinance.com/articles/optimi-health-begins-cultivation-of-natural-psilocybin-for-use-in-clinical-trials https://www.psychedelicfinance.com/articles/optimi-health-clears-final-base-shelf-prospectus https://www.psychedelicfinance.com/articles/optimi-health-completes-expansion-of-on-site-analytical-laboratory https://www.psychedelicfinance.com/articles/optimi-health-completes-first-production-of-novel-mdma-drug-candidate-opti-mhcl https://www.psychedelicfinance.com/articles/optimi-health-completes-largest-legal-natural-psilocybin-harvest-in-canadian-history https://www.psychedelicfinance.com/articles/optimi-health-completes-otc-markets-uplisting-to-otcqb https://www.psychedelicfinance.com/articles/optimi-health-completes-pre-clinical-trial-application-meeting https://www.psychedelicfinance.com/articles/optimi-health-corp-closes-oversubscribed-non-brokered-private-placement-for-gross-proceeds-of-4-5-million https://www.psychedelicfinance.com/articles/optimi-health-corp-completes-oversubscribed-20-7-million-initial-public-offering-and-announces-listing-on-the-cse https://www.psychedelicfinance.com/articles/optimi-health-corp-receives-health-canada-psychedelic-research-exemption-and-files-preliminary-prospectus-for-initial-public-offering-of-units https://www.psychedelicfinance.com/articles/optimi-health-corp-receives-receipt-for-final-prospectus-and-conditional-approval-to-list-on-the-cse https://www.psychedelicfinance.com/articles/optimi-health-dealers-license-granted-by-health-canada https://www.psychedelicfinance.com/articles/optimi-health-engages-expert-management-consultancy-to-drive-corporate-visibility https://www.psychedelicfinance.com/articles/optimi-health-engages-u-s-based-law-firm-for-patent-support https://www.psychedelicfinance.com/articles/optimi-health-enters-into-international-collaborative-research-and-supply-agreement-with-promises-innovative-recovery-center https://www.psychedelicfinance.com/articles/optimi-health-enters-into-psilocybin-supply-agreement-with-filament-health https://www.psychedelicfinance.com/articles/optimi-health-expands-functional-mushroom-sales-network-with-additional-brokers-distribution-agreements https://www.psychedelicfinance.com/articles/optimi-health-finalizes-partnership-and-psilocybin-supply-agreement-with-atma-journey-centers https://www.psychedelicfinance.com/articles/optimi-health-finalizes-planned-build-out-of-mushroom-production-and-research-facility https://www.psychedelicfinance.com/articles/optimi-health-finalizes-psilocybin-supply-agreement-with-bloom-psychedelic-therapy-and-research-centre https://www.psychedelicfinance.com/articles/optimi-health-granted-amendment-to-controlled-substances-dealers-licence https://www.psychedelicfinance.com/articles/optimi-health-granted-amendment-to-dealers-licence-by-health-canada-to-supply-special-access-program https://www.psychedelicfinance.com/articles/optimi-health-granted-natural-health-product-site-licence-by-health-canada https://www.psychedelicfinance.com/articles/optimi-health-initiates-agreement-with-sabi-mind-for-therapeutic-supplies-of-psilocybin-mdma https://www.psychedelicfinance.com/articles/optimi-health-initiates-pathway-to-nasdaq-listing https://www.psychedelicfinance.com/articles/optimi-health-joins-first-psychedelic-exchange-traded-fund https://www.psychedelicfinance.com/articles/optimi-health-large-scale-multi-purpose-mushroom-facility-advances-towards-completion-and-licensing https://www.psychedelicfinance.com/articles/optimi-health-launches-e-commerce-platform-featuring-all-natural-functional-mushroom-supplements https://www.psychedelicfinance.com/articles/optimi-health-natural-psilocybin-extraction-breakthrough-submitted-for-provisional-patent-application https://www.psychedelicfinance.com/articles/optimi-health-opens-canadas-largest-gmp-grade-licensed-psilocybin-cultivation-facility https://www.psychedelicfinance.com/articles/optimi-health-partnership-with-numinus-wellness-provides-update-on-first-all-natural-psilocybin-protocol https://www.psychedelicfinance.com/articles/optimi-health-provides-dealer-license-update-and-comments-on-health-canadas-amendments-to-the-special-access-program-sap https://www.psychedelicfinance.com/articles/optimi-health-provides-progress-report-on-year-of-commercialization https://www.psychedelicfinance.com/articles/optimi-health-receives-dealers-license-inspection-and-introduces-quality-assurance-department https://www.psychedelicfinance.com/articles/optimi-health-receives-health-canada-npn-product-licenses-in-preparation-for-q2-sales-launch https://www.psychedelicfinance.com/articles/optimi-health-requests-approval-to-manufacture-mdma-other-synthetic-psychedelics https://www.psychedelicfinance.com/articles/optimi-health-requests-final-inspection-for-dealers-license https://www.psychedelicfinance.com/articles/optimi-health-signs-first-international-mushroom-supply-agreement-with-uk-based-avida-global https://www.psychedelicfinance.com/articles/optimi-health-signs-psilocybin-supply-agreement-with-halucenex-life-sciences-inc https://www.psychedelicfinance.com/articles/optimi-health-strengthens-clinical-and-regulatory-expertise https://www.psychedelicfinance.com/articles/optimi-health-submits-natural-psilocybin-combined-drug-delivery-and-extraction-formulations-for-provisional-patent https://www.psychedelicfinance.com/articles/optimi-health-submits-phase-i-clinical-trial-application-combining-the-use-of-proprietary-psilocybin-and-mdma-drug-candidates-in-healthy-therapists https://www.psychedelicfinance.com/articles/optimi-health-supports-patient-focused-psilocybin-advocacy-by-therapsil https://www.psychedelicfinance.com/articles/optimi-health-to-launch-therapeutic-psilocybin-product-in-partnership-with-patient-advocate-thomas-hartle https://www.psychedelicfinance.com/articles/optimi-health-unveils-canadas-first-natural-therapeutic-psilocybin-product-for-approved-patients https://www.psychedelicfinance.com/articles/optimi-health-updates-build-out-of-mushroom-production-and-research-facility https://www.psychedelicfinance.com/articles/optimi-health-updates-launch-of-online-functional-mushroom-sales https://www.psychedelicfinance.com/articles/origin-therapeutics-announces-leadership-team https://www.psychedelicfinance.com/articles/origin-therapeutics-files-preliminary-prospectus-and-announces-initial-portfolio-companies https://www.psychedelicfinance.com/articles/origin-therapeutics-launches-to-fund-emerging-psychedelics-companies https://www.psychedelicfinance.com/articles/origin-therapeutics-portfolio-company-tripsitter-expands-to-eight-additional-states https://www.psychedelicfinance.com/articles/origin-therapeutics-to-be-a-silver-sponsor-for-major-psychedelics-conference-wonderland-miami https://www.psychedelicfinance.com/articles/osmind-raises-40m-series-b-round-led-by-dfj-growth-to-expand-platform-for-breakthrough-mental-health-research-and-treatment https://www.psychedelicfinance.com/articles/otc-markets-group-welcomes-optimi-health-corp-to-otcqx https://www.psychedelicfinance.com/articles/otsuka-pharmaceutical-to-acquire-mindset-pharma https://www.psychedelicfinance.com/articles/palliative-canadians-await-august-4th-decision-on-psilocybin-mushroom-approval-therapsil-urges-health-minister-to-do-the-right-thing https://www.psychedelicfinance.com/articles/pasithea-therapeutics-announces-successful-treatment-of-first-patients-in-the-uk-with-ketamine-infusion-therapy https://www.psychedelicfinance.com/articles/pasithea-therapeutics-corp-and-evotec-se-enter-into-drug-development-agreement https://www.psychedelicfinance.com/articles/pasithea-therapeutics-opens-its-first-ketamine-therapy-clinic-in-the-united-kingdom https://www.psychedelicfinance.com/articles/patent-application-published-for-pharmala-biotechs-mdma-analogs https://www.psychedelicfinance.com/articles/patient-screening-to-resume-in-intelgenxs-buena-montelukast-versafilm-r-phase-2a-clinical-trial-in-patients-with-mild-to-moderate-alzheimers-disease https://www.psychedelicfinance.com/articles/paul-glavine https://www.psychedelicfinance.com/articles/perception-neuroscience-and-otsuka-pharmaceutical-announce-collaboration-on-development-of-pcn-101-r-ketamine-in-japan-for-treatment-of-depressive-disorders https://www.psychedelicfinance.com/articles/perception-neuroscience-initiates-phase-2a-study-of-pcn-101-r-ketamine-for-treatment-resistant-depression https://www.psychedelicfinance.com/articles/pharmadrug-advances-dmt-analogue-program-for-glaucoma-with-production-of-medical-device-designed-to-provide-sustained-control-of-elevated-intraocular-pressure https://www.psychedelicfinance.com/articles/pharmadrug-advances-opthalmology-program-with-final-selection-of-lead-dmt-analogue-to-provide-sustained-control-of-elevated-intraocular-pressure-for-glaucoma https://www.psychedelicfinance.com/articles/pharmadrug-advances-pd-001-its-patented-improved-version-of-cepharanthine-for-oncology-and-infectious-disease https://www.psychedelicfinance.com/articles/pharmadrug-advances-programs-in-oncology-and-infectious-disease-through-completion-of-cgmp-drug-substance-manufacturing https://www.psychedelicfinance.com/articles/pharmadrug-advances-programs-in-oncology-with-filing-of-pct-application-detailing-the-use-of-pd-001-for-treatment-of-prostate-cancer https://www.psychedelicfinance.com/articles/pharmadrug-advances-psychedelics-pharmaceutical-program-focused-on-dmt-and-dmt-analogues https://www.psychedelicfinance.com/articles/pharmadrug-advances-psychedelics-program-with-analogue-dmt-formulations-to-treat-eye-diseases https://www.psychedelicfinance.com/articles/pharmadrug-announces-addition-of-dr-cindy-hutnik-president-of-the-canadian-glaucoma-society-to-their-scientific-advisory-board-to-enhance-ongoing-dmt-studies-to-treat-glaucoma https://www.psychedelicfinance.com/articles/pharmadrug-announces-addition-of-dr-cindy-hutnik-president-of-the-canadian-glaucoma-society-to-their-scientific-advisory-board-to-enhance-ongoing-dmt-studies-to-treat-glaucoma-2 https://www.psychedelicfinance.com/articles/pharmadrug-announces-appointment-of-auditor https://www.psychedelicfinance.com/articles/pharmadrug-announces-clinical-research-collaboration-with-the-johns-hopkins-university-to-evaluate-dmt-in-a-comparative-clinical-study https://www.psychedelicfinance.com/articles/pharmadrug-announces-filing-of-us-provisional-patent-for-cepharanthine-to-treat-prostate-cancer https://www.psychedelicfinance.com/articles/pharmadrug-announces-initiation-of-manufacturing-of-cepharanthine-pd-001-for-clinical-programs-in-rare-cancers https://www.psychedelicfinance.com/articles/pharmadrug-announces-interim-positive-findings-for-the-combination-of-cepharanthine-and-frontline-chemotherapy-for-ind-enabling-prostate-cancer-study https://www.psychedelicfinance.com/articles/pharmadrug-announces-loi-to-acquire-sairiyo-therapeutics-inc https://www.psychedelicfinance.com/articles/pharmadrug-announces-non-brokered-offering-of-650-000-of-convertible-secured-debentures-and-issuances-of-common-shares https://www.psychedelicfinance.com/articles/pharmadrug-announces-positive-findings-for-the-combination-of-cepharanthine-and-frontline-chemotherapy-for-ind-enabling-esophageal-cancer-study https://www.psychedelicfinance.com/articles/pharmadrug-announces-positive-research-results-of-cepharanthine-to-treat-multiple-cancers https://www.psychedelicfinance.com/articles/pharmadrug-announces-stock-ticker-symbol-change-to-cse-phrx https://www.psychedelicfinance.com/articles/pharmadrug-appoints-world-renowned-dmt-expert-dr-steven-a-barker-to-its-scientific-advisory-board-for-psychedelic-pharmaceuticals https://www.psychedelicfinance.com/articles/pharmadrug-collaborates-with-pharmather-for-development-of-dmt-transdermal-patch https://www.psychedelicfinance.com/articles/pharmadrug-commences-trading-on-the-otcqb-market-in-the-united-states https://www.psychedelicfinance.com/articles/pharmadrug-completes-acquisition-of-sairiyo-therapeutics-inc https://www.psychedelicfinance.com/articles/pharmadrug-engages-octagon-media-and-affiliated-wall-street-reporter-for-investor-marketing-campaign https://www.psychedelicfinance.com/articles/pharmadrug-enters-definitive-agreement-for-acquisition-of-sairiyo-therapeutics-inc-who-recently-received-orphan-drug-designation-from-fda-for-esophageal-cancer https://www.psychedelicfinance.com/articles/pharmadrug-expands-product-offering-to-prepare-for-potential-adult-use-market-in-germany https://www.psychedelicfinance.com/articles/pharmadrug-files-for-fda-orphan-drug-designation-for-dmt-in-stroke https://www.psychedelicfinance.com/articles/pharmadrug-forms-research-collaboration-with-terasaki-institute-for-novel-ocular-drug-formulation-program-to-deliver-dmt-and-other-tryptamines-to-treat-eye-disease https://www.psychedelicfinance.com/articles/pharmadrug-grants-stock-options https://www.psychedelicfinance.com/articles/pharmadrug-inc-completes-strategic-mutual-investment-with-red-light-holland-corp https://www.psychedelicfinance.com/articles/pharmadrug-provides-corporate-update-and-balance-sheet-status https://www.psychedelicfinance.com/articles/pharmadrug-provides-research-results-and-initiates-ind-enabling-studies-for-cepharanthine-in-the-treatment-of-multiple-cancers https://www.psychedelicfinance.com/articles/pharmadrug-receives-positive-results-for-dmt-analogue-program-to-treat-glaucoma https://www.psychedelicfinance.com/articles/pharmadrug-reports-positive-preclinical-study-results-of-cepharanthine-to-treat-cancers https://www.psychedelicfinance.com/articles/pharmadrug-signs-supply-agreement-with-global-cannabis-supplier-and-provides-update-on-german-operations-and-balance-sheet-improvements https://www.psychedelicfinance.com/articles/pharmadrug-successfully-completes-key-milestone-to-support-cgmp-production-of-clinical-lead-candidate-pd-001-its-patented-orally-available-version-of-cepharanthine-for-oncology-and-infectious-disease https://www.psychedelicfinance.com/articles/pharmadrugs-super-smart-launches-slim-mycowerx-brand-of-functional-mushrooms https://www.psychedelicfinance.com/articles/pharmala-appoints-dr-leah-mayo-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/pharmala-biotech-adds-david-purcell-as-director-of-sales https://www.psychedelicfinance.com/articles/pharmala-biotech-announces-listing-on-the-canadian-securities-exchange https://www.psychedelicfinance.com/articles/pharmala-biotech-applauds-sen-cory-booker-and-sen-rand-pauls-bill-to-include-mdma-in-right-to-try-legislation https://www.psychedelicfinance.com/articles/pharmala-biotech-appoints-kevin-roy-to-its-board-of-directors https://www.psychedelicfinance.com/articles/pharmala-biotech-closes-purchase-order-with-emyria-ltd-completes-filing-of-laneo-trademark-in-australia https://www.psychedelicfinance.com/articles/pharmala-biotech-completes-filing-of-patent-application-for-6-mdma-analogs https://www.psychedelicfinance.com/articles/pharmala-biotech-contracts-with-intervivo-solutions-to-validate-novel-mdma-analogs https://www.psychedelicfinance.com/articles/pharmala-biotech-expands-mdma-distribution-with-ccrest-labs https://www.psychedelicfinance.com/articles/pharmala-biotech-first-publicly-traded-company-to-produce-gmp-mdma https://www.psychedelicfinance.com/articles/pharmala-biotech-granted-an-export-permit-for-300-grams-of-laneo-tm-mdma https://www.psychedelicfinance.com/articles/pharmala-biotech-initiates-research-at-the-university-of-arkansas-for-medical-sciences https://www.psychedelicfinance.com/articles/pharmala-biotech-named-exclusive-mdma-supplier-to-intervivo-solutions https://www.psychedelicfinance.com/articles/pharmala-biotech-ready-to-assist-alberta-government-with-clinical-mdma-supply https://www.psychedelicfinance.com/articles/pharmala-biotech-registers-trademark-for-mdma https://www.psychedelicfinance.com/articles/pharmala-biotech-sabi-mind-announce-mdma-supply-agreement https://www.psychedelicfinance.com/articles/pharmala-biotech-supports-decision-to-decriminalize-possession-of-mdma-in-british-columbia https://www.psychedelicfinance.com/articles/pharmala-biotech-to-supply-major-australian-research-institute-with-laneo-tm-mdma-for-phase-3-clinical-trial https://www.psychedelicfinance.com/articles/pharmala-biotech-to-supply-mind-medicine-australia-with-gmp-mdma-for-clinical-trial https://www.psychedelicfinance.com/articles/pharmala-biotech-to-supply-university-of-california-clinical-trial-with-laneo-tm-mdma https://www.psychedelicfinance.com/articles/pharmala-biotech-to-supply-university-of-sydney-clinical-trial-with-laneo-tm-mdma https://www.psychedelicfinance.com/articles/pharmala-contracts-with-clerkenwell-to-bring-safer-mdma-analogue-to-us-uk https://www.psychedelicfinance.com/articles/pharmala-received-guidance-on-ala-002-from-mhra-launches-clinical-program-with-university-of-sydney https://www.psychedelicfinance.com/articles/pharmala-submits-pre-ind-dossier-for-novel-mdma-analog-to-fda https://www.psychedelicfinance.com/articles/pharmather-added-to-the-north-american-psychedelics-index-and-first-psychedelic-exchange-traded-fund https://www.psychedelicfinance.com/articles/pharmather-advancing-research-for-novel-microneedle-delivery-of-ketamine https://www.psychedelicfinance.com/articles/pharmather-and-tsrl-enter-into-co-development-agreement-for-microneedle-patch-delivery-technology-for-psychedelics-and-antivirals https://www.psychedelicfinance.com/articles/pharmather-and-vitruvias-enter-into-collaboration-agreement-for-commercialization-of-ketarx-tm-racemic-ketamine-in-the-u-s https://www.psychedelicfinance.com/articles/pharmather-announces-application-for-otcqb-listing https://www.psychedelicfinance.com/articles/pharmather-announces-cad-10-million-private-placement-with-institutional-investors https://www.psychedelicfinance.com/articles/pharmather-announces-closing-of-cad-10-million-private-placement-with-institutional-investors https://www.psychedelicfinance.com/articles/pharmather-announces-completion-of-ind-enabling-pharmacokinetic-and-tolerability-study-with-ketarx-tm-ketamine-patch https://www.psychedelicfinance.com/articles/pharmather-announces-dtc-eligibility-of-its-common-shares-in-the-united-states https://www.psychedelicfinance.com/articles/pharmather-announces-exclusive-license-agreement-with-the-university-of-arizona-for-the-commercialization-of-ketamine-in-the-treatment-of-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-announces-fda-approval-of-investigational-new-drug-ind-application-for-ketamine-to-treat-als https://www.psychedelicfinance.com/articles/pharmather-announces-fda-approval-of-ketamine-ind-in-the-treatment-of-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-announces-fda-orphan-drug-designation-granted-to-ketamine-for-prevention-of-ischemia-reperfusion-injury-from-organ-transplantation https://www.psychedelicfinance.com/articles/pharmather-announces-grant-of-u-s-patent-on-formulation-and-production-process-of-ketamine-and-ketamine-analogs https://www.psychedelicfinance.com/articles/pharmather-announces-grant-of-u-s-patent-on-ketamine-formulation https://www.psychedelicfinance.com/articles/pharmather-announces-late-breaking-abstract-presentation-of-positive-efficacy-and-safety-data-from-phase-1-2-clinical-study-of-ketamine-in-the-treatment-of-levodopa-induced-dyskinesia-in-parkinsons-disease-at-the-mds-international-congress https://www.psychedelicfinance.com/articles/pharmather-announces-notice-of-allowance-for-u-s-patent-covering-ketamine-for-the-potential-treatment-of-parkinsons-disease-and-motor-disorders https://www.psychedelicfinance.com/articles/pharmather-announces-positive-research-results-for-lsd-microneedle-patch https://www.psychedelicfinance.com/articles/pharmather-announces-positive-research-results-for-pharmapatch-tm-with-n-n-dimethyltryptamine-dmt-and-strategic-investment-into-sairiyo-therapeutics https://www.psychedelicfinance.com/articles/pharmather-announces-positive-research-results-for-psilocybin-microneedle-patch https://www.psychedelicfinance.com/articles/pharmather-announces-positive-results-from-study-for-ketamine-microneedle-patch https://www.psychedelicfinance.com/articles/pharmather-announces-positive-results-from-study-of-ketabet-tm-for-depression https://www.psychedelicfinance.com/articles/pharmather-announces-positive-topline-results-from-clinical-study-of-ketamine-for-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-announces-poster-presentation-of-positive-efficacy-and-safety-data-from-phase-1-2-clinical-study-of-ketamine-in-the-treatment-of-levodopa-induced-dyskinesia-in-parkinsons-disease-at-neuroscience-2022-by-the-society-for-neuroscience https://www.psychedelicfinance.com/articles/pharmather-announces-research-collaboration-with-terasaki-institute-for-novel-microneedle-delivery-of-psychedelic-pharmaceuticals https://www.psychedelicfinance.com/articles/pharmather-announces-sale-of-psilocybin-program https://www.psychedelicfinance.com/articles/pharmather-announces-submission-of-ind-application-with-the-fda-for-phase-2-clinical-trial-evaluating-ketamine-in-the-treatment-of-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-announces-successful-completion-of-pre-ind-meeting-with-fda-for-the-clinical-development-of-ketamine-in-the-treatment-of-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-applies-for-fda-orphan-drug-designation-for-ketamine-to-treat-rare-neurological-disorder-status-epilepticus https://www.psychedelicfinance.com/articles/pharmather-approved-to-trade-on-the-otcqb-venture-market https://www.psychedelicfinance.com/articles/pharmather-collaborates-with-medisynergics-to-develop-patented-ketamine-formulation-for-pain-disorders-and-to-discover-novel-psychedelic-formulations https://www.psychedelicfinance.com/articles/pharmather-engages-alcami-for-clinical-and-commercial-manufacturing-of-novel-ketamine-products https://www.psychedelicfinance.com/articles/pharmather-engages-clarus-securities-as-capital-markets-advisor https://www.psychedelicfinance.com/articles/pharmather-enters-into-exclusive-option-agreement-with-case-western-reserve-university-to-develop-and-commercialize-ketamine-for-rett-syndrome https://www.psychedelicfinance.com/articles/pharmather-enters-into-process-development-agreement-with-lts-lohmann-for-ketamine-microneedle-patch https://www.psychedelicfinance.com/articles/pharmather-enters-into-research-collaboration-agreement-with-revive-therapeutics-for-development-of-psilocybin-microneedle-patch https://www.psychedelicfinance.com/articles/pharmather-enters-into-research-collaboration-agreement-with-revive-therapeutics-for-development-of-psilocybin-microneedle-patch-2 https://www.psychedelicfinance.com/articles/pharmather-enters-into-research-collaboration-with-revive-therapeutics-for-psilocybin-and-panaceai-tm-psychedelic-discovery-ai-platform https://www.psychedelicfinance.com/articles/pharmather-expands-patent-portfolio-with-filing-of-u-s-patent-application-for-ketamine-and-repurposing-of-psychedelics-with-panaceai-tm https://www.psychedelicfinance.com/articles/pharmather-expands-patent-portfolio-with-filing-of-u-s-patent-for-novel-use-of-psilocybin-to-treat-cancer https://www.psychedelicfinance.com/articles/pharmather-expands-psychedelic-patent-portfolio-with-filing-of-u-s-patent-application-for-novel-ketamine-formulation https://www.psychedelicfinance.com/articles/pharmather-expands-research-partnership-with-university-health-network-for-development-of-digital-therapeutics-platform https://www.psychedelicfinance.com/articles/pharmather-expands-to-neuromuscular-diseases-with-exclusive-license-agreement-for-ketamine-in-the-treatment-of-lou-gehrigs-disease https://www.psychedelicfinance.com/articles/pharmather-files-fda-pre-ind-meeting-request-and-briefing-package-for-ketabet-tm-to-treat-depression https://www.psychedelicfinance.com/articles/pharmather-files-fda-pre-ind-meeting-request-for-ketamine-in-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-files-for-fda-orphan-drug-designation-for-ketamine-in-neuropathic-pain https://www.psychedelicfinance.com/articles/pharmather-files-for-fda-orphan-drug-designation-for-ketamine-in-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-files-for-fda-orphan-drug-designation-for-ketamine-to-treat-lou-gehrigs-disease https://www.psychedelicfinance.com/articles/pharmather-files-u-s-patent-for-novel-combinations-of-psilocybin-and-fda-approved-drugs-to-treat-neurological-disorders https://www.psychedelicfinance.com/articles/pharmather-granted-fda-orphan-drug-designation-for-ketamine-to-treat-amyotrophic-lateral-sclerosis https://www.psychedelicfinance.com/articles/pharmather-granted-fda-orphan-drug-designation-for-ketamine-to-treat-amyotrophic-lateral-sclerosis-2 https://www.psychedelicfinance.com/articles/pharmather-granted-fda-orphan-drug-designation-for-ketamine-to-treat-complex-regional-pain-syndrome https://www.psychedelicfinance.com/articles/pharmather-granted-fda-orphan-drug-designation-for-ketamine-to-treat-status-epilepticus https://www.psychedelicfinance.com/articles/pharmather-granted-new-japanese-patent-for-ketabet-tm-ketamine-combination-formulation-strengthening-global-patent-portfolio https://www.psychedelicfinance.com/articles/pharmather-granted-pre-ind-meeting-with-the-fda-for-ketamine-in-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-holdings-announces-fda-grant-of-orphan-drug-designation-to-ketarx-tm-ketamine-for-the-treatment-of-rett-syndrome https://www.psychedelicfinance.com/articles/pharmather-holdings-announces-grant-of-u-s-patent-covering-ketamine-for-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-holdings-provides-update-for-ketarx-tm-racemic-ketamine-development-programs-and-expected-milestones-for-2023 https://www.psychedelicfinance.com/articles/pharmather-holdings-submits-fast-track-application-to-fda-for-ketarx-tm-ketamine-for-the-treatment-of-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-holdings-submits-fda-meeting-package-to-discuss-phase-3-program-and-fast-track-designation-for-ketarx-tm-ketamine-in-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-holdings-submits-for-fda-orphan-drug-designation-for-ketamine-to-treat-rett-syndrome https://www.psychedelicfinance.com/articles/pharmather-initiates-phase-2-clinical-trial-of-ketamine-for-the-treatment-of-parkinsons-disease https://www.psychedelicfinance.com/articles/pharmather-provides-business-highlights-and-releases-annual-financials-for-fiscal-year-ended-may-31-2021 https://www.psychedelicfinance.com/articles/pharmather-provides-business-highlights-and-releases-audited-annual-financials-for-fiscal-year-ended-may-31-2022 https://www.psychedelicfinance.com/articles/pharmather-provides-business-update-and-releases-financial-results-for-the-first-quarter-of-fiscal-2022 https://www.psychedelicfinance.com/articles/pharmather-provides-product-pipeline-updates-and-anticipated-milestones-for-q4-2021-and-2022 https://www.psychedelicfinance.com/articles/pharmather-provides-research-and-development-update-and-milestones-for-2021 https://www.psychedelicfinance.com/articles/pharmather-provides-research-update-on-microneedle-patch-delivery-technologies-for-psychedelics https://www.psychedelicfinance.com/articles/pharmather-provides-update-on-its-psychedelic-pharmaceuticals-programs https://www.psychedelicfinance.com/articles/pharmather-provides-update-on-product-pipeline-and-expected-milestones-for-2022 https://www.psychedelicfinance.com/articles/pharmather-provides-update-on-psychedelic-product-programs https://www.psychedelicfinance.com/articles/pharmather-reports-financial-results-for-the-third-quarter-of-fiscal-2022-and-provides-recent-business-highlights-and-update https://www.psychedelicfinance.com/articles/pharmather-retains-former-fda-psychiatry-division-director-dr-thomas-laughren-as-regulatory-affairs-advisor https://www.psychedelicfinance.com/articles/pharmather-secures-exclusive-rights-to-novel-microneedle-delivery-technology-for-psychedelic-pharmaceuticals https://www.psychedelicfinance.com/articles/pharmather-signs-exclusive-worldwide-license-agreement-for-patented-formulation-and-production-process-of-ketamine-and-ketamine-analogs https://www.psychedelicfinance.com/articles/pharmather-signs-exclusive-worldwide-license-agreement-for-patented-ketamine-formulation-targeting-mental-health-neurological-and-pain-disorders https://www.psychedelicfinance.com/articles/pharmather-signs-exclusive-worldwide-license-agreement-for-patented-microneedle-delivery-technology-to-deliver-ketamine https://www.psychedelicfinance.com/articles/pharmather-signs-loi-to-sell-psilocybin-program-to-revive-therapeutics https://www.psychedelicfinance.com/articles/pharmather-to-develop-and-commercialize-novel-wearable-ketamine-delivery-device-in-collaboration-with-ccbio https://www.psychedelicfinance.com/articles/pharmather-to-participate-in-grizzle-psychedelics-con https://www.psychedelicfinance.com/articles/pharmather-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference https://www.psychedelicfinance.com/articles/pharmather-to-present-at-the-h-c-wainwright-psychedelics-in-psychiatry-and-beyond-virtual-conference https://www.psychedelicfinance.com/articles/phase-2-clinical-trial-of-lsd-for-suicide-headaches-begins-treating-patients https://www.psychedelicfinance.com/articles/philip-young-lobe-sciences https://www.psychedelicfinance.com/articles/pierre-bou-mansour-coo-novamind https://www.psychedelicfinance.com/articles/pilz-bioscience-senior-team-members-to-participate-in-upcoming-microdose-conference https://www.psychedelicfinance.com/articles/positive-bnc210-7-day-dosing-pharmacokinetic-study-exceeds-blood-exposure-projected-for-phase-2b-ptsd-trial https://www.psychedelicfinance.com/articles/positive-uk-mhra-meeting-as-cyb003-heads-to-p1-2a https://www.psychedelicfinance.com/articles/professor-david-nutt-joins-awakn-life-sciences https://www.psychedelicfinance.com/articles/prolific-parkinsons-researcher-dr-alberto-j-espay-joins-pharmather-as-scientific-advisor https://www.psychedelicfinance.com/articles/psfc-and-maps-to-provide-major-update-on-campaign-to-fund-research-for-mdma-assisted-psychotherapy-to-treat-ptsd https://www.psychedelicfinance.com/articles/psilera-and-usf-collaborators-at-morsani-college-of-medicine-receive-additional-funding-to-support-preclinical-studies-on-new-chemical-entities https://www.psychedelicfinance.com/articles/psilera-collaborates-with-the-national-institute-on-drug-abuse-nida-to-research-dmt-and-new-analogues-to-combat-addiction https://www.psychedelicfinance.com/articles/psilera-confirms-psil-002-a-new-dmt-derivative-is-well-tolerated-and-non-hallucinogenic-from-in-vivo-behavioral-studies https://www.psychedelicfinance.com/articles/psileras-award-winning-co-founders-to-be-featured-speakers-at-upcoming-industry-conferences-across-the-country https://www.psychedelicfinance.com/articles/psilocybin-data-study-agreement-reached-between-ehave-inc-and-silo-wellness-using-brain-scientific-mapping-neurocap https://www.psychedelicfinance.com/articles/psilocybin-for-alcohol-dependence-trial-by-b-more-principal-investigator-michael-bogenschutz-recognized-as-pivotal-psychedelic-breakthrough-for-2022 https://www.psychedelicfinance.com/articles/psilocybin-for-depression-will-be-studied-in-a-clinical-trial-at-karolinska-institutet-first-time-in-sweden https://www.psychedelicfinance.com/articles/psybio-and-miami-university-broaden-partnership-agreement-for-the-continued-advancement-of-its-neuropsychiatric-drug-discovery-platform-expediting-its-ind-submission-to-the-fda https://www.psychedelicfinance.com/articles/psybio-announces-closing-of-first-tranche-of-private-placement-and-provides-corporate-update https://www.psychedelicfinance.com/articles/psybio-completes-reverse-take-over-transaction https://www.psychedelicfinance.com/articles/psybio-strengthens-its-leadership-team-with-appointment-of-dr-michael-spigarelli-as-chief-medical-officer https://www.psychedelicfinance.com/articles/psybio-therapeutics-adds-nmda-receptor-antagonists-and-associated-analogues-into-its-intellectual-property-portfolio https://www.psychedelicfinance.com/articles/psybio-therapeutics-and-leo-acquisitions-announce-closing-of-cad-14-5-million-oversubscribed-private-placement https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-electronic-clearing-and-settlement-by-depository-trust-company https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-expansion-of-patent-portfolio-with-additional-global-patent-applications https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-inclusion-in-nyse-listed-advisorshares-psychedelics-exchange-traded-fund https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-non-brokered-private-placement-financing https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-participation-in-upcoming-investor-conferences-in-september-2021 https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-pre-ind-application-request-has-been-submitted-to-the-united-states-food-and-drug-administration https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-proposed-acquisition-of-everest-pharma-pty-ltd-a-lesotho-company-in-southern-africa-as-part-of-its-ongoing-impact-investment-strategy https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-retention-of-market-maker https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-tsxv-approval-of-share-buyback-program https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-uplisting-to-otcqb-venture-market https://www.psychedelicfinance.com/articles/psybio-therapeutics-appoints-pharmaceutical-veteran-bob-oliver-to-its-board-of-directors https://www.psychedelicfinance.com/articles/psybio-therapeutics-augments-intellectual-property-portfolio-with-filing-of-next-novel-psychedelic-compositions-and-methods-of-treatment-patent https://www.psychedelicfinance.com/articles/psybio-therapeutics-awarded-approval-to-manufacture-biosynthetic-tryptamines-at-scale https://www.psychedelicfinance.com/articles/psybio-therapeutics-begins-filing-global-provisional-patent-conversion-applications-to-further-strengthen-biosynthetic-patent-portfolio https://www.psychedelicfinance.com/articles/psybio-therapeutics-ceo-evan-levine-to-participate-in-panel-discussion-at-the-medtech-innovation-conference-on-october-29th https://www.psychedelicfinance.com/articles/psybio-therapeutics-corp-begins-trading-on-the-tsx-venture-exchange https://www.psychedelicfinance.com/articles/psybio-therapeutics-develops-commercial-purification-process-for-second-generation-psycho-targeted-compound https://www.psychedelicfinance.com/articles/psybio-therapeutics-files-four-u-s-patent-cooperation-treaty-pct-patent-applications-further-expanding-its-patent-portfolio https://www.psychedelicfinance.com/articles/psybio-therapeutics-files-patent-application-with-uspto-for-production-methods-of-methylated-trypatamines-and-associated-analogs https://www.psychedelicfinance.com/articles/psybio-therapeutics-furthers-intellectual-property-portfolio-with-six-new-manufacturing-patent-applications https://www.psychedelicfinance.com/articles/psybio-therapeutics-increases-intellectual-property-portfolio-with-filing-of-novel-genetic-optimization-pathways-for-psychedelic-medication-biosynthesis https://www.psychedelicfinance.com/articles/psybio-therapeutics-initiates-blood-brain-barrier-permeability-testing-for-pipeline-compounds-to-enhance-portfolio-development https://www.psychedelicfinance.com/articles/psybio-therapeutics-initiates-clinical-trial-site-selection-process https://www.psychedelicfinance.com/articles/psybio-therapeutics-initiates-commercial-biosynthetic-based-process-development-for-psycho-targeted-and-psychoactive-compounds https://www.psychedelicfinance.com/articles/psybio-therapeutics-initiates-european-manufacturing-of-proprietary-biosynthetic-psychedelic-compounds-including-psilocybin-with-france-based-biose-industrie https://www.psychedelicfinance.com/articles/psybio-therapeutics-initiates-pilot-scale-development-of-proprietary-biosynthetic-psilocybin-with-global-contract-research-development-and-manufacturing-organization https://www.psychedelicfinance.com/articles/psybio-therapeutics-initiates-process-development-of-proprietary-biosynthetic-norbaeocystin https://www.psychedelicfinance.com/articles/psybio-therapeutics-latest-u-s-pct-non-provisional-patent-application-accepted https://www.psychedelicfinance.com/articles/psybio-therapeutics-reaches-agreement-to-conduct-initial-psilocybin-clinical-trial https://www.psychedelicfinance.com/articles/psybio-therapeutics-reports-annual-2021-financial-results https://www.psychedelicfinance.com/articles/psybio-therapeutics-reports-first-quarter-2021-financial-results-provides-shareholder-update-and-announces-intention-to-institute-share-buyback-program https://www.psychedelicfinance.com/articles/psybio-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corporate-update-on-intellectual-property-and-clinical-development-milestones https://www.psychedelicfinance.com/articles/psybio-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corporate-update-on-intellectual-property-and-clinical-development-milestones https://www.psychedelicfinance.com/articles/psybio-therapeutics-reports-second-quarter-2022-financial-results https://www.psychedelicfinance.com/articles/psybio-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corporate-update-on-intellectual-property-and-clinical-development-milestones https://www.psychedelicfinance.com/articles/psybio-therapeutics-reports-third-quarter-2022-financial-results https://www.psychedelicfinance.com/articles/psybio-therapeutics-retains-kcsa-strategic-communications-for-investor-relations-services https://www.psychedelicfinance.com/articles/psybio-therapeutics-sponsors-16-collaborative-research-abstract-presentations-at-two-scientific-conferences https://www.psychedelicfinance.com/articles/psybio-therapeutics-strengthens-ip-portfolio-through-filing-of-data-to-support-previously-submitted-provisional-biosynthetic-production-patent-application https://www.psychedelicfinance.com/articles/psybio-therapeutics-successfully-completes-first-pre-ind-meeting-with-the-united-states-food-and-drug-administration https://www.psychedelicfinance.com/articles/psybio-therapeutics-successfully-demonstrates-commercial-scale-manufacturing-feasibility https://www.psychedelicfinance.com/articles/psybio-therapeutics-takes-initial-step-to-help-protect-the-sonoran-desert-toad-as-it-files-three-new-provisional-patent-applications-including-intellectual-property-protection-for-the-biosynthetic-production-of-5-meo-dmt https://www.psychedelicfinance.com/articles/psybio-therapeutics-to-participate-in-the-2022-maxim-group-virtual-growth-conference-on-march-28-30-2022 https://www.psychedelicfinance.com/articles/psybio-therapeutics-to-participate-in-upcoming-investor-conferences-in-april-2022 https://www.psychedelicfinance.com/articles/psybio-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference https://www.psychedelicfinance.com/articles/psybio-therapeutics-to-present-at-the-h-c-wainwright-2nd-annual-psychedelics-conference https://www.psychedelicfinance.com/articles/psybio-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-conference https://www.psychedelicfinance.com/articles/psybio-therapeutics-to-present-at-upcoming-investor-events-in-september-2022 https://www.psychedelicfinance.com/articles/psybio-therapeutics-to-seek-approval-of-proposed-share-consolidation-at-annual-and-special-meeting-of-shareholders https://www.psychedelicfinance.com/articles/psyched-wellness-advisor-kevin-feeney-releases-book-on-amanita-muscaria https://www.psychedelicfinance.com/articles/psyched-wellness-and-the-national-research-council-of-canada-announce-preliminary-data-from-studies-of-neuroprotective-properties-of-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-announces-additional-positive-results-from-the-14-day-oral-toxicity-study-of-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-announces-c-3m-bought-deal-private-placement-led-by-canaccord-genuity https://www.psychedelicfinance.com/articles/psyched-wellness-announces-changes-to-the-board-of-directors https://www.psychedelicfinance.com/articles/psyched-wellness-announces-commencement-of-next-pre-clinical-study-on-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-announces-completion-of-its-90-day-oral-toxicity-study https://www.psychedelicfinance.com/articles/psyched-wellness-announces-date-for-their-pilot-production-run-of-the-first-legal-amanita-muscaria-tincture-product-calm https://www.psychedelicfinance.com/articles/psyched-wellness-announces-del-mahabadi-to-join-as-international-marketing-manager https://www.psychedelicfinance.com/articles/psyched-wellness-announces-ecommerce-fulfillment-partnership-with-shiphero https://www.psychedelicfinance.com/articles/psyched-wellness-announces-findings-from-an-ongoing-study-with-the-national-research-council-of-canada https://www.psychedelicfinance.com/articles/psyched-wellness-announces-inclusion-in-advisorshares-psychedelics-exchange-traded-fund-etf https://www.psychedelicfinance.com/articles/psyched-wellness-announces-july-19th-2022-as-the-official-date-to-commence-pre-orders-for-calm https://www.psychedelicfinance.com/articles/psyched-wellness-announces-key-findings-from-the-90-day-oral-toxicity-study-on-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-announces-key-findings-from-the-90-day-oral-toxicity-study-on-ame-1-2 https://www.psychedelicfinance.com/articles/psyched-wellness-announces-launch-of-ecommerce-fulfillment-with-shiphero8 https://www.psychedelicfinance.com/articles/psyched-wellness-announces-launch-of-new-logo-branding-and-website-prepares-to-release-industry-first-amanita-muscaria-tincture https://www.psychedelicfinance.com/articles/psyched-wellness-announces-marketing-agreement-with-north-equities-corp-and-issuance-of-restricted-share-units https://www.psychedelicfinance.com/articles/psyched-wellness-announces-matthew-singh-joins-team-as-cpg-and-branding-consultant https://www.psychedelicfinance.com/articles/psyched-wellness-announces-new-otcqb-ticker-psycf https://www.psychedelicfinance.com/articles/psyched-wellness-announces-participation-in-the-h-c-wainwright-23rd-annual-global-investment-conference https://www.psychedelicfinance.com/articles/psyched-wellness-announces-path-to-market-for-ame-1-derived-products-in-the-usa https://www.psychedelicfinance.com/articles/psyched-wellness-announces-positive-toxicology-assessment-and-provides-path-to-market-for-a-legal-psychedelic-mushroom-product https://www.psychedelicfinance.com/articles/psyched-wellness-announces-preliminary-data-showing-potential-new-functional-property-and-health-benefit-of-amanita-muscaria-mushroom-ame-1-to-inhibit-human-mast-cell-activation https://www.psychedelicfinance.com/articles/psyched-wellness-announces-purchase-agreement-with-choice-wholesale-for-60-000-units-of-their-amanita-muscaria-tincture-calm https://www.psychedelicfinance.com/articles/psyched-wellness-announces-sales-partnership-with-spacestation-cpg https://www.psychedelicfinance.com/articles/psyched-wellness-announces-share-purchase-by-chief-executive-officer-jeffrey-stevens https://www.psychedelicfinance.com/articles/psyched-wellness-announces-successful-pilot-run-final-flavour-profile-for-calm-and-shipping-pre-orders-in-october https://www.psychedelicfinance.com/articles/psyched-wellness-announces-successful-up-listing-to-the-otcqb-venture-market https://www.psychedelicfinance.com/articles/psyched-wellness-announces-that-the-amanita-muscaria-mushroom-has-been-successfully-added-to-the-natural-health-products-ingredients-database-nhpid-of-canada https://www.psychedelicfinance.com/articles/psyched-wellness-announces-the-official-launch-of-their-new-ecommerce-online-store https://www.psychedelicfinance.com/articles/psyched-wellness-announces-vantage-hemp-co-as-contract-manufacturing-organization-partner-to-bring-ame-1-derived-products-to-market https://www.psychedelicfinance.com/articles/psyched-wellness-appoints-chief-commercial-officer-to-lead-sales-and-marketing-of-ame-1-and-launch-cpg-products https://www.psychedelicfinance.com/articles/psyched-wellness-closes-6-603-000-bought-deal-private-placement https://www.psychedelicfinance.com/articles/psyched-wellness-commences-antioxidant-and-anti-inflammatory-study-on-muscimol https://www.psychedelicfinance.com/articles/psyched-wellness-commences-neurobehavioral-preclinical-trial-study-on-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-commences-next-pre-clinical-study-on-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-commences-pre-clinical-trials-of-amanita-muscaria https://www.psychedelicfinance.com/articles/psyched-wellness-commences-preorders-for-calm-in-path-to-commercialization-of-proprietary-amanita-muscaria-extract https://www.psychedelicfinance.com/articles/psyched-wellness-completes-initial-data-review-to-determine-clinical-path-for-muscimol https://www.psychedelicfinance.com/articles/psyched-wellness-enters-into-a-service-agreement-with-cannalabs-to-begin-stability-tests-on-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-gras-dossier-approved-by-panel-of-experts-providing-green-light-to-market-products-in-the-united-states https://www.psychedelicfinance.com/articles/psyched-wellness-has-added-a-new-bottle-size-for-their-amanita-muscaria-extract-calm https://www.psychedelicfinance.com/articles/psyched-wellness-has-commenced-research-on-muscimol-for-various-ailments https://www.psychedelicfinance.com/articles/psyched-wellness-hires-ad-agency-dacs-marketing-to-build-the-branding-and-marketing-strategy-for-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-hires-del-mahabadi-as-digital-marketing-consultant-to-drive-ame-1-product-launch https://www.psychedelicfinance.com/articles/psyched-wellness-hires-the-national-research-council-of-canada-to-test-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-included-in-first-psychedelic-exchange-traded-fund https://www.psychedelicfinance.com/articles/psyched-wellness-initiates-a-clinical-sleep-study-on-humans-for-a-structure-function-claim-for-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-initiates-study-on-ame-1-extract-for-gut-health https://www.psychedelicfinance.com/articles/psyched-wellness-initiates-the-next-pre-clinical-trial-study-on-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-ltd-adds-aaron-slater-to-the-advisory-board https://www.psychedelicfinance.com/articles/psyched-wellness-ltd-adds-kevin-feeney-to-the-advisory-board https://www.psychedelicfinance.com/articles/psyched-wellness-ltd-adds-professor-david-nutt-to-the-board-of-directors https://www.psychedelicfinance.com/articles/psyched-wellness-ltd-adds-scientific-advisor-brian-tancowny https://www.psychedelicfinance.com/articles/psyched-wellness-ltd-advisor-professor-david-nutt-to-speak-at-psytech-conference https://www.psychedelicfinance.com/articles/psyched-wellness-ltd-announces-insider-buying-and-option-grant-to-professor-nutt https://www.psychedelicfinance.com/articles/psyched-wellness-ltd-applied-to-up-list-to-the-otcqb-and-dtc-eligibility https://www.psychedelicfinance.com/articles/psyched-wellness-ltd-to-commence-trading-on-the-cse-on-october-22-2020 https://www.psychedelicfinance.com/articles/psyched-wellness-ltd-to-present-at-h-c-wainwright-conference-on-june-17-2021 https://www.psychedelicfinance.com/articles/psyched-wellness-presents-ame-1-to-health-canada-in-pre-submission-meeting https://www.psychedelicfinance.com/articles/psyched-wellness-provides-corporate-update https://www.psychedelicfinance.com/articles/psyched-wellness-provides-update-on-annual-general-and-special-meeting https://www.psychedelicfinance.com/articles/psyched-wellness-provides-update-on-anti-inflammatory-study-with-the-national-research-council-of-canada https://www.psychedelicfinance.com/articles/psyched-wellness-provides-update-on-antioxidant-and-anti-inflammatory-study-of-muscimol https://www.psychedelicfinance.com/articles/psyched-wellness-provides-update-on-pre-clinical-trial-of-its-muscimol-extract-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-receives-226-500-cad-from-sale-of-non-core-assets https://www.psychedelicfinance.com/articles/psyched-wellness-receives-dtc-eligibility https://www.psychedelicfinance.com/articles/psyched-wellness-receives-positive-results-from-its-14-day-oral-toxicity-preclinical-study https://www.psychedelicfinance.com/articles/psyched-wellness-signs-supply-agreement-for-amanita-muscaria https://www.psychedelicfinance.com/articles/psyched-wellness-strengthens-ip-portfolio https://www.psychedelicfinance.com/articles/psyched-wellness-submits-a-provisional-patent-application-for-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-submits-an-application-to-register-a-trademark-for-the-companys-unique-extraction https://www.psychedelicfinance.com/articles/psyched-wellness-submits-applications-for-four-further-provisional-patents-surrounding-its-work-on-the-ame-1 https://www.psychedelicfinance.com/articles/psyched-wellness-successfully-completes-extraction-of-a-legal-psychedelic-mushroom https://www.psychedelicfinance.com/articles/psyched-wellness-successfully-completes-its-largest-extraction-and-shipment-of-ame-1-to-asia https://www.psychedelicfinance.com/articles/psyched-wellness-successfully-completes-writing-the-final-extraction-protocol-the-assembly-of-safety-efficacy-narratives-and-writing-the-safety-data-sheet-sds-for-its-first-product https://www.psychedelicfinance.com/articles/psyched-wellness-to-participate-in-canaccord-genuitys-new-paradigms-and-treatment-approaches-in-mental-health-conference https://www.psychedelicfinance.com/articles/psyched-wellness-to-participate-in-upcoming-investor-conferences-in-april-2022 https://www.psychedelicfinance.com/articles/psyched-wellness-to-present-at-the-psychedelic-investment-series-on-monday-may-31-2021 https://www.psychedelicfinance.com/articles/psyched-wellness-unveils-new-product-name-and-visual-identity-elements https://www.psychedelicfinance.com/articles/psyched-wellness-upsizes-previously-announced-bought-deal-offering https://www.psychedelicfinance.com/articles/psychedelic-books-recommended-reading https://www.psychedelicfinance.com/articles/psychedelic-drugs-market-projected-to-reach-6-85-billion-by-2027 https://www.psychedelicfinance.com/articles/psychedelic-expert-core-one-labs-reports-milestone-acquisition https://www.psychedelicfinance.com/articles/psychedelic-glossary-faq https://www.psychedelicfinance.com/articles/psychedelic-headlines-may-20 https://www.psychedelicfinance.com/articles/psychedelic-headlines-may-27th https://www.psychedelicfinance.com/articles/psychedelic-medical-start-up-awakn-life-sciences-enters-the-uk-market-with-dr-ben-sessa https://www.psychedelicfinance.com/articles/psychedelic-pharmaceutical-startup-ninnion-announces-formation-of-world-renowned-scientific-advisory-board https://www.psychedelicfinance.com/articles/psychedelic-pharmaceutical-startup-ninnion-announces-patent-filings-and-development-of-nin-s119-for-ischemic-stroke https://www.psychedelicfinance.com/articles/psychedelic-research-fundraising-campaign-attracts-30-million-in-donations-in-6-months-prepares-mdma-assisted-psychotherapy-for-fda-approval https://www.psychedelicfinance.com/articles/psychedelic-science-leader-eleusis-announces-four-new-board-appointments-further-strengthening-leadership https://www.psychedelicfinance.com/articles/psychedelic-science-leader-eleusis-to-become-public-company-in-merger-with-silver-spike-acquisition-corp-ii https://www.psychedelicfinance.com/articles/psychedelic-stocks https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-august-12th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-august-19th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-august-26th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-august-5th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-july-15th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-july-22nd https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-july-29th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-july-8th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-june-10 https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-june-17th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-june-30th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-october-14 https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-october-7 https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-september-16th https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-september-23 https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-september-2nd https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-september-30 https://www.psychedelicfinance.com/articles/psychedelic-weekly-headlines-september-9th https://www.psychedelicfinance.com/articles/psychedelic-weekly-news-headlines-june-24 https://www.psychedelicfinance.com/articles/psychedelics-company-havn-life-announces-commencement-of-public-trading-on-the-cse https://www.psychedelicfinance.com/articles/psychedelics-company-silo-wellness-announces-financing-commitment-of-cad-5-950-000-in-convertible-debentures https://www.psychedelicfinance.com/articles/psychedelics-company-silo-wellness-expands-its-shareholder-base-to-europe-by-commencing-trading-on-the-german-borse-frankfurt-fra-exchange-under-ticker-symbol-3k70 https://www.psychedelicfinance.com/articles/psychiatrist-and-addiction-researcher-dr-henry-kranzler-joins-entheon-advisory-board https://www.psychedelicfinance.com/articles/psyence-and-eden-labs-announce-extraction-and-product-development-collaboration https://www.psychedelicfinance.com/articles/psyence-and-filament-health-announce-worldwide-licensing-agreement-of-psilocybin-capsule-for-palliative-care https://www.psychedelicfinance.com/articles/psyence-and-filament-health-enter-into-exclusive-licensing-agreement-for-natural-psilocybin-products https://www.psychedelicfinance.com/articles/psyence-announces-business-combination-between-wholly-owned-subsidiary-psyence-biomed-corp-and-nasdaq-listed-newcourt-acquisition-corp https://www.psychedelicfinance.com/articles/psyence-awarded-iso-certification-through-the-british-standards-institute-for-its-natural-psilocybin-production-facility https://www.psychedelicfinance.com/articles/psyence-group-and-pure-extracts-sign-jv-letter-of-intent-for-the-extraction-of-psilocybin-from-psychedelic-mushrooms-and-development-of-psilocybin-formulations https://www.psychedelicfinance.com/articles/psyence-group-and-pure-extracts-sign-jv-letter-of-intent-for-the-extraction-of-psilocybin-from-psychedelic-mushrooms-and-development-of-psilocybin-formulations-2 https://www.psychedelicfinance.com/articles/psyence-group-and-uk-psychedelic-cro-partners-to-conduct-uk-palliative-care-clinical-trial https://www.psychedelicfinance.com/articles/psyence-group-announces-amendment-and-closing-of-previously-announced-private-placement https://www.psychedelicfinance.com/articles/psyence-group-announces-appointment-of-new-chief-executive-officer https://www.psychedelicfinance.com/articles/psyence-group-announces-closing-of-fourth-tranche-of-private-placement-and-conversion-of-convertible-debt-note https://www.psychedelicfinance.com/articles/psyence-group-announces-collaboration-with-the-scientific-research-council-src-of-jamaica-for-psilocybin-product-development https://www.psychedelicfinance.com/articles/psyence-group-announces-commencement-of-trading-on-otcqb-and-dtc-eligibility-of-common-shares-in-the-united-states-under-the-ticker-psygf https://www.psychedelicfinance.com/articles/psyence-group-announces-dtc-eligibility-approval-in-the-u-s https://www.psychedelicfinance.com/articles/psyence-group-announces-partnership-with-base-pair-health-and-strengthens-management-team https://www.psychedelicfinance.com/articles/psyence-group-announces-private-placement https://www.psychedelicfinance.com/articles/psyence-group-announces-strategic-private-placement https://www.psychedelicfinance.com/articles/psyence-group-announces-the-commencement-of-online-sales-and-distribution-of-goodmind-products https://www.psychedelicfinance.com/articles/psyence-group-completes-export-of-pharma-grade-psilocybin-extract-to-uk https://www.psychedelicfinance.com/articles/psyence-group-completes-export-of-psilocybin-mushrooms-to-canada https://www.psychedelicfinance.com/articles/psyence-group-completes-export-of-psilocybin-mushrooms-to-portugal https://www.psychedelicfinance.com/articles/psyence-group-completes-first-cultivation-cycle-of-medical-psilocybin-mushrooms-at-its-commercially-licensed-facility https://www.psychedelicfinance.com/articles/psyence-group-corporate-update https://www.psychedelicfinance.com/articles/psyence-group-corporate-update-2 https://www.psychedelicfinance.com/articles/psyence-group-functional-mushroom-brand-goodmind-tm-commences-national-roll-out-in-south-africas-largest-coffee-retail-chain https://www.psychedelicfinance.com/articles/psyence-group-inc-completes-reverse-takeover-transaction-and-completes-non-brokered-financing https://www.psychedelicfinance.com/articles/psyence-group-invited-as-first-psychedelic-company-to-present-at-the-15th-annual-global-wellness-summit https://www.psychedelicfinance.com/articles/psyence-group-jamaica-chief-medical-officer-dr-dingle-spence-to-headline-two-conferences-on-psychedelics https://www.psychedelicfinance.com/articles/psyence-group-launches-its-functional-mushroom-brand-goodmind-makes-board-changes https://www.psychedelicfinance.com/articles/psyence-group-presenting-at-canaccord-genuity-conference-new-paradigms-treatment-approaches-in-mental-health https://www.psychedelicfinance.com/articles/psyence-group-receives-phase-iia-clinical-trial-approval-from-the-uk-medicines-and-healthcare-products-regulatory-agency-mhra https://www.psychedelicfinance.com/articles/psyence-group-signs-collaboration-agreement-with-leading-jamaican-psilocybin-retreat-provider-to-conduct-observational-study https://www.psychedelicfinance.com/articles/psyence-group-to-commence-trading-cse-psyg-on-january-27-2021 https://www.psychedelicfinance.com/articles/psyence-looks-to-expand-capital-market-opportunities-in-the-uk-and-europe https://www.psychedelicfinance.com/articles/psyence-partners-with-ingenu-for-palliative-care-clinical-trial-in-australia https://www.psychedelicfinance.com/articles/psyence-signs-letter-of-intent-with-australian-cro-ingenu https://www.psychedelicfinance.com/articles/psyence-taps-another-pharma-exec-to-drive-its-clinical-program https://www.psychedelicfinance.com/articles/psyence-to-present-at-the-h-c-wainwright-2nd-annual-psychedelics-conference-december-6 https://www.psychedelicfinance.com/articles/psygen-announces-successful-closing-of-oversubscribed-convertible-debenture-financing-sets-value-at-30mm https://www.psychedelicfinance.com/articles/psygen-announces-that-psilocybin-from-its-patent-pending-process-has-been-used-in-human-trial https://www.psychedelicfinance.com/articles/psygen-industries-ltd-and-larose-ventures-ltd-announce-reverse-takeover-transaction-of-1290442-b-c-ltd-by-psygen-industries-ltd-and-brokered-financing-led-by-eight-capital-and-canaccord https://www.psychedelicfinance.com/articles/psygen-receives-dealers-licence-from-health-canada https://www.psychedelicfinance.com/articles/psylo-engages-csiro-to-evaluate-neuroplasticity-of-novel-psychedelic-compounds https://www.psychedelicfinance.com/articles/psyrx-announces-appointment-of-prof-itamar-grotto-as-new-executive-chairman-of-the-board-p https://www.psychedelicfinance.com/articles/psytech-to-merge-with-wesana-mycotopia-shareholders-will-benefit-from-the-transactions https://www.psychedelicfinance.com/articles/pure-extract-technologies-inc-receives-health-canada-standard-processing-license https://www.psychedelicfinance.com/articles/pure-extracts-advances-plans-for-the-processing-of-functional-mushroom-formulations https://www.psychedelicfinance.com/articles/pure-extracts-and-psyence-group-form-joint-venture-for-psychedelic-medicinal-mushroom-extracts https://www.psychedelicfinance.com/articles/pure-extracts-and-shroombloom-sign-psychedelic-mushroom-supply-letter-of-intent https://www.psychedelicfinance.com/articles/pure-extracts-announces-dtc-eligibility-of-its-common-shares-in-the-united-states https://www.psychedelicfinance.com/articles/pure-extracts-announces-submission-for-class-1-natural-product-number-npn https://www.psychedelicfinance.com/articles/pure-extracts-applauds-health-canada-sap-for-psilocybin-assisted-psychotherapy-inclusion https://www.psychedelicfinance.com/articles/pure-extracts-closes-upsized-8-5-million-offering-with-strong-retail-demand https://www.psychedelicfinance.com/articles/pure-extracts-collaborates-with-dr-alexander-macgregor-on-cannabis-and-mushroom-formulations https://www.psychedelicfinance.com/articles/pure-extracts-commences-build-out-of-facility-in-preparation-for-mushroom-extraction-and-dealers-licence https://www.psychedelicfinance.com/articles/pure-extracts-commences-study-on-psilocybin-oral-tablets-capsules-and-nasal-gel https://www.psychedelicfinance.com/articles/pure-extracts-corp-ipo-round https://www.psychedelicfinance.com/articles/pure-extracts-delineates-study-on-psilocybin-oral-tablets-capsules-and-nasal-gel https://www.psychedelicfinance.com/articles/pure-extracts-enters-into-biomass-purchase-agreements-to-support-oil-extract-production https://www.psychedelicfinance.com/articles/pure-extracts-now-listed-on-the-otc-markets-under-the-symbol-prxtf https://www.psychedelicfinance.com/articles/pure-extracts-orders-first-shipment-of-functional-mushrooms-for-e-commerce-store https://www.psychedelicfinance.com/articles/pure-extracts-preparing-application-for-dealers-licence https://www.psychedelicfinance.com/articles/pure-extracts-signs-loi-with-the-nutraceutical-medicine-company-owner-of-the-purica-tm-brand-of-wellness-products https://www.psychedelicfinance.com/articles/pure-extracts-submits-dealers-licence-application-to-health-canada https://www.psychedelicfinance.com/articles/pure-extracts-technologies-closes-3-million-lead-order-and-announces-upsizing-of-private-placement-to-5-million-to-accommodate-investor-demand https://www.psychedelicfinance.com/articles/pure-extracts-technologies-corp-welcomes-dwight-duncan-to-its-board-of-directors https://www.psychedelicfinance.com/articles/pure-extracts-technologies-corporate-update https://www.psychedelicfinance.com/articles/pure-extracts-technology-corp-to-commence-trading-on-the-canadian-securities-exchange https://www.psychedelicfinance.com/articles/r-gordon-wasson https://www.psychedelicfinance.com/articles/red-light-holland-advisory-board-member-to-participate-in-bloomberg-citylab-2022-in-amsterdam-the-netherlands https://www.psychedelicfinance.com/articles/red-light-holland-and-advocacy-group-psychedelic-medicine-alliance-washington-celebrate-the-success-of-their-collaboration-as-washington-legislature-funds-psilocybin-wellness-workgroup https://www.psychedelicfinance.com/articles/red-light-holland-and-disruptive-pharma-announce-intention-to-form-joint-venture-in-brazil https://www.psychedelicfinance.com/articles/red-light-holland-and-headland-west-indies-lead-svgstrong-a-relief-effort-in-st-vincent-and-the-grenadines https://www.psychedelicfinance.com/articles/red-light-holland-and-mistercap-llc-partnership-update https://www.psychedelicfinance.com/articles/red-light-holland-and-superstar-wiz-khalifa-to-launch-naturally-occurring-psilocybin-and-mushrooms-wellness-brand-mistercap https://www.psychedelicfinance.com/articles/red-light-holland-announces-5-million-bought-deal-equity-financing https://www.psychedelicfinance.com/articles/red-light-holland-announces-closing-of-11-6-million-bought-deal-financing https://www.psychedelicfinance.com/articles/red-light-holland-announces-closing-of-9-77-million-bought-deal-financing https://www.psychedelicfinance.com/articles/red-light-holland-announces-closing-of-final-tranche-of-fully-subscribed-private-placement-including-strategic-mutual-investment-with-pharmadrug https://www.psychedelicfinance.com/articles/red-light-holland-announces-exercise-of-warrants-for-gross-proceeds-of-over-5-million https://www.psychedelicfinance.com/articles/red-light-holland-announces-filing-of-amended-and-restated-fs-and-md-a-for-the-three-and-six-month-period-ended-september-30-2020-and-material-change-report https://www.psychedelicfinance.com/articles/red-light-holland-announces-increase-in-bought-deal-equity-financing-to-10-million https://www.psychedelicfinance.com/articles/red-light-holland-announces-increase-in-bought-deal-equity-financing-to-8-5-million https://www.psychedelicfinance.com/articles/red-light-holland-announces-live-investor-q-a-session-at-2-00-pm-est-on-thursday-september-8-2022 https://www.psychedelicfinance.com/articles/red-light-holland-announces-mushroom-home-grow-kits-produced-by-happy-caps-mushroom-farm-are-now-available-for-purchase-in-30-retail-stores-across-canada https://www.psychedelicfinance.com/articles/red-light-holland-announces-updated-cash-position-of-approximately-30-million https://www.psychedelicfinance.com/articles/red-light-holland-announces-upgrade-from-otc-pink-to-otcqb https://www.psychedelicfinance.com/articles/red-light-holland-appoints-new-chief-financial-officer https://www.psychedelicfinance.com/articles/red-light-holland-appoints-new-chief-marketing-officer https://www.psychedelicfinance.com/articles/red-light-holland-closes-acquisition-of-100-acres-of-farmland-in-ontario-canada-expanding-its-mushroom-farms-division-in-north-america https://www.psychedelicfinance.com/articles/red-light-holland-closes-acquisition-of-80-of-happy-caps-mushroom-farm-specializing-in-grow-at-home-mushroom-kits https://www.psychedelicfinance.com/articles/red-light-holland-closes-acquisition-of-cutting-edge-silicon-valley-applied-sciences-company-radix-motion-becoming-a-leader-in-psychedelic-technology https://www.psychedelicfinance.com/articles/red-light-holland-closes-acquisition-of-sr-wholesale-becoming-a-leader-in-distribution-of-psychedelics https://www.psychedelicfinance.com/articles/red-light-holland-commences-growing-1-000-000-grams-of-magic-truffles https://www.psychedelicfinance.com/articles/red-light-holland-commences-magic-truffles-growth-operation-in-the-netherlands-months-ahead-of-schedule https://www.psychedelicfinance.com/articles/red-light-holland-ctio-sarah-hashkes-publishes-microdosing-article-and-will-be-participating-in-an-online-webinar-by-harvards-project-on-psychedelics-law-and-regulation-poplar-at-the-petrie-flom-center-at-harvard-law-school https://www.psychedelicfinance.com/articles/red-light-holland-engages-akwasi-owusu-bempah-respected-academic-author-and-drug-law-reform-and-drug-equity-expert-as-advisor-to-advisory-board https://www.psychedelicfinance.com/articles/red-light-holland-engages-former-canadian-special-operations-forces-officer-glenn-cowan-founder-of-one-9-investments-to-advisory-board https://www.psychedelicfinance.com/articles/red-light-holland-engages-former-health-minister-the-honourable-tony-p-clement-as-senior-advisor-to-advisory-board https://www.psychedelicfinance.com/articles/red-light-holland-engages-graham-pechenik-respected-patent-and-ip-lawyer-and-editor-at-large-of-psilocybin-alpha-as-senior-advisor-to-advisory-board https://www.psychedelicfinance.com/articles/red-light-holland-engages-marketing-veteran-and-brand-strategist-ridley-doolittle-as-advisor-to-advisory-board https://www.psychedelicfinance.com/articles/red-light-holland-enters-into-letter-of-intent-to-acquire-controlling-stake-in-happy-caps-mushroom-farm-based-in-halifax-nova-scotia https://www.psychedelicfinance.com/articles/red-light-holland-expected-merger-partner-creso-pharma-completes-acquisition-of-halucenex-life-sciences-inc https://www.psychedelicfinance.com/articles/red-light-holland-files-international-patent-application-for-find-your-dose-customization-of-microdosing-kits-based-on-biometric-and-movement-data https://www.psychedelicfinance.com/articles/red-light-holland-files-new-patent-technology-and-devices-for-monitoring-information-and-influencing-behavior-involving-carbon-dioxide-emissions https://www.psychedelicfinance.com/articles/red-light-holland-imicro-digital-care-app-and-telecounseling-goes-live https://www.psychedelicfinance.com/articles/red-light-holland-imicrodose-pack-receives-authorization-for-the-first-legal-import-and-sale-of-psilocybin-truffles-to-brazil https://www.psychedelicfinance.com/articles/red-light-holland-increases-points-of-sale-for-imicrodose-packs-in-the-netherlands-by-more-than-140 https://www.psychedelicfinance.com/articles/red-light-holland-launches-new-logo-and-interactive-wisdom-truffle-companion-created-by-internationally-renowned-award-winning-designer-karim-rashid https://www.psychedelicfinance.com/articles/red-light-holland-looking-to-receive-exemption-for-controlled-substances-from-government-of-canada-engages-wellington-dupont-public-affairs https://www.psychedelicfinance.com/articles/red-light-holland-names-medical-and-scientific-division https://www.psychedelicfinance.com/articles/red-light-holland-places-first-order-for-psychedelic-truffles-microdosing-packs https://www.psychedelicfinance.com/articles/red-light-holland-provides-corporate-update https://www.psychedelicfinance.com/articles/red-light-holland-psilocybin-truffles-sold-in-the-netherlands-complete-first-evaluation-under-a-health-canada-approved-cgmp-laboratory https://www.psychedelicfinance.com/articles/red-light-holland-psilocybin-truffles-sold-in-the-netherlands-complete-first-stability-test-under-a-health-canada-approved-cgmp-laboratory https://www.psychedelicfinance.com/articles/red-light-holland-psilocybin-truffles-sold-in-the-netherlands-complete-second-evaluation-under-a-health-canada-approved-cgmp-laboratory https://www.psychedelicfinance.com/articles/red-light-holland-receives-patent-pending-status-for-find-your-dose-customization-of-microdosing-kits-based-on-biometric-and-movement-data https://www.psychedelicfinance.com/articles/red-light-holland-receives-receipt-for-final-short-form-prospectus-for-previously-announced-10-million-bought-deal-public-offering https://www.psychedelicfinance.com/articles/red-light-holland-reports-2022-audited-year-end-results https://www.psychedelicfinance.com/articles/red-light-holland-reports-first-quarter-2022-financial-results https://www.psychedelicfinance.com/articles/red-light-holland-reports-fiscal-third-quarter-results https://www.psychedelicfinance.com/articles/red-light-holland-reports-second-quarter-2021-results https://www.psychedelicfinance.com/articles/red-light-holland-sells-approximately-350-000-grams-of-magic-truffles-and-increases-points-of-sale-for-imicrodose-packs-to-six-more-smart-shops https://www.psychedelicfinance.com/articles/red-light-holland-signs-definitive-agreement-with-mera-life-sciences-and-files-annual-financial-statements https://www.psychedelicfinance.com/articles/red-light-holland-sponsors-first-of-its-kind-group-microdosing-concert-in-the-netherlands https://www.psychedelicfinance.com/articles/red-light-holland-successfully-completes-canadas-largest-legal-sale-and-import-of-psilocybe-truffles-into-canada-under-a-health-canada-approved-psilocybin-import-permit https://www.psychedelicfinance.com/articles/red-light-holland-successfully-completes-sale-and-import-of-imicrodose-psychedelic-truffles-into-canada-under-a-health-canada-approved-psilocybin-import-permit https://www.psychedelicfinance.com/articles/red-light-holland-successfully-imports-200-psilocybin-imicrodose-packs-sold-in-the-netherlands-into-canada-under-a-third-health-canada-approved-psilocybin-import-permit-to-cgmp-laboratory https://www.psychedelicfinance.com/articles/red-light-holland-successfully-imports-psilocybin-imicrodose-packs-into-st-vincent-and-the-grenadines-under-a-first-ever-authorized-import-approval-process-by-the-countrys-bureau-of-standards-and-the-ministry-of-health https://www.psychedelicfinance.com/articles/red-light-holland-to-acquire-two-wellness-shops-in-the-netherlands-smartshop-utrecht-and-smartshop-oss https://www.psychedelicfinance.com/articles/red-light-holland-to-collaborate-with-advocacy-group-psychedelic-medicine-alliance-washington-to-promote-proposed-psilocybin-legalization-bill-in-washington-state https://www.psychedelicfinance.com/articles/red-light-holland-to-make-groundbreaking-investment-in-st-vincent-and-the-grenadines-plant-based-wellness-and-psychedelics-industry https://www.psychedelicfinance.com/articles/red-light-holland-to-partner-with-leading-fresh-and-dried-mushroom-producers-on-east-coast-facility https://www.psychedelicfinance.com/articles/red-light-holland-to-purchase-100-acres-of-farmland-in-ontario-canada-as-its-mushroom-farms-division-expands-in-north-america https://www.psychedelicfinance.com/articles/red-light-holland-update-plans-to-enter-oregon-legal-psilocybin-service-market-to-promote-diversity-and-equity-in-alignment-with-measure-109-regulations https://www.psychedelicfinance.com/articles/red-light-holland-updates-acquisition-and-development-of-100-acres-of-farmland-in-ontario-canada-expanding-its-mushroom-farms-division-in-north-america https://www.psychedelicfinance.com/articles/red-light-hollands-imicro-digital-care-app-launches-virtual-telecounseling-with-a-membership-program-led-by-certified-therapist-and-microdosing-expert https://www.psychedelicfinance.com/articles/red-light-hollands-partner-ccrest-laboratories-approved-by-health-canada-to-supply-psilocybin-to-the-special-access-program https://www.psychedelicfinance.com/articles/red-light-hollands-psychedelic-virtual-reality-experience-wisdom-narrated-by-global-comedy-superstar-russell-peters-accepted-to-steam-the-largest-digital-distribution-platform-for-pc-gaming https://www.psychedelicfinance.com/articles/red-light-hollands-wholly-owned-subsidiary-radix-motion-receives-favorable-international-preliminary-report-on-patentability-on-its-patent-application-utilizing-3d-movement-data-for-psychedelic-therapy https://www.psychedelicfinance.com/articles/regulatory-approvals-place-filament-health-at-the-forefront-of-natural-psychedelic-research-and-manufacturing https://www.psychedelicfinance.com/articles/regulatory-approvals-place-numinus-lab-at-the-forefront-of-global-psychedelics-research https://www.psychedelicfinance.com/articles/renowned-psychedelic-researcher-james-fadiman-phd-joins-wesana-health-scientific-advisory-board https://www.psychedelicfinance.com/articles/reunion-neuroscience-appoints-chief-financial-officer-and-vice-president-medical-affairs https://www.psychedelicfinance.com/articles/reunion-neuroscience-appoints-robert-alexander-as-chief-medical-officer https://www.psychedelicfinance.com/articles/reunion-neuroscience-ceo-to-participate-on-panel-at-2022-horizons-perspectives-on-psychedelics-conference https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-announces-2022-annual-general-meeting-of-shareholders https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-appoints-greg-mayes-as-president-and-chief-executive-officer https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-completes-interim-data-analysis-for-phase-1-clinical-trial-with-novel-serotonergic-psychedelic-re104 https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-completes-interim-data-analysis-for-phase-1-clinical-trial-with-novel-serotonergic-psychedelic-re104-105 https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-formerly-field-trip-health-ltd-reports-fiscal-first-quarter-2023-financial-results-completed-corporate-reorganization-on-august-11-2022 https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-provides-2023-corporate-update https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-provides-business-update-and-reports-fiscal-second-quarter-2023-financial-results https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-to-commence-trading-on-the-toronto-stock-exchange-on-august-17-2022 https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-to-participate-in-upcoming-investor-conferences https://www.psychedelicfinance.com/articles/reunion-neuroscience-inc-to-participate-in-upcoming-investor-conferences-in-december https://www.psychedelicfinance.com/articles/reunion-neuroscience-provides-business-update-and-reports-fiscal-third-quarter-2023-financial-results https://www.psychedelicfinance.com/articles/reunion-neuroscience-schedules-fiscal-second-quarter-2023-conference-call-for-monday-november-14-2022-at-8-30-a-m-et https://www.psychedelicfinance.com/articles/reunion-neuroscience-schedules-fiscal-third-quarter-2023-conference-call-for-tuesday-february-14-2023-at-8-30-a-m-et https://www.psychedelicfinance.com/articles/reunion-neuroscience-to-participate-in-the-cantor-neurology-psychiatry-conference https://www.psychedelicfinance.com/articles/reunion-neuroscience-to-present-at-upcoming-november-conferences https://www.psychedelicfinance.com/articles/review-of-bipolar-disorders-confirms-early-diagnosis-and-treatment-can-improve-patient-quality-of-life https://www.psychedelicfinance.com/articles/revitalist-achieves-300-month-over-month-growth-serving-veterans-with-psychedelic-therapies-in-the-us-with-coverage-from-va https://www.psychedelicfinance.com/articles/revitalist-and-pharmather-announce-collaboration-to-develop-and-advance-novel-and-standardized-ketamine-treatment-protocols-for-mental-health-disorders-and-chronic-pain-syndromes https://www.psychedelicfinance.com/articles/revitalist-and-wake-network-announce-joint-venture-partnership-to-open-psychedelic-clinics-and-retreats-in-the-united-states https://www.psychedelicfinance.com/articles/revitalist-and-wake-network-enter-joint-venture-offering-national-and-international-access-to-psychedelics-for-veterans https://www.psychedelicfinance.com/articles/revitalist-and-wake-network-joins-forces-with-retired-delta-force-command-sergeant-major-tom-satterly-addressing-veterans-access-to-mental-health-resources https://www.psychedelicfinance.com/articles/revitalist-announces-close-of-private-placement-totaling-3-944-000 https://www.psychedelicfinance.com/articles/revitalist-announces-closing-of-private-placement https://www.psychedelicfinance.com/articles/revitalist-announces-private-placement-offering-of-up-to-cdn-6-million https://www.psychedelicfinance.com/articles/revitalist-announces-release-of-three-proprietary-service-lines-advancing-their-comprehensive-footprint-in-the-mental-health-and-psychedelic-wellness-space https://www.psychedelicfinance.com/articles/revitalist-ceo-awarded-professional-service-practitioner-of-the-year-by-microdose https://www.psychedelicfinance.com/articles/revitalist-ceo-invests-2-332-000-in-the-companys-first-tranche-financing-of-3-869-000 https://www.psychedelicfinance.com/articles/revitalist-exceeds-growth-expectations-in-the-month-of-june-with-record-breaking-visits-while-also-advancing-their-reach-for-veterans-across-the-united-states https://www.psychedelicfinance.com/articles/revitalist-increases-clinic-count-to-10-with-the-acquisition-of-a-virginia-ketamine-clinic https://www.psychedelicfinance.com/articles/revitalist-increases-patient-access-making-care-more-affordable-by-financing-the-cost-with-m-lend-financial https://www.psychedelicfinance.com/articles/revitalist-non-profit-community-change-foundation-receives-1m-grant-to-address-adolescent-mental-health-and-school-violence https://www.psychedelicfinance.com/articles/revitalist-releases-supplement-line-to-enhance-the-results-of-psychedelic-medicines https://www.psychedelicfinance.com/articles/revitalist-reports-2021-financial-results-and-provides-business-update https://www.psychedelicfinance.com/articles/revitalist-reports-fourteen-months-of-consecutive-monthly-visit-growth-and-a-466-increase-year-over-year-for-march-2022 https://www.psychedelicfinance.com/articles/revitalist-reports-q1-2022-financial-results-and-provides-business-update https://www.psychedelicfinance.com/articles/revitalist-updates-infrastructure-for-aggressive-growth-strategy-in-2022 https://www.psychedelicfinance.com/articles/revitalists-kathryn-walker-and-awakns-prof-david-nutt-to-host-webinar-on-ketamine-assisted-therapy-for-veterans-suffering-with-addictions https://www.psychedelicfinance.com/articles/revitalists-strategic-initiatives-continue-to-exceed-expectations-for-execution-giving-company-record-high-revenues-since-opening-in-2018 https://www.psychedelicfinance.com/articles/revive-adjourns-annual-and-special-meeting https://www.psychedelicfinance.com/articles/revive-collaborates-with-university-of-health-sciences-antigua-to-pioneer-clinical-research-of-psychedelics https://www.psychedelicfinance.com/articles/revive-provides-dial-in-information-for-annual-and-special-meeting https://www.psychedelicfinance.com/articles/revive-reschedules-annual-and-special-meeting-and-provides-dial-in-information https://www.psychedelicfinance.com/articles/revive-therapeutics-advances-mdma-transdermal-patch-development-with-purchase-of-mdma-supply-from-pharmala-biotech https://www.psychedelicfinance.com/articles/revive-therapeutics-announces-10-million-bought-deal-offering-of-units https://www.psychedelicfinance.com/articles/revive-therapeutics-announces-closing-of-23-0-million-short-form-prospectus-offering https://www.psychedelicfinance.com/articles/revive-therapeutics-announces-fda-recommendation-for-type-c-meeting-to-discuss-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19 https://www.psychedelicfinance.com/articles/revive-therapeutics-announces-research-collaboration-with-north-carolina-state-university-for-natural-biosynthesis-enzymatic-platform-to-develop-psilocybin https://www.psychedelicfinance.com/articles/revive-therapeutics-announces-successful-research-results-for-oral-thin-film-psilocybin-and-filing-of-u-s-provisional-patent-application https://www.psychedelicfinance.com/articles/revive-therapeutics-announces-successful-research-results-for-psilocybin-to-treat-traumatic-brain-injury-and-filing-of-international-patent-application https://www.psychedelicfinance.com/articles/revive-therapeutics-announces-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19 https://www.psychedelicfinance.com/articles/revive-therapeutics-announces-upsize-to-previously-announced-bought-deal-offering https://www.psychedelicfinance.com/articles/revive-therapeutics-approved-to-trade-on-the-otcqb-market https://www.psychedelicfinance.com/articles/revive-therapeutics-enters-into-feasibility-agreement-with-lts-lohmann-to-develop-oral-psilocybin-thin-film-strip https://www.psychedelicfinance.com/articles/revive-therapeutics-enters-into-research-collaboration-agreement-with-pharmather-for-development-of-mdma-transdermal-patch https://www.psychedelicfinance.com/articles/revive-therapeutics-files-business-acquisition-report https://www.psychedelicfinance.com/articles/revive-therapeutics-files-for-fda-orphan-drug-designation-for-psilocybin-in-traumatic-brain-injury https://www.psychedelicfinance.com/articles/revive-therapeutics-included-in-advisorshares-r-newly-launched-psychedelics-etf https://www.psychedelicfinance.com/articles/revive-therapeutics-included-in-first-psychedelic-exchange-traded-fund https://www.psychedelicfinance.com/articles/revive-therapeutics-ltd-announces-offering-of-up-to-5-million https://www.psychedelicfinance.com/articles/revive-therapeutics-ltd-closes-4-3-million-offering https://www.psychedelicfinance.com/articles/revive-therapeutics-provides-corporate-update-on-its-psychedelics-therapeutics-programs https://www.psychedelicfinance.com/articles/revive-therapeutics-provides-update-of-psilocybin-pharmaceutical-programs https://www.psychedelicfinance.com/articles/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19 https://www.psychedelicfinance.com/articles/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19-with-planned-completion-and-emergency-use-authorization-request https://www.psychedelicfinance.com/articles/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19-with-plans-on-emergency-use-access https://www.psychedelicfinance.com/articles/revive-therapeutics-provides-update-on-oral-thin-film-product-with-psilocybin https://www.psychedelicfinance.com/articles/revive-therapeutics-provides-update-on-psychedelics-clinical-product-pipeline https://www.psychedelicfinance.com/articles/revive-therapeutics-provides-update-on-the-psilocybin-clinical-study-for-methamphetamine-use-disorder-and-oral-psilocybin-thin-film-strip-program https://www.psychedelicfinance.com/articles/revive-therapeutics-receives-fda-orphan-drug-designation-for-bucillamine-in-the-prevention-of-ischemia-reperfusion-injury-during-liver-transplantation https://www.psychedelicfinance.com/articles/revive-therapeutics-receives-receipt-for-final-short-form-prospectus-for-previously-announced-20-million-bought-deal-public-offering https://www.psychedelicfinance.com/articles/revive-therapeutics-secures-mdma-supply-from-pharmala-biotech-for-mdma-transdermal-patch-development https://www.psychedelicfinance.com/articles/revive-therapeutics-signs-exclusive-worldwide-license-agreement-for-medicinal-mushroom-ganoderma-lucidum-to-treat-cancer https://www.psychedelicfinance.com/articles/revive-therapeutics-signs-supply-agreement-with-havn-life-sciences-for-psychedelic-compounds https://www.psychedelicfinance.com/articles/revive-to-present-at-the-h-c-wainwright-psychedelics-in-psychiatry-and-beyond-virtual-conference https://www.psychedelicfinance.com/articles/rick-strassman-dmt-stroke-program-consultant-algernon-pharmaceuticals https://www.psychedelicfinance.com/articles/rob-tessarolo-president-ceo-neonmind-biosciences https://www.psychedelicfinance.com/articles/robert-roscow-cso-mydecine-innovations-group https://www.psychedelicfinance.com/articles/robin-carhart-harris-scientific-advisory-board-tryp-therapeutics https://www.psychedelicfinance.com/articles/rojo-resources-ltd-announces-the-conditional-approval-of-reverse-take-over-transaction-with-salvation-botanicals https://www.psychedelicfinance.com/articles/roth-capital-partners-initiates-coverage-on-cybin-with-buy-rating-and-usd-10-price-target https://www.psychedelicfinance.com/articles/roth-capital-partners-initiates-coverage-on-mydecine-with-buy-rating-and-c-3-price-target https://www.psychedelicfinance.com/articles/rritual-announces-dr-mike-hart-as-president https://www.psychedelicfinance.com/articles/rritual-tm-announces-suite-of-premium-functional-mushroom-and-adaptogenic-elixirs https://www.psychedelicfinance.com/articles/ryan-moss-director-of-research-filament-health https://www.psychedelicfinance.com/articles/sansero-life-sciences-announces-joint-study-with-the-university-of-toronto-to-advance-clinical-research-of-psychedelic-medications https://www.psychedelicfinance.com/articles/scisparc-and-clearmind-collaboration-strengthens-ip-portfolio-with-three-provisional-patent-applications-in-the-us https://www.psychedelicfinance.com/articles/scisparc-ltd-and-clearmind-medicine-inc-collaboration-yields-new-patent-application-for-psychedelic-combination-treatment-for-binge-behaviors https://www.psychedelicfinance.com/articles/scisparc-ltd-announces-additional-positive-results-for-the-cocaine-addiction-treatment-of-its-psychedelic-based-pharma-collaboration-with-clearmind-medicine-inc https://www.psychedelicfinance.com/articles/scisparc-ltd-announces-initial-positive-results-for-the-cocaine-addiction-treatment-of-clearmind-medicine-inc https://www.psychedelicfinance.com/articles/second-maps-sponsored-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-completed https://www.psychedelicfinance.com/articles/second-united-states-patent-granted-for-small-pharmas-psychedelics-portfolio https://www.psychedelicfinance.com/articles/seelos-therapeutics-added-to-the-russell-2000-r-russell-3000-r-and-russell-microcap-r-indexes https://www.psychedelicfinance.com/articles/seelos-therapeutics-announces-a-strategic-device-partnership-with-aptargroup-inc https://www.psychedelicfinance.com/articles/seelos-therapeutics-announces-positive-topline-data-from-the-open-label-study-of-sls-002 https://www.psychedelicfinance.com/articles/seelos-therapeutics-announces-the-participation-of-acadia-healthcare-in-the-registration-directed-study-of-sls-002-for-acute-suicidal-ideation-and-behavior-in-patients-with-major-depressive-disorder https://www.psychedelicfinance.com/articles/seelos-therapeutics-receives-a-research-and-development-grant-from-the-michael-j-fox-foundation-for-parkinsons-research-for-sls-004 https://www.psychedelicfinance.com/articles/seelos-therapeutics-receives-european-orphan-drug-designation-for-sls-005-trehalose-in-amyotrophic-lateral-sclerosis-als https://www.psychedelicfinance.com/articles/silo-wellness-and-entheon-biomedicals-wholly-owned-subsidiary-halugen-life-sciences-announces-psychedelics-genetic-test-kit-partnership https://www.psychedelicfinance.com/articles/silo-wellness-announces-3-million-u-s-sales-and-distribution-partnership-for-marley-one-line-of-functional-mushrooms https://www.psychedelicfinance.com/articles/silo-wellness-announces-approval-for-trading-on-the-otcqb-under-symbol-silff https://www.psychedelicfinance.com/articles/silo-wellness-announces-corporate-updates https://www.psychedelicfinance.com/articles/silo-wellness-announces-five-new-psychedelic-wellness-retreats-in-jamaica https://www.psychedelicfinance.com/articles/silo-wellness-announces-intellectual-property-licensing-agreement-of-psilocybin-nasal-spray-in-colombia-and-brasil https://www.psychedelicfinance.com/articles/silo-wellness-announces-latest-psychedelic-retreat-offerings https://www.psychedelicfinance.com/articles/silo-wellness-announces-loi-for-potentially-largest-psilocybin-retreat-center-in-oregon-and-the-world-if-novembers-election-is-favorable-and-an-oregon-real-estate-law-and-psilocybin-industry-primer https://www.psychedelicfinance.com/articles/silo-wellness-announces-portland-area-rural-oregon-psilocybin-service-center-and-cultivation-real-estate-partner https://www.psychedelicfinance.com/articles/silo-wellness-announces-subsidiarys-branding-licensing-agreement-terminated https://www.psychedelicfinance.com/articles/silo-wellness-announces-successful-launch-of-2022-psilocybin-retreat-schedule-and-other-corporate-updates https://www.psychedelicfinance.com/articles/silo-wellness-appoints-ceo-douglas-k-gordon-to-board-of-directors-and-provides-corporation-updates https://www.psychedelicfinance.com/articles/silo-wellness-appoints-phytomedicine-business-leader-as-board-member https://www.psychedelicfinance.com/articles/silo-wellness-brings-marley-one-mushrooms-to-the-u-k-market-through-distribution-agreement-with-locosoco-limited https://www.psychedelicfinance.com/articles/silo-wellness-closes-acquisition-of-dyscovry-science-and-its-psilocybin-pharmaceutical-biosynthesis-and-research-portfolio https://www.psychedelicfinance.com/articles/silo-wellness-debuts-marley-one-the-first-global-functional-and-psychedelic-mushroom-brand-in-collaboration-with-the-bob-marley-family https://www.psychedelicfinance.com/articles/silo-wellness-executes-definitive-agreement-to-acquire-dyscovry-science-and-its-psilocybin-pharmaceutical-biosynthesis-and-research-portfolio https://www.psychedelicfinance.com/articles/silo-wellness-hires-two-veterans-of-lifestyle-marketing-and-cannabis-industry-to-promote-marley-line-of-functional-psychedelic-mushroom-brand https://www.psychedelicfinance.com/articles/silo-wellness-inc-announces-successful-completion-of-reverse-take-over-transaction https://www.psychedelicfinance.com/articles/silo-wellness-issues-shareholder-letter-and-announces-new-chief-executive-officer https://www.psychedelicfinance.com/articles/silo-wellness-kicks-off-second-oregon-psychedelic-wellness-retreat https://www.psychedelicfinance.com/articles/silo-wellness-marley-one-line-of-functional-mushrooms-now-sold-on-amazon https://www.psychedelicfinance.com/articles/silo-wellness-organizes-jamaican-psilocybin-retreat-team-and-advocates-to-speak-to-lane-county-eugene-oregon-commissioners-regarding-bm109-optout-vote-lane-county-declines-to-refer-a-psilocybin-ban-to-voters https://www.psychedelicfinance.com/articles/silo-wellness-partners-with-kaivalya-kollectiv-to-include-5-meo-dmt-in-psychedelic-portfolio-offering https://www.psychedelicfinance.com/articles/silo-wellness-partners-with-mushe-inc-to-establish-first-legal-brick-mortar-psychedelic-and-functional-mushroom-shop-in-the-western-hemisphere https://www.psychedelicfinance.com/articles/silo-wellness-requests-oregon-property-owner-expressions-of-interest-for-collaborating-on-psilocybin-licensing-other-corporate-updates https://www.psychedelicfinance.com/articles/silo-wellness-to-create-a-psychedelic-pharmaceutical-manufacturing-and-research-portfolio-with-proposed-acquisition-of-dyscovry-science https://www.psychedelicfinance.com/articles/silo-wellness-to-testify-on-oregon-psilocybin-therapy-land-use-restrictions-at-jackson-county-planning-commissions-thursday-hearing-other-corporate-updates https://www.psychedelicfinance.com/articles/silo-wellness-wins-amendment-to-proposed-land-use-ordinance-for-oregon-psychedelic-ranch-corporate-update-shareholder-faqs https://www.psychedelicfinance.com/articles/small-pharma-announces-appointment-of-lyne-fortin-as-chair-of-the-board https://www.psychedelicfinance.com/articles/small-pharma-announces-completion-of-spl026-phase-iia-trial-and-secures-new-intellectual-property https://www.psychedelicfinance.com/articles/small-pharma-announces-positive-six-month-data-from-phase-iia-trial-of-spl026 https://www.psychedelicfinance.com/articles/small-pharma-announces-tsxv-approval-of-normal-course-issuer-bid https://www.psychedelicfinance.com/articles/small-pharma-announces-update-on-intellectual-property-portfolio-with-two-new-patents-approved-for-issue https://www.psychedelicfinance.com/articles/small-pharma-announces-upgrade-to-the-otcqb-r-and-dtc-eligibility https://www.psychedelicfinance.com/articles/small-pharma-completes-enrollment-in-phase-iia-dmt-assisted-psychotherapy-clinical-trial-in-patients-with-major-depressive-disorder https://www.psychedelicfinance.com/articles/small-pharma-completes-reverse-take-over-transaction https://www.psychedelicfinance.com/articles/small-pharma-engages-lifesci-advisors-as-investor-relations-agency https://www.psychedelicfinance.com/articles/small-pharma-enters-into-automatic-share-purchase-plan https://www.psychedelicfinance.com/articles/small-pharma-establishes-psychedelic-assisted-therapy-training-program https://www.psychedelicfinance.com/articles/small-pharma-expands-potential-of-commercial-portfolio-with-dmt-based-psychedelic-assets https://www.psychedelicfinance.com/articles/small-pharma-granted-fast-track-designation-from-u-k-regulator-for-dmt-assisted-therapy-for-major-depressive-disorder https://www.psychedelicfinance.com/articles/small-pharma-inc-expands-phase-i-iia-clinical-trial-with-additional-study-site https://www.psychedelicfinance.com/articles/small-pharma-inc-to-commence-trading-on-the-tsx-venture-exchange-on-may-6-2021 https://www.psychedelicfinance.com/articles/small-pharma-included-in-advisorshares-r-newly-launched-psychedelics-etf https://www.psychedelicfinance.com/articles/small-pharma-provides-update-to-patent-portfolio-including-receipt-of-an-in-order-for-grant-notice-for-its-patent-related-to-psychedelic-tryptamines https://www.psychedelicfinance.com/articles/small-pharma-receives-approval-for-dmt-assisted-psychotherapy-and-ssri-drug-interaction-study https://www.psychedelicfinance.com/articles/small-pharma-receives-approval-for-first-in-human-phase-i-clinical-trial-with-spl028 https://www.psychedelicfinance.com/articles/small-pharma-reports-fiscal-second-quarter-2023-highlights https://www.psychedelicfinance.com/articles/small-pharma-reports-highlights-for-the-fiscal-year-ended-february-28-2022 https://www.psychedelicfinance.com/articles/small-pharma-reports-positive-top-line-results-from-phase-iia-trial-of-spl026-in-major-depressive-disorder https://www.psychedelicfinance.com/articles/small-pharma-shares-business-update-ahead-of-annual-financial-results https://www.psychedelicfinance.com/articles/small-pharma-successfully-completes-phase-i-clinical-trial-of-dmt-in-combination-with-supportive-psychotherapy https://www.psychedelicfinance.com/articles/small-pharma-to-announce-results-of-spl026-phase-iia-trial-for-major-depressive-disorder-and-host-conference-call-on-wednesday-january-25 https://www.psychedelicfinance.com/articles/small-pharma-to-participate-in-november-investor-and-healthcare-conferences https://www.psychedelicfinance.com/articles/small-pharma-to-participate-in-the-h-c-wainwright-1st-annual-mental-health-conference-on-june-27-2022 https://www.psychedelicfinance.com/articles/small-pharma-to-participate-in-the-psych-symposium-london-2022 https://www.psychedelicfinance.com/articles/small-pharma-to-participate-in-upcoming-september-investor-conferences https://www.psychedelicfinance.com/articles/small-pharma-to-present-at-the-jefferies-healthcare-conference-in-new-york-city-on-june-10-2022 https://www.psychedelicfinance.com/articles/small-pharma-to-present-at-the-kcsa-psychedelics-virtual-investor-conference-on-april-28-2022 https://www.psychedelicfinance.com/articles/small-pharma-to-present-at-the-kcsa-psychedelics-virtual-investor-conference-on-october-13-2021 https://www.psychedelicfinance.com/articles/small-pharma-to-present-progress-and-innovations-in-dmt-assisted-therapy-for-the-treatment-of-depression-at-upcoming-conferences https://www.psychedelicfinance.com/articles/solactive-publishes-north-american-psychedelic-index-underyler-of-horizons-psyk-etf https://www.psychedelicfinance.com/articles/spencer-hawkswell-ceo-of-therapsil https://www.psychedelicfinance.com/articles/spencer-hawkswell-ceo-therapsil https://www.psychedelicfinance.com/articles/spotlight-dr-denton-hoyer-scientific-advisor-mydecine https://www.psychedelicfinance.com/articles/spotlight-dr-marvin-hausman-chief-of-scientific-advisory-board-for-nova-mentis https://www.psychedelicfinance.com/articles/spotlight-dr-rakesh-jetly-chief-medical-officer-mydecine https://www.psychedelicfinance.com/articles/spotlight-interview-carey-turnbul-vp-heffter-institute-founder-b-more-ceruvia https://www.psychedelicfinance.com/articles/spotlight-interview-julia-joyes-research-director-at-therapsil https://www.psychedelicfinance.com/articles/spotlight-james-gilligan-president-and-chief-scientific-officer-tryp-therapeutics https://www.psychedelicfinance.com/articles/spotlight-jr-rahn https://www.psychedelicfinance.com/articles/spotlight-larry-norder-vp-manufacturing-tryp https://www.psychedelicfinance.com/articles/spotlight-matthew-johnson https://www.psychedelicfinance.com/articles/spotlight-nethaji-gallage-ceo-founder-octarine-bio https://www.psychedelicfinance.com/articles/spotlight-paul-austin-founder-the-third-wave https://www.psychedelicfinance.com/articles/spotlight-payton-nyquvest https://www.psychedelicfinance.com/articles/spotlight-professor-david-nutt-board-of-directors-psyched-wellness https://www.psychedelicfinance.com/articles/spotlight-robin-carhart-harris https://www.psychedelicfinance.com/articles/spotlight-roger-mcintyre https://www.psychedelicfinance.com/articles/spotlight-ronan-levy-founder-executive-chairman-of-field-trip https://www.psychedelicfinance.com/articles/spotlight-srinivas-rao https://www.psychedelicfinance.com/articles/spotlight-tom-dorazio-coo-tryp-therapeutics https://www.psychedelicfinance.com/articles/statement-from-the-multidisciplinary-association-for-psychedelic-studies-maps-on-drug-policy-reform-in-the-2020-u-s-election https://www.psychedelicfinance.com/articles/stephen-bardin-to-join-atai-life-sciences-as-cfo-designate https://www.psychedelicfinance.com/articles/steve-sadoff-ceo-cannaglobal https://www.psychedelicfinance.com/articles/study-mdma-assisted-psychotherapy-will-be-more-cost-effective-than-other-treatments-for-ptsd https://www.psychedelicfinance.com/articles/sunstone-therapies-collaborates-with-maps-to-conduct-clinical-trial-of-mdma-assisted-therapy-for-ptsd https://www.psychedelicfinance.com/articles/telescope-announces-acquisition-of-rights-to-synthetic-psilocybin-research https://www.psychedelicfinance.com/articles/telescope-announces-acquisition-of-rights-to-synthetic-psilocybin-research-2 https://www.psychedelicfinance.com/articles/the-addition-of-three-mental-health-clinics-to-irwin-naturals-florida-footprint-solidifies-the-companies-impact-as-one-of-the-fastest-growing-chains-of-mental-health-clinics https://www.psychedelicfinance.com/articles/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing https://www.psychedelicfinance.com/articles/the-chopra-foundation-announces-partnership-with-cybin-inc-to-increase-education-and-awareness-of-the-potential-use-of-psychedelics-in-supporting-well-being-and-mental-health https://www.psychedelicfinance.com/articles/the-good-shroom-co-delivers-again-with-another-sku-launching-today-expected-to-gain-more-market-share https://www.psychedelicfinance.com/articles/the-good-shroom-co-enters-into-private-labeling-agreement https://www.psychedelicfinance.com/articles/the-good-shroom-co-receives-authorization-to-commence-sales-of-the-velada-cannabis-and-functional-mushroom-product-line https://www.psychedelicfinance.com/articles/the-good-shroom-co-records-6x-growth-quarter-over-quarter https://www.psychedelicfinance.com/articles/the-good-shroom-co-signs-agreement-with-rob-leichman-of-the-lyric-group-to-lead-its-retail-launch-and-initiates-podcast-marketing-deal https://www.psychedelicfinance.com/articles/the-good-shroom-co-signs-contract-with-top-tier-canadian-retail-distributor-ecotrend https://www.psychedelicfinance.com/articles/the-good-shroom-co-to-launch-in-all-central-market-locations-in-texas https://www.psychedelicfinance.com/articles/the-psyence-group-announces-its-formal-entry-into-jamaica-with-the-incorporation-of-its-wholly-owned-subsidiary-psyence-jamaica-limited https://www.psychedelicfinance.com/articles/the-world-boxing-council-and-wesana-health-announce-multi-year-joint-efforts-to-research-the-impact-of-psychedelics-on-traumatic-brain-injury https://www.psychedelicfinance.com/articles/the-worlds-largest-medical-psilocybin-access-and-data-project-set-to-launch-led-by-canadian-non-profit-therapsil-real-world-data-aims-to-inform-development-of-regulated-psilocybin-therapy https://www.psychedelicfinance.com/articles/thoughtful-brands-announces-binding-letter-of-intent-for-reverse-takeover-of-franchise-cannabis https://www.psychedelicfinance.com/articles/threed-capital-increases-its-investment-in-nirvana https://www.psychedelicfinance.com/articles/timothy-ko-ceo-entheon-biomedical https://www.psychedelicfinance.com/articles/toms-shoes-founder-blake-mycoskie-commits-100-million-to-psychedelic-research https://www.psychedelicfinance.com/articles/tripsitter-clinic-announces-services-now-available-to-almost-half-the-united-states https://www.psychedelicfinance.com/articles/tripsitter-clinic-launches-new-app-for-at-home-ketamine-therapy https://www.psychedelicfinance.com/articles/tripsitter-clinic-ltd-announces-the-closing-of-assets-acquisition-deal-with-reconcious-medial-and-appointment-of-dr-mark-braunstein-as-chairman https://www.psychedelicfinance.com/articles/tryp-appoints-dr-jim-gilligan-phd-mbis-as-president-and-chief-scientific-officer https://www.psychedelicfinance.com/articles/tryp-therapeutics-and-massachusetts-general-hospital-sign-letter-of-intent-for-clinical-study-investigating-the-use-of-psilocybin-assisted-psychotherapy-for-the-treatment-of-patients-suffering-from-irritable-bowel-syndrome-ibs https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-2-000-000-financing-and-changes-in-management-board-of-directors https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-advancement-of-phase-2a-clinical-trial-in-binge-eating-disorder https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-amendment-to-option-plan-and-option-grant https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-application-to-list-on-otcqb https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-appointment-of-greg-mckee-as-executive-chairman https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-collaboration-with-researchers-at-the-university-of-wisconsin-madison https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-formation-of-psilocybin-scientific-advisory-board https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-full-exercise-of-over-allotment-option-on-initial-public-offering https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-grant-of-stock-options https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-inclusion-in-advisorshares-psychedelics-etf https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-interim-results-for-its-phase-ii-clinical-trial-for-the-treatment-of-binge-eating-disorder-with-psilocybin-assisted-psychotherapy https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-listing-on-otcqb-and-dtc-eligibility https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-plans-for-phase-2a-clinical-trial-for-fibromyalgia-with-the-university-of-michigan https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-poster-presentations-on-the-reduction-of-chronic-pain-in-a-rodent-model-with-psilocybin-and-intravenous-psilocybin-alters-brain-network-dynamics-in-rats-at-the-2022-society-for-neuroscience-conference https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-private-placement-of-secured-convertible-debentures-for-gross-proceeds-of-a-minimum-of-aud-2-000-000 https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-provisional-patent-filing-for-improved-administration-of-psychedelics https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-publication-of-international-pct-patent-application-for-the-intravenous-administration-of-psilocin-and-psilocybin https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-q2-2021-financial-results https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-q3-2021-financial-results https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-results-of-first-patient-dosed-in-its-phase-ii-clinical-trial-for-the-treatment-of-binge-eating-disorder https://www.psychedelicfinance.com/articles/tryp-therapeutics-announces-strategic-investment-of-2-000-000-led-by-marc-lustig https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-dennis-langer-m-d-j-d-as-senior-advisor https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-dr-joel-castellanos-as-clinical-advisor https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-dr-robin-carhart-harris-to-scientific-advisory-board https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-dr-william-k-schmidt-to-its-scientific-advisory-board https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-greg-mckee-as-chief-executive-officer https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-jim-oneill-as-chief-financial-officer https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-luke-hayes-as-chief-financial-officer https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-new-chief-operating-officer https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-peter-guzzo-phd-as-vice-president-drug-development https://www.psychedelicfinance.com/articles/tryp-therapeutics-appoints-robin-carhart-harris-ph-d-as-sab-chairman-and-adds-daniel-clauw-m-d-as-scientific-advisor https://www.psychedelicfinance.com/articles/tryp-therapeutics-begins-trading-on-the-canadian-securities-exchange https://www.psychedelicfinance.com/articles/tryp-therapeutics-completes-2-million-strategic-financing https://www.psychedelicfinance.com/articles/tryp-therapeutics-completes-initial-public-offering https://www.psychedelicfinance.com/articles/tryp-therapeutics-completes-psychotherapy-training-for-phase-2a-study-at-the-university-of-florida https://www.psychedelicfinance.com/articles/tryp-therapeutics-completes-psychotherapy-training-for-planned-phase-2a-clinical-trial-at-massachusetts-general-hospital https://www.psychedelicfinance.com/articles/tryp-therapeutics-doses-first-patient-in-phase-ii-psilocybin-assisted-therapy-clinical-trial https://www.psychedelicfinance.com/articles/tryp-therapeutics-files-final-prospectus-and-announces-initial-public-offering https://www.psychedelicfinance.com/articles/tryp-therapeutics-inc-announces-amendment-to-terms-of-private-placement-and-closing-of-3-000-000-second-tranche https://www.psychedelicfinance.com/articles/tryp-therapeutics-inc-announces-board-changes-and-closing-of-first-tranche-of-private-placement https://www.psychedelicfinance.com/articles/tryp-therapeutics-inc-announces-upsizing-of-previously-announced-private-placement https://www.psychedelicfinance.com/articles/tryp-therapeutics-inc-cse-tryp-otcqb-trypf-leading-next-wave-of-psychedelic-drug-development https://www.psychedelicfinance.com/articles/tryp-therapeutics-initiates-enrollment-for-binge-eating-disorder-study-in-partnership-with-university-of-florida https://www.psychedelicfinance.com/articles/tryp-therapeutics-invited-to-present-at-global-healthcare-psychedelic-conferences https://www.psychedelicfinance.com/articles/tryp-therapeutics-invited-to-present-at-investing-in-psychedelics-conference https://www.psychedelicfinance.com/articles/tryp-therapeutics-partners-with-albany-molecular-research-inc-to-manufacture-a-proprietary-psilocybin-based-drug https://www.psychedelicfinance.com/articles/tryp-therapeutics-partners-with-alcami-for-proprietary-formulations https://www.psychedelicfinance.com/articles/tryp-therapeutics-partners-with-calvert-labs-to-conduct-exploratory-studies-for-proprietary-psilocybin-formulations https://www.psychedelicfinance.com/articles/tryp-therapeutics-partners-with-clinlogix-for-clinical-trial-support https://www.psychedelicfinance.com/articles/tryp-therapeutics-partners-with-fluence-for-psychotherapy-design https://www.psychedelicfinance.com/articles/tryp-therapeutics-partners-with-the-university-of-michigan-to-evaluate-proprietary-formulations https://www.psychedelicfinance.com/articles/tryp-therapeutics-plans-phase-2a-eating-disorder-clinical-trial-with-dr-jennifer-miller https://www.psychedelicfinance.com/articles/tryp-therapeutics-reaches-milestone-on-psilocybin-drug-manufacturing-program https://www.psychedelicfinance.com/articles/tryp-therapeutics-receives-confirmation-from-fda-to-proceed-with-phase-2a-clinical-trial-in-patients-with-ibs-at-massachusetts-general-hospital https://www.psychedelicfinance.com/articles/tryp-therapeutics-receives-confirmation-from-fda-to-proceed-with-phase-2a-study-in-fibromyalgia https://www.psychedelicfinance.com/articles/tryp-therapeutics-reports-on-key-milestones-for-2021 https://www.psychedelicfinance.com/articles/tryp-therapeutics-retains-ims-investor-relations https://www.psychedelicfinance.com/articles/tryp-therapeutics-strengthens-board-of-directors-with-appointment-of-chris-ntoumenopoulos-as-independent-director https://www.psychedelicfinance.com/articles/tryp-therapeutics-strengthens-board-of-directors-with-appointment-of-gregory-m-mckee https://www.psychedelicfinance.com/articles/tryp-therapeutics-strengthens-intellectual-property-portfolio-with-provisional-patent-applications-for-fibromyalgia-treatment-and-for-crystalline-forms-of-trp-8803 https://www.psychedelicfinance.com/articles/tryp-therapeutics-strengthens-ip-portfolio-with-provisional-patent-application-for-binge-eating-disorder-treatment https://www.psychedelicfinance.com/articles/tryp-therapeutics-submits-ind-application-for-phase-2a-clinical-trial-in-eating-disorders https://www.psychedelicfinance.com/articles/tryp-therapeutics-submits-ind-application-for-phase-2a-clinical-trial-in-fibromyalgia https://www.psychedelicfinance.com/articles/tryp-therapeutics-submits-investigational-new-drug-ind-application-to-us-fda-for-planned-phase-2a-clinical-trial-in-patients-with-ibs-at-massachusetts-general-hospital https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-host-investor-day-on-april-22 https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-host-q3-investor-day-on-july-29-2021 https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-15th-annual-pain-therapeutics-summit https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-biotech-showcase-on-monday-january-9-2023 https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-canaccord-genuity-annual-growth-conference https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-h-c-wainwright-annual-global-investment-conference https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-oppenheimer-fall-healthcare-summit https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-the-h-c-wainwright-psychedelics-conference https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-the-h-c-wainwright-psychedelics-conference-on-december-6-2021 https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-the-ksca-psychedelics-virtual-investor-conference https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-the-ladenburg-thalmann-healthcare-conference https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-the-psych-investor-summit https://www.psychedelicfinance.com/articles/tryp-therapeutics-to-present-at-the-stifel-gmp-healthcare-conference https://www.psychedelicfinance.com/articles/ty-tashiro-joins-mindcure-as-the-senior-translational-and-psychometric-architect-for-istryms-ai-driven-psychedelic-digital-therapeutic-technology https://www.psychedelicfinance.com/articles/u-k-member-of-parliament-crispin-blunt-to-inaugurate-psilocybin-cultivation-facility-at-optimi-health-grand-opening https://www.psychedelicfinance.com/articles/u-s-fda-approves-nova-mentis-orphan-drug-application https://www.psychedelicfinance.com/articles/u-s-fda-clears-myco-001-for-multi-site-government-funded-trial-in-smoking-cessation https://www.psychedelicfinance.com/articles/u-s-patent-grant-to-strengthen-small-pharmas-dmt-patent-strategy-with-injectable-formulation https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-approval-for-trading-on-the-otcqb-venture-market https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-chief-clinics-officer-dr-ian-rabb https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-engagement-of-investor-relations-advisor https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-enhancement-of-board-of-directors-2 https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-expansion-of-executive-team-andgrant-of-stock-options https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-formation-of-advisory-board https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-frankfurt-stock-exchange-listing https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-kelburn-reopening-date https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-re-opening-of-the-kelburn-recovery-center https://www.psychedelicfinance.com/articles/universal-ibogaine-announces-results-of-annual-general-meeting https://www.psychedelicfinance.com/articles/universal-ibogaine-appoints-nick-karos-to-the-board-of-directors https://www.psychedelicfinance.com/articles/universal-ibogaine-commences-development-plan-at-kelburn-in-preparation-for-ibogaine-treatments-and-provides-update-on-drug-supply https://www.psychedelicfinance.com/articles/universal-ibogaine-commences-trading-on-the-tsx-v https://www.psychedelicfinance.com/articles/universal-ibogaine-engages-investor-relations-firm-blue-digital-media https://www.psychedelicfinance.com/articles/universal-ibogaine-enters-drug-supply-agreement https://www.psychedelicfinance.com/articles/universal-ibogaine-expands-research-team-with-julie-dumouchel-director-of-clinical-trials https://www.psychedelicfinance.com/articles/universal-ibogaine-highlights-2022-accomplishments https://www.psychedelicfinance.com/articles/universal-ibogaine-inc-to-webcast-live-at-otc-markets-virtualinvestorconferences-com-march-10th https://www.psychedelicfinance.com/articles/universal-ibogaine-provides-update-on-kelburn-recovery-center https://www.psychedelicfinance.com/articles/universal-ibogaine-provides-update-on-kelburn-recovery-center-operations https://www.psychedelicfinance.com/articles/universal-ibogaine-retains-shayne-nyquvest-as-capital-markets-advisor https://www.psychedelicfinance.com/articles/universal-ibogaine-signs-memorandum-of-understanding-with-the-osoyoos-indian-band https://www.psychedelicfinance.com/articles/universal-ibogaine-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-group-llc-and-hosted-by-m-vest-on-march-28th-30th-from-9-00-a-m-5-00-p-m-edt https://www.psychedelicfinance.com/articles/universal-ibogaine-undertaking-offering-of-convertible-debt-securities-and-common-shares https://www.psychedelicfinance.com/articles/vic-neufeld-director-havn-life-sciences https://www.psychedelicfinance.com/articles/video-dr-evan-wood-numinus-wellness https://www.psychedelicfinance.com/articles/virtual-psychedelic-therapy-company-tripsitter-clinic-is-joined-by-reconcious-medical https://www.psychedelicfinance.com/articles/wake-network-receives-approval-for-phase-2b-psilocybin-microdosing-trial https://www.psychedelicfinance.com/articles/weekly-headlines-april-22-2022 https://www.psychedelicfinance.com/articles/weekly-headlines-april-29-2022 https://www.psychedelicfinance.com/articles/weekly-headlines-june-3 https://www.psychedelicfinance.com/articles/weekly-headlines-may-13 https://www.psychedelicfinance.com/articles/weekly-headlines-may-6-2022 https://www.psychedelicfinance.com/articles/wellbeing-announces-definitive-agreement-to-divest-irp-health https://www.psychedelicfinance.com/articles/wellbeing-announces-delay-in-filing-its-financial-statements-and-management-cease-trade-order https://www.psychedelicfinance.com/articles/wellbeing-ceo-joins-benzingas-psychedelic-advisory-board https://www.psychedelicfinance.com/articles/wellbeing-corporate-update-in-a-letter-from-the-ceo-to-its-shareholders https://www.psychedelicfinance.com/articles/wellbeing-digital-and-subsidiary-kgk-science-applauds-the-government-of-albertas-move-to-regulate-the-use-of-psychedelics https://www.psychedelicfinance.com/articles/wellbeing-digital-announces-change-of-auditor https://www.psychedelicfinance.com/articles/wellbeing-digital-announces-the-appointment-of-mohammad-sharifi-to-board-of-directors https://www.psychedelicfinance.com/articles/wellbeing-digital-reports-financial-results-for-the-fourth-fiscal-quarter https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-announces-q3-financial-results-and-provides-corporate-update https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-announces-the-appointment-of-natalie-dolphin-as-vp-of-marketing-and-investment-relations https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-appoints-najla-guthrie-as-chief-executive-officer https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-becomes-a-founding-sponsor-of-the-women-in-psychedelics-network https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-delivers-its-first-iv-ketamine-treatment-under-the-inpatient-kite-program https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-dr-corey-hilmas-invited-to-participate-as-a-regulatory-panelist-at-probiota-americas-event https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-forms-special-committee-to-explore-advances-in-digital-therapeutics-for-mental-health https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-inc-changes-year-end https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-new-ceo-unveils-evolved-competitive-strategy https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-provides-commercial-and-corporate-updates-for-kgk-science https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-reports-financial-results-for-the-second-fiscal-quarter-of-2022 https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-reveals-recent-achievement-by-its-kgk-science-subsidiary https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-signs-mou-with-pathway-health-regarding-the-potential-sale-of-certain-assets https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-subsidiary-irp-health-approved-as-part-of-coveted-chronic-pain-centre-of-excellence-for-canadian-veterans-network https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-subsidiary-irp-health-receives-approval-from-veterans-affairs-canada-for-reactivation-program https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-subsidiary-kgk-science-engaged-by-lophos-pharmaceuticals-for-novel-peyote-study https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-subsidiary-kgk-science-forms-tactical-partnership-with-nova-mentis https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-welcomes-dr-michael-ho-as-new-medical-director-of-mindscape-clinic-in-houston https://www.psychedelicfinance.com/articles/wellbeing-digital-sciences-welcomes-najla-guthrie-as-chief-executive-officer https://www.psychedelicfinance.com/articles/wellbeing-digital-signs-loi-manage-additional-clinics https://www.psychedelicfinance.com/articles/wellbeing-digital-subsidiary-kgk-to-participate-in-microdose-wonderland-miami-conference https://www.psychedelicfinance.com/articles/wellbeing-digital-subsidiary-kgk-to-participate-in-the-supply-side-west-conference https://www.psychedelicfinance.com/articles/wellbeing-digital-to-participate-at-this-years-wonderland-miami-conference https://www.psychedelicfinance.com/articles/wellbeing-digital-to-participate-in-the-cantor-fitzgerald-symposium-on-mental-health-clinics https://www.psychedelicfinance.com/articles/wellbeing-digital-to-participate-in-the-microdose-psychedelic-capital-conference https://www.psychedelicfinance.com/articles/wellbeing-digital-to-participate-in-the-psychedelic-medicine-association-webinar https://www.psychedelicfinance.com/articles/wellbeing-provides-bi-weekly-default-status-report https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-irp-health-toronto-location-approved-by-veterans-affairs-canada-for-its-reactivation-program https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-and-the-international-probiotics-association-ipa-applauds-fdas-commitment-to-release-ndi-draft-guidance-documents-in-the-near-future https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-and-the-international-probiotics-association-ipa-applauds-fdas-commitment-to-release-ndi-draft-guidance-documents-in-the-near-future-2 https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-announces-akl-no-objection-status-for-progo-r-branded-ingredient-from-fda https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-announces-positive-clinical-trial-results-of-gj-191-jointalive-r-supplementation-in-treating-oa https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-announces-psilocybin-microdose-capsule-formulation-to-be-submitted-to-health-canada-for-phase-2a-trial https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-announces-successful-delivery-of-cbd-and-thc-through-the-skin-of-healthy-volunteers https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-announces-successful-results-of-up446-a-nutraceutical-ingredient-in-positive-immune-defense-response https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-applies-for-a-controlled-substances-dealers-license-and-receives-approval-to-proceed-with-buildout https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-begins-recruitment-in-first-of-its-kind-health-canada-approved-psilocybin-trial https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-enters-into-research-contract-with-halucenex-for-phase-ii-clinical-trial https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-enters-into-research-contract-with-nova-mentis-for-phase-ii-a-clinical-trial https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-opens-new-clinical-research-center-to-reimagine-a-healthier-future https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-receives-approval-for-first-of-its-kind-psylocibin-clinical-trial https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-receives-exemption-under-section-56-of-the-controlled-drugs-and-substances-act-to-begin-psilocybin-clinical-trial https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-kgk-science-submits-cta-for-phase-iia-clinical-trial https://www.psychedelicfinance.com/articles/wellbeing-subsidiary-mindscape-treats-its-1-000th-patient https://www.psychedelicfinance.com/articles/wesana-announces-first-quarter-2022-financial-results https://www.psychedelicfinance.com/articles/wesana-announces-participation-at-upcoming-events-in-june-2021 https://www.psychedelicfinance.com/articles/wesana-announces-sale-of-clinic-management-services-organization https://www.psychedelicfinance.com/articles/wesana-announces-second-quarter-2022-financial-results https://www.psychedelicfinance.com/articles/wesana-announces-singular-focus-on-drug-development-prompting-a-strategic-review-of-its-clinics-and-other-care-delivery-assets https://www.psychedelicfinance.com/articles/wesana-completes-filing-of-pct-patents-for-novel-drug-protocols https://www.psychedelicfinance.com/articles/wesana-health-announces-closing-of-c-16-1-million-oversubscribed-private-placement https://www.psychedelicfinance.com/articles/wesana-health-announces-closing-of-psytech-acquisition https://www.psychedelicfinance.com/articles/wesana-health-announces-closing-of-reverse-takeover-transaction https://www.psychedelicfinance.com/articles/wesana-health-announces-definitive-agreement-to-acquire-psytech-inc https://www.psychedelicfinance.com/articles/wesana-health-announces-inclusion-in-the-advisorshares-psychedelics-etf https://www.psychedelicfinance.com/articles/wesana-health-announces-listing-on-otcqb-r-venture-market https://www.psychedelicfinance.com/articles/wesana-health-announces-new-findings-indicating-psylocibin-potentiates-impact-of-an-anti-depressant https://www.psychedelicfinance.com/articles/wesana-health-announces-positive-findings-from-animal-study-on-novel-depression-treatment-protocol-combining-psilocybin-and-cannabidiol https://www.psychedelicfinance.com/articles/wesana-health-announces-sale-of-sana-13-assets-to-lucy-scientific-discovery https://www.psychedelicfinance.com/articles/wesana-health-appoints-meghna-a-gaeta-as-chief-marketing-officer https://www.psychedelicfinance.com/articles/wesana-health-ceo-daniel-carcillo-to-keynote-charles-river-symposium-re-imagining-substance-abuse-addiction-and-mental-health-disorders-with-psychedelic-therapies https://www.psychedelicfinance.com/articles/wesana-health-ceo-daniel-carcillo-to-speak-at-several-leading-investor-and-industry-events https://www.psychedelicfinance.com/articles/wesana-health-clinics-surpass-4-000-administered-ketamine-treatments https://www.psychedelicfinance.com/articles/wesana-health-commences-functional-animal-study-for-treatment-of-traumatic-brain-injury https://www.psychedelicfinance.com/articles/wesana-health-commences-trading-on-the-cse https://www.psychedelicfinance.com/articles/wesana-health-commits-funding-of-1-5-million-to-support-maps-research-pipeline https://www.psychedelicfinance.com/articles/wesana-health-expands-research-leadership-team-with-mark-wingertzahn-phd-as-chief-scientific-officer https://www.psychedelicfinance.com/articles/wesana-health-granted-us-fda-pre-ind-meeting-for-sana-013 https://www.psychedelicfinance.com/articles/wesana-health-highlights-recent-appointments-to-board-of-directors https://www.psychedelicfinance.com/articles/wesana-health-outlines-accelerated-drug-development-pathway https://www.psychedelicfinance.com/articles/wesana-health-partners-with-university-of-south-carolina https://www.psychedelicfinance.com/articles/wesana-health-provides-strategic-and-operational-updates https://www.psychedelicfinance.com/articles/wesana-health-reports-q3-2021-financial-results https://www.psychedelicfinance.com/articles/wesana-health-reports-q4-2021-financial-results-and-provides-subsequent-period-highlights https://www.psychedelicfinance.com/articles/wesana-health-to-present-live-at-kcsa-virtual-investor-conference-april-28th https://www.psychedelicfinance.com/articles/wesana-is-exploring-broadening-sana-013-lead-indication-to-treat-major-depressive-disorder https://www.psychedelicfinance.com/articles/wesana-provides-updates-on-build-out-of-third-clinic https://www.psychedelicfinance.com/articles/william-bill-j-ciprick-ceo-optimi-healt https://www.psychedelicfinance.com/articles/william-garner-executive-director-tryp-therapeutics https://www.psychedelicfinance.com/articles/world-leading-depression-researcher-dr-maurizio-fava-joins-pharmather-as-scientific-and-clinical-advisor https://www.psychedelicfinance.com/articles/world-leading-drug-delivery-researcher-professor-ryan-donnelly-joins-pharmather-as-scientific-and-technical-advisor https://www.psychedelicfinance.com/articles/world-renowned-physician-joins-core-one-labs-as-chief-medical-officer https://www.psychedelicfinance.com/articles/worlds-first-clinical-trial-for-dmt-assisted-therapy-in-major-depressive-disorder-shows-consistent-quality-of-psychedelic-response-in-phase-i https://www.psychedelicfinance.com/articles/yales-department-of-psychiatry-chair-to-join-clearmind-medicine https://www.psychedelicfinance.com/articles/yield-growth-announces-name-change-and-provides-corporate-update https://www.psychedelicfinance.com/articles/yukoterre-announces-conditional-approval-of-reverse-takeover-transaction-with-silo-wellness https://www.psychedelicfinance.com/company/aja-ventures https://www.psychedelicfinance.com/company/albert-labs https://www.psychedelicfinance.com/company/algernon-pharmaceuticals https://www.psychedelicfinance.com/company/apex-labs https://www.psychedelicfinance.com/company/atai-life-sciences https://www.psychedelicfinance.com/company/awakn-life-sciences https://www.psychedelicfinance.com/company/b-more https://www.psychedelicfinance.com/company/beckley-foundation https://www.psychedelicfinance.com/company/beckley-psytech https://www.psychedelicfinance.com/company/betterlife-pharma https://www.psychedelicfinance.com/company/bexson-biomedical https://www.psychedelicfinance.com/company/biomind-labs https://www.psychedelicfinance.com/company/bionomics https://www.psychedelicfinance.com/company/braxia-scientific https://www.psychedelicfinance.com/company/bright-minds https://www.psychedelicfinance.com/company/cannaglobal-wellness https://www.psychedelicfinance.com/company/cb-therapeutics https://www.psychedelicfinance.com/company/ceruvia-lifesciences https://www.psychedelicfinance.com/company/clairvoyant-therapeutics-rx https://www.psychedelicfinance.com/company/clearmind-medicine https://www.psychedelicfinance.com/company/clexio-biosciences https://www.psychedelicfinance.com/company/cognetivity-neurosciences https://www.psychedelicfinance.com/company/compass-pathways https://www.psychedelicfinance.com/company/core-one-labs-inc https://www.psychedelicfinance.com/company/creso-pharma https://www.psychedelicfinance.com/company/cube-psytech https://www.psychedelicfinance.com/company/cybin-corp https://www.psychedelicfinance.com/company/delic https://www.psychedelicfinance.com/company/delix-therapeutics https://www.psychedelicfinance.com/company/diamond-therapeutics https://www.psychedelicfinance.com/company/doseology-sciences https://www.psychedelicfinance.com/company/egf-theramed-health-corp https://www.psychedelicfinance.com/company/ehave https://www.psychedelicfinance.com/company/ei-ventures https://www.psychedelicfinance.com/company/eleusis https://www.psychedelicfinance.com/company/entheon-biomedical https://www.psychedelicfinance.com/company/enveric-biosciences https://www.psychedelicfinance.com/company/field-trip-health https://www.psychedelicfinance.com/company/filament-health https://www.psychedelicfinance.com/company/fluence https://www.psychedelicfinance.com/company/freedom-to-operate https://www.psychedelicfinance.com/company/fsd-pharma https://www.psychedelicfinance.com/company/gilgamesh-pharmaceuticals https://www.psychedelicfinance.com/company/havn-life https://www.psychedelicfinance.com/company/hmnc-brain-health https://www.psychedelicfinance.com/company/horizons-etfs-management-inc https://www.psychedelicfinance.com/company/husch-blackwell https://www.psychedelicfinance.com/company/incannex-healthcare https://www.psychedelicfinance.com/company/intelgenx https://www.psychedelicfinance.com/company/irwin-naturals https://www.psychedelicfinance.com/company/ixtlan-bioscience https://www.psychedelicfinance.com/company/johns-hopkins-medicine https://www.psychedelicfinance.com/company/ketamine-one https://www.psychedelicfinance.com/company/levitee-labs https://www.psychedelicfinance.com/company/lobe-sciences https://www.psychedelicfinance.com/company/lophora https://www.psychedelicfinance.com/company/magical-brands https://www.psychedelicfinance.com/company/maps https://www.psychedelicfinance.com/company/mind-cure-health https://www.psychedelicfinance.com/company/mind-medicine-mindmed https://www.psychedelicfinance.com/company/mindbio-therapeutics https://www.psychedelicfinance.com/company/mindset-pharma https://www.psychedelicfinance.com/company/molecular-science-corp https://www.psychedelicfinance.com/company/mycotopia-therapies https://www.psychedelicfinance.com/company/mycrodose-therapeutics https://www.psychedelicfinance.com/company/mydecine-innovations-group https://www.psychedelicfinance.com/company/mynd-diagnostics https://www.psychedelicfinance.com/company/neonmind-biosciences-inc https://www.psychedelicfinance.com/company/neural-therapeutics https://www.psychedelicfinance.com/company/ninnion https://www.psychedelicfinance.com/company/nirvana-life-sciences https://www.psychedelicfinance.com/company/nova-mentis-life-science https://www.psychedelicfinance.com/company/novamind-ventures https://www.psychedelicfinance.com/company/numinus https://www.psychedelicfinance.com/company/octarine-bio https://www.psychedelicfinance.com/company/optimi-health https://www.psychedelicfinance.com/company/origin-therapeutics https://www.psychedelicfinance.com/company/orthogonal-thinker https://www.psychedelicfinance.com/company/osmind https://www.psychedelicfinance.com/company/pasithea-therapeutics https://www.psychedelicfinance.com/company/pharmadrug-inc https://www.psychedelicfinance.com/company/pharmala-biotech https://www.psychedelicfinance.com/company/pharmather https://www.psychedelicfinance.com/company/psilera https://www.psychedelicfinance.com/company/psilotec-health-solutions https://www.psychedelicfinance.com/company/psybio-therapuetics https://www.psychedelicfinance.com/company/psyched-wellness https://www.psychedelicfinance.com/company/psyence-group https://www.psychedelicfinance.com/company/psygen-labs https://www.psychedelicfinance.com/company/psylo https://www.psychedelicfinance.com/company/psyrx https://www.psychedelicfinance.com/company/pure-extracts-corp https://www.psychedelicfinance.com/company/quantified-citizen https://www.psychedelicfinance.com/company/red-light-holland https://www.psychedelicfinance.com/company/reunion-neuroscience https://www.psychedelicfinance.com/company/revitalist-lifestyle-and-wellness https://www.psychedelicfinance.com/company/revive-therapeutics https://www.psychedelicfinance.com/company/seelos-therapeutics https://www.psychedelicfinance.com/company/silo-wellness https://www.psychedelicfinance.com/company/small-pharma https://www.psychedelicfinance.com/company/telescope-innovation https://www.psychedelicfinance.com/company/the-good-shroom-co https://www.psychedelicfinance.com/company/therapsil https://www.psychedelicfinance.com/company/tripsitter https://www.psychedelicfinance.com/company/tryp-therapeutics https://www.psychedelicfinance.com/company/universal-ibogaine https://www.psychedelicfinance.com/company/unlimited-sciences https://www.psychedelicfinance.com/company/wake-network https://www.psychedelicfinance.com/company/wesana-health https://www.psychedelicfinance.com/company/woke-pharmaceuticals https://www.psychedelicfinance.com/company/woven-science